CONVENTION ISSUE

BIOTECHGAZINE

生物科技誌

SEPTEMBER 2025

BIOHK2025

香港國際生物科技論壇暨展覽

SEPTEMBER 10 WED - 13 SAT

香港會議展覽中心

BIOHK2025
主辦單位

EtownBio
亦庄生物医药

链接全球医药创新合作伙伴
Connecting Global Pharmaceutical Innovation Partners

北京亦庄国际生物医药投资管理有限公司成立于2010年，系北京市属国企亦庄控股旗下专业平台，同时也是北京经开区"管委会+平台公司"模式下的生物医药平台公司。公司定位为经开区生物医药产业生态的核心运营商，通过整合空间、资本、政策、技术等资源要素，为产业发展提供全链条支撑。公司以服务生物技术和大健康产业战略为导向，打造"具有全国引领作用的生物技术和大健康产业平台"，助力北京经开区建设全球"新药智造"产业高地。

Etown Bio was established in 2010 as a specialised platform under Yizhuang Holdings, a state-owned enterprise of Beijing Municipality. It also serves as the biomedical platform company within the Beijing Economic-Technological Development Area's 'Administrative Committee + Platform Company' model. Positioned as the core operator of the development area's biomedical industry ecosystem, the company provides comprehensive support across the entire industrial chain by integrating spatial, capital, policy, technological and other resource elements. Guided by a strategy to serve the biotechnology and broader health industries, the company aims to establish 'a nationally leading platform for biotechnology and health industries,' thereby supporting Beijing Economic-Technological Development Area's ambition to become a global hub for 'intelligent new drug manufacturing.'

打造具有全国引领作用的
生物技术和大健康产业平台
ESTABLISH A NATIONALLY LEADING PLATFORM
FOR THE BIOTECHNOLOGY AND HEALTH INDUSTRY

生物科技誌
BIOTECHGAZINE

SEPT 2025

出版社 Publisher

海康生命出版社有限公司 H. K. Life Publishing Limited

電話 Tel : (852) 2111 2123
傳真 Fax: (852) 2111 9762
電郵 Email: editorial@hkbio.org.hk
地址 香港新界沙田石門安耀街3號 匯達大廈1615-18室
Units 15-18, 16/F South Wing Delta House, 3 On Yiu Street, Shatin, N.T. Hong Kong

廣告查詢 Advertising
電郵 Email: editorial@hkbio.org.hk

出版日期 Publishing Date 2025年9月 SEPT 2025
定價 Price HK$60
ISSN 2959-6971

Contents

About The Convention

Exclusive Interview

Speaker Biographies

Resources

Welcome Message

Dear Distinguished Guests and Participants,

A very warm welcome to BIOHK2025! We are thrilled to have you join us at the Hong Kong Convention and Exhibition Center from September 10 to 13. This year's congress will feature two grand Opening Ceremonies—the Main Forum Opening and the Biotechnology Investment Forum Opening—each bringing together global leaders to set the tone for an inspiring week.

BIOHK2025 has significantly expanded both the depth and breadth of its program, featuring two grand opening ceremonies. The congress is centered around a four-day Main Forum, featuring over 250 distinguished speakers—including the Vice Chairman of the National Committee of the Chinese People's Political Consultative Conference Leung Chun-ying, Hong Kong Financial Secretary Paul Chan Mo-po, Secretary for Innovation, Technology and Industry Sun Dong, Secretary for Health Lo Chung-mau, Chinese Academy of Sciences Academician Gao Fu, University of California San Francisco Vice Chancellor Professor Jennifer Rubin Grandis, Hong Kong University of Science and Technology Provost Professor Guo Yi-ke, GSK Chairman Sir Jonathan Symonds, DEFTA Partners Group Chairman and CEO Ambassador George Hara, and BGI Group CEO Dr. Yin Ye—who will share cutting-edge insights across fields such as brain science, public health, artificial intelligence, stem cell research, and international collaboration.

Additionally, dozens of thematic sessions will dive into key areas including biotech investment, modernizing traditional Chinese medicine, AI applications, innovative drug R&D, infectious disease control, stem cell and cell therapy, gene therapy, neurodegenerative diseases, IVD, and medical device regulations. These forums are designed to provide a comprehensive overview of the latest trends and future opportunities within global biotechnology.

Set in Hong Kong—a city known as the "Super Connector" between East and West—BIOHK2025 offers a unique environment for building meaningful partnerships. Looking ahead, BIOHK will further expand its global reach in the coming year, evolving into a world-class investment summit with global capital influence, aiming to become the "Asian edition" of the J.P. Morgan Healthcare Conference. Whether you are seeking research collaboration, investment opportunities, market entry, or connections with innovators and experts, this event provides the ideal platform to foster cooperation and spark transformative ideas.

We believe that great innovations emerge through collaboration, and it is our goal to facilitate connections that drive the biotechnology industry forward. Thank you for being part of this inspiring gathering. Let's work together to shape the future of biotech.

Wishing you an engaging and productive experience at BIOHK2025.

Yours sincerely,

Professor Albert Cheung-hoi YU, PhD, JP
President, BIOHK2025

BIOHK2025 Governance

**Alphabetical Listing by Last Name*

President	
Albert Cheung-hoi YU	President,BIOHK2025;Hong Kong Biotechnology Organization
Vice Presidents	
Chrank CHEN	Partner, Ausvic Capital Limited Investment
Gordon CHENG	Chief Executive Officer, Cameron Pace China Limited
Chun Yuan CHIANG	Vice-Chair & Deputy Secretary-General, CCG Hong Kong
Charles HU	Founder & CEO, Ryoden Medical Holdings & Incando Therapeutics Group
Yuan HUANG	Founder &CEO, Quantum Life Limited; Managing Director, HK Longevity Medical Centre
Chuen Yan LEUNG	Co-founder, Silver Dart Capital Partner (Healthcare Investments), Value Partners Group
Da LIU	Managing Director, CR CP Life Science Fund
Andrew NG	Managing Director and Head of Healthcare, VMS Group; Investment Partner, Panacea Venture
WAN Mu, Maki	Former President, Rotary Club Kowloon Golden Mile
Leon Shaw	Executive President，Warton Economic Institute（HK）
Alister WONG	Associate, Philip K.H. Wong, Kennedy Y.H. Wong & Co Legal and Business
Ben YU	Business Director, Nan Hai Corporation Limited; Director, HK01
Peter ZHENG	Founding and Executive Partner, CDF Capital Orion Fund and Orion Technology Fund

BIOHK2025 Organizing Committee

**Alphabetical Listing by Last Name*

Su Juan BA	President and CEO, National Foundation for Cancer Research
Jing Hua CAO	Executive Director, ANSO Secretariat, Alliance of International Science Organizations (ANSO)
Wilton CHAU	Chairman, Pan Asia Venture Development Platform (PAVD)
Kathryn CHEAH	Chair Professor of Biochemistry, School of Biomedical Sciences, The University of Hong Kong
Michelle CHEN	Chief Business Officer, Insilico Medicine
Xin Lorna CHEN	Asia Regional Managing Partner and Head of Greater China, Shearman & Sterling
Ralph CHOW	CEO, Chinese Manufacturers' Association of Hong Kong (CMA)
Yiu Ming CHOW	Chief Financial Officer, Lee's Pharmaceutical Holdings Limited
John CHUNG	Former Superintendent, Hong Kong Police Force
Mark GU	Co-founder, Ying Sen Health Technology
Kai HONG	CEO & Founder, Xiyou Health
Wendy HSIAO	Professor, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology
Hoi Shan HSU	Beijing-Hong Kong Academic Exchange Center, Director
Dennis HUANG	Executive Director, Youth Committee for Sustainable Development (China)

Simon JE	Chairman of the Board, Great Treasure International / Galaxy Treasure Group
Claire JIANG	CEO, Queens (Shenzhen) Biotechnology Co., Ltd.
Gina JIANG	Managing Director, Hong Kong Institute of Biotechnology (HKIB)
Ru Hong JIANG	Chairman, CEO and President of ASC Therapeutics Inc.
Stephen LAM	Honorary Professor of Faculty of Medicine, CUHK； Director, Clinical Genetics Service, Hong Kong Sanatorium & Hospital
Philip LAW	Lead Partner, Venture Capital & Private Equity, Deloitte
Tin Lap LEE	Associate Professor, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong
Lydia LEUNG	CEO of Belun Technology Chairman of Hong Kong Medical and Healthcare Device Industries Association
Thomas LEUNG	Lo Ka Chung Charitable Foundation Professor in Pharmaceutical Sciences Professor and DoULS
Min Din LIN	CEO & Editor in Chief, Global Bio & Investment Monthly
Andy LIU	President, Healthcare Division, BaseBit Technologies
Kitty LO	Chairman and CEO, Finet Group Ltd
Ming Hua LU	Founding Partner, eChinaHealth
Ai Ping LYU	Vice-President (Research and Development), Hong Kong Baptist University
Lars MONTELIUS	Director General, International Iberian Nanotechnology Laboratory

Kimberly NEARING	Venture Partner, Bvcf Management, Ltd
Kevin Orr	Vice President, Winner Medical Group
Pei Yuan QIAN	Head and Chair Professor, Department of Ocean Science, Hong Kong University of Science and Techonology
Jason QIN	Scientific Director, Beijing ITAI Technology
Bjorn SEGERBLOM	Honorary Chaiman and Hong Kong Representative, International Iberian Nanotechnology Laboratory
Victor Shi	CEO, Adicon Clinical Laboratories
Fei SUN	Assistant Professor, Chemical and Biological Engineering, The Hong Kong University of Science and Technology
Nan SUN	Deputy Inspector, Shenzhen Association for Science and Technology
Paul TAM	Vice President& Chair Professor/Macau University of Science and Technology
C. Mark TANG	Managing Director, Good Health Capital (New York)
Yao Lin TIAN	CEO, ShenZhen Govita Medical Laboratory
Victor TSUI	COO, Powder Pharmaceuticals Incorporated
Ji Guang WANG	Assistant Professor, Division of Life Science, The Hong Kong University of Science and Technology
Jing WANG	Center for Advanced Measurement Science, National Institute of Metrology, China
Yi Tao WANG	Director, Institute of Chinese Medical Sciences, University of Macau

Bing Lou WONG	Adjunct Professor, Department of Biochemistry, Chinese University of Hong Kong
Vivian WONG	Hon Professor, School of Chinese Medicine, The University of Hong Kong
George WU	Corporate partner, DLA Piper Hong Kong
Jia Sheng XIE	Director & Executive President, Guangdong Medical Valley (GDMV)
Hai Ding YANG	Executive Director and Founding Team Leader, Healthcare sector of Cathay Capital
Ling YANG	Managing Director, The Carlyle Group
Ray YANG	Partner, Marathon Venture Partners
Michael YAO	Board Co Chairman, China Biotech Services Holdings Limited
Edmond YAU	Founder & CEO, Koln 3D Technology (Medical) Limited
Raymond YIP	Executive Vice Chairman, Dashun Foundation； Vice Chairman, Belt and Road Global Development Alliance
Duncan YU	President, MGI
Kin Lam, Ken Yung	Professor and Associate Head, Department of Biology, Faculty of Science, Hong Kong Baptist University
Jimmy ZHANG	Founding member, Former Chairman of BayHelix Group
Joan ZUO	Vice-president, The Society of Hong Kong Scholars

BIOHK2025
香港國際生物科技論壇暨展覽

FLOOR PLAN

Exhibitor List

Booth No.	Exhibitor
T01	Shanghai Waigaoqiao Biomedical Industry Development Co., Ltd.
T02	City University of Hong Kong
T03	苏州生物医药产业园（BioBAY） PharmCube Lychix RONGKE(SUZHOU)MEDICAL TECHNOLOGY CO.,LTD. JW Therapeutics (Suzhou) Co., Ltd.
T04	GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.
T05	SHANGHAI PUDONG BIO INDUSTRY ASSOCIATION SHANGHAI PUDONG LIFE SCIENCE INDUSTRY DEVELOPMENT CO., LTD. 3SBIO INC. HUTCHMED LIMITED HUA MEDICINE (SHANGHAI) CO., LTD. SHANGHAI INNOSTAR BIO-TECH CO., LTD. SHANGHAI YUGUAN BIOTECH CO., LTD. SHANGHAI REINOVAX BIOLOGICS CO., LTD. SHANGHAI HEPO BIOTECHNOLOGY CO., LTD.
T06	TOWN BIO Beijing QS Medical Technology Co., Ltd. Beijing WeMed Medical Technology Co., Ltd. UnionStrong (Beijing) Technology Co., Ltd.
T07	Miskawaan Health Group
T08	InSilico Medicine Hong Kong Limited
T09	SHUIMU SCIENTIFIC (HK) LIMITED
T10	Hangzhou Transfar Biotech Development Co., Ltd.
T11	YUNNAN BAIYAO GROUP CO.,LTD YNBY INTERNATIONAL LIMITED
3E-A08	Hong Kong Chamber of Commerce in Sweden
3E-A09	Weihai Shideyuan Biotechnology Co., Ltd.
3E-A10	Orbiva Limited
3E-A12	Limu International Decoration Engineering Co.,Ltd

Booth No.	Exhibitor
3E-B01	BOC Life
3E-B02	Hai Kang Life Corporation Limited
3E-B03	Oranssibio Limited SPH Biotherapeutics (HK) Limited
3E-B04	Hong Kong Council for Testing & Certification
3E-B05	Futu Financial Limited
3E-B06	First Aid
3E-B08	Reed Sinopharm Exhibitions Co., Ltd.
3E-B09 3E-B10	CHINESE PEPTIDE COMPANY
3E-D01 3E-D02 3E-D03	THE CHINESE UNIVERSITY OF HONG KONG
3E-D04	The Hong Kong Polytechnic University
3E-D05	Kangchu Technology (Guangdong) Co., Ltd
3E-D06	Morecell Biomedical Technology Development Co., Ltd. Shenzhen
3E-D07	Milecell Biological Science & Technology Co., Ltd.
3E-D08	Hong Kong Science & Technology Parks Corporation
3E-D09	Centre for Virology, Vaccinology and Therapeutics Limited
3E-D10	The Hong Kong Jiangmen General Chamber of Commerce
3E-D11	Jiangmen Shuotong Medical Apparatus and Instruments Technologies Company Limited
3E-D12	QUICK GENE BIOTECH

Booth No.	Exhibitor
3E-D13	GenScript
3E-D14	Nanjing Probio Biotech Co., Ltd.
3E-E07	Novotech Clinical Research (Hong Kong) Limited
3E-E08	Labcorp Pharmaceutical Research and Development (Shanghai) Co., Ltd.
3E-E09	Pudong Construction
3E-E10	PDG ・Neo Force
3E-E11	Hong Kong Biotechnology Organization
3E-E12	Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
3E-E13	BeOne Medicine
3E-E14	Syneos Health
3D-A01 3D-A02 3D-A06 3D-A07	Hong Kong Shenzhen Innovation & Technology Park Ltd.
3D-A03	GREENLIGHT CLINICAL
3D-A04	Stimuliver
3D-A05	Grandville Trading Ltd.
3D-A08	Global Incubator Network Austria
3D-A09	MUNG Blockchain Law Firm
3D-A10	NESTA
3D-A11 3D-A12	Consulate General of Finland in Hong Kong and Macao

Booth No.	Exhibitor
3E-S01	Gynae Solution Limited
3E-S02	C-Ray Therapeutics (Chengdu) Co., Ltd.
3E-S03	Seinda Biomedical Corporation
3E-S04	上海腾翼搏时国际货运代理股份有限公司
3E-S05	Meddy Technology (Hong Kong) Limited
3E-S06	Guangzhou Targene Biotech Co., Ltd.
3E-S07	JETRO HK
3E-S08	Consulate General of Canada to Hong Kong and Macao
3E-S09	GenEditBio Limited
3E-S10	Rain Biotech Solutions Ltd.
OTO-01	One2one Partnering 01
OTO-02	One2one Partnering 02
OTO-03	One2one Partnering 03
OTO-04	One2one Partnering 04
OTO-05	One2one Partnering 05
OTO-06	One2one Partnering 06
OTO-07	One2one Partnering 07
OTO-08	One2one Partnering 08
OTO-09	One2one Partnering 09
OTO-10	One2one Partnering 10

PROGRAM

DAY 1 Wednesday September 10

**This is an September 6th version schedule, subject to change.*

08:30 — EVENT REGISTRATION 注 册

09:00 - 10:30 — OPENING CEREMONY 开幕式

Welcome address by Prof. Albert Yu, President of BIOHK2025 BIOHK2025主席于常海教授致欢迎辞

Opening remarks by Prof. Sun Dong, Secretary for Innovation, Technology and Industry 香港创新科技及工业局局长孙东教授致开幕辞

Speech by Prof. Lo Chung-mau, Secretary for Health 香港医务卫生局局长卢宠茂教授致辞

Keynote speech by the Hon. Leung Chun-ying, Vice Chairperson, National Committee of the Chinese People's Political Consultative Conference
全国政协副主席梁振英先生主题演讲

10:30 - 12:00

Prevention as the Best Medicine: Combining Innovation and Data to Drive Economic Growth and Improve Health Outcomes
KEYNOTE SESSION - Sir Jonathan Symonds Chairman，GSK
大会报告 - Sir Jonathan Symond 葛兰素史克董事会主席

Unveiling the Mysteries of the Mind is a Formidable Challenge Facing Science 探索心智奥秘是科学面临的重大挑战
KEYNOTE SESSION - Prof. Xiongli Yang Academician，Fudan University
大会报告 - 杨雄里院士 复旦大学

AI-Empowered Drug and Vaccine Developments
KEYNOTE SESSION - Prof. George Fu Gao Academician，Chinese Center For Disease Control And Prevention
大会报告 - 高福院士 中国疾病预防控制中心

From Algorithm to Human Clinical Trials: Accelerating Drug Discovery and Development With Generative AI and Laboratory Automation
KEYNOTE SESSION - Dr. Alex Zhavoronkov Founder & CEO，Insilico Medicine
大会报告 - Dr. Alex Zhavoronkov 英矽智能创始人兼CEO

Bridging Basic Research With Clinical Applications and Space Research at the Nencki Institute of Experimental Biology, Polish Academy of Sciences
KEYNOTE SESSION - Prof. Jerzy Duszyński Academician, Advisor to the President of Polish Academy of Sciences
大会报告 - Prof. Jerzy Duszyński 中国科学院外籍院士，波兰科学院院长顾问

LUNCH BREAK 午休

BIOHK Executive Luncheon - presented by Dark Horse Consulting (Invitation Only) Time: 12:00 - 14:30 Venue: The St. Regis Hong Kong

	MAIN STAGE	THEATER 1	THEATER 2	THEATER 3	THEATER 4
13:00 - 14:00	Traditional Chinese Medicine in the Modern Era I 岐黄新篇：中医药现代化论坛 I *Detailed agenda on P14，详细日程见P14	AI Sub-Forum: Advancing Towards Superintelligence in Pharmaceuticals (Insilico Medicine Session) 迈向制药超级智能 (Insilico Medicine 专场) *Detailed agenda on P16，详细日程见P16	Hong Kong's Biotech Ecosystem: Advantages, Policies, and Collaborative Opportunities 香港生物科技生态系统：优势、政策与合作机遇 *Detailed agenda on P17，详细日程见P17	Global Regulatory Shifts: Hong Kong's CMPR New Era - Strategies for Biopharma 全球监管变局：香港CMPR新时代 *Detailed agenda on P15，详细日程见P15	A New Era in Stem Cells & Cell Therapy 干细胞与细胞治疗新纪元 *Detailed agenda on P19，详细日程见P19
14:00 - 14:30			The Hong Kong Experiment: All the Ingredients for a Biotech Hub, Awaiting the Master Chef *Detailed agenda on P17，详细日程见P17		
14:30 - 15:00					
15:00 - 16:00			The AI + Pandemic Defense Forum AI赋能传染病防控高峰论坛 *Detailed agenda on P18，详细日程见P18	Beijing Yizhuang Group Presents: Biotech Industrial Policy& Investment Forum 北京亦庄生物科技产业项目政策推介	
16:30 - 18:00					

**This is an September 6th version schedule, subject to change.*

Traditional Chinese Medicine in the Modern Era I

Sept 10 13:00-18:00 | **Main Theater**

Sub-Forum Co-Organized by School of Chinese Medicine, Hong Kong Baptist University 香港浸会大学中医药学院合办分论坛

Innovation Across the TCM Industrial Chain
中医药全产业链及现代化创新论坛

Co-Chair 主席

Prof. Wendy Hsiao 萧文鸾教授 (The State Key Laboratory of Quality Research in Chinese Medicine Macau University of Science and Technology 澳门科技大学中药质量研究国家重点实验室)

Prof. Ming-yuen Lee 李铭源教授 (DoRCOcean & Chair Professor, Biomedical Sciences of The Hong Kong Polytechnic University 香港理工大學中医药创新研究中心成员兼食品科学与营养系讲座教授)

Speakers 演讲人

Session 1: Keynote Speech 主旨演讲

Prof. Aiping Lyu 吕爱平教授 (Vice-President (Research and Development) cum Dean of Graduate School, Hong Kong Baptist University 香港浸会大学副校长) - Integrative Medicine and Future Medicine Development: My Experience in Rheumatoid Arthritis Research

Session 2: Strategy & Industry: The New Landscape of TCM Development
战略与产业：中医药发展的新格局

Mr. Hong Li 黎洪先生 (广州白云山医药集团股份有限公司 总经理)

Dr. Wuzhou Wan 万五洲博士 (President, Central Research Institute, Yunnan Baiyao Group 云南白药集团中央研究院院长) - Unlocking the New Value of TCM: Evidence-Based and Innovation-Driven Approach Lead Modernization 解锁中药新价值：循证与创新引领现代化升级

Dr. Jie Zhang 张洁博士 (Chairman and General Manager of JiuZhang Biotech 九章生物董事长兼总经理) - 中医药&中医药的产业化

Session 3: Clinical Practice & Evidence: The Depth of Integrative Medicine
临床与循证：中西医结合的深度实践

Prof. Mianzhi Zhang 张勉之教授 President of Tianjin Hospital of Integrated Traditional Chinese and Western Medicine (Tianjin Nankai Hospital)
天津市中西医结合医院 (天津市南开医院) 院长 - 中西医结合治疗多脏器损害及病因寻踪

Prof. Kun Zhang 张昆教授 (Director, Acupuncture Unit, The Third Affiliated Hospital of Sun Yat-sen University 中山大附属第三医院针灸科主任) - Research on Key Technologies and Treatment Protocols for Integrated Traditional Chinese and Western Medicine In Combined Allergic Rhinitis and Asthma Syndrome 过敏性鼻炎哮喘综合征的中西医结合诊疗关键技术及方案研究

冯奕斌教授 (Professor and Director, School of Chinese Medicine The University of Hong Kong, 香港大学中医药学院院长) - Advancing Chinese Medicine in Oncology: Bridging Traditional Wisdom and Modern Evidence

Session 4: Technology & Innovation: Leading the Future of TCM
技术与创新：引领中医药的未来

Prof. Cong Yan 闫聪教授 (Beijing University of Chinese Medicine 北京中医药大学威高研究院院长) - 中医+人工智能：生命科学发展的未来

Dr. Erik Ko 高俊熙博士 (Senior Technical Manager, Nano and Advanced Materials Institute 纳米及先进材料研发院 高级技术经理) - Application of Advanced Materials in Delivering TCM Active Ingredients and Enhancing Efficacy 先进材料于递送中草药活性成分与提升疗效的应用

**This is an September 6th version schedule, subject to change.*

Roundtable 圆桌论坛 - Innovative Practices in Modernizing Traditional Chinese Medicine 中医药现代化的创新实践

Panelists 小组人员

- **Prof. Cong Yan 闫聪教授 (Beijing University of Chinese Medicine 北京中医药大学威高研究院院长)**
- **Dr. Erik Ko 高俊熙博士 (Senior Technical Manager, Nano and Advanced Materials Institute 纳米及先进材料研发院 高级技术经理)**
- **Mr. Jie Zhang 张洁先生 (Chairman and General Manager of JiuZhang Biotech 九章生物董事长兼总经理)**
- **Prof. Ming-yuen Lee 李铭源教授 (DoRCOcean & Chair Professor, Biomedical Sciences of The Hong Kong Polytechnic University 香港理工大學中医药创新研究中心成员兼食品科学与营养系讲座教授)**
- **Prof. Wendy Hsiao 萧文鸾教授 (The State Key Laboratory of Quality Research in Chinese Medicine Macau University of Science and Technology 澳门科技大学中药质量研究国家重点实验室)**
- **Mr. Ruifeng Zhang 张锐锋 (中健产融科技公司 董事、总经理)**

Global Regulatory Shifts: Hong Kong's CMPR New Era - Strategies for Biopharma

Sept 10 13:00-14:30 | **Theater 3**

Chair 主席

- **Prof. Lo Yuk Lam 卢毓琳教授 (President，HK Bio-Med Innotech Association 香港生物医药创新协会会长)**

Speakers 演讲人

- **Mr. Lot Chan 陈诗涛先生 (Assistant Director (Preparatory Office for Centre of Medical Products Regulation), Department of Health, the Government of HKSAR 助理署长(药物及医疗器械监督管理中心筹备办公室), 香港特别行政区政府卫生署) - CMPR: Future of Hong Kong's Medical Products Regulation**

Panelists 小组成员

- **Mr. Lot Chan 陈诗涛先生 (Assistant Director, Preparatory Office for Centre of Medical Products Regulation, Department of Health, the Government of HKSAR 药物及医疗器械监督管理中心筹备办公室助理署长, 香港特别行政区政府卫生署)**
- **Dr. Yaning Wang 王亚宁博士 (Founder&CEO，Rui Ning Kang Pharma 瑞宁康生物医药创始人兼CEO)**
- **Ms. Hua Cai 蔡华女士 (General Manager ，CITIC Medical Fund 中信医疗基金总经理)**
- **Dr. Ben Zhao 赵孝斌博士 (Founder & President Haichang Biotech 海昶生物创始人兼总裁)**
- **Mr. Dawei Li 李大伟先生 (Innovative Institute of Basic Medical Sciences of Zhejiang University 浙江大学基础医学创新研究院副院长)**

**This is an September 6th version schedule, subject to change.*

AI Sub-Forum: Advancing Towards Superintelligence in Pharmaceuticals (Insilico Medicine Session)

Sept 10 13:00-18:00 | **Theater 1**

Opening Speech 开场致辞

Ms. Clara Chan 陈家齐女士 (CEO, Hong Kong Investment Corporation Limited 香港投资管理有限公司行政总裁) - Hong Kong's Biomedicine Innovation Era: Policies, Platforms, and Future Ecosystem 香港生物医药创新时代：政策、平台与未来生态

Prof. Albert Yu 于常海教授 (Chairman, Hong Kong Biotechnology Organization 香港生物科技协会主席)

Mr. Guoying Cao 曹国英先生 (Former First-level Inspector, Deputy Director-General, Department of High Technology & Industrialize, Ministry of Science an Technology 中国科技部资源配置与管理司原副司长)

Fireside Chat-Building AI Driven Biopharmaceutical Ecosystem 围炉对话-打造AI驱动的生物医药生态圈

Moderator 主持

Dr. Richard Stone (Senior International Correspondent, Science Magazine 《科学》杂志高级记者)

Panelists 小组成员

Dr. Alex Zhavoronkov (CEO, Insilico Medicine 英矽智能CEO)

Dr. Feng Ren 任峰博士 (Co-CEO and CSO, Insilico Medicine 英矽智能联合首席执行官)

Roundtable-Accelerating Drug R&D and Innovation Practices with AI 圆桌论坛-人工智能加速药物研发与创新实践

Moderator 主持

Ms. Carmen Sze (Senior Director, Hong Kong Investment Corporation 香港投资管理有限公司高级总监)

Panelists 小组成员

Dr. Feng Ren 任峰博士 (Co-CEO and CSO, Insilico Medicine 英矽智能联合首席执行官)

Dr. Xiang Li 李翔博士 (Chief Scientific Officer, Innovative Medicines Division; Co-President, Global Research and Development Centre, Fosun Pharma 复星医药创新药物事业部CSO、全球研发中心联席总裁)

Dr. Houjiang Zhou 周厚江博士 (Deputy General Manager of the R&D Centre and Head of the Innovative Drug Research Institute, Hisun Pharma 海正药业研发中心副总经理兼创新药研究院院长)

Mr. Xin Xie 谢炘先生 (Executive Director & Vice President, Sino Pharma 中国生物制药执行董事&副总裁)

Dr. Hua Zhang 张骅博士 (Vice President & Chief Scientific Officer, SPH BIOTHERAPEUTICS LIMITED 上海医药集团生物治疗技术有限公司副总经理&首席科学家)

Roundtable-Trend Analysis of AI Empowering Bio Pharmaceutical: Capital Flows and Industry Prosperity 圆桌论坛-人工智能赋能生物医药的趋势研判：资本流向和产业繁荣

Moderator 主持

Ms. Amber Tong (Senior reporter, Bloomberg 彭博财经资深记者)

Panelists 小组成员

Mr. Joshua Chang (Deal captain & Director, Hong Kong Investment Corporation 香港投资管理有限公司交易负责人&总监)

Dr. Chuen Yan Leung 梁传昕博士 (Vice President, Hong Kong Biotechnology Organization 香港生物科技协会副主席)

Mr. Ming Yang 杨明先生 (Chief Economist, Pudong Development Group & Pudong construction 浦发集团首席经济师)

Mr. Leo SHI 施珑先生 (Managing Director, Warburg Pincus 华平资本董事总经理&医药团队负责人)

Mr. Scott Cai 蔡翔先生 (Managing Director, Prosperity7VC 董事总经理)

**This is an September 6th version schedule, subject to change.*

Hong Kong's Biotech Ecosystem: Advantages, Policies, and Collaborative Opportunities

Sept 10 13:00-14:00 | **Theater 2**

Speakers 演讲人

- **Dr. Stella Sun 孙泳芬博士 [Principal Manager, Life & Health Sciences, InvestHK 香港投资推广署首席经理(生命与健康科学)] - Topic TBC 题目待定**
- **Ms. Angela Chan 陈嘉慧女士 [Senior Manager(Hong Kong Talent Engage) Business Partnership, Labour and Welfare Bureau 劳工及福利局高级经理 (香港人才服务办公室) 业务伙伴] - Topic TBC 题目待定**
- **Dr. Weng Li Yoon 袁永丽博士 [Associate Director (Therapeutics, Life and Health Technology), Hong Kong Science and Technology Parks Corporation 香港科技园公司转化研发所医药与治疗副总监] - Topic TBC 题目待定**

The Hong Kong Experiment: All the Ingredients for a Biotech Hub, Awaiting the Master Chef

Sept 10 14:00-15:00 | **Theater 2**

Moderator 主持

- **Dr. Charles Hu 胡正忠博士 (Founder & CEO of Ryoden Medical Holdings Ltd 菱电医疗创始人&CEO)**
- **Ms. Josephine Wu (Founder &CIO，Aionious Capital Management)**

Panelists 小组成员

- **Prof. Tim Hirst (Chairman & CEO of GPN Vaccines Ltd)**
- **Dr. Ricky Chiu 招彦熹博士 (CEO, PHASE Scientific 相达生命科技首席执行官)**
- **Dr. Bettina Ernest (Director ，Bernia Bioinvest/Vice President, Swiss Biotech Association)**
- **Dr. Anna Plater-Zyberk (Head of International Affairs 波兰科学院国际事务部主任)***

**This is an September 6th version schedule, subject to change.*

The AI + Pandemic Defense Forum

Sept 10 15:00-18:00 | **Theater 2**

Sub-Forum Co-Organized by Chinese Society of Biotechnology 中国生物工程学会合办分论坛

Opening Speech 开场致辞

Prof. George Fu Gao 高福院士 (Academician，Chinese Center For Disease Control And Prevention 中国疾病预防控制中心)

Chairman 主席

Prof. Jinghua Cao 曹京华教授 (中国生物工程学会国际合作委员会主任)

Speakers 演讲人

Prof. Guanghui Ma 马光辉院士 (Academician of Chinese Academy of Sciences, Institute of Process Engineering, Chinese Academy of Sciences 中国科学院过程工程研究所) -Biodegradable Transformable Micro-Nano Particles: Design and Application in Biochemical and Biomedical Engineering 生物可降解可变构纳微颗粒：设计制备及其在生化工程和医药工程中的应用

Dr. Gabriel da Luz Wallau (Instituto Aggeu Magalhães (IAM) - Fundação Oswaldo Cruz (Fiocruz), 巴西奥斯瓦尔多·克鲁兹基金会) - Uncovering the Untapped Animal Virome of Brazil's Threatened Biodiversity-Rich Biomes to Strengthen Epidemic Prevention and Control

Dr. Daxi Wang 王达希博士 (Head of Infection Omics Research Center, BGI Research) - Driving Advances in Infectious Disease Research: From Detection to Interaction Via Multi-omics Integration

Prof. Yi Shi 施一教授 (Guangzhou National Laboratory 广州国家实验室) - Development of Broad-spectrum Antiviral Countermeasures Against Emerging Coronaviruses

Prof. Zhou Tong 仝舟教授 (Institute of Microbiology，CAS 中国科学院微生物研究所) - I Beyond Conventional Antibody Development: Addressing Rapid Mutation Challenges in SARS-CoV-2 with New Strategic Frameworks

Prof. Jie Zhou 周婕教授 (Department of Microbiology, The University of Hong Kong 香港大学微生物学系) - Respiratory Organoids: A Robust Preclinical Platform for Evaluating Infectivity and Developing Therapeutics Against Respiratory Viruses

Roundtable-Governing Pandemic Resilience: Intelligent Systems for Global Health Security 圆桌论坛-下一场疫情：探索后疫情时代的全球影响，通过智慧构建韧性

Moderator 主持

Prof. Yi Shi 施一 (Guangzhou Laboratory 广州国家实验室)

Panelists 小组人员

Prof. George Fu Gao 高福院士 (Academician，Chinese Center for Disease Control and Prevention 中国疾病预防控制中心)

Prof. Guanghui Ma 马光辉院士 (Academician of Chinese Academy of Sciences, Institute of Process Engineering, Chinese Academy of Sciences 中国科学院过程工程研究所)

Dr. Hui Li 李慧博士（CEO & Co-Founder, Caike 彩科生物CEO）

**This is an September 6th version schedule, subject to change.*

A New Era in Stem Cells & Cell Therapy

Sept 10 13:00-16:30 | **Theater 4**

Co-Chair 主席

Dr. Gina Jiang 江宜蓁医生 (Managing Director, Hong Kong Institute of Biotechnology 香港生物技术研究院院长)

Prof. Howard Yuanyuan Shi 史渊源教授 (Chairman, Shenzhen Cell Valley Biopharmaceuticals 深圳细胞谷生物医药有限公司董事长)

Speakers 演讲人

Prof. Paul Tam 谭广亨教授 (Vice President& Chair Professor, Macau University of Science and Technology 澳门科技大学副校长 & 讲座教授) -Regenerative Medicine for Liver Diseases 再生医学在肝脏疾病中的应用

Prof. Duanqing Pei 裴端卿教授 (Chair Professor of Regenerative Biology at School of Life Sciences, Westlake University 西湖大学讲席教授) - Applications of Stem Cell-Derived Cardiac Organoids in Drug Screening and Myocardial Infarction Repair

Prof. Chi-Kong Li 李志光教授 (Department of Paediatrics, The Chinese University of Hong Kong 香港中文大学儿科学系) - Point-of-Care Manufacturing of CAR-T Cells for Treatment of Blood Cancers

Prof. Rocky S. Tuan 段崇智教授 (Former Vice-Chancellor and President, The Chinese University of Hong Kong 香港中文大学前校长) - Human Stem Cell-Based Articular Tissue Engineering: From Joint Regeneration to Joint-on-a-Chip (MiniJoint)

Prof. Hung-Fat Tse 谢鸿发教授 (Department Chairperson, Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong 香港大学内科学系主任) -Therapeutic Application of Mesenchymal Stem Cells Derived from Pluripotent Stem Cells

Prof. Kam Tong Leung 梁錦堂教授 (Department of Paediatrics, The Chinese University of Hong Kong 香港中文大学儿科学系) - Addressing the unmet needs of CAR T therapy in blood cancers through a new angle 以嶄新角度应对CAR T細胞治疗于血液肿瘤中的临床需求

Prof. Stephen Dalton (The Chinese University of Hong Kong 香港中文大学) - Human Pluripotent Stem Cells and Organoids as Platforms for Therapeutic Development

Prof. Guangjin Pan 潘光锦教授 (Director - Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences 中国科学院香港创新研究院再生医学与健康创新中心主任) - Generation of Therapeutic Blood / Immune Cells from Human Induced Pluripotent Stem Cells

Dr. Haifeng Chen 陈海峰博士 (Chairman/Chief Technology Officer, AAVivo, Inc. AAVivo 股份有限公司董事長，首席技术官) - PACE: A Breakthrough AAV Capsid Engineering Platform Enabling in Vivo CAR-T Therapy and Precision Gene Delivery
PACE：推动体内CAR-T疗法与精准基因治疗的开创性AAV壳体工程技术平台

Prof. Jie Ma 马洁教授 (Head of National Center for Clinical Laboratories and Biotherapy Center at Beijing Hospital 北京医院国家卫生健康委临床检验中心及生物治疗中心主任) - Cell Therapy Boosts the Advancement of Nanomedicine 细胞治疗助力纳米医学发展

PROGRAM
DAY 2
Thursday September 11

**This is an September 6th version schedule, subject to change.*

08:30 **EVENT REGISTRATION 注册**

MAIN THEATER

09:00 - 09:30

OPENING CEREMONY of Biotechnology Investment Forum 生物科技投资峰会开幕式
Mr. Paul Chan 陈茂波先生(Hong Kong Financial Secretary 香港财政司司长)-Opening Speech 开幕致辞

09:30 - 11:30

Commercialization of Advanced Therapies in the West - Lessons for the East
KEYNOTE SESSION - Mr. Anthony Davies Founder of Dark Horse Consulting
大会报告 - Mr. Anthony Davies Dark Horse Consulting创始人

Surgical Robotics of Multiscale: From Innovation to Clinical Applications
KEYNOTE SESSION - Prof. Philip CHIU Wai-yan Dean, Faculty of Medicine, The Chinese University of Hong Kong
大会报告 - 赵伟仁教授 香港中文大学医学院院长

The Approaching Singularity: Emergence of Silicon-Based Intelligence and Prospect of Carbon-Based Near-Immortality
KEYNOTE SESSION - Dr. Ye Yin BGI Group CEO
大会报告 - 尹烨博士 华大集团首席执行官

A Novel STAT3 Inhibitor for Head and Neck Cancer
KEYNOTE SESSION - Prof. Jennifer Rubin Grandis Associate Vice Chancellor for Clinical and Translational Research, UCSF
大会报告 - Prof. Jennifer Rubin Grandis 加州大学旧金山分校临床与转化研究副校长

Synthetic Biology Empowers the Modernization of Traditional Chinese Medicine 合成生物学赋能中医药现代化
KEYNOTE SESSION - Prof. Guoping Zhao Academician，Chinese Academy of Sciences，The World Academy of Sciences，Fellow of the American Academy of Microbiology
大会报告 - 赵国屏教授 中国科学院院士，发展中国家科学院院士，美国微生物科学院院

Pioneering Stem Cell Commercialization: Journey in Advancing IPSC-based Myocardial Cell Patch Therapy and Startup Growth
KEYNOTE DIALOGUE - Ambassador George Hara Group chairman & CEO, DEFTA Partners 原丈人大使 DEFTA Partners 集团主席兼首席执行官
Mr. Takayuki Kusanagi CEO of CUORiPS Takayuki Kusanagi先生 CUORiPS首席执行官

	MAIN STAGE	THEATER 1	THEATER 2	THEATER 3	THEATER 4
09:30 - 11:30	KEYNOTE SESSION & DIALOGUE	Biotechnology Investment Forum 生物科技投资峰会 *Detailed agenda on P22，详细日程见P22	AI + Traditional Eastern Health Sciences AI + 传统东方保健科学：天然健康品安全与品质保证高峰论坛 *Detailed agenda on P24，详细日程见P24	Frontiers in Cell and Gene Therapy 细胞基因治疗前沿 *Detailed agenda on P27，详细日程见P27	Data Infrastructure with AI Shaping Life Sciences (Sponsored by Shuimu Bio) AI赋能生命科学的数据基础设施建设 (水木未来冠名专场) *Detailed agenda on P29，详细日程见P29
11:30 - 12:30	Innovative Drugs Forum I 创新药论坛 I:创新药的全球合作与未来 *Detailed agenda on P21，详细日程见P21				
11:30 - 12:30		Pudong Development Group Presents: Biotech Industrial Policy & Investment Forum 浦发生物科技产业项目政策推介			

LUNCH BREAK 午休

14:00 - 15:00	Prevention Forum: Building Prevention-based Healthcare *Detailed agenda on P26，详细日程见P26	Biotechnology Investment Forum 生物科技投资峰会	创新医疗器械 (体外诊断) 规管与发展 The Policy, Development, and Opportunities of Innovative Medical Devices (IVD) *Detailed agenda on P25，详细日程见P25	Mesenchymal Stromal Cell Seminar: New Business Opportunities under Japan-Hong Kong Collaboration 间充质干细胞研讨会：日港合作下的新机会 *Detailed agenda on P28，详细日程见P28	Office of Canton Investment Development Commission Event 广州投发委活动
15:00 - 15:15	Miskawaan Health Group Event *Detailed agenda on P23，详细日程见P23	Chuanhua Presents：Biotech Industrial Policy & Investment Forum 传化生物科技产业项目政策推介			
15:15 - 16:00		Biotechnology Investment Forum 生物科技投资峰会 ——IPO Company Roadshow 递表公司路演 *Detailed agenda on P23，详细日程见P23			
16:00 - 18:00	Innovative Drugs Forum II：CGT 创新药论坛 II：CGT产业突围 *Detailed agenda on P21，详细日程见P21		FDA Reform and Global Pharmaceutical Regulations FDA的改革与全球药政法规 *Detailed agenda on P26，详细日程见P26		AI-Driven Breakthroughs in Life Sciences 人工智能在生命科学的创新突破 *Detailed agenda on P30，详细日程见P30

**This is an September 6th version schedule, subject to change.*

Innovative Drugs Forum I

Sept 11 11:30-13:00 | **Main Theater**

Opening Speech 开场致辞

Prof. Rocky S. Tuan 段崇智教授 (Former Vice-Chancellor and President, The Chinese University of Hong Kong 香港中文大学前校长)

Speakers 演讲人

Prof. Aimin Hui 回爱民教授 (Chairman & CEO, Encuregenpharma 惠正奇医药董事长兼CEO) - mRNA Medicine: The Paradigm Shift from Covid-19 to Oncology

Dr. Juan Valencia S. (Senior Product Marketing Manager， PharmCube 医药魔方高级产品营销经理) - China's Innovative Pharma Industry: A Decade of Transformation & Rise to Leadership 中国创新医药产业：转型与崛起的十年

Mr. Xin Xie 谢炘先生 (Executive Director and Senior Vice President, Sino Biopharmaceutical 中国生物制药执行董事、资深副总裁) - Collaboration for Innovation 以合作推动创新

Prof. Ao Zhang 张翱教授 (Dean，School of Pharmacy, Shanghai Jiao Tong University上海交通大学药学院院长) - Research on Targeted KRAS Drugs: Progress and Prospects 靶向KRAS药物研究：进展及展望

Innovative Drugs Forum II：CGT

Sept 11 16:00-18:00 | **Main Theater**

Speakers 演讲人

Mr. Chunlai Cao 曹春来先生 (Manager，United Biotechnology 联邦生物总经理) - Introduction to Weight Loss Drugs Developed Based on Gastrointestinal Hormones 基于肠胃道激素开发的减重药物介绍

Dr. Nancy Chou 周蕾博士 (Head of South China Region, SpeedGL 腾翼搏时华南区负责人) - Introuduction of Temperature Controlled Transportation

Dr. Xiaohu Fan 范晓虎博士 (Founder & CEO, Wondercel Therapeutics 湾岛细胞创始人、CEO) - Commercial Competition and Market Positioning of Next-generation Universal CAR-T Technology 下一代通用型CAR-T技术的商业化竞争与市场定位

Dr. James Wang 王永增博士 (CTO，Heyuan Biotechnology,合源生物 CTO) - Bottlenecks and Solutions of CAR-T Therapy Manufacturing Process CAR-T细胞治疗的产业化瓶颈与解决方案

Prof. Hao Shen 沈浩教授 (CEO，Biosyngen百吉生物 CEO) - Engineered Immune Cell Therapyfor Solid Tumor -the Next Frontier 实体瘤的工程免疫细胞疗法——下一个前沿

Dr. Grace Guoying Zhou 周国瑛博士 (ImmVira Bioscience Inc. CEO/Chairperson 亦诺微医药 首席执行官及董事长) - How Extracellular Vesicles Achieve Value Creation 外泌体如何实现价值创造

*This is an September 6th version schedule, subject to change.

Biotechnology Investment Forum

Sept 11 09:30-12:30 | **Theater 1**

Biotech Leader Forum: A Dialogue with Global Leaders on the Future of Biopharma
生物科技领袖论坛：全球领袖对话生物医药的未来

Moderator 主持

- Mr. Xin Zhou (Technology editor, South China Morning Post)

Panelists 小组人员

- Mr. Ming Tang (CEO, YNBY International Limited)
- Mr. Chao Zhou (CEO, Grand Pharmaceutical Group)
- Mr. Bo Chen (CSO, China Resources Pharmaceutical Group Limited)
- Mr. Song Huang (Co-founder, Huahui Health Ltd.)
- Mr. Gongxin He (CEO, Shanghai CureGene Pharmaceutical Co., Ltd.)

Roundtable - Global Trends and Investment Patterns in the Biotechnology Industry
圆桌论坛 - 全球生物科技产业发展趋势与投资格局

Moderator 主持

- Dr. Chuen Yan Leung (Vice President, HKBIO)

Panelists 小组人员

- Prof. Alireza Haghighi (Chief Executive and Director, Harvard Medical School International Center for Genetic Disease)
- Dr. Rose Ritts (Managing Partner, BOSS Group)
- Dr. Laurent Metz (Partner，Robin Hood Ventures)
- Mr. Tim Hirst (Chairman and CEO, GPN Vaccines)
- Ms. Cynthia Chen (Chairlady, Pulnovo Medical Ltd.)

Roundtable - Track Selection and Portfolio Construction of Long - Term Capital Investment in Biotechnology
圆桌论坛 - 长期资本的生物科技投资的赛道选择与组合构建

Moderator 主持

- Mr. Andrew Ng 伍兆威先生 (Partner & Head of Healthcare, VMS Group，VMS集团合伙人兼医疗健康主管)

Panelists 小组人员

- Mr. Qingming Yu 于清明先生 (Director, China National Pharmaceutical Investment Co., Ltd., 中国医药投资有限公司董事)
- Ms. Hua Cai 蔡华女士 (General Manager, CITIC Medical Fund 中信医疗基金总经理)
- Mr. George Li 李喆 (Managing Partner, Proxima Ventures 比邻星投资创始人)
- Mr. Yi Wang 王一先生 (Partner, Legend Star 北京联想之星投资管理有限公司合伙人)
- Mr. Pandy Song 宋高广先生 (Partner，Northern Light Venture Capital 北极光创投合伙人)

**This is an September 6th version schedule, subject to change.*

Biotechnology Investment Forum

Sept 11 13:00-18:00 | **Theater 1**

Roundtable - International Opportunities and Development of Biotechnology Hong Kong Stocks
圆桌论坛 - 生物科技港股的国际机遇与发展

Moderator 主持

Dr. Chuen Yan Leung (Vice President, HKBIO)

Panelists 小组人员

Mr. Johnson Chui 徐经纬先生 (Managing Director，HKEX 香港交易所董事总经理)
Mr. Shawn Lee 李湘先生 (Co-Founder, Medtide Inc.泰德医药联合创始人)
Ms. Fan Jiang 姜帆女士 (Vice President & CFO，Innogen Pharmaceutical 广州银诺医药集团股份有限公司副总裁&CFO)
Mr. David Lau (Managing Director, J.P. Morgan)

IPO Company Roadshow 递表公司路演

Moderator 主持

Mr. Da Liu 柳达先生 (Managing Director, CR CP Life Science Fund 华润正大生命科学基金董事总经理)

Speakers 演讲人

Mr. Carl Yeung 杨家康先生 (CFO，Immvira Bioscience Inc. 亦诺微医药首席财务官)

Dr. Chenbing Wu 吴辰冰博士 (Founder and CEO，EpimAb Biotherapeutics Inc. 岸迈生物科技有限公司创始人兼CEO)

Dr. Chenghai Zhang 张成海博士 (CEO，Hunan Mabgeek Biotech Co., Ltd. 湖南麦济生物技术股份有限公司 CEO)

Dr. Ziping Wei 魏紫萍博士 (Co-founder, Chairman, CEO，BlissBio Inc. 百力司康生物医药有限公司 联合创始人、董事长、首席执行官)

Dr. Darren Ji 纪晓辉博士 (Co-Founder, Chairman & CEO，Elpiscience Biopharmaceuticals, Inc. 科望医药联合创始人、董事长、CEO)

Miskawaan Health Group Event

Sept 11 15:00-16:00 | **Main Theater**

Mr. David Boehm (CEO & Founder, Miskawaan Health Group) - Cross-Border Investment and Cooperation Strategies for Biotechnology Enterprises

Mr. Niccole Santi (CEO，OROJIN Miskawaan Health Group) -Investment and Incubation of Biotechnology Projects

**This is an September 6th version schedule, subject to change.*

AI + Traditional Eastern Health Sciences

Sept 11 09:30-13:00 | **Theater 2**

Keynotes

Mr. Siddharth Chatterjee (UN Resident Coordinator in China，联合国驻华大使) - Optimal Breathing as Self-Therapy to Enhance Health as Witnessed by Personal Experience of a Busy Senior Executive of International Organisation 恰当呼吸作为启发身体自我疗法，国际组织高管的亲身经验

Prof. Yike Guo 郭毅可教授 (Provost & 1st VP Hong Kong University of Science Technology 香港科技大学首席副校长) - Impact of AI on Future Bio & West-East Life-Science 人工智慧对于未来生物科技和东、西方生命科学发展的影响

Prof. Albert-László Barabási (Northeastern University，Associate Professor HARVARD UNIVERSITY, 哈佛大学副教授) - *Impact of NEJM 2025* "Food is Medicine" & Nutritional Dark Matters (NDM) Database on the Future Health Industry- 2025 新英格兰医学杂志: “食物即良药”与营养暗物质（NDM）数据库-未来健康产业展望

Mr. Tamas Hajba (Senior Advisor, Global Relations Secretariat OECD 高级顾问，经合组织全球关系秘书处) - The Adoption of Digitization & AI on the Safety & Quality Supply of Global Health Goods 数字化与人工智能在全球健康产品安全与质量保障中的应用

Prof. Yibin Feng 冯奕斌教授 (Co-Director of the HKUMed Centre of Integrative Medicine & Director of School of Chinese Medicine, The University of Hong Kong 香港大学中医药学院院长) - Traditional Chinese Medicine, AI ，Health & Wellness 中医药、AI与大健康

Prof. Dejian Huang, 黄德建教授 (Deputy Head, Food Science & Technology, National University Singapore NUS; Bezos Centre for Sustainable Protein 新加坡国立大学食品科学与工程系副主任、佐治贝斯蛋白可持续中心主任研究员) - Latest Technologies in Natural Health Products: Singapore’s Research & Achievement 天然保健品的最新技术：新加坡的研究与成就

Mr. Martin Taylor (WHO-Director of Digital Health 世界卫生组织数字健康司司长) - Topic TBC 题目待定

Roundtable 1: Empowering the Longevity Capital: How Hong Kong Leverages AI and Innovation to Share a New Global Health Experience
圆桌论坛 1：科技赋能长寿之都：香港如何以AI与创新引领全球健康生活新体验

Moderator 主持

D.J. Clark (Executive Director of Multimedia, CHINA DAILY Asia Pacific 多媒体执行总监，《中国日报》亚太区)

Ms. Amelia Lo Esq 卢彦桦律师 (Master of Public Health, Harvard University Co-Founder of HK Centre for Longevity, Wellness and AI Foundation 哈佛大学公共卫生硕士 香港长寿, 健康快乐及智能科技基金会联合始创人)

Panelists 小组人员

Prof. Yike Guo 郭毅可教授 (Provost & 1st VP Hong Kong University of Science Technology 香港科技大学首席副校长)

Mr. Hui Tian 田晖先生 (CEO & Founder, Axbio International Limited 安序源科技CEO 创始人)

Dr. Walter Greenleaf (Former Director of Mind Division, Stanford Centre on Longevity 前斯坦福长寿研究中心主任)

Senior Representative from Insurance Companies (TBC)

Dr. Bill Liang 梁文青博士 (Chairman & CEO, CF PharmTech 长风药业董事长&CEO)

Dr. Chunyuan CHIANG 蒋忠远医生 (Vice-Chair CCG Centre for China & Globalisation Director of Anti-Inflammation Professional Committee CCG 全球化智库香港委员会副主席, 香港生物科技协会抗炎专业委员会主任)

This is an September 6th version schedule, subject to change.

Roundtable 2: Analysis & Selection Criteria for Listed Healthcare Stocks
圆桌论坛 2：主要国际投行专家对于大健康板块的选择和分析

Panelists 小组人员

- Chief Investment Officer, UBS
- Chief Equity Strategist, J.P. Morgan
- China International Capital Corporation (CICC) Capital
- CCB International
- Chairman, Hong Kong Institute of International Finance
- Financial Media Representative

The Policy, Development, and Opportunities of Innovative Medical Devices (IVD)

Sept 11 14:00-16:00 | **Theater 2**

Chair 主席

- Dr. Desmond Hau 侯国宝博士 (CEO, Pangenia 新亚生物科技有限公司行政总裁)

Speakers 演讲人

- Mr. Ir Lam Kam Chun, Tommy 林鑫骏工程师 (Senior Electronics Engineer (Medical Device) 1, Department of Health卫生署医疗器械科) - Medical Device Administrative Control System in Hong Kong and its Development - 医疗器械行政管理制度介绍
- Dr. You Li 李游博士 (President, CBA 美国华人医药生物科技协会主席) - Overview of FDA Medical Device Regulation 美国FDA医疗器械法规监管
- Dr. Alex Chan 郑有志博士 (Senior Accreditation Officer, Hong Kong Accreditation Service Innovation and Technology Commission 创新科技署香港认可处高级认可主任) - HKAS Accreditation for Medical Testing 香港认可处 医务化验认可服务

Roundtable - The Policy, Development, and Opportunities of In Vitro Diagnostics (IVD) and Testing Industry 圆桌论坛 - IVD医疗器械及检验行业的创新发展与监管

- Dr. Desmond Hau 侯国宝博士 (CEO, Pangenia 新亚生物科技有限公司行政总裁)
- Mr. Qingming Yu 于清明先生 (Director, Sinopharm Group Co., Ltd. 中国医药投资有限公司董事)
- Dr. You Li 李游博士 (President, CBA 美国华人医药生物科技协会主席)
- Dr. Albert Liu 刘星博士 (Hong Kong, Macao and Taiwan General Manager , BGI 华大港澳台总经理)
- Dr. Gergely Tóth (CEO, CSO and Founder of Cantabio Pharmaceuticals)

**This is an September 6th version schedule, subject to change.*

FDA Reform and Global Pharmaceutical Regulations

Sept 11 16:00-18:00 | **Theater 2**

Sub-Forum Co-Organized by CBA 美国华人医药生物科技协会合办分论坛

Chair 主席

Dr. Angela Yuxin Men 门宇欣博士 (CMO, Haichang Biotech 海昶生物首席医学官)

Speakers 演讲人

Dr. Yaning Wang 王亚宁博士 (Founder & CEO, Rui Ning Kang Pharma 瑞宁康生物医药创始人兼首席执行官) - Impact of FDA's New Leadership on New Drug Approval

Dr. Hang Lu 陆航博士 (Founder & CEO, NextTranslate Biopharmaceutical 嘉译生物医药创始人及首席执行官) - Harmonization of Vaccine Safety & Quality Standards: an Industry Perspective

Dr. Xin Du 杜新博士 (CEO, Evergreen Therapeutics, CEO埃格林医药 首席执行官) -Harmonization of Global Pharmaceutical Quality Standards

Roundtable - Enhancing Regulatory Cooperation Between China, HK & the USA

Panelists 小组成员

Dr. Angela Yuxin Men 门宇欣博士 (CMO, Haichang Biotech 海昶生物首席医学官)

Dr. You Li 李游博士 (President, CBA 美国华人医药生物科技协会主席)

Dr. Yaning Wang 王亚宁博士 (Founder & CEO, Rui Ning Kang Pharma 瑞宁康生物医药创始人兼首席执行官)

Dr. Ben Zhao 赵孝斌博士 (Chairman, CEO of Zhejiang Haichang Biotech Co., Ltd. 海昶生物董事长)

Dr. Hang Lu 陆航博士 (Founder & CEO, NextTranslate Biopharmaceutical 嘉译生物医药创始人及首席执行官)

Dr. Xin Du 杜新博士 (CEO, Evergreen Therapeutics, CEO埃格林医药 首席执行官)

Prevention Forum: Building Prevention-based Healthcare

Sept 11 14:00-15:00 | **Main Theater**

Speakers 演讲人

Prof. Yu Wang 王宇教授 (Chairman, Chinese Foundation for Hepatitis Prevention and Control 中国肝炎防治基金会理事长) - Topic TBC 题目待定

Prof. Lai Koon Chi Christopher 賴贯之教授 (President, Hong Kong Society for Microbiology and Infection; Department of Microblology, Facuity of Medlcine, Chinese University of Hong Kong 香港微生物及传染病学会主席,香港中文大学医学院微生物系) - Topic TBC 题目待定

Mr. Nicholas Teo 张泽峰先生 (General Manager, GSK Hong Kong & Macau , GSK港澳总经理) - Topic TBC 题目待定

**This is an September 6th version schedule, subject to change.*

Frontiers in Cell and Gene Therapy

Sept 11 09:30-13:00

Theater 3

Co-Chair 主席

Prof. Jianguo Chen 陈建国教授 (School of Life Sciences, Peking University 北京大学生命科学学院)

Dr. Shengjiang Liu 刘胜江博士 (CEO & CSO, Avirmax Inc. 首席执行官 & 首席科学家)

Speakers 演讲人

Dr. Jianxun Wang 王建勋博士 (Chief Scientific Officer, Shenzhen Cell Valley Biopharmaceuticals Co., LTD. 深圳细胞谷生物医药有限公司首席科学家） - Manufacture of CAR-T/CAR-NK Cells Using eVLP-Based Cas9/gRNA RNP Deilvery System

Dr. Shengjiang Liu 刘胜江博士 (CEO & CSO, Avirmax Inc. 首席执行官 & 首席科学家) - Gene Therapy: Unblocking the Potentials of AAV Genetic Medicines for Hundreds of Millions of Patients

Prof. Zongli Zheng 郑宗立教授 (Associate Professor, City University of Hong Kong 香港城市大学生物医学科学系) - Therapeutic in Vivo Genome Editing for TGFBI Corneal Dystrophy 体内基因编辑治疗TGFBI角膜营养不良症

Prof. Gong Chen 陈功教授 (Founder and President, NeuExcell Therapeutics 神曦生物 创始人 董事长) - 大脑原位神经再生技术与临床转化

Dr. Grace Guoying Zhou 周国瑛博士 (ImmVira Bioscience Inc. CEO/Chairperson 亦诺微医药 首席执行官及董事长) - Oncolytic Immunotherapy -Clinical Breakthroughs from Intratumoral to Intravenous and Intravesical Administration

Dr. Sangeeta Bardhan Cook (Chief Innovation Officer, Fox Chase Cancer Center) - Running Your First US CGT Trial: How Asian Innovators Can Accelerate Global Commercialization Through NCI Cancer Center Partnerships

Prof. Yuhong Cao 曹宇虹教授 (National Center for Nanoscience and Technology 国家纳米科学中心) - CircRNA in vivo CAR-T Cell Therapy for Cancer and Autoimmune Diseases

Prof. Alireza Haghighi (Chief Executive and Director, Harvard Medical School International Center for Genetic Disease 哈佛医学院国际遗传疾病中心首席执行官兼董事) - Investing in the Future: AI and Genomics at the Frontier of Life Sciences 投资未来：AI与基因组学在生命科学前沿

*This is an September 6th version schedule, subject to change.

Mesenchymal Stromal Cell Seminar: New Business Opportunities under Japan-Hong Kong Collaboration

Sept 11 14:00-18:00

Theater 3

Opening Speech 开场致辞

Ambassador George Hara 原丈人大使 (Group chairman & CEO, DEFTA Partners DEFTA Partners 集团主席兼首席执行官)

Speakers 演讲人

Prof. Pengtao Liu 刘澎涛教授 (SY and HY Cheng Professor in Stem Cell Biology and Regenerative Medicine，The University of Hong Kong香港大学干细胞生物学及再生医学教授) - Expanded Potential Stem Cells for Fundamental Research and Clinical Applications 扩大潜在干细胞在基础研究和临床的应用

Prof. Wayne Lee 李郁伟教授 (Assistant Professor，The Chinese University of Hong Kong 香港中文大学助理教授) - Advancing MSCs Therapies for Sarcopenia: Challenges and Opportunities from R & D to Production 推进MSCs疗法治疗肌细胞减少症：从研发到生产的挑战与机遇

Prof. Blocki Anna Maria（Associate Professor，The Chinese University of Hong Kong 香港中文大学副教授) - IGFBP7-Mediated Paracrine Effects of MSCs' Insoluble Secretome: A Key Driver of Angiogenesis and Wound Healing IGFBP7介导的MSCs不溶性分泌组旁分泌效应：血管生成和伤口愈合的关键驱动因素

Dr. Lo Hau Yi Paulisally（Senior Scientist, ROHTO Pharmaceutical 乐敦制药高级科学家) - From Culture Medium to Cell Therapy: Rohto's Journey in Mesenchymal Stem Cell R&D 从培养基到细胞治疗：乐敦的间充质干细胞研发之旅

Dr. Abby Gao (Deputy Head & Director of Investment Research, DEFTA Partners Hong Kong DEFTA 香港副主管兼投资研究总监) - Mesenchymal Stromal Cell Technology: From Lab to Market 间充质基质细胞技术：从实验室到市场

Roundtable: Opportunities & Challenges in the New Era of MSCs
圆桌论坛：MSCs新时代的机遇与挑战

Moderator 主持

Dr. Abby Gao (Deputy Head & Director of Investment Research, DEFTA Partners Hong Kong DEFTA 香港副主管兼投资研究总监)

Panelists 小组成员

Prof. Pengtao Liu 刘澎涛教授 [S Y and H Y Cheng Professor in Stem Cell Biology and Regenerative Medicine，The University of Hong Kong 香港大学 S Y and H Y Cheng教授（干细胞生物学及再生医学)]

Prof. Wayne Lee 李郁伟教授 (Assistant Professor ，The Chinese University of Hong Kong 香港中文大学助理教授)

Prof. Blocki Anna Maria（Associate Professor，The Chinese University of Hong Kong 香港中文大学副教授)

Dr. Lo Hau Yi Paulisally（Senior Scientist, ROHTO Pharmaceutical 乐敦制药高级科学家)

*This is an September 6th version schedule, subject to change.

Data Infrastructure with AI Shaping Life Sciences (Sponsored by Shuimu Bio)

Sept 11 09:30-13:00

Theater 4

Opening Speech

Mr. Allen Guo 郭春龙先生 (CEO, ShuimuBio 水木未来首席执行官）- 开场演讲构建AI驱动的数据平台以推动生命科学创新的策略

Keynote Speech 主题演讲

Prof. Jingyi Yu 虞晶怡教授 (Professor, ShanghaiTech University 上海科技大学教授）- 面向药物研发的新兴数据驱动型冷冻电镜流程：从可供人工智能使用的数据资产到基础模型Emerging Data-Driven Cryo-EM Pipelines for Drug Discovery: From AI-Ready Data Assets to Foundation Models

Roundtable 圆桌论坛

Cloud Computing Connects Global Protein Data with Leading Scientific Expertise. The Session will Examine how Shared Data and Computing Platforms, Combined with AI Models, can Drive the Next Generation of Pharmaceutical Innovation. 人工智能与云战略：重塑生命科学创新范式

Panelists 小组成员

Mr. Frank Pun (Head of Hong Kong, Insilico Hong Kong 英硒智能大湾区负责人)

Mr. Ziyao Xu 徐子尧先生(Strategic General Manager, Biomap 百图生科战略总经理)

Mr. Jia Yao 姚加先生 (Senior Specialist, Solid-State R&D, XtalPi 晶泰科技固态研发高级专家)

Mr. Haibin Liu刘海宾先生 (AI Principal Scientist, ShuimuBio 水木未来AI主任科学家)

Company Introduction 公司介绍

Brief Introduction of Shuimu Biosciences, Highlighting the Company's Vision, Achievements, and Contributions to AI-Driven Life Science Innovation 水木未来

Mr. Yangyu Wu 吴杨宇先生 (Chief Scientist, ShuimuBio 水木未来首席科学家）

Roundtable 圆桌论坛

Leaders from Government, Industry, Academia, Research, and Investment will Discuss Strategies for Building AI-Powered Data Platforms to Advance Life Science Innovation
人工智能+智能化冷冻电镜基础设施平台塑造未来生命科学产业

Panelists 小组成员

Prof. Yike Guo 郭毅可首席副校长 (Provost, The Hong Kong University of Science and Technology 香港科技大学首席副校长）

Ms.Pheona Kan (Director, New Ventures, Hong Kong Science Park 香港科学园新创项目总监)

Mr.Alex Wang (Bytedance, 字节跳动架构科学家)

Mr. Allen Guo 郭春龙先生 (CEO, ShuimuBio 水木未来首席执行官）

Mr. Jiangtao Yu (Partner, Gaorong Capital 高榕资本合伙人）

**This is an September 6th version schedule, subject to change.*

AI-Driven Breakthroughs in Life Sciences

Sept 11 16:00-18:00 | **Theater 4**

Sub-forum Co-organized by School of Life Sciences, Tsinghua University
清华大学生命科学学院合办分论坛

Chair 主席

Dr. Christine Huang 黄园博士 (Vice President, HKBIO, HK Longevity Medical Center 香港生物科技协会副主席)

Speakers 演讲人

Dr. Qiangfeng Zhang 张强锋博士 (School of Life Sciences, Tsinghua University 清华大学生命科学学院) - Deciphering of Cell-Cell Interactions and Integrative Tissue Comparison in Spatial Omics

Dr. Tong Wang 王童博士 (School of Life Sciences, Tsinghua University清华大学生命科学学院) - The Coming Age of AI Driven Biomolecular Dynamics Simulation

Dr. Zhengdan Zhu 朱正诞博士 (Co-president of the Drug Discovery Department, DP Technology 深势科技药物发现事业部联席总裁) - Intelligent R&D Framework and Applications in Life Sciences

Dr. Xuerui Yang 杨雪瑞博士 (School of Life Sciences, Tsinghua University 清华大学生命科学学院) - Dissection of the Context-Dependent RNA Colocalization landscapes with Subcellular Spatial Transcriptome Data

Dr. Yu Rong 荣钰博士 (Senior Staff Algorithm Engineer, Alibaba DAMO Academy 阿里达摩院) - Applications of Multimodal AI in Life Science and Healthcare

Mr. Wallace Wong 王晓东先生 (Vice Chairman of Digital Primary Healthcare Sub-Committee of Hong Kong Biotechnology Organization 香港生物科技协会数字化基础医疗健康分会副理事长) - AIoT居家健康开启智慧健康新纪元

PROGRAM
DAY 3
Friday September 12

**This is an September 6th version schedule, subject to change.*

08:30 — EVENT REGISTRATION 注册

MAIN THEATER

09:00 - 10:00

Biotechnological Advances that Accelerate Clinical Trial Development
KEYNOTE SESSION - Prof. Chak-sing Lau Vice-President & Pro-Vice-Chancellor (Health)，Dean of Medicine，The University of Hong Kong
大会报告 - 刘泽星教授 香港大学副校长(健康)、医学院院长

AI In Precision Medicine
KEYNOTE SESSION - Prof. Raju Kucherlapti Paul C. Cabot Professor of Genetics, Harvard University
大会报告 - Prof. Raju Kucherlapti 哈佛大学

	MAIN STAGE	THEATER 1	THEATER 2	THEATER 3	THEATER 4
09:00 -09:30	Keynote Session	Challenge Works - NESTA			
09:30 -10:00		Pitching 项目路演专场	Innovative in Vitro Diagnostics and Laboratory Medicine IVD创新诊断论坛 *Detailed agenda on P35，详细日程见P35		Neuropharmacology Forum: Where Neuropharmacology Meets Biotechnology 神经药理与转化论坛 *Detailed agenda on P36，详细日程见P36
10:00 - 12:00	Innovative Drugs Forum III：Development of Next-Generation Anti-Tumor and Self-Immune New Drugs 创新药论坛 III：下一代抗肿瘤与自免新药开发 *Detailed agenda on P32，详细日程见P32				
12:00 - 13:00		Biotech Finland Forum 生物科技芬兰论坛			

LUNCH BREAK 午休

14:00 - 15:00					Brain-Computer Interfaces Frontier: Reshaping Senses and Thought 脑机接口：重塑感官与思想的未来 *Detailed agenda on P35，详细日程见P35
15:00 - 17:00	Innovative Drugs Forum IV：Frontiers in Biotechnology and Global Development of Innovative Drugs 创新药论坛 IV：创新药新范式与创新产业链构建 *Detailed agenda on P33，详细日程见P33	Biotechnology Investment Forum 生物科技投资峰会 *Detailed agenda on P34，详细日程见P34	Frontiers in RNA Research RNA研究前沿进展 *Detailed agenda on P32，详细日程见P32		Science Café in China 《科学》杂志咖啡沙龙（BIOHK特别专场） Degenerative Neurological Diseases Frontier 退行性神经系统疾病前沿 *Detailed agenda on P37，详细日程见P37
17:00 - 18:00			Hong Kong Jiangmen General Chamber of Commerce 香港江门总商会活动		

Innovative Drugs Forum III：Development of Next-Generation Anti-Tumor and Self-Immune New Drugs

Sept 12 10:00-13:00 | **Main Theater**

Speakers 演讲人

- **Dr. Alex Huang 黄士铭 (Global VP and Head of Cell Therapy, BeOne Medicines 百济神州副总裁兼细胞治疗研发中心负责人)** - Advancing Innovative Platforms for Breakthrough Therapeutics
- **Prof. Han Chong Toh 杜汉忠教授 (Deputy CEO, National Cancer Centre Singapore 新加坡国家癌症中心副首席执行官)** - Immunotherapy for Gastrointestinal Cancer-Dawn of a New Age
- **Prof.Bin Li 李斌教授 (Shanghai Institute of Immunology 上海市免疫学研究所)** - Personalized Immunotherapy for Anti-tumor and Anti-Autoimmune Diseases个体化抗肿瘤免疫疗法的现状与未来
- **Dr. John A. Dangerfield (Chief Scientist Miskawann, Miskawann首席科学家)** - Novel Injectable Polyphenol Therapy for Cancer: Clinical Insights and Data from Chlorogenic Acid 新型注射用多酚类癌症疗法——基于绿原酸的临床数据与见解
- **Dr. Richard Stone (Senior International Correspondent，Science Magazine 《科学》杂志高级记者)** - Autoimmune Brain Disorders & The Rise of Precision Psychiatry 自身免疫性脑病与精准精神病学的兴起
- **Dr. Naping Tang 汤纳平博士 (Manager ,Toxicology Division of Shanghai InnoStar Bio-Tech 益诺思毒理事业部总经理)** - 自身免疫性疾病相关双特异抗体的研发进展及非临床评价策略
- **Dr. Tongtong Xue 薛彤彤博士 (Chairman & CEO, MediLink Therapeutics 宜联生物董事长兼CEO)** - ADC New Drug Development: Current Status and Future ADC新药开发：现状与未来
- **Dr. Wenzhi Tian 田文志博士 (Founder, Chairman & CEO, ImmuneOnco Biopharmaceuticals (Shanghai) 宜明昂科创始人、董事长兼CEO)** - Differential Analysis of Different Antibody Molecules in Autoimmune Indications 不同抗体分子在自免适应症的差异化分析
- **Dr. Xiaowu Chen 陈小五博士 (CureGene 上海柯君医药科技有限公司化学研发副总裁)** - 新一代“璞玉”AI 前药技术研发平台
- **Dr. Haisheng Zhang 张海生博士 (CEO, Signet Therapeutics 希格生科CEO)** - Developing Novel Cancer Targeted Therapies Based on Organoid Models + AI 类器官+AI赋能弥漫性胃癌首款靶向药的研发

Frontiers in RNA Research

Sept 12 14:00-17:00 | **Theater 2**

Sub-Forum Co-Organized by School of Life Sciences, Peking University 北京大学生命科学学院合办分论坛

Chair 主席

- **Prof. Yangming Wang 汪阳明教授 (College of Future Technology, Peking University 北京大学未来技术学院)**

Speakers 演讲人

- **Prof. Yangming Wang 汪阳明教授 (College of Future Technology, Peking University 北京大学未来技术学院)** - Decoding and Manipulating RNA Pathways for Studying and Treating Diseases
- **Prof. Yuanyu Huang 黄渊余教授 (School of Life Sciences, Beijing Institute of Technology 北京理工大学)** - Challenges in the Development and Clinical Translation of RNA Therapies
- **Prof. Jinzhong Lin 林金钟教授 (School of Life Sciences, Fudan University 复旦大学生命科学学院)** - Synthetic Translation: Dissecting Human mRNA Regulatory Elements in a Purified System
- **Prof. Qiang Cheng 程强教授 (College of Future Technology and Beijing Advanced Center of RNA Biology (BEACON), Peking University 北京大学未来技术学院)** - Development and Application of Tissue-Selective mRNA-LNP Delivery System
- **Prof. Hsiang-Ying Lee 李湘盈教授 (School of Life Sciences, Peking University 北京大学生命科学学院)** - From RNA Control of Red Cell Development to Next-Generation Nucleic Acid Delivery

*This is an September 6th version schedule, subject to change.

Innovative Drugs Forum IV：Frontiers in Biotechnology and Global Development of Innovative Drugs

Sept 12 14:00-18:00 | **Main Theater**

Roundtable - The Rise of Innovative Drugs in China and the Construction of Innovative Ecology
圆桌论坛 - 中国创新药的崛起与创新生态建设

Moderator 主持

Dr. Xuanhui Xie 谢暄晖博士 (Chief Innovation and Investment Officer, IASO Bio 驯鹿生物首席创新及投资官)

Panelists 小组人员

Mr. Guotao Yang 杨国韬 (COO，Quark Pharmaceuticals 夸克医药首席运营官)

Mr. Kevin Xu (Global Chairman & CEO, ClinChoice 昆翎全球董事长兼CEO)

Ms. Danjie Huang 黄丹洁 (Vice President of Bayer Prescription Drug Division and Head of China Cooperative Innovation Center 拜耳处方药事业部副总裁、中国合作创新中心负责人)

Mr. Fenping Zhang 张芬平 (CEO，GenOway 基锘威生物CEO)

Speakers 演讲人

Prof. Fanyi Zeng 曾凡一教授 (Director, Shanghai Jiao Tong University Institute of Medical Genetics 上海交通大学医学遗传研究所所长) - Frontiers Advances in BioPharmaceutical Sciences: Fundamental and Applied Research from Embryonic Genetic Engineering to Animal Bioreactor 生物制药科学前沿进展：从胚胎基因工程到动物生物反应器的基础和应用研究

Dr. Graeme Spencer (HDR National science director) - Translational Velocity: Infrastructure-Led Bench-to-Bedside Acceleration 转化速率进程：基建驱动的实验室至临床转化加速

Dr. Genwei Zhang 张根卫博士 (Head of Peptide Research at XtalPi 晶泰科技多肽研发高级总监) - AI Accelerates Peptide and Nucleic Acid-Based Therapeutic Development AI加速多肽和核酸类大分子药物开发

Dr.Yunlong Song 宋云龙博士 (Manager，Yishi Medicine 翊石医药总经理) - Research and Development Practice of Small Molecule Innovative Drugs in the AI Era AI时代的小分子创新药研发实践

Dr.Yonghong Zhu 朱永红博士 (CMO，EpimAb Biotherapeutics 岸迈生物CMO) - Immune Reset: T-cell Engagers (TCEs) on Fast Track toward Curing Autoimmunity

Dr. Qunsheng Ji 冀群升博士 (CEO, Sirius Therapeutics 靖因药业CEO) - siRNA疗法：转变慢性心血管疾病和肥胖管理的临床格局

Dr. Gergely Tóth (CEO, CSO and Founder of Cantabio Pharmaceuticals， Cantabio Pharmaceuticals创始人兼CEO, CSO) - Development of Small Molecule Pharmacological Chaperones Targeting the Aggregation of Intrinsically Disordered Proteins as a Therapeutic Approach for Alzheimer's and Parkinson's Disease 靶向内在无序蛋白聚集体的小分子药物伴侣研发——阿尔茨海默病及帕金森病治疗新策略

Prof. Hoi Leong Xavier Wong 王凯亮教授 (School of Chinese Medicine, Hong Kong Baptist University，香港浸会大学中医药学院) - Human-Microbial Pathway Interplay in Metabolic Diseases and Treatment 代谢性疾病与微生物组介导途径的相互作用及治疗策略

Dr.Yuanyuan Song 孙媛媛博士 (CEO，Zinta Health Biotech 双运生物CEO) - New Paradigm of Artificial Intelligence in Innovative Drug Development 人工智能用于创新药研发中的新范式

Ms. Ivy Chao 钞贺赟女士 (Vice President of Corporate Development, C-Ray Therapeutics 通瑞生物企业发展部高级副总裁) - Trends and Developments in Global Radiopharmaceuticals R & D Innovation and Industrial Chain Development 全球放射性药物研发创新及产业链发展动态及趋势

*This is an September 6th version schedule, subject to change.

Biotechnology Investment Forum

Sept 12 14:00-18:00 | **Theater 1**

Roundtable - Cross-Border Investment and Cooperation Strategies for Biotechnology Enterprises
圆桌论坛 - 生物科技企业跨境投资与合作策略

Moderator 主持

- Mr. Da Liu (Managing Director, CR CP Life Science Fund)

Panelists 小组人员

- Mr. Lihan Zhou (CEO, Mirxes)
- Mr. Piers Ingram (CEO & Co-Founder, Hummingbird Bioscience)
- Mr. Nathan Tirtana (President Director, PT Etana Biotechnologies Indonesia)
- Mr. David Boehm (Chairman, Miskawaan)
- Mr. William Cao (Founder, Former Chairman & CEO of Gracell Biotechnologies Ltd./AstraZeneca)
- Mr. Norazli Mohamad Nor (Venture Partner, Xeraya Capital)

Roundtable - Value Creation and Development Trends of Mergers and Acquisitions and Transactions in the Biopharmaceutical Industry from a Global Perspective
圆桌论坛 - 全球视野下生物医药企业并购与交易的价值创造与发展趋势

Moderator 主持

- Dr. Mark Tang (Founding Partner, Good Health Capital)

Panelists 小组人员

- Mr. Uli Stilz (CVP-R & ED External Innovation Partners, Novo Nordisk)
- Mr. Bing Chen (VP, BD & Venture, Astrazeneca)
- Mr. Michael Li (Head of BD/Quality, 3SBio Inc.)
- Mr. Robert Markelewicz MD (Chief Medical Officer, Abpro Group)
- Mr. Will Liu (Managing Director, Bioventures BeOne Medicines)

Roundtable - Investment and Incubation of Biotechnology Projects
圆桌论坛 - 生物科技项目的投资与孵化

Moderator 主持

- Ms. Holly Meng (CEO, Exin Pharma; Co-Founder & CEO, GB-Partner)
- Ms. Jiawei Tang (Co- Founder & COO,GB-Partner)

Panelists 小组人员

- Ms. Amber Chen (General Manager of Industrial Investment Promotion Department, HangZhou TransfarPolis Co.,Ltd.)
- Mr. Bob Rovinsky (Associate Director of Operations, B+labs)
- Mr. Patrick Day (Principal Consultant, Lachman Consultants)
- Mr. J. Christopher Giffin (President & COO, Bench International Search Inc.)
- Mr. Max Yu (Former Senior Strategy Expert, China Resources Group)

*This is an September 6th version schedule, subject to change.

Innovative In Vitro Diagnostics and Laboratory Medicine

Sept 12 09:00-13:00 | **Theater 2**

Chair 主席

Dr. Xinzhu Wang 王心竹博士 (COO, Haikang Life 海康生命首席运营官)

Speakers 演讲人

Prof. Cheng-Hock Toh (Professor of Hematology, University of Liverpool 利物浦大学血液病学教授) - From Bench to Bedside: Aligning Diagnostic Innovation with Real-World Clinical Needs

Prof. I-Ming Hsing 邢怡铭教授 (Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology 香港科技大学) – Engineering CRISPR/Cas Systems for At-Home Diagnostics

Dr. Lihan Zhou 周砺寒博士 (CEO, MiRXES 觅瑞首席执行官) - Applications of miRNA (MicroRNA) in Early Cancer Screening miRNA (微小核酸) 在癌症早筛方面的应用 *

Dr. Raul V. Destura (President & CEO, Manila Health Tek, Manila Health Tek主席兼CEO) - From Innovation to Impact: Leveraging the Quintuple Helix of Innovation for Accessible Healthcare in the Philippines

Dr. Peng Yin 殷鹏博士 (CSO, PHASE Scientific 相达生命科技首席技术官) - Clinical Performance of a Urine-Based HPV DNA Test with a Novel Purification and Concentration Technology

Prof. Olga Tkacheva (Russian Clinical and Research Center of Gerontology 俄罗斯国家老年医学研究与临床中心主任) - Russ Age: the Largest Trail of the Biomarkers of Human Aging in Russia

Dr. Kate Qi (CEO，SG Diagnostics) - STRIDE: A Scalable Model for Population Health Management Through Decentralized Diagnostics

Dr. Kseniia Eruslanova (Head of the Laboratory of the Cardiovascular Aging, Pirogov Russian National Research Medical University) - Biomarkers of Aging and Cardiovascular Risk Factors in Centenarians

Brain-Computer Interfaces Frontier: Reshaping Senses and Thought

Sept 12 14:00-15:00 | **Theater 4**

Chair 主席

Dr. Charles Hu 胡正忠博士 (Ryoden Medical Holdings 菱电医疗)

Speakers 演讲人

Mr. Lei Peng 彭雷先生 (Founder of NeuroXess 脑虎科技创始人) - The Development History and Latest Trends of BCI Technology 脑机接口技术的发展历程及最新趋势

Prof. Jiayi Zhang 张嘉漪教授 (Principal Investigator and vice dean, Institutes of Brain Science, Fudan University，复旦大学脑科学研究院) - Artificial Retina: Restoration and Augmentation

*This is an September 6th version schedule, subject to change.

Neuropharmacology Forum: Where Neuropharmacology Meets Biotechnology

Sept 12 09:00-13:00

Theater 4

Chair 主席

Prof. Yonghua Ji 吉永华教授(Hebei University 河北大学)

Speakers 演讲人

Prof. Piu Chan 陈彪教授(Xuanwu Hospital, Capital Medical University 首都医科大学宣武医院)- The Concept and Unmet Needs for Continuous Dopamine Stimulation Therapy for Parkinson's Disease

Prof. Zhenghong Qin 秦正红教授(Director of Institute of Health Technology, Suzhou Gaobo Vocational College)- Turning an α-Neurotoxin Cobrotoxin into a Neuro Therapeutics- a Reality or Imagination?

Prof. Hongjie Wang 王红杰教授(School of Basic Medical Sciences, Hebei University 河北大学基础医学院)- Insights into the Dynamic Regulation of Influenza Virus RNA Synthesis

Prof. Chi Him Eddie MA 马智谦教授(Professor of Neuroscience and Director of the Laboratory Animal Research Unit, City University of Hong Kong 香港城市大学神经科学教授、实验动物研究中心主任)- Novel Therapeutic Strategies for Glaucoma: A Drug Repurposing Approach

Prof. Jiguang Guo 郭继光教授(School of Basic Medical Sciences, Hebei University 河北大学基础医学院)- Therapeutic Effects and Mechanisms of Gastrodia elata Polysaccharides in Parkinson's Disease 天麻多糖对帕金森病的治疗作用和机制

Prof. Jie Tao 陶杰教授(Director，Nanxiang Branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine上海交通大学医学院附属瑞金医院南翔分院)- Antiepileptic Effects of Scorpion and Its Active Components by Targeting Ion Channels

Dr. Liche Zhou 周立彻博士 (Ruijin Hospital, Shanghai Jiaotong University School of Medicine上海交通大学附属瑞金医院)- Neuromodulation Therapy for Parkinson’s Disease

Prof. Jian Qu 屈健教授 (Department of Pharmacy, the Second Xiangya Hospital, Central South University 湘雅二院药学部) - Super Enhancers as Master Gene Regulators and Novel Therapeutic Targets in Brain Tumors 超级增强子作为脑肿瘤的主要基因调控因子和新的治疗靶点

*This is an September 6th version schedule, subject to change.

Degenerative Neurological Diseases Frontier

Sept 12 15:00-18:00

Theater 4

Science Café in China (Hong Kong) 《科学》杂志咖啡沙龙（BIOHK特别专场）

Opening Speech 开场致辞

Mr. Bill Moran 比尔•莫兰先生 （Publisher, Science Family of Journals 《科学》系列期刊出版人）

Moderator 主持

Prof. Jiayi Zhang 张嘉漪教授 (Principal Investigator and vice dean, Institutes of Brain Science, Fudan University 复旦大学脑科学研究院)

Dr. Shoupeng Liu 刘首鹏博士 (Science/AAAS外联与战略伙伴发展副总监)

Speakers 演讲人

Prof. Bo Peng 彭勃教授 (Fudan Universitiy 复旦大学) - Turnover and Replacement of Microglia: From Bench to Clinical Therapies

Prof. Yong Liu 刘勇教授 (Beijing University of Posts and Telecommunications 北京邮电大学) - Macroscale Connectome Topographical Structure Reveals the Biomechanisms of Brain Dysfunction in Alzheimer's Disease

Prof. Peng Yuan 袁鹏教授 (Institute for Translational Brain Research, Fudan University 复旦大学脑科学转化研究院) - Data-Driven Target Identification and Validation for Neurodegenerative Diseases

Prof. Changyong Tang 汤常永教授 (The Third Affiliated Hospital of SUN Yat-sen University 中山大学附属第三医院) - CHI3L1/YKL40 Signaling Inhibits Neurogenesis in Models of Alzheimer's Diseases

Roundtable - Future Diagnosis & Treatment in Degenerative Neurological Diseases
绘制大脑"分子星图"——神经退行性疾病的未来诊疗

Panelists 小组人员

Prof. Piu Chan 陈彪教授(Xuanwu Hospital, Capital Medical University 首都医科大学宣武医院)

Prof. Bo Peng 彭勃教授 (Fudan Universitiy 复旦大学)

Prof. Yong Liu 刘勇教授 (Beijing University of Posts and Telecommunications 北京邮电大学)

Prof. Peng Yuan 袁鹏教授 (Institute for Translational Brain Research, Fudan University 复旦大学脑科学转化研究院)

Prof. Changyong Tang 汤常永教授 (The Third Affiliated Hospital of SUN Yat-sen University 中山大学附属第三医院)

PROGRAM

DAY 4

Saturday September 13

**This is an September 6th version schedule, subject to change.*

08:30	Event Registration 注册				
	MAIN THEATER				
09:20 - 10:00	Health Management and AI Precision Medicine KEYNOTE SESSION - Mr. Hua Zhou Vice President and Secretary - General, Chinese Health Association 大会报告 - 周华先生 中国健康管理协会副会长兼秘书长				
	MAIN STAGE	THEATER 1	THEATER 2	THEATER 3	THEATER 4
10:00 - 11:30	Popular Science Lecture on Biotechnology 生物科技科普讲座 *Detailed agenda on P39，详细日程见P39	U.S. - China Biotech & RWA Investment Cooperation Forum 中美生物科技 + RWA 投资合作论坛 *Detailed agenda on P40，详细日程见P40	Traditional Chinese Medicine in the Modern Era II 岐黄新篇：中医药现代化论坛 II	Biotech Investment Workshop: Capturing the Next 100X Pharma Stock 生物科技创富工作坊：抓住下一只百倍股	Frontiers of Bio-Innovation: From Discovery to Tomorrow's Medicine 生物科技创新前沿：从科学发现到未来医学 *Detailed agenda on P39，详细日程见P39
11:30 - 13:00	Little Scientist: STEAM Education and Biotechnology 小小科学家		Traditional Chinese Medicine in the Modern Era III 岐黄新篇：中医药现代化论坛 III *Detailed agenda on P42，详细日程见P42		
LUNCH BREAK 午休					
14:00 - 17:00	Little Scientist: STEAM Education and Biotechnology 小小科学家	Global Public Health Forum: From Chikungunya to Future Pandemic Preparedness 全球公共卫生论坛：从基孔肯雅热到未来疫情防御 *Detailed agenda on P41，详细日程见P41	Traditional Chinese Medicine in the Modern Era III 岐黄新篇：中医药现代化论坛 III *Detailed agenda on P42，详细日程见P42		

**This is an September 6th version schedule, subject to change.*

Popular Science Lecture on Biotechnology

Sept 13 10:00-11:30 | **Main Theater**

Chair 主席

Prof. Jianguo Chen 陈建国教授 (School of Life Sciences, Peking University 北京大学生命科学学院)

Speakers 演讲人

Prof. Xuemei Chen 陈雪梅教授 (Professor and Dean, School of Life Sciences, Peking University 北京大学生命科学学院 院长) - RNA-Based Biotechnology

Prof. Zhi Lu 吕植教授 (Peking University Boya Distinguished Professor 北京大学博雅特聘教授) -Living in Harmony with Nature: Experiences with the Giant Panda

Special Guest Representatives Invited from Ocean Park Hong Kong 香港海洋公园特邀嘉宾代表 *

Prof. Jiayi Zhang 张嘉漪教授 (Principal Investigator and vice dean, Institutes of Brain Science, Fudan University 复旦大学脑科学研究院) - Artificial Retina: Restoration and Augmentation

Prof. Xitong Liang 梁希同教授 (College of Life Sciences, Peking University 北京大学生命科学学院) - Alien Intelligence Under the Sea: Motor Control of Cuttlefish Skin and Octopus's Arms 解密章鱼的"外星智慧"

Frontiers of Bio-Innovation: From Discovery to Tomorrow's Medicine

Sept 13 10:00-13:00 | **Theater 4**

Chair 主席

Dr. Xinzhu Wang 王心竹博士 (COO, Haikang Life 海康生命 首席运营官)

Speakers 演讲人

Prof. Tim Hirst (Chairman & CEO, GPN Vaccines) - Topic TBC 题目待定

Prof. Jack, Wing Tak Wong 黄永德教授 (Founder NutrigeneAI Biotech Limited) - Harnessing Type 2 Cytokines for the Treatment of Peripheral Arterial Diseases 基于II型细胞因子的外周动脉疾病治疗策略

Dr. Yuanyuan JIN 金源源博士 (Bound Therapeutics) - AI-Driven RNA-Targeted Therapy: Unlocking MicroRNA's Potential in Oncology and Beyond 人工智能驱动的RNA靶向疗法：释放microRNA在肿瘤及其他疾病中的潜力*

Dr. Rasool SUHAIL (Suninflam Inc.) - Suppression of Neuroinflammatory Response to Platinum Wire Implanted in Mouse Brain by Monoclonal Antibody SIF001 Against Galectin-3*

Dr. Anna FROSTEGARD (Annexin Pharmaceuticals AB) - ANXV (Annexin A5) as a New Therapeutic in Ophthalmology and Oncology *

*This is an September 6th version schedule, subject to change.

U.S. - China Biotech & RWA Investment Cooperation Forum

Sept 13 10:00-13:00 | **Theater 1**

Opening Speech 开场致辞

Mr. Ping Wang 王平先生

主理嘉宾致辞

中联办领导

Mr. Hua Zhou 周华先生 (Vice President and Secretary - General, Chinese Health Association 中国健康管理协会副会长兼秘书长)

Prof. Albert Yu 于常海教授 (Chairman, Hong Kong Biotechnology Organization 香港生物科技协会主席)

中美 RWA 合作主题演讲

Speakers 演讲人

Mr. Ming Li 李鸣先生（Executive President, Hong Kong Web3.0 Standardization Association 香港 web3 标准化协会执行会长 ）- Topic TBC 题目待定

Mr. Skylar Wong（Vice President, American Mergers & Acquisitions Association 美国并购协会副会长）- Topic TBC 题目待定

Mr. Huachen Zhang 张华晨先生（香港数字资产上市公司协会会长 President, Hong Kong Listed Digital Asset Association）- Topic TBC 题目待定

Mr. Fangxiong Gong 龚方雄先生（Global Chairman, MINAX Global Brand Exchange，MINAX 全球品牌交易所全球主席）- Topic TBC 题目待定

生物科技 RWA 全面合作签约仪式

香港 web3 标准化协会

中美大健康产业投资并购联盟

MINAX 全球品牌交易所

专场论坛一：全球并购协会揭牌仪式

Mr. Ming Ge 葛明先生（Supervisory Board Chairman/Senior Advisor，China Alliance of Mergers and Acquisitions 中国全联并购公会监事长/高级顾问）

全球并购协会揭牌仪式

国际并购交易师培训教材发布仪式

专场论坛二：脑健康专题

Moderator 主持

Ms. Huanming Liu 刘焕明女士

中美大健康产业投资并购联盟脑健康协会成立仪式/授牌：周华

Speakers 演讲人

Dr. Dong Qiao 乔栋博士（华西韦素研究院）- Topic TBC 题目待定

Prof. Lei Zhou 周雷教授（ 香港理工大学 The Hong Kong Polytechnic University）- Topic TBC 题目待定

Dr. Jingyi Liu 刘静怡博士（ 纳菲科技）- Topic TBC 题目待定

Dr. Haihong Zhang 张海宏博士（Chinese Academy of Sciences 中国科学院）- Topic TBC 题目待定

Dr. Weiyang Kuang 邝纬阳博士 - Topic TBC 题目待定

专场论坛三：生物科技 RWA 发行仪式

Moderator 主持

Mr. Di Deng 邓迪先生

挂牌仪式-雅韵科技、四环制药

*This is an September 6th version schedule, subject to change.

专场论坛四：RWA 公益论坛

Moderator 主持

Mr.Shengwen Luo 罗盛文（中国慈善基金会副主席）

项目介绍-AIWEB3 超级生物孵化器、嘉检医学、雅韵科技、芨影科技

中国慈善基金会合作签约

大湾区合作专场：推介及签约

Global Public Health Forum：From Chikungunya to Future Pandemic Preparedness

Sept 13 14:00-17:00 | **Theater 1**

Chair 主席

Prof. Yu Wang 王宇教授 (Chairman, Chinese Foundation for Hepatitis Prevention and Control 中国肝炎防治基金会理事长)

Session 1

Speakers 演讲人

Dr. Albert AU 欧家荣医生 (Head, Communicable Disease Branch, Centre for Health Protection, Department of Health 卫生署卫生防护中心传染病处主任) - Preparedness Measures for Chikungunya Fever in Hong Kong

Dr. Raul V. Destura (President & CEO, Manila Health Tek, Manila Health Tek主席兼CEO) - Topic TBC 题目待定

Prof. Emily Chan 陈英凝教授 (CEO, GX Foundation, 共享基金会总干事) - Topic TBC 题目待定

Session 2

Roundtable 圆桌论坛 - Cross-Regional Foundation Cooperation: From Mosquito-Borne Diseases to Global Public Health跨区域基金会合作：从蚊媒传染病到全球公共卫生

Moderators 主持人

Prof. Dong Dong 董咚教授 The Jockey Club School of Public Health and Primary Care，The Chinese University of Hong Kong 香港中文大学赛马会公共卫生及基层医疗学院)

Prof. Daisy Zhang 张德杏教授 (School of Nursing, Hong Kong Polytechnic University 香港理工大学护理学院)

Panelists 小组成员

Prof. Yu Wang 王宇教授 (Chairman, Chinese Foundation for Hepatitis Prevention and Control 中国肝炎防治基金会理事长)

Dr. Zhijie Zheng 郑志杰博士 (Director, China Country Office, Gates Foundation 盖茨基金会首席代表)

Prof. Emily Chan 陈英凝教授 (CEO, GX Foundation 共享基金会总干事)

Session 3

Speakers 演讲人

Prof. Jinghua LI 李菁华教授 (Department of Public Health and Medicinal Administration, Faculty of Health Sciences, University of Macau 澳门大学) - Cost-effectiveness Analysis of Hepatitis E Screening and Vaccination: Targeting Vulnerable Populations in Outbreak and Sporadic Settings in China

Prof. Yang Yang 杨扬教授 (National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital 国家感染性疾病临床医学研究中心, 深圳市第三人民医院) - From Dengue to Chikungunya: Guangdong as a Sentinel for Arboviral Threats in East Asia

*This is an September 6th version schedule, subject to change.

Traditional Chinese Medicine in the Modern Era II&III

Sept 13 10:00-17:00 | **Theater 2**

Sub-Forum Co-Organized by School of Chinese Medicine, Hong Kong Baptist University
香港浸会大学中医药学院合办分论坛

Transforming Traditional Chinese Medicine Hospitals: Directors Forum
中医医院发展新视角：院长论坛

Chair 主席

- **Prof. Min Li 李敏教授 (Dean, School of Chinese Medicine, Hong Kong Baptist University，香港浸会大学中医药学院院长)**

Speakers 演讲人

- **Prof. Zhaoxiang Bian 卞兆祥教授 (Hospital Chief Executive, Hong Kong Chinese Medicine Hospital, 香港中医医院院长) - 香港中医医院的发展与未来**

Roundtable 圆桌论坛 - Development of Traditional Chinese Medicine Hospitals in the New Era 新时代下的中医医院发展

- **Prof. Zhaoxiang Bian 卞兆祥教授 (Hospital Chief Executive, Hong Kong Chinese Medicine Hospital, 香港中医医院院长)**
- **Prof. Ka-Kit Hui 許家傑教授 (Professor and Director, UCLA Center for East-West Medicine UCLA东西医学中心主任)**
- **Prof. Mianzhi Zhang 张勉之教授 (President of Tianjin Hospital of Integrated Traditional Chinese and Western Medicine (Tianjin Nankai Hospital)**
  天津市中西医结合医院 (天津市南开医院) 院长)

Traditional Chinese Medicine Continuing Education Forum
中医药继续教育论坛

- **Prof. Cong Yan 闫聪教授 (Beijing University of Chinese Medicine 北京中医药大学威高研究院院长)**

Session 1: Keynote Speech 主旨演讲

- **Prof. Guoping Zhao 赵国屏院士 (Academician，The Chinese Acadamic of Science, The World Academy of Sciences, Fellow of the American Academy of Microbiology, 中科院院士，发展中国家科学院院士，美国微生物科学院院士) - 合成生物学赋能中药现代化**

Session 2: Exploring and Practicing the Dao of TCM in Modern Clinics 中医之道在现代临床中的探索与实践

- **Prof. Dong Zhang 张东教授 (Xiyuan Hospital of CACMS 中国中医科学院西苑医院) - 元气神机—先秦中医之道**
- **Prof. Weiwei Cheng 程薇薇教授 (Xiyuan Hospital of CACMS 中国中医科学院西苑医院) -基于中西医结合诊治疾病思维与策略------初探罕见疾病临床疗效的研究**
  Based on the Thinking and Strategy of Treating Diseases Through the Combination of East Chinese Medicine Western Medicine ——An Initial Exploration of the Research on the Clinical Efficacy of Rare Diseases
- **Prof. Na Lang 郎娜教授 (Xiyuan Hospital of CACMS 中国中医科学院西苑医院) - 察象握机，立竿见影**

Session 3: Decoding TCM:When Ancient Image-Number Science Meets Modern Artificial Intelligence
解码中医：当古老象数遇见现代人工智能

- **Prof. Li Yang 杨力教授 (Graduate School, CACMS 中国中医科学院研究生院) - 伟大的象数科学**
- **Prof. Xiaolin Wang 王小林教授 (Beijing Institute of Nanoenergy and Nanosystems, Chinese Academy of Sciences 中国科学院北京纳米能源与系统研究所研究员) - AI-Assisted Precision Diagnosis and Treatment Platform for Traditional Chinese Medicine Based on Nanosensing 基于纳米传感的AI中医精准辅助诊疗平台**

**This is an September 6th version schedule, subject to change.*

Closed-Door Discussion 闭门会议

Invitation Only
仅限邀请嘉宾

Venue: HKCEC, 4/F, G405

2025-09-10, Wednesday 16:30-18:00	Cell Therapy Regulation Closed-Door Meeting 细胞治疗监管闭门会议
2025-09-11, Thursday 10:00-11:30	Building the First-Tier Approval Framework for the Hong Kong Centre for Medicines and Medical Devices Regulatory (CMPR) 香港药物及医疗器械监管中心（CMPR）“第一层审批”制度建设研讨
2025-09-12, Friday 10:00-11:30	Strategic Opportunities in the Northern Metropolis & Hong Kong’s Biotechnology Industry 北都会建设与香港生物科技产业的战略机遇
2025-09-12, Friday 14:00-15:30	From Regional Biotech Conference to Global Healthcare Investment Forum: BIOHK’s Future Positioning and Growth Roadmap 如何将BIOHK打造成为具有全球资本影响力的投资峰会

Nicholas Teo of GSK:
Advancing Healthcare Through Prevention and Innovation

Nicholas Teo
General Manager of GSK Hong Kong & Macau

As Hong Kong's healthcare system strides toward internationalization and innovation, Nicholas Teo, General Manager of GSK Hong Kong and Macau, shares insights into the company's strategic vision for the region. In this exclusive interview, he discusses GSK's focus on preventive healthcare, data-driven decision-making, and cross-border collaboration within the Greater Bay Area. From leveraging the new CMPR regulatory pathway to fostering partnerships at BIOHK 2025, Teo highlights how GSK is working to transform healthcare—not just for patients, but for the entire ecosystem. Explore how prevention and innovation are shaping the future of healthcare in Hong Kong and beyond.

Q **Could you outline GSK's core strategy and key priorities for the Hong Kong and Macau markets?**

- At GSK, our strategy in Hong Kong and Macau focuses on getting ahead of disease together—through prevention, early intervention, and innovation. We are committed to expanding access to adult immunisation, particularly for diseases like shingles and RSV, which pose significant risks to aging populations and bringing innovative medicines to Oncology and specialty areas whilst continuing to serve patients with our established and trusted portfolio.
- Our key priorities include:
  - Accelerating access to innovation through partnerships and real-world data generation.
  - Investing in vaccines and specialty medicines to help reduce long-term healthcare burden.
  - Collaborating with stakeholders, e.g. patient advocacy groups and insurers, to improve awareness, access, and affordability.
  - Leveraging Hong Kong's strategic location to explore opportunities for regional collaboration and innovation.
- These efforts align with broader healthcare goals in Hong Kong, including a shift toward prevention-based healthcare and data-driven decision-making.

Q **From your perspective, what impact will the establishment of Hong Kong's Center for Medical Products Regulation (CMPR) have? Furthermore, is GSK preparing any product portfolios to leverage this new pathway for faster patient access?**

- The establishment of CMPR is a major step forward for Hong Kong's healthcare system. By moving toward independent drug approvals based on local scientific review, Hong Kong has the potential to become a more attractive market for pharmaceutical innovation—regionally and globally.
- Becoming a primary regulator in the future potentially further accelerates innovative medicines entering the Hong Kong market as reviews go in tandem with other major regulators like EMA and US FDA and could also serve as a reference for China mainland submissions.
- At GSK, we welcome efforts to streamline regulatory processes, align with international standards, and improve patient access. We're engaging constructively with the evolving framework and monitoring its development closely.
- In terms of portfolio readiness:
  - We anticipate 5–6 innovations in the coming years, including first-in-class therapies for multiple myeloma, severe asthma, nasal polyps, and hepatitis B.
  - We continue to invest in real-world data to support regulatory submissions and guide early intervention.
  - We are exploring collaborative opportunities that align with CMPR's objectives, particularly in areas such as personalised medicine and novel therapies.
- CMPR represents a meaningful opportunity to strengthen Hong Kong's position as a regional hub for biomedical innovation—and we're committed to supporting its success.

Q **Is GSK pursuing any R&D or commercial collaborations within the Greater Bay Area, and are there any successes you can share?**

- GSK sees the Greater Bay Area (GBA) as a strategic platform for scalable healthcare innovation. With a population of over 87 million and growing infrastructure for clinical research, the region offers strong potential for real-world data generation and cross-border collaboration.
- Evidence generation to guide data-driven decision-making for Hong Kong healthcare policy and public health initiatives, or serve as reference for other markets is an key area of interest for GSK, especially in the areas of adult vaccination like Shingles & RSV, as well as in our oncology and specialty portfolios.
- We continue to engage closely with government stakeholders to leverage real-world data in the adult vaccination space. We look forward to sharing more about an upcoming initiative in due course.
- These efforts reflect our broader commitment to getting ahead of disease—through prevention, collaboration, and data-driven decision-making.

Q **What were GSK's primary goals for participating in BIOHK, and how has the event delivered value in terms of partnership opportunities?**

- As a gold sponsor of BIOHK 2025, GSK is contributing to a platform that aligns closely with our strategic focus—prevention, innovation, and data-driven healthcare.
- Our involvement reinforces several key priorities:
  - Prevention-first mindset: Being one of the speakers at the Prevention Forum provides a timely opportunity to advocate for adult immunisation and early intervention, which are central to how we aim to reduce long-term disease burden.
  - Collaborative healthcare: Engaging with stakeholders across sectors supports our belief that sustainable healthcare requires shared responsibility and coordinated action.
  - Innovation with impact: By highlighting how science and real-world data can improve outcomes and create economic value, we're reinforcing our commitment to getting ahead of disease—not just for patients, but for the healthcare system.
- BIOHK is not just an event—it's a strategic touchpoint that reflects where GSK is heading and how we aim to contribute to Hong Kong's healthcare future.

*GSK plc is a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at gsk.com

Sir Jonathan Symonds, Chairman of GSK, at the Keynote Session of BIOK2024

BeOne Medicines：以多元研發管線與細胞治療創新重塑腫瘤治療版圖

Dr. Alex Huang

在全球生技產業持續尋求突破之際，BeOne Medicines 正以其廣泛且多樣化的腫瘤創新研發管線，吸引市場高度關注。BeOne Medicines 為全球腫瘤治療創新公司，設址於瑞士，將於 9 月 12日登上 BioHK 大會舞台，由全球副總裁暨細胞治療研發中心負責人黃士銘博士（Dr. Alex Huang） 親自分享該公司最新研發進展與細胞治療策略，成為本屆論壇的亮點之一。

打造全球領先的腫瘤研發版圖

BeOne 自成立以來，便秉持「高效、可及、可負擔」的理念，致力將前沿科研成果快速轉化為臨床可用的新藥。**公司已建立起橫跨血液腫瘤與實體腫瘤的龐大研發管線資產：**

- 逾 40 項臨床及商業階段產品，涵蓋 BTK 抑制劑、BCL-2 抑制劑、CDK4 抑制劑、抗體藥物偶聯物 (ADC) 與新一代 嵌合式降解激活化合物（CDAC）技術。
- 預計未來 3–6 年內將有多達 10 個自主研發的新分子實體（NME）進入臨床，進一步鞏固研發能量與商業化布局。

其中，**BTK 抑制劑 BRUKINSA®（zanubrutinib）**已成為血液腫瘤領域的標竿療法，展現公司在研發與全球市場拓展上的雙重實力。而 sonrotoclax 與 BTK CDAC 的最新臨床數據（涵蓋單藥與聯合療法）同樣備受關注，展現滿足 CLL 治療需求的潛力。

在實體腫瘤領域，特別在乳癌、肺癌及腸胃道癌症領域之相關研發管線，包括**CDK4 抑制劑、B7-H4 ADC、PRMT5 抑制劑**等，展現出令人期待的進展，不僅回應腫瘤異質性的挑戰，也為未來的臨床應用提供更多可能。

細胞治療：以 iPSC 平台開啟次世代創新

除了傳統藥物與抗體外，BeOne 亦積極投入細胞治療領域。全球副總裁黃士銘博士指出，傳統自體細胞治療（Autologous CAR-T）雖已展現療效，但在成本、品質穩定性與可及性上仍存挑戰。

為突破限制，BeOne 將研發重點放在**誘導性多潛能幹細胞（iPSC）**，以打造同種異體、可即時使用的**「off-the-shelf」細胞療法**。這一策略透過基因編輯與製程優化，讓 iPSC 衍生細胞具備高度同源性(homogenous)與一致性(consistency)，並能自單一細胞株持續產製，理論上劑量無上限。

此一創新平台不僅奠定了細胞療法可量產、可負擔的基礎，更展現推動治療普及化的潛力，讓更多癌症患者得以受惠。

以亞洲為舞台，拓展全球影響

BioHK 2025 將成為 BeOne 展示全球研發能量的重要舞台。黃士銘博士將在 **「Innovative Drugs Forum III：Development of next-generation anti-tumor and self-immune new drugs」** 專場，闡述 BeOne 如何透過廣泛且多元的研發管線與細胞治療平台，重新定義腫瘤創新療法的未來。

對於亞洲市場而言，這不僅是一次窺見 全球腫瘤治療新趨勢的機會，也彰顯了香港作為連結國際生技創新與投資的重要橋樑角色。

隨著 BioHK 倒數計時，BeOne Medicines 的亮相備受期待。從 BTK 抑制劑到 ADC，再到 iPSC 同種異體細胞療法，公司完整的研發版圖展現其成為 「全方位腫瘤治療創新公司」 的雄心。未來，隨著更多臨床成果釋出，BeOne 將如何在全球癌症治療版圖中奠定新標準，值得持續關注。

*聆聽Dr.Huang 的精彩演講，請鎖定：**Innovative Drugs Forum III**
9月12日 10:00 - 13:00 Main Theater

A Conversation with Dr. Robert Lin: GreenLight Clinical's Strategy for Early-Phase Trials and APAC Expansion

In this interview, we speak with Dr. Robert Lin,CEO of GreenLight Clinical. A healthcare executive with over 20 years of clinical and managerial experience, Dr. Lin discusses the company's mission to efficiently 「greenlight」 early-phase clinical trials. He shares insights into GLC's differentiated approach, leveraging Australia's advantageous research environment, and outlines their strategic plans for collaboration and growth in the Asia-Pacific region.

Robert Lin
CEO
GreenLight Clinical

- Dr Lin is the CEO of GreenLight Clinical. He is a highly qualified healthcare executive with over 20 years of clinical and managerial experience.
- As a healthcare professional who is passionate about advancing medical facilities, treatments and patient-centric care, Dr Lin has extensive experience in managing private, public and international hospitals and other facilities. His expertise in this area spans strategic planning, improving operational efficiency, team building and project management.
- With a commitment to share his knowledge and skills to enhance healthcare in the community, Dr Lin has been Chairman of the NSW Radiation Therapist Research Group and Clinical Specialist Director of the Australian Medical Radiation Sciences Accreditation Council. He also served as a member of the expert panel of the Trans-Tasman Radiation Oncology Group and the lung cancer reference group for Cancer Australia.
- Dr Lin's professional insights are widely published, and he is a reviewer and invited author of the Journal of Medical Radiation Sciences.
- As someone who drives positive development in the healthcare industry, Dr Lin believes that optimal outcomes and improved patient experiences are best achieved through understanding difficult concepts, turning ideas into logical strategies and implementing appropriate systems.

Q **What was the original intention behind establishing Greenlight Clinical? Does the company name "Greenlight" hold any special meaning?**

GreenLight Clinical (GLC) was established to facilitate and progress clinical research in Australia for local and global sponsors. There are several advantages in conducting clinical trials in Australia including stream-lined regulatory processes and tax incentives. GLC aims to 「greenlight」 your projects as efficiently and smoothly as possible.

Q **What is Greenlight Clinical's differentiated positioning compared to other larger or traditional CROs?**

At GLC, we focus on early phase studies to help smaller sponsors start their studies sooner with individualized support. We understand the intricacies involved in early phase research from a clinical and regulatory perspective to help navigate the landscape.
Our experienced staff have extensive knowledge and hands-on clinical experience in Ophthalmology, Oncology, Rare Diseases, Gene & Cell therapy and Devices.

Q **Hong Kong and the Greater Bay Area are important hubs for biotech collaboration. How does Greenlight Clinical view the opportunities in this market?**

With the increased interest in Hong Kong and the Greater Bay Area, GLC have already established partnerships in the area and have clinical staff located in the respective areas to help strengthen clinical collaborative research in the APAC area. With Hong Kong's mature medical systems and its close proximity to the Greater Bay area, this is a perfect gateway to China.

Q **What are your specific expectations and goals for participating in BIOHK2025?**

GLC hopes to help strengthen existing collaborations and partnerships whilst welcoming new relationships. We hope to promote the advantages of the Australian clinical research services and how we can support the APAC region.

▼ BIOHK has set up one-on-one meeting areas, providing an excellent opportunity for attendees to find partners. The photo is from BIOHK2024.

BIOHK2025
香港國際生物科技論壇暨展覽

KEYNOTE SPEAKER BIOGRAPHIES

*Surname in Alphabetical Order

Philip Wai Yan CHIU

Dean
Faculty of Medicine, The Chinese University of Hong Kong

Professor Philip Chiu is Dean of the Faculty of Medicine, Shun Hing Education and Charity Fund Professor of Robotic Surgery, Director of Multi-Scale Medical Robotics Center, and Director of Endoscopy Center, Institute of Digestive Disease of The Chinese University of Hong Kong. He is also a Steering Committee member of Health and Medical Innovation Development of the Health Bureau of the HKSAR Government.

Professor Chiu is a pioneer in minimally invasive procedures, having performed Hong Kong's first endoscopic submucosal dissection (ESD) for the treatment of early gastrointestinal cancers in 2004, as well as the world's first robotic gastric ESD and colorectal ESD in 2011 and 2020 respectively. His research interests include esophageal cancer management, minimally invasive and robotic esophagectomy, novel endoscopic technologies for diagnosis of early GI cancers, endoscopic surgery, as well as robotics for endoluminal surgery. Professor Chiu has published nearly 400 peer-reviewed manuscripts and 6 book chapters. Among these, his seminal world's first robotic colorectal ESD clinical study earned Endoscopy's Most Innovative Paper Award (2024). Other accolades include the State Scientific Technology and Progress Award from the People's Republic of China (2007), 2nd class award in Technological Advancement, Ministry of Education of the People's Republic of China (2011), Spirit of Hong Kong Award on Innovation (2020), two Gold Medals with Congratulations of Jury at the International Exhibitions of Inventions of Geneva (2019, 2023), Honorary Member of the European Association of Endoscopic Surgery (2023) and Foreign Member of the Academia Europaea (2025).

Anthony Davies

Chief Executive Officer & Founder
Dark Horse Consulting Group

Anthony founded Dark Horse Consulting in 2014, bringing his 20+ years of leadership experience in product, process and manufacturing development to cell and gene therapy companies in need. Anthony's responsibilities as CEO include defining the strategic growth and focus of the practice, team building, liaising with key clients, and developing business for the company. He is a highly sought-after keynote speaker and chair of national and international conferences and seminars, noted for his provocative, thoughtful, and sometimes contrarian presentations.
Previously, Anthony served as a senior executive for multiple publicly traded and privately held companies, building a reputation for innovation, dedication and competency. A certified Six Sigma Champion, Anthony's recent industry positions were at Capricor Therapeutics, where he served as CTO, and Geron Corporation, where he was VP of Product Development. At Geron, Anthony led the process development, technical operations, pilot plant, analytical development, and cGMP manufacturing functions. He was responsible for all CMC-related regulatory filings, including the first ever IND to secure FDA clearance for initiation of clinical testing of an hESC-derived product. At Capricor Therapeutics, Anthony was responsible for development and expansion of the company's cardiovascular therapeutics portfolio, including but not limited to in-house and in-licensed stem cell and peptide products.
At an earlier position at Onyx Pharmaceuticals, after critical contributions to the development of the oncology drugs Nexavar® and Ibrance®, Anthony built manufacturing teams for the adenovirus gene therapy ONYX-015, running a multi-thousand litre, pre-commercial process for this first-in-class product.

Jerzy Duszynski

Former President
Polish Academy of Sciences

Jerzy Duszynski was the President of the Polish Academy of Sciences (PAS) in 2015 – 2022. He is a professor at the Nencki Institute of Experimental Biology, PAS (he was a Director of the Institute in years 2002 -2008). Duszynski's research interests focus on bioenergetics, the role of mitochondria in cell functioning and neurodegenerative diseases. He published numerous scientific papers in prestigious scientific journals: Science, Biochemistry, Nature Prot., J. Biol. Chem., Biochem. Biophys. Acta, FEBS Letter etc. He served as a Deputy Minister responsible for science at the Polish Ministry of Science and Higher Education (2008 – 2009). He is a member of Academia Europaea, Chinese Academy of Sciences (foreign member) and National Academy of Sciences of Ukraine (foreign member). He serves as a member of advisory board of Chinese Academy of Medical Sciences. received numerous foreign awards: French Officer of Academic Palms, Doctor Honoris Causa from National Ukrainian Academy of Sciences, Japanese Medal of Rising Sun with Ribbons etc. He was a Member of the Board of Trustees at Barcelona Institute for Research in Biomedicine.

George Fu Gao

Academician of the Chinese Academy of Sciences (CAS)
Chinese Center For Disease Control And Prevention

George Fu Gao has been a key leader in the public health field, making remarkable contributions to research and discovery through basic research, clinical evaluation and advocacy. He has made many remarkable contributions to the scientific field of control and prevention of emerging infectious diseases. He obtained his DPhil degree from Oxford University, UK and did his postdoc work in both Oxford University and Harvard University (with a brief stay in Calgary University).
Gao worked in Beijing Agricultural University (1986-1991), Oxford University (2001-2006), Institute of Microbiology, Chinese Academy Sciences (2004-2008, Director-General). China CDC (Director-General, 2017-2022), National Science Foundation of China (Vice-President, 2018-2022). Gao is a member (academician) of Chinese Academy of Sciences (CAS), an international member of the U.S. National Academy of Sciences (NAS), a foreign member of the U.K. Royal Society (RS), a member of the German National Academy of Sciences Leopoldina, a fellow of African Academy of Sciences and a fellow of The World Academy of Sciences (TWAS).

Jennifer Rubin Grandis

Associate Vice Chancellor for Clinical and Translational Research , UCSF

Dr. Jennifer R. Grandis received her medical degree from the University of Pittsburgh School of Medicine, Pennsylvania, and completed her internship from the same institution. Dr. Grandis completed both a residency and an Infectious Disease fellowship from the University of Pittsburgh School of Medicine, Pennsylvania. Prior to joining UCSF, Dr. Grandis was the UPMC Endowed Chair in Head and Neck Cancer Surgical Research and Distinguished Professor of Otolaryngology and Pharmacology and Chemical Biology at the University of Pittsburgh. She led the Head and Neck Cancer Program and was the Vice Chair for Research in the Department of Otolaryngology.
Dr. Grandis's research focuses on the signal transduction in head and neck squamous cell carcinoma (HNSCC) development and progression with the ultimate goal of targeting key pathways for therapeutic benefit. By taking key findings from the clinic and investigating mechanisms in a series of preclinical models, as well as developing novel therapeutic approaches in the laboratory and carrying out innovative clinical trials that employ these treatment strategies.
Dr. Grandis is an American Cancer Society Clinical Research Professor, and a member of the American Society for Clinical Investigation, the American Association of Physicians and the Institute of Medicine of the National Academies. She has published over 260 peer-reviewed articles. She has also contributed to more than 50 review articles and book chapters.

George Hara

Group Chairman and CEO
DEFTA Partners

In private sector, he founded DEFTA Partners in 1985. He was considered one of the most prominent Silicon Valley venture capitalists in the 1990s. He led more than twenty tech companies to success in the U.S., Europe, UK, Israel, and Japan, including Borland, PictureTel, SCO, Tradex, Unify, Oplus Technolgies, Fortinet, CUORiPS. Mr. Hara also founded DEFTA Hong Kong Office, to invest and to foster next generation of entrepreneurs, to promote collaboration between Hong Kong and Japan, and to make Hong Kong China's international innovation and technology hub.
He has served several posts in public office, such as Special Adviser to the Cabinet Office of the Prime Minister of Japan, Special Adviser to the Ministry of Finance, and the Prime Minister's Special Commissioner on the Government Tax Panel. He is an advisor to the Ministry of Internal Affairs and Communications, and he used to be the Intergovernmental Ambassador Extraordinary and Plenipotentiary to United Nations.
Ambassador George Hara also serves as Chairman of the Alliance Forum Foundation, and endeavours to promote the cultivation of new industries for a new era and to foster global leadership around the development of a next-generation core industry.

Raju Kucherlapti

Paul C. Cabot Professor of Genetics
Harvard University

Dr. Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of Medicine at the Harvard Medical School since 2001. He was the founding Director of the Harvard Partners Center for Genetics and Genomics. He obtained his PhD from the University of illinois, conducted post-doctoral studies at Yale University and held faculty positions at Princeton University. Before moving to Harvard, Dr. Kucherlapati was the University Chairman and the Lola and Saul Kramer Professor and chair of the Department of Molecular Genetics at the Albert Einstein College of Medicine in New York. Dr. Kucherlapati was a part of the Human Genome Project and the Cancer Genome Atlas project. He is a member of the National Academy of Medicine, USA.

Takayuki Kusanagi

CEO
Cuorips, Inc.

Mr. Takayuki Kusanagi earned his MBA from Harvard Business School in 1985 and a BA in Economics from Keio University in 1981. Mr. Kusanagi is currently the CEO of Cuorips, Inc, where he has led the company since 2020 and successfully guided its IPO in 2023. Before becoming CEO, he joined as an Advisor and board member to prepare the company for its IPO.
Mr. Kusanagi has over 40 years of experience in finance and investment management. He previously served as General Manager at Entrust, Inc, where he designed tax-saving schemes, created family office and advised on private investments. Earlier, he was CIO of YMR, overseeing Japanese equities, and General Manager of the Investment Banking Products Department at Mizuho Securities, leading securitization and M&A. He also held fund manager role at Daiichi IBJ Asset Management and spent nearly 20 years at the Industrial Bank of Japan (now Mizuho Bank) in different functions spanning international banking, credit analyst, investment management, derivatives trading, and securities analyst.

Chak-sing Lau

Vice-President & Pro-Vice-Chancellor (Health)
Dean of Medicine
The University of Hong Kong

Professor Chak-sing Lau is currently Vice-President & Pro-Vice-Chancellor (Health) and Dean of Medicine at The University of Hong Kong. He is meanwhile Chair and Daniel CK Yu Professor in Rheumatology and Clinical Immunology of the University's Li Ka Shing Faculty of Medicine (HKUMed).
He presided over the Hong Kong Academy of Medicine (2016 – 2020), a statutory body for medical and dental specialist training in Hong Kong which is also a key advisory body to the HKSAR Government on health-related policies. Today, he sits on numerous strategic committees/ working groups of the Health Bureau, Hospital Authority and Department of Health. He is also a member of the Research Council under the Health Bureau.
Professor Lau is known as a pioneer for establishing and advancing rheumatology in Hong Kong, Asia and beyond. In 2022, he was selected as an Honorary Member of the European Alliance of Associations for Rheumatology (EULAR), and elected as Member of Academia Europaea in 2023, and conferred the degree of Doctor of Science honoris causa by the University of Glasgow in 2024. He is Honorary Fellow of the American College of Physicians; the Academy of Medicine, Singapore; Singapore College of Physicians; Royal College of Physicians of Thailand; Academy of Medicine of Malaysia; the Royal College of Physicians of Ireland; and the Hong Kong Academy of Medicine.



Jonathan Symonds

Chairman
GSK

Sir Jonathan Symonds has extensive international financial, life sciences and governance experience. In July 2021, Sir Symonds co-chaired with Professor Sir John Bell the preparation of the UK Life Science Vision, which sets out a strategy for UK life sciences in the post-Covid world and seeks to capitalise on many of the UK's scientific successes through the pandemic.

In financial services, Sir Symonds served as an Independent Non-Executive Director of HSBC Holdings plc from April 2014, and as Deputy Group Chairman from August 2018, until his retirement from the Board in February 2020. He was previously Chairman of HSBC Bank plc from April 2014 to July 2018 and oversaw the formation of the ring-fence bank HSBC UK plc. He was also a partner and managing director at Goldman Sachs between July 2007 and September 2009.

Sir Symonds was Chief Financial Officer of Novartis AG from September 2009 to January 2014 and Chief Financial Officer of AstraZeneca plc from October 1997 and July 2007, a period which included the negotiation and completion of the merger with Astra. As a CFO, Sir Symonds chaired the 100 Group of Finance Directors, co-chaired the HMRC business tax committee and co-founded the Centre for Business Taxation at the Said Business School.

Prior to joining Zeneca in 1997, Sir Symonds was a Partner at KPMG, specialising in large scale business transformation in the chemicals and pharmaceuticals industries. His additional governance experience includes roles as Non-Executive Director and Chair of the Audit Committees of Diageo plc and QinetiQ Group plc; Non-Executive Chair of Proteus Digital Health Inc; Non-Executive Director, Rubius Therapeutics Inc.

Xiongli Yang

Academician of the Chinese Academy of Sciences (CAS)
Professor and Director of Academic Committee, Institutes of Brain Science, Fudan University

Member of Chinese Academy of Sciences; Director of Academic Committee, IOBS, Fudan University.

Professor Xiongli Yang obtained a Bachelor's degree in Biology from Shanghai University of Science and Technology in 1963, and a Ph.D. degree in Neuroscience from Shizuoka University and National Institute for Physiological Sciences, Japan in 1982.

He was a foreign fellow at Harvard University (1985-1986), a visiting professor at Baylor College of Medicine (1987-2003). He was appointed as professor in the Shanghai Institute of Physiology, Chinese Academy of Sciences in 1986 and served as director of that institute (1988-1999). He is currently professor at the Institutes of Brain Science, Fudan University. He was elected to the Chinese Academy of Sciences (1991) and the Academy of Sciences for the Developing World (2006). During his long scientific career, he has made an impressive record in the studies of information processing in the retina and the pathogenesis of major retinal diseases, such as myopia and glaucoma, and published more than 250 articles in Science, PNAS, Science Advances, Journal of Neuroscience, Glia, Journal of Physiology, Journal of Neurophysiology, Progress in Neurobiology, Progress in Retinal and Eye Research, etc.

Yin Ye

CEO
BGI Group

Ye Yin is CEO of BGI Group. He is PhD from Copenhagen University, Senior Scientist in genomics research, Adjunct Professor in Dalian University of Technology, Member of Expert Panel on Human Genetic Resources Management in China, Committee Member of Chinese Society for Measurement in Biology, Standing Committee Member of CACA Committee on Cancer Public Education, Director-General of Guangdong Innovation and Technology Alliance of IVD(ITA-IVD), Director-General of Shenzhen Life-tech Industry Alliance and Director-General of Shenzhen Association of Standardization.

Alex Zhavoronkov

Founder
CEO of Insilico Medicine

Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leading clinical-stage biotechnology company pioneering next-generation generative AI and automated platforms for drug discovery. Repeatedly nominated for the Clarivate Analytics Highly Cited Researchers list, Dr. Zhavoronkov is an internationally recognized innovator in artificial intelligence for life sciences. Since 2014, he has developed critical technologies in generative AI and reinforcement learning for creating novel molecular structures and synthetic biological data. He also pioneered the application of deep learning techniques, including transformers, for predicting human biological age, transfer learning from aging into disease, target identification, and signaling pathway modeling.
Dr. Zhavoronkov spent his early career in senior roles at ATI Technologies, which was acquired by AMD, before transitioning to biotechnology. He has published over 200 peer-reviewed papers and authored three books.
In addition to his role at Insilico, Dr. Zhavoronkov serves on the editorial boards of several top journals and co-chairs the Annual Aging Research and Drug Discovery conference, the world's largest event on aging research. He is also an adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.

Hua Zhou

Vice President and Secretary- General/Chinese Health Association

Vice President and Secretary-General of the Chinese Health Association
Vice Chairman of the Board of Directors of China High-Tech Magazine
Vice Chairman of the Nobel Laureates' Home
Member of the National Commission for the Review of Scientific and Technological Terminology
Distinguished Expert at the National Elderly Network
Vice President and Deputy Director of the Expert Committee at the New Century Institute of Management Science and Engineering
Deputy Director of the Expert Committee for the National Charity Federation's Grand Health Industry Committee

Professional Background:
Extensive leadership experience in government departments and China's top-tier tertiary hospitals.
Co-editor-in-chief of Digital Health Management: Theory and Practice and Food Studies (textbook for primary and secondary school students).

BIOHK2025
香港國際生物科技論壇暨展覽

SUB SESSION SPEAKER BIOGRAPHIES

*Surname in Alphabetical Order

Albert Au

Head
Communicable Disease Branch, Centre for Health Protection, Department of Health of Hong Kong SAR Government

Dr Albert Au is a specialist in Public Health Medicine. He has served in various areas of public health in the Department of Health since 2003. His work mainly focuses on surveillance, prevention, and control of communicable diseases, as well as managing major epidemics, including the SARS outbreak in 2023, H1N1 influenza pandemic in 2009, MERS, avian influenza, and COVID-19.
From 2023 to 2024, he was Head of the Emergency Response and Programme Management Branch of Centre for Health Protection (CHP), responsible for developing contingency plans, coordinating drills and exercises to enhance public health crisis preparedness and response mechanisms, and overseeing the planning, implementation, and enhancement of various vaccination programmes.
Currently, Dr Au serves as Head of the Communicable Disease Branch of CHP. He oversees communicable disease surveillance, epidemiological investigations of infectious disease outbreaks, enforcement of the Prevention and Control of Disease Ordinance (Cap. 599) and the International Health Regulations, and implementation of other related public health measures. He is also an ex-officio member of the Scientific Committee on Emerging and Zoonotic Diseases of the CHP.

Zhaoxiang Bian

Hospital Chief Executive
The Chinese Medicine Hospital of Hong Kong

Professor Bian Zhaoxiang is a leading expert in Chinese Medicine clinical studies, a highly regarded Chinese Medicine research scientist in the field of gut dysbiosis, and a passionate advocate for the integration of Chinese Medicine into holistic healthcare system.
Professor Bian's academic pursuit at Nanjing University of Chinese Medicine, where he obtained a degree in Chinese Medicine. He then pursued a Master of Philosophy in Chinese Medicine from Beijing University of Chinese Medicine, followed by a Doctor of Philosophy in Integrative Medicine from Guangzhou University of Chinese Medicine.
Since joining HKBU in 2001, Professor Bian has held various positions, including the Tsang Shiu Tim Endowed Professor in Chinese Medicine Clinical Studies, Director and Chair Professor of the Clinical Division, Director of the Centre for Chinese Herbal Medicine Drug Development, Director of the Chinese EQUATOR Centre, and Director of the Vincent VC Woo Chinese Medicine Clinical Research Institute.
As the CMHHK's Hospital Chief Executive, Professor Bian is leading the Core Management Team, healthcare professionals, and all other hospital staff to pursue the preparatory work for the hospital's commissioning, with a view to commencing services in phases from December 2025 onwards.



David Boehm

CEO & Founder
Miskawaan Health Group

David Boehm, Founder of Miskawaan Health Group, was amazed by the transformative effects after personally experiencing Chlorogenic Acid extension in deep sleep duration, improvement in morning vitality and significant enhancement in immunoglobulin levels. This inspired him to introduce this revolutionary compound to Asian markets. Driven by a profound passion for functional medicine, David champions a philosophy that heals not just individuals, but also contributes to global wellness. As he often says, “If an herb has proven medicinal value or the potential to benefit human health—no matter where in the world it originates—I will undoubtedly study it thoroughly and explore its practical applications. This is not just a professional pursuit, but a personal passion rooted in my deep respect for traditional medicine and natural healing. His commitment to holistic health and a vision where transformative care reaches communities worldwide and together with Chairman Zhang joined forces to develop and market this product under the brand name OROJIN.

Hua Cai

General Manager
CITIC MED FUNDS

Cai Hua is the General Manager of CITIC Healthcare Fund. His other roles include expert at CITIC Think Tank, senior researcher at the CITIC Reform and Development Research Foundation, vice president of the China Pharmaceutical Materials Association, deputy director of the Internet Healthcare Working Committee of the Internet Society of China, director of the China Geriatric Healthcare Research Association, and a standing member of the Pharmacoeconomics and Drug Evaluation Committee of the China Association for the Promotion of Traditional Chinese Medicine Research. He holds a CEIBS Executive MBA from Shandong University and a doctorate in pharmacoeconomics from China Pharmaceutical University. He previously served as regional general manager of Merck (China) and managing director of China Capital Partners.

Scott Cai

Managing Director
Prosperity 7 in China

Scott Cai, Managing Director of Prosperity 7 in China, with 20 years of investment experience ranging from venture capital to strategic investments.
Before Prosperity 7, he served as the Group Vice President in Baidu and TAL, leading strategic investment and corporate funds. Prior to that, he was a Partner at SAIF, a leading venture capital fund in Asia, focusing in TMT investment and serving as President in a RMB fund. Earlier, he was a management consultant with A.T. Kearney.
He obtained his MBA from Harvard Business School and BS from Tsinghua University.

Chunlai Cao

CEO
The United Bio-Technology (Hengqin) Co., Ltd

A senior pharmaceutical engineer and master's supervisor at Zunyi Medical College, he served as Director of the Biological Research Institute at Zhuhai United Pharmaceutical Co., Ltd. and Director of the Guangdong Diabetes Biopharmaceutical Engineering Technology Center. He has 20 years of experience in recombinant protein drug development, particularly in the development and research of diabetes biopharmaceuticals, and has successfully marketed four biopharmaceuticals. He currently manages a pipeline of over 20 biopharmaceutical products, including those in diabetes, weight management, lipid management, skin health management, excipients, and animal health. His GLP-1/GIP/GCG triple agonist has successfully filed for registration in both China and the United States, has completed Phase 1 clinical trials, and in March of this year, licensed the rights outside of China to Novo Nordisk. He has received a second-class Guangdong Provincial Science and Technology Award and first-class Zhuhai and Zhongshan Municipal Science and Technology Awards.

Guoying Cao

Former First-level Inspector，deputy director-general of department of high technology & industrialize, Ministry of Science an technology.

From 2001, the chief of division of Science and Technology, the Department of Education and Technology, the Liaison Office of the Central People's Government in the Hong Kong Special Administrative Region
From 2007, the Deputy Director of the Education and Technology Department of the Liaison Office of the Central People's Government in the Hong Kong Special Administrative Region
From 2013, the Deputy Director of the Basic Research Department of the Ministry of Science and Technology of China
From 2014, the First-level Inspector and Deputy Director of the High-tech and Industrialization Department of the Ministry of Science and Technology of China
From 2021, the First-level Inspector and Deputy Director of the Department of Resource Allocation and Management of the Ministry of Science and Technology of China.

Jinghua Cao

Director
Committe for International Cooperation and Overseas Affairs of the Chinese Society Biotechnology

Prof. CAO Jinghua，Director, Committe for International Cooperation and Overseas Affairs of the Chinese Society Biotechnology. Prior to this position，he served as Executive Director of the Secretariat of the Alliance of International Science Organizations (ANSO). An English major and graduate from the Beijing Foreign Languages Institute in 1982 and a master in international politics from CCNY, US in 1987, he worked in different posts in international affairs at the Chinese Academy of Sciences (CAS) such as Deputy Director of the Office of External Financing, the Chinese Academy of Sciences (CAS), Deputy Director and Director of the Office of American and Oceanian Affairs, Bureau of International Cooperation (BIC), Assistant Director, Deputy Director General and Director General of BIC, CAS. He also worked as a Second and First Secretary in the S&T Section of the Chinese Embassy in Washington D.C. from 1995 to 1997. His research interests are science policy and international cooperation in science and engineering. His publication includes a few articles in international SCI journals.



William Wei CAO

Founder, Former Chairman & CEO
Gracell Biotechnologies Ltd./AstraZeneca

Dr. William Cao brings over 30 years of R&D experience in biotech industry, including founding two Nasdaq-listed companies: Gracell Biotechnologies (formerly Nasdaq: GRCL) and Cellular Biomedicine Group (formerly Nasdaq: CBMG), with focus on novel cell therapies for cancer and autoimmune diseases. His industry experience also includes roles at Chiron (later Novartis and Bayer) and Affymetrix (now ThermoFisher Scientific).
Dr. Cao holds a Bachelor of Medicine degree from Fudan University Medical College of Shanghai, China, and a Ph.D. in Pharmacology from the Medical College of Virginia. He pursued extensive academic research in immunopharmacology at Harvard Medical School and Stanford Medical Center, authoring over 100 publications, including manuscripts, issued patents, and applications for advanced cell therapies.
On February 22, 2024, Gracell was successfully acquired by AstraZeneca for $1.2 billion, marking it as the first Chinese biotech company fully acquired by a multinational corporation. Dr. Cao has received several prestigious honors, including PharmaVoice 100 Most Inspiring Life Science Leaders Award, BioCentury/BayHelix M&A Deal of the Year 2024, and the HYSTA Entrepreneur of the Year Award 2024.
Dr. Cao is a sought-after speaker at professional conferences, such as the 2024 Harvard China Forum to share his entrepreneurial insights.



Yuhong Cao

Professor
National Center for Nanoscience and Technology

Dr. Yuhong Cao received her B.S. in chemistry from Linfield College, OR, USA (2011). She conducts graduate work on the development of a nondestructive nanostraw system for longitudinal living cell sampling with Prof. Nicholas Melosh at the Stanford University, CA, USA and got her Ph.D in materials science and engineering (2018). She pursued her postdoctoral training on T cell engineering by applying CRISPR-Cas technology with Prof. Peidong Yang in partnership with Prof. Jennifer Doudna at the University of California, Berkeley, CA, USA and then returned to Stanford University for her second postdoctoral training with Prof. Steven Chu. She returned to Beijing, China where she joined the National Center for Nanoscience and Technology, CAS as a professor and principal investigator.

Alex Yau Chi CHAN

Senior Accreditation Officer
Hong Kong Accreditation Service (HKAS),
Innovation and Technology Commission (ITC)

Dr Chan Joined HKAS as an Accreditation Officer in November 2012. Before joining the family, Dr Chan worked as a Post-Doctoral Fellow and an Honorary Research Associate in Stem Cell Biology research at the University of Hong Kong (HKU) for 4 years. Dr Chan holds the degree of Doctor of Philosophy (Medicine) from HKU, as well as the degrees of Master of Philosophy (Physiology) and Bachelor of Science (Biology) from the Chinese University of Hong Kong (CUHK).
In 2004, Dr Chan received research training at the University of British Columbia (Canada). Two years later, he was invited to be a visiting scholar at the University of California, Davis (U.S.) and underwent research training at Shriners Hospitals for Children – Northern California (Sacramento, U.S.). In the past, Dr Chan was a Chartered Biologist and a member of the Society of Biology (U.K.).
In HKAS, Dr Chan is responsible for the accreditation of medical testing laboratories and proficiency testing providers.

Lot CHAN

Assistant Director
Preparatory Office for Centre of Medical Products Regulation, Department of Health, the Government of HKSAR

Mr Lot Chan studied pharmacy in UK and public health in Hong Kong. He has joined the Department of Health of the Government of Hong Kong Special Administrative Region for 30 years. For may years he has been involved in the approval of pharmaceutical products registration and clinical trials, import/export control of medicines, licensing and inspection of pharmaceutical traders, and enforcement of drug-related laws. During his service in the Department of Health, Mr Lot Chan has led the application for the accession to the Pharmaceutical Inspection Co-operation Scheme and the statutory regulation of advanced therapy products.
Currently, Mr Lot Chan is the Assistant Director of Health, responsible for the preparatory work of the establishment of the Centre for Medical Products Regulation (CMPR).

Piu Chan

Director
National Center for Geriatric Disorders
Xuanwu Hospital of Capital Medical University

Piu Chan, MD, PhD, Professor of Neurology and Geriatrics, is the Chair of the faculty of Geriatrics and the Director of Clinical and Research Center for Parkinson's Disease (PD), Capital Medical University. He serves as the director of National Clinical Research Center for Geriatric Disorders, and Parkinson's Disease Center of Beijing Institutes of Brain Disorders, Xuanwu Hospital. He is also the council member of the International Association of Gerontology and Geriatrics (IAGG), past Secretary of the IAGG Asia-Oceania Region, and the deputy President of the Chinese Association of Gerontology and Geriatrics (CAGG). He has participated in the development of WHO ICOPE project and its implementation in China. He Dr. Chan has participated in drafting the Clinical Diagnostic Criteria for PD and for Prodromal PD of MDS. He published more than 400 peer reviewed SCI articles with a Google H-index of 92. Dr Chan has been the Principal Investigator for more than 10 international and domestic multi-center clinical register trials, served as consultant for NMPA-CDE. He is currently served as associate editor of Neuropharmacology and Therapy.



Ivy Chao

SVP of Corporate Development
C-Ray Therapeutics

Ivy oversees strategy formulation, BD and fund raising at C-Ray Therapeutics where she orchestrated the $100M+ Series A+ fund raising in 2024. Prior to C-Ray, she spearheaded value-creating transactions including M&A, BD, JV, strategic investment and financing in China's leading radiopharmaceutical company Dongcheng Pharmaceutical, a global leading healthcare company-Covidien (Medtronic) China, and other healthcare companies.
Education:
· B.S. in Management Engineering — Shanghai Jiao Tong University
· International MBA — University of Hong Kong & Fudan University

Amber Chen

General Manager of Industrial Investment Promotion Department，HangZhou TransfarPolis Co.,Ltd.

She has previously worked for the Bureau of Shanghai World Expo Coordination and Alibaba, providing services to international enterprises and academic institutions such as Baosteel, Infosys (India), and Wageningen University (Netherlands). She has managed and operated biotechnology industrial parks spanning over 1 million square meters, and served biopharmaceutical and bio-manufacturing companies including Dzenshine Pharma, Zhejiang Guobang Pharma, Qihan Biotech, Asta Biotech, and Gancao Doctor. She is dedicated to "empower scientists, accelerate futures”

Amy Chen

Founder, Chairperson, and General Manager
Platinum Life Excellence Biotech (Beijing) Co., Ltd.

Dr. Chen Xiao Ying holds the Doctor degree of Business Administration (DBA) from Singapore Management University. She has served as a member of the 9th, 10th, 11th, and 12th National Committee of the Chinese People’s Political Consultative Conference (CPPCC), and has served as a Permanent Honorary Member since the 13th National Committee. She is the initiator of China’s drug electronic supervision code and the founder of Alibaba Health. She previously held executive positions including Vice Chairperson and Executive Director of Alibaba Health Information Technology Limited (formerly known as “CITIC 21CN Company Limited”), and Non-Executive Director of China Resources Power Holdings Company Limited.

Since 2003, Dr. Chen has dedicated herself to innovative stem cell drug development. She founded Platinum Life Excellence Biotech (Beijing) Co., Ltd. in 2010, where she serves as Chairperson and General Manager. The company is a China Beijing-based company that has grown into a global innovation leader and a pioneer in the large-scale industrialization of the stem cell industry, having independently developed Amimestrocel Injection (human umbilical cord mesenchymal stem cell), China’s first approved stem cell drug. This achievement marks a historic breakthrough in the pharmaceutical sector and the commercialization of stem cell drugs in China.

Bing Chen

Vice President,
AstraZeneca International Business Development and Venture Fund

Mr. CHEN Bing is currently Vice President of AstraZeneca International Business Development and Venture Fund, Co-founding Managing Director of AZ-CICC Healthcare Investment Fund. With rich industry experience and business acumen, Bing has successfully led numerous strategic collaborations and investments both domestically and internationally, driving continuous business growth. He also spearheaded the establishment of the AstraZeneca-CICC Healthcare Investment Fund, which focuses on identifying and incubating early-stage local pharm innovations, supporting the global expansion of China's innovation.

Bo Chen

Chief Scientific Officer
China Resources Pharmaceutical Group Limited

Dr. Bo Chen is a specially-appointed expert for overseas high-level talents . He is currently the Chief Scientific Officer at China Resources Pharmaceutical Group Limited. He has more than 20 years of international career in the biotechnology and pharmaceutical industries, including basic research and innovative drug R&D team leadership in top scientific research institutions and pharmaceutical companies such as the National Institutes of Health, AstraZeneca, etc.
He has R&D background in the entire R&D value chain from target discovery to clinical development and commercial operation. He received his PhD. degree from the Air Force Medical University (China), completed the postdoctoral fellowship at the National Institutes of Health in the United States, and later obtained an MBA degree from Hood College (U.S.A).
He has published dozens of academic papers, book chapters and patents in peer-reviewed journals, including papers published in top journals such as Annals of the Rheumatic Diseases, Nature Communication, Nature Immunology, Nature Medicine, PNAS, etc.



Cynthia Chen

Chairwoman and President
Pulnovo Medical

Ms. Cynthia Chen serves as Chairman and Executive Chairman of Pulnovo Medical, the first Chinese cardiovascular medical device company to be included in international guidelines. She provides China with the first globally approved cardiac interventional treatment for patients with heart failure and pulmonary hypertension.
Ms. Chen previously worked at the World Health Organization headquarters in Switzerland and at Medtronic. She has been named twice to Forbes Asia and Forbes China Under 30, and twice to Hurun Under 30 China Entrepreneurs. She is also listed in Forbes China's Top 100 Global Chinese Elite and 36Kr's Most Noteworthy Female Entrepreneurs. She was selected for the United Nations-European and Central European Outstanding Technology Entrepreneurship Program and was recognized as a "Technology Leader" by the Suzhou Industrial Park.
Ms. Chen holds a bachelor's degree in sociology and psychology from Emory University, a master's degree in healthcare policy analysis and management from Columbia University, and an Executive MBA from the University of Chicago Booth School of Business.

Haifeng Chen

Chairman, Chief Technology Officer
AAVivo, Inc.

Dr. Haifeng Chen is a globally recognized leader in gene therapy, with over 30 years of pioneering contributions to adeno-associated virus (AAV) technology. He earned his B.S. in Biology from Sun Yat-sen University (1982), M.S. from Sichuan University (1985), and Ph.D. from the University of Saarland, Germany (1992). That same year, he was awarded the prestigious Marion-Merrell-Dow Post-Doctoral Fellowship to conduct research at the University of Kansas Medical Center.
Dr. Chen has held senior scientific and leadership positions at leading gene therapy companies, including Cell Genesys, Genovo, Avigen, and Asklepios BioPharmaceutical. In 2006, he co-founded Virovek, where he invented the BAC-to-AAV system—revolutionizing AAV manufacturing by achieving significantly higher yields using baculovirus and Sf9 cells. He later co-founded Avirmax, serving as Chief Technology Officer and Chief Operating Officer until 2022.
After returning to Virovek as Chief Scientific Officer in 2022, Dr. Chen developed PACE (Precision AAV Capsid Engineering), a groundbreaking platform for cell-specific AAV targeting. This innovation led to the launch of AAVivo, now advancing in vivo CAR-T and solid tumor immunotherapies.
Dr. Chen has served on the ASGCT Viral Vector Committee and the editorial board of Molecular Therapy – Methods & Clinical Development, continuing to shape the future of gene and cell therapy.

Gong Chen

Founder and President
NeuExcell Therapeutics

Professor Chen Gong is a National Distinguished Expert and serves as the Director of the Center for Brain Repair at the Jinan University Institute of CNS Regeneration for the Guangdong-Hong Kong-Macao Greater Bay Area. He graduated from Fudan University in 1987 and earned his Ph.D. in Neurobiology from the Shanghai Institute of Physiology, Chinese Academy of Sciences in 1993. In 1994, he conducted postdoctoral research at Yale University and Stanford University in the United States. From 2002 onward, he served as Assistant Professor, Associate Professor (with tenure), and Full Professor at Penn State University, and was appointed as the Verne M. Willaman Endowed Chair Professor in 2013.

In 2020, he joined Jinan University full-time as the Director of the Center for Brain Repair, driving the translation of in situ brain neuroregeneration technology toward clinical applications. Professor Chen's team achieved a milestone by reporting for the first time the highly efficient in situ reprogramming of endogenous glia into functional neurons using the neural transcription factor NeuroD1. This groundbreaking work was named the "2014 Best Paper" by the top-tier stem cell journal Cell Stem Cell, pioneering a novel neuroregenerative gene therapy for brain repair. In 2015, he published again in Cell Stem Cell on small-molecule-induced reprogramming of cultured human glial cells into functional neurons, laying the foundation for drug-based neuronal regeneration therapies. In 2020, his team reported another milestone achievement—the first successful in situ neuroregeneration in the primate brain.

Professor Chen holds 58 granted patents in China, the U.S., EU, Japan, and other major economies. In 2021, NeuExcell Therapeutics, founded by Professor Chen, entered a collaboration agreement with Spark Therapeutics, a member of the Roche Group. In 2023, NeuExcell received the "Asia-Pacific Gene Therapy Innovation Award" from Frost & Sullivan and won the First Prize in the National Innovation and Entrepreneurship Competition Finals. In 2024, NeuExcell's glioma gene therapy product NXL-004 achieved the world's first successful NeuroD1 AAV gene therapy administration in a patient with malignant glioma, marking a historic zero-to-one breakthrough from bench to bedside. In March and April 2025, the company further initiated first-in-class clinical trials for in situ neuroregeneration therapy targeting stroke and Alzheimer's disease, bringing new hope to millions of patients worldwide.

Xiaowu Chen

Vice President of Chemical R&D
CureGene

Dr. Xiao-Wu Chen has over 25 years of experience in innovative drug R&D, with extensive expertise and achievements in structural biology and AI-driven computational chemistry.
At Gilead Sciences, he contributed to the late-stage development of Tamiflu® (oseltamivir) and played a key role in developing major antiviral therapies, including Biktarvy® for HIV and Vosevi® for hepatitis C. Dr. Chen holds a bachelor's degree from Xiamen University, a Ph.D. in Biophysics/Biochemistry from Pennsylvania State University, completed postdoctoral research at UC San Francisco, and was a visiting scholar at Stanford University.

Xuemei Chen

Professor and Dean
School of Life Sciences , Peking University

Xuemei Chen received a B.S. degree from Peking University, China in 1988 and a doctorate from Cornell University, USA in 1995. After postdoctoral training at California Institute of Technology, she started her assistant professor position in 1999 at the Waksman Institute at Rutgers University. She was promoted to associate professor in 2005 and won the Board of Trustees Research Fellowship for Scholarly Excellence at Rutgers University. She moved to University of California, Riverside in 2005 as an associate professor and was promoted to full professor in 2009 and distinguished professor in 2013. In 2006, she received the prestigious Charles Albert Shull award from American Society of Plant Biologists. In 2011, she was elected an AAAS Fellow. She was an HHMI-GBMF investigator from 2012 to 2018. In 2013, she was elected into the US National Academy of Sciences. She received the Martin Gibbs Medal from American Society of Plant Biologists in 2023 and the Qiu Shi Outstanding Scientist Award from Qiu Shi Science & Technologies Foundations in 2024. In 2023, she returned to China to take up a full-time academic position and currently serves as Chair Professor and Dean of the School of Life Sciences at Peking University, as well as Director of Beijing Advanced Center for RNA Biology (BEACON). Her work has focused on flower development, small RNAs, and RNA modifications in plants.

Qiang Cheng

Assistant Professor
College of Future Technology and Beijing Advanced Center of RNA Biology (BEACON), Peking University

Dr. Qiang Cheng obtained his Ph.D. from Peking University in 2016 and subsequently completed his postdoctoral training at the University of Texas Southwestern Medical Center (UTSW) during 2017 to 2021. Since September 2021, Dr. Cheng established his research lab as an Assistant Professor at Peking University. His research interests focus on mRNA targeted delivery. The core is to innovate lipid nanoparticle (LNP) delivery technology to achieve targeted delivery of mRNA in tissues and cells, providing a powerful tool for precise mRNA-based therapy to address unmet clinical needs. To date Dr. Cheng has developed tissue-targeted (SORT, PILOT, STAR) and cell-targeted (SELECT) mRNA-LNP delivery platforms, enabling targeted delivery and treatment of mRNA drugs in various major organs and cells, including the liver, lungs, spleen, bone, muscle, thymus, kidneys, and tumors. These works have been published as first or corresponding author in journals including Nature Materials (2025, 2021), Nature Nanotechnology (2020), Nature Communications (2023, 2020), PNAS (2023, 2021), and Advanced Materials (2024, 2023, 2018). Notably, the Selective Organ Targeting (SORT) mRNA-LNP technology was highlighted in "Seven Technologies to Watch in 2022" by Nature. Several international patents resulting from his research have been commercialized, leading to the advancement of at least two pipeline projects into Phase 1 clinical trials and the initiation of multiple new mRNA drugs into Investigator Initiated Trial (IIT).

Weiwei Cheng

Department of Experts
Xiyuan Hospital, China Academy of Chinese Medical Sciences

Department of Xiyuan Hospital, China Academy of Chinese Medical Sciences, a national-level expert in stroke diseases and geriatrics. With a postgraduate degree in medicine and dual master's and doctoral degrees, I have been engaged in medical teaching and research as well as clinical practice for 50 years. In 1993, a national medical postgraduate student was admitted to the China Academy of Chinese Medical Sciences, where he studied under Professor Zhou Wenquan. In 1993, he passed the exam with excellent grades and ranked first in the credit list, earning 120 credits. Average score: 89.8 points. After graduating from the Graduate School of China Academy of Chinese Medical Sciences, I pursued a part-time doctoral program with excellent academic performance. I passed the examinations and completed the required doctoral credits. The first batch of mentorship mentors of the National Administration of Traditional Chinese Medicine and postgraduate supervisors of the China Academy of Chinese Medical Sciences. The Graduate School of the Department of Foreign Languages and Literatures, School of Humanities and Social Sciences, Tsinghua University, exceeded its target and passed the required credits for master's and doctoral courses with excellent grades. All course exams were passed with excellent grades after classroom study at the Tsinghua & Columbia Global Policy Research Center. Later, he studied under dozens of professors, including Academician Tian Jinzhou, Professor Cao Hongxin, Professor Nie Huimin of the Chinese Academy of Engineering, Professor Huang Yining and Professor Wu Liwen of Peking Union Medical College, Professor Wang Yongjun, a member of the Academic Division, and Professor LIYING, a senior professor of neuroscience at the University of Michigan. In the past three years, I have continued my research and study at Tsinghua University: taking courses such as neuro-linguistics, psycholinguistics, and syntax, completing all courses in the lifelong education Classroom of the School of Economics and Management at Tsinghua University, the "Philosophy Class" of Tsinghua University, and the Advanced Research Class on the Transformation and Development strategy of the Pharmaceutical Industry at the School of Humanities and Social Sciences of Tsinghua University.

Ricky Chiu

Chairman and CEO
PHASE Scientific International Limited

Dr. Ricky Chiu is a pioneering biomedical engineer, inventor, entrepreneur, and educator devoted to advancing diagnostic technology and global health. As Founder and CEO of PHASE Scientific, Dr. Chiu developed PHASiFY™, a patented liquid-phase extraction platform that redefines sensitivity in liquid biopsy and infectious disease diagnostics, enabling more accurate and accessible testing for cancer and infectious diseases. His work includes leading the development of the worlds first urine DNA-based HPV test for non-invasive cervical cancer screening, which leverages patented technology for highly accurate results and broad impact on women's health globally. During the COVID-19 pandemic, Dr. Chiu led teams in developing and distributing high-efficiency RNA extraction kits and rapid antigen tests, supporting mass testing in Hong Kong and globally. With over 55 granted patents, successful regulatory approvals, and collaborations across Asia and the U.S., Dr. Chiu has established PHASE Scientific as an international innovator in diagnostics. He is also an Adjunct Associate Professor at the Chinese University of Hong Kong, where he promotes innovation and talent development through academic engagement, lectures, and hands-on industry-academia initiatives.



Nancy Chou

Head of South China Region
Tengyi Boxi

With 16 years of deep expertise in the international logistics industry, and 8 years in temperature controlled area. Specializing in the international pharmaceuticals, blood products, and cells transporstion, with comprehensive knowledge of international and domestic import-export regulations.

Xiaoying Chu

Director, International Collaboration & Partner Publishing Science/AAAS

Xiaoying Chu is the Director of Global Collaboration & Partner Publishing (Asia), Science/AAAS. In her role, Xiaoying leads the Science/AAAS Asia office, being responsible for developing and executing the strategic plans for collaborations with universities and associations, representing the Science family of journals in the region, working on scientific meetings, workshops, prizes, and publishing projects.

Xiaoying played a key role in the establishment of AAAS's Science Partner Journal (SPJ) program in 2017, and launch of the first partner journal in AAAS's history – Research, in collaboration with CAST (China Association for Science and Technology) in 2018. Sixteen SPJ titles have been published by the AAAS by July 2024.

Johnson Chui

Managing Director, Head of Global Issuer Services HKEX

Mr Johnson Chui joined HKEX as Managing Director and Head of Global Issuer Services in September 2024.

In his role, Mr Chui leads HKEX's Global Issuer Services teams based in Hong Kong, Mainland China, London and Singapore, driving the Group's efforts to further diversify and expand its listed issuer base.

Mr Chui has more than 25 years of experience working in international capital markets. Prior to joining HKEX, he held senior positions at Nomura, where he was Managing Director, Vice Chairman of Investment Banking and Head of Equity Capital Markets, Asia ex-Japan.

Prior to Nomura, Mr Chui spent nearly 18 years at Credit Suisse, where he was Head of Equity Capital Markets for Asia-Pacific and a member of the Operating Committees for Global Equity Capital Markets and Asia Pacific Investment Banking & Capital Markets. He has also held senior investment banking roles at Citigroup and Goldman Sachs in Hong Kong.

Mr Chui holds Bachelor of Laws and Bachelor of Commerce (Finance) degrees from the University of New South Wales in Australia.

Sangeeta Bardhan Cook

Chief Innovation Officer
Fox Chase Cancer Center

At Fox Chase Cancer Center, Temple Health, Sangeeta Bardhan Cook, PhD, MBA, leads the institution's AI and digital health strategy, forging high-impact partnerships across industry, academia, and start-ups to accelerate the clinical deployment of machine learning innovations. She oversees technology transfer, intellectual property, licensing, and joint ventures for AI platforms, and has driven Fox Chase's pioneering investments in companies such as Nucleus and Segmed AI. In collaboration with Temple Health leadership, she helped establish an internal AI governance framework to ensure the ethical and scalable deployment of data-driven solutions across the health system, with a special focus on oncology. She mentors spin-off ventures from ideation through commercialization globally and routinely advises on health economics models for AI-enabled diagnostics and therapeutics designed to accelerate treatment decisions now and in the future.

Stephen Dalton

Professor
The Chinese University of Hong Kong

Before joining the Chinese University of Hong Kong as Global Stem Scholar and Professor in the Faculty of Medicine, Stephen Dalton (SD) was Professor and Endowed Chair in Molecular Cell Biology at the University of Georgia where he was founding Director of the "Center for Molecular Medicine", and Georgia Cancer Coalition Distinguished Scholar. Originally from the UK, Dr. Dalton received his Ph.D. from the University of Adelaide in Australia, followed by post-doctoral research at the Imperial Cancer Research Fund in London, with Sir Richard Treisman. Following this, SD was appointed to the Roche Institute of Molecular Biology (Hoffman La Roche, New Jersey, USA), with an academic appointment at Columbia University in New York City. Since then, SD has continued research on the therapeutic use of stem cells. This includes collaborations with Johnson and Johnson (New Jersey, USA), Nestle' (Lausanne, Switzerland) and Viacyte Inc. (San Diego, USA), which was recently acquired by Vertex Pharmaceuticals. Dr. Dalton's current work focusses on developing cell-therapy and gene-editing technologies for the treatment of human disease.

John Dangerfield

Chief Scientific Officer
Miskawaan Health Group

John is a scientific leader with 25 years of experience spanning research, biotech/medtech R&D and operations, incl. clinical settings. As Chief Scientific Officer at MiskawaanHealth Group, he oversees the clinical development and integration of advanced therapeutic products—including cell therapies, regenerative technologies, and natural medicines—into functional and integrative healthcare for cancer, chronic diseases, and healthy ageing. John's expertise covers oncology, medical devices, stem cells and targeted delivery systems for therapeutics and nutraceuticals. He leads multidisciplinary teams in the development of next-generation therapies, managing multiple clinical trials, registration of new products, procurement of medicines, and drives the international expansion of longevity clinics. His core scientific skills include molecular and cellular biology, cell encapsulation, virology, microbiome and microbiology, with a strong focus on translating research into innovative medical solutions.

Patrick Day

Principal Consultant
Lachman Consultants

Patrick is an established pharmaceutical executive and practitioner with proven leadership in proactive risk identification, deployment of strategies to enhance compliance controls, and implementation of detection systems to eliminate blind spots. He is skilled in policy deployment, Computer System Validation, Data Integrity/Governance, Risk Management, Supply Chain Logistics and application of AI for the next generation of quality professionals. He has trained FDA field inspectors for facility inspection techniques and has delivered talks on deployment of risk strategies and modern signal detection. His expertise also includes outsourcing and integrating efficient governance of Facilities Management and laboratory services across US/UK and Asia-Pacific. Pat's frequent blogs and articles help educate the industry become aware of emerging global risks, technologies, and their effect on the global supply chain.

RAUL V. DESTURA

President and Chief Executive Officer
Manila HealthTek Inc.

Dr. Destura is a molecular microbiologist and infectious disease specialist. He took his bachelor's degree in Microbiology at the University of Sto. Tomas and his medical degree and specialty in internal medicine at the De la Salle Health Sciences Institute. He went to the University of the Philippines for his subspecialty training in Infectious Diseases.

He received a research scholarship to the International Training and Fellowship on Emerging Infectious Diseases at the Center for Global Health, University of Virginia School of Medicine. He also holds a master's degree in Business Administration from Ateneo Graduate School of Business.

He is a diplomate and fellow in InfectiousDiseases. He joined the NIH Philippines and became director of the National Institute of Molecular Biology and Biotechnology.

He dedicated his work to identification of diagnostic targets and evaluation of diagnostic platforms best suited in developing country scenario. His most important work is the "Lab-in-a-mug" project which functions as a multi-infectious disease diagnostic platform with its principal product the Biotek-MTMDengue aqua kit that received local and international recognition such as NSTW Outstanding Technology Commercialization Award given by the National Academy of Science and Technology (2016), as gold medalist in the 46th International Invention Exhibition in Geneva Switzerland in 2018, Gawad Dagisik for Medical Sciences given by the Department of Science and Technology in 2019.

Through the Technology Transfer Act of 2009, he built the Manila HealthTek Incorporated, the very first university spin-off company from the University of the Philippines in Health Biotechnology. He is a recipient of national and international awards including the Bill and Melinda Gates travel scholarship in Molecular Helminthology in 2005, Outstanding Young Scientist of the Philippines for Medicine in 2008; UP Manila Research Productivity award, the Top 20 Young Physician Leaders from the Inter-academy Medical Panel in Berlin, Germany, and The Outstanding Young Men (TOYM) all given in 2011; Dr. Jose P. Rizal National Award in Research from the Philippine Medical Association and Dr. Eusebio Y. Garcia Award in Molecular Biology and Molecular Pathology from the National Research Council of the Philippines in 2015. In 2019, he received the Presidential Lingkod Bayan Award from the President of the Philippines. In 2020, he was named among top 100 Asian Scientist in the Asian Science Magazine. His latest work is the local RT-PCR kit for the detection of the SARS CoV 2 virus. In 2024 he received the Alberto G. Romualdez, Jr. Outstanding Health Research Award (Biomedical Research Category) from the Department of Health –PCHRD for his research on the "Molecular Diagnosis of Infectious Diseases Program."

Dong Dong

Assistant Professor, JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong

Dr Dong Dong is currently an Assistant Professor at the JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong (CUHK); a Research Fellow (by courtesy) at the CUHK Centre for Bioethics; an Associate Researcher at the CUHK Shenzhen Research Institute; and the Director of the Rare Disease Real-World Data Lab.

Dr. Dong adopts an interdisciplinary, multi-method approach to health research with a patient-centered focus and strong commitment to community–academic partnerships. Her work centers on the health challenges of marginalized populations, with rare diseases as a primary focus. Since 2014, she has examined the burden of rare diseases on patients and families, including quality of life, social support, diagnostics, and treatment adherence. As Principal Investigator, she has secured over USD2 million in funding and produced 100+ peer-reviewed articles, four books, and more than 100 scholarly reports and conference papers.

Dr Dong serves as a committee member of the Rare Disease Specialty Committee under the Chinese Hospital Association, and holds leadership or advisory roles in the Asia-Pacific Alliance of Rare Disease Organizations (APARDO), the China Alliance for Rare Diseases, the Illness Challenge Foundation, Beijing Aili Myasthenia Gravis Care Center, Rare Disease Hong Kong, and Hong Kong Neuro-Muscular Disease Association.

Xin Du

CEO
Evergreen Therapeutics

Dr. Du Xin, the CEO of Shenzhen Eglion Pharmaceuticals Co., Ltd. and a former FDA review expert, obtained his Ph.D. from the University of Florida and completed his postdoctoral training at the National Institutes of Health (NIH). He has worked at the FDA and several pharmaceutical companies. Currently, he serves as the CEO of Shenzhen Eglion Pharmaceuticals Co., Ltd. Dr. Du Xin has extensive experience in biopharmaceuticals and small molecule products, and possesses unique regulatory experience combining FDA and industry perspectives. He is well-versed in the regulations of the FDA and globally regarding drug development, production, quality management, clinical design, and trials.

Bettina Ernst

Director, Bernina BioInvest Ltd
Vice President, Swiss Biotech Association (SBA)

Dr. Bettina Ernst is a biotech entrepreneur and investor. She has been investing in healthcare companies for the past 10 years. She also serves on the board of several early-stage biotech companies, on the board of the Swiss Biotech Association, and as a member of the advisory board of the Swiss Entrepreneur Fund and of the Innovation Council of Innosuisse. Bettina is a co-founder of two biotech companies. Prior to her investment and entrepreneurial activities, she worked for 10 years in fundamental immunology in the US (Scripps Research, San Diego, CA) and in Europe. Bettina holds a PhD in immunology and an undergraduate degree in natural science from the Federal Institute of Technology (ETH) in Zurich. Bettina resides in Switzerland.



Kseniia Eruslanova

Head of the Laboratory of the Cardiovascular aging
Pirogov Russian National Research Medical University

Kseniia A. Eruslanova, MD, MSc, PhD (Cand. Med. Sci.), is a cardiologist and geriatrician serving as Head of Laboratory. She earned her MD in General Medicine from I.M. Sechenov First Moscow State Medical University in 2009 and completed a cardiology residency at the Russian Cardiology Research and Production Center in 2011. In 2017, she received an MSc in Cardiovascular Research from King's College London. She completed the Harvard Medical School Global Clinical Scholars Research Training Program (1-year certificate) in 2022 and defended her Candidate of Sciences dissertation on cardiovascular status and outcomes of comprehensive geriatric assessment in individuals aged 95 years and older at the Pirogov Russian National Research Medical University the same year. She is a member of the Russian Society of Cardiology, European Society of Cardiology, American Heart Association, American College of Cardiology, Russian Association of Gerontologists and Geriatricians, and the European Geriatric Medicine Society.

Frank (Xiaohu) Fan

Founder CEO
Wondercel Biotechnology HK

Dr. Frank Fan is the founder of Legend Biotech, the cell therapy company with the highest market capitalization globally. In 2017, Dr. Fan developed Carvykti™, a groundbreaking CAR-T therapy that achieved curative outcomes and was co-developed with Johnson & Johnson for global commercialization. By 2025, Carvykti™ generated approximately $2 billion in revenue, marking it as the first Chinese-originated blockbuster drug to penetrate the global market.
Recognized by Endpoints News as one of the "Top 20 Most Influential Biopharma R&D Leaders Worldwide," Dr. Fan also received China's National Science and Technology Progress Award (First Prize) in 2024. Carvykti™ earned nominations for the prestigious Galen Prize, widely regarded as the "Nobel Prize of Pharmaceuticals."
In 2022, Dr. Fan transitioned to establish Wondercel Therapeutics, where he successfully pioneered a low-cost universal cell technology platform for the treatment of cancers.

Yibin Feng

Professor and Director
School of Chinese Medicine，The University of Hong Kong

Professor Feng Yibin has been recognized as one of the top 1% highly cited researchers globally by Clarivate Analytics ESI for eight consecutive years since 2017. In 2024, he received the honor of "Global Highly Cited Researcher," placing him in the top 0.1% worldwide. He has published over 630 papers. Additionally, Stanford University has listed him among the top 2% of scientists globally for 2022-2024. According to the 2024 AD Scientific Index, Professor Feng ranks 7th worldwide and 1st in Hong Kong in the field of Complementary and Integrative Medicine.

Abby Gao

Director of Investment Research，Deputy Head
DEFTA Partners (Hong Kong)

Dr. Abby Gao is the Deputy Head of DEFTA Partners Hong Kong and oversees the operation of the Hong Kong based activities. She works as an investor in a wide range of biotech areas in Hong Kong to identify the advanced technology with potential, work closely with researchers, and help the tech-based startup grow. Before DEFTA, she worked in Hong Kong Science and Technology Parks Corporation (HKSTP) promoting development and commercialization of innovative technology in therapeutic area and facilitating the business development of biotech companies in Hong Kong. Before moved to Hong Kong, Dr. Gao was trained as a scientist with Ph.D. in Chemistry and worked in Merck Sharp & Dohme focusing on drug discovery in the U.S..



J. Christopher Giffin

President & COO
Bench International Search, Inc.

Chris Giffin's career in biotechnology has spanned 40 years, including 16 years with biotechnology pioneer Amgen where he held roles in research, human resources, business development and corporate development. During his tenure in human resources, Chris led the company's recruitment activities during some of the company's most dramatic periods of growth as it evolved from a biotechnology research and development organization into a fully-integrated pharmaceutical company. As a result, his recruitment responsibilities spanned the spectrum of the company's operations including research, clinical development, manufacturing, and commercialization. As a business development executive with Amgen, Chris played a leadership role in the evaluation and negotiation of multiple corporate collaborations and partnerships focusing on both product and technology opportunities. Following Amgen and prior to Bench, he held executive management positions with two privately held biotechnology companies, where he played a leadership role in business development and financing activities. With Bench, Chris leads executive recruitment and advisory services focused on C-level and Board roles for a broad range of life sciences clients, including biotechnology, pharmaceuticals, instrumentation, and medical devices. Chris holds a B.S. degree in Microbiology from the University of Oklahoma, and an M.S. degree in Cell Biology from the University of California, Riverside.



Chunlong Guo

Chairman and CEO
Shuimu BioSciences

Founder and CEO of Shuimu, Chunlong Guo leads the company, a pioneer in advancing AI driven cryo-electron microscopy (cryo-EM). Under his stewardship, Shuimu built the largest CryoEM platform on this planet with 8 300kv CryoEM's and has broken global monopolies by developing TOTEM 300s, a 300kv CryoEM flagship model, achieving 1.4A resolution, while ensuring data security—critical for life science research and drug discovery.
Guo drives end-to-end innovation, from developing the proprietary SMART cryo-EM computing platform (boosting structural analysis efficiency) to building global supply chains. He also fosters strategic collaborations, establishing R&D bases and open structural biology platforms with universities, accelerating next generation AI driven cryo-EM adoption.

Jiguang Guo

associate professor
Heibei University

Guo Jiguang, Ph.D., is an associate professor and master's supervisor at the School of Basic Medical Sciences, Hebei University. His main research areas include the pathogenesis of Parkinson's disease and therapeutic drugs. Received a bachelor's degree in Biology from the University of Science and Technology of China in 2001, a Doctor of Science degree from Shanghai Institutes for Life Sciences, Chinese Academy of Sciences in 2009, and a visiting scholar at UCLA in 2016. He has presided over one project funded by the National Natural Science Foundation of China and several provincial-level projects, and participated in 973, 863 and several national-level projects. Published works such as "Pathogenic Biology", and published more than ten SCI papers in international journals such as Cell Research, Genome Biology, and Peer J at home and abroad, and won the second prize of Science and Technology Progress of Baoding City

Yike Guo

Provost
The Hong Kong University of Science and Technology

Professor Yike Guo is the Provost of the Hong Kong University of Science and Technology, Chair Professor in the Department of Computer Science and Engineering as well as Department of Electronic and Computer Engineering, and also Director of Hong Kong Generative AI Research and Development Center. He is a world-renowned computer scientist who has led several large-scale AI and data science research projects in Hong Kong, Mainland China, the UK and other European countries. He was the Founding Director of the Data Science Institute at Imperial College London, one of its seven Global Institutes, as well as the Vice President (Research and Development) at Hong Kong Baptist University. He is a Fellow of the Royal Academy of Engineering (FREng), a Member of Academia Europaea (MAE), Fellow of the Hong Kong Academy of Engineering Sciences (FHKEng), Fellow of the Institute of Electrical and Electronics Engineers (FIEEE), Fellow of the British Computer Society (FBCS), and Fellow of Chinese Association for Artificial Intelligence (FCAAI).

Professor Guo was awarded the Outstanding Contribution Award of the 2022 Wu Wenjun Artificial Intelligence Science and Technology Award, which is considered to be the highest award for Chinese AI science and technology.
In 2025, Professor Guo was selected by Sing Tao News Corporation Limited and the Leader of the Year 2024 Selection Committee as the winner of the "Leader of the Year 2024 (Education/ Professions/ Technology & Innovation Category)". This election has been held since 1994 and aims to recognize leaders who have made significant contributions to Hong Kong, Mainland China, and the world.

Alireza Haghighi

Chief Executive and Founding Director
Harvard International Center for Genetic Disease

Professor of Medicine, Harvard University
Chief Executive and Director, Harvard International Center for Genetic Disease, Harvard Medical School
President of the Advancement Initiative for Medicine and Science

Dr. Alireza Haghighi is a Pioneering leader transforming global health through groundbreaking advancements in life science and AI. He is internationally recognized for his leadership in projects aimed at improving health and well-being worldwide. Dr. Haghighi regularly advises government leaders and industry executives on national health policies and initiatives. He is the founder of multiple startups at the intersection of AI and life sciences.

Dr. Haghighi is the Director and Principal Investigator of the Bahrain National Genome Program and has contributed to the design, development, and leadership of national projects in other countries. He is also the Founding President of the Advancement Initiative for Medicine and Science (AIMS), a global foundation dedicated to advancing medical science and healthcare worldwide, which has improved the health of people across the globe.

Dr. Haghighi has received numerous prestigious awards and prizes, including the Global Health Pioneer Award for his innovative strategies and initiatives to enhance the quality of life of people around the world and the International Genetic Disorders Prevention Award.

Dr. Haghighi is an American board-certified geneticist, and a clinician-scientist at Mass General Brigham. He completed his graduate and clinical training at the University of Oxford and Harvard Medical School.

Desmond Hau

Chief Executive Officer
Pangenia Inc.

Dr. Desmond HAU obtained his Bachelor of Science (Honors) [B.Sc. (Hons)] in Applied Biology from Hong Kong Baptist College (University) (Year 1990), Master of Philosophy (M.Phil.) in Biochemistry from The University of Hong Kong (Year 1993), and Doctor of Philosophy (Ph.D.) in Research & Development Division of School of Chinese Medicine from Hong Kong Baptist University (Year 2012).

After serving as the Scientific Officer (Medical) for 2 years in Department of Clinical Oncology of Queen Elizabeth Hospital, he founded Bio-Gene Technology Ltd (Bio-Gene; www.bio-gene.com.hk), a leading regional company specializing in distribution of research and medical instruments, reagents and consumables since Year 1993. Currently, the business of Bio-Gene spans from Hong Kong, Macau, mainland China to Southeast Asia markets.

To enter the business of clinical diagnostic testing services and in vitro diagnostic (IVD) products, Dr. HAU invested and joined Pangenia Inc. (www.pangenia.com), a leading local molecular diagnostic testing services company, and DiagCor Life Science Ltd. (www.diagcorlifescience.com), an IVD products company focused on R&D, manufacturing & QC, product registration and export sales, as Board of Director and Chief Executive Officer since Year 2016. Collaborating with the School of Chinese Medicine of Hong Kong Baptist University in Year 2008, Dr. HAU established and introduced a series of Chinese Medicinal health food products into the market through the branding “BU Health” and, after Year 2018, a new brand called “One Health”.

Dr. HAU has over 30 years of experience in technology identification & commercialization, market development and business management, specializing in biomedical sciences, clinical diagnostics, medical devices and pharmaceutical products markets in various countries and cities.
Dr. Hau has also served as External Grant Assessor at Knowledge Transfer Office of City University of Hong Kong, a member of the Faculty of Science Advisory Committee of Hong Kong Baptist University, and Programme Advisory Panel Member at School of Medical and Health Sciences of Tung Wah College.

Gongxin He

CEO
CureGene

Dr. He is the Founder and CEO of CureGene. CureGene is a clinical stage small molecule and Oligonucleotide biotech, focusing on cardio-cerebrovascular and antiviral disease areas. By utilizing its advanced prodrug technology platform, CureGene developed several best-in-class and first-in-class assets in pipeline.

Dr. He formerly served as Senior R&D Director at Gilead Sciences in the U.S., and the first General Manager of Gilead China. He is also a globally recognized expert in prodrug technology. Dr. He has led and participated in the development of multiple world-class new drugs. He is the principal inventor and project leader of tenofovir alafenamide (TAF), the most widely used global blockbuster for treating HIV and hepatitis B, developed using his proprietary targeted prodrug technology. He is also a co-inventor of several antiviral therapies, making significant contributions across influenza, HIV, HCV, and HBV treatment areas. A world-leading expert in targeted prodrug development, he has authored textbook chapters on prodrug technology for U.S. universities. Dr. He possesses extensive expertise in medicinal chemistry, R&D management, supply chain operations, and enterprise administration. He has deep knowledge of China's pharmaceutical system and broad industry connections. Additionally, he has a proven track record in pharmaceutical entrepreneurship, successfully translating scientific innovation into clinical and commercial impact. His work bridges cutting-edge drug design and practical healthcare solutions, advancing global antiviral therapy. With a strong background in both science and management, Dr. He has played a key role in bringing innovative medicines from concept to market, improving patient outcomes worldwide. His leadership combines technical excellence with strategic vision in drug development and commercialization.



Tim Hirst

Chairman & CEO
GPN Vaccines Inc

Dr Tim Hirst is the Chairman and CEO of GPN Vaccines Inc.(https://gpnvaccines.com) a US biotechnology company with an Australian subsidiary conducting clinical trials of a new vaccine against the world's foremost bacterial pathogen, Streptococcus pneumoniae. He is an entrepreneur and investor with extensive expertise in the life sciences, executive management and venture capital investment. He was previously CEO of ANU Connect Ventures, a $30M pre-seed VC fund based in Canberra, the Vice President and Deputy Vice Chancellor for Research & Innovation at The University of Sydney and Professor & Head of Microbiology at the University of Bristol, UK. He is an active angel investor working with investment groups throughout Australia and US to assist early-stage companies to raise capital and develop their innovative technologies. He is a Trustee Director of Griffin Accelerator Holdings Pty Ltd, Canberra's leading business incubator. In 2022, TechBoard named him, Australian Angel Investor of the Year. Tim also holds positions as Non-Executive Chairman of Brain Changer Pty Ltd, Flex-G Pty Ltd, Dentroid Pty Ltd and Gamma Vaccines Pty Ltd, and as Director of PPB Technology Pty Ltd. He is also an Honorary Adjunct Professor at the University of Adelaide.

I-ming Hsing

Professor, Department of Chemical and Biological Engineering (CBE)
The Hong Kong University of Science and Technology

Dr. I-Ming Hsing is Professor and Former Head of Chemical and Biological Engineering at the Hong Kong University of Science and Technology (HKUST). He holds a BSc from National Taiwan University (1990) and an MSCEP and PhD from MIT (1994, 1997). Dr. Hsing's research integrates molecular biology, reaction engineering, and micro/nanofabrication to advance nucleic acid engineering and biomaterials. His group develops innovative diagnostics, including CRISPR-based platforms for point-of-care testing and community surveillance, and nature-derived biomaterials for chronic wound care. A pioneer in molecular diagnostics, he holds multiple patents and has published extensively. Dr. Hsing serves on the editorial boards of leading journals, serves as a member of the Hong Kong SAR Government's Research Grants Council, and is the Founding President of the Asia Pacific Biomedical Engineering Consortium, fostering collaboration in biomedical engineering and translational medicine.



Alex Huang

Global VP and Head of Cell Therapy
BeOne Medicines

Dr. Alex Shih-Min Huang joined BeOne Medicines in April 2021 and is the Vice President, Head of Cell Therapy. He is an experienced leader of science and people in pharmaceutical R&D with substantial proficiency in drug discovery and development. Over the span of more than 20 years, he built a command of portfolio oversight and hands-on, proven track record spanning target discovery/validation, hit-to-lead, lead nomination, lead optimization, development candidate selection, early/late development, life cycle management, clinical biomarkers, and forward/reverse translational research, at Novartis, Sanofi, Genentech, BMS, and AbbVie with increasing responsibility.

Prior to joining BeOne Medicines, Alex was deeply engaged in the clinical development space at Genentech, BMS, and AbbVie. Most recently, he was the Senior Director of Precision Medicine Oncology at AbbVie, leading a group of ~50 seasoned scientific personnel, delivering translational research/clinical biomarker/CDx strategies, critical data packages, and relevant interpretations to facilitate development and commercial decisions from pre-GLP tox to Ph1/2/3 trials and life cycle management, covering >20 pipeline molecules consist of various therapeutic modalities (CAR-T, bispecific, ADC, naked therapeutic antibody, small molecule, etc.) targeting diverse biological space including immuno-oncology, apoptosis, and B cell signaling pathways in both solid tumors and hematological malignancies. Prior to entering the translational medicine space, Alex was a drug discovery program PTL with Novartis Institutes for Biomedical Research (NIBR) and Sanofi Oncology, leading drug discovery teams to advance multiple programs spanning target discovery/validation, hit finding, lead optimization, lead nomination, development candidate selection, and pre-clinical translational research.

Dr. Huang obtained his doctoral degree in Microbiology and Immunology from the University of Rochester Medical Center and completed his post-doctoral training at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego.

Betty Huang

VP, Head of Collaborate to Cure Hub China
Bayer Pharmaceutical

Betty Huang is currently Head of Collaborate to Cure (CtC) Hub China at Bayer Pharmaceuticals. She is responsible for steering regional business development strategy, driving key initiatives and deal making as well as managing strategic alliances covering both commercial and academic collaborations for Bayer Pharmaceuticals in China.
With more than 20 years of extensive experience, Betty Huang is a seasoned professional in the arena of business development and licensing and has accumulated expertise and know-hows in finance, investment, and healthcare industry. Since September 2022, she has served as Executive Chairman of the China Healthcare Business Development Alliance (CHBD) and made outstanding contributions to promoting pharma innovation ecosystem and BD community, elevating professional capabilities and cultivating talents.



Song Huang

Deputy Director
National Institute of Biological Sciences, Beijing

Dr. Song Huang is currently the deputy director of National Institute of Biological Sciences, Beijing (NIBS). He received his B.S. degree from Peking University and his Ph.D. degree of Biological Chemistry from University of Texas Southwestern Medical Center at Dallas. Dr. Huang has accumulated rich experience in developing and promoting NIBS—part of a strategic government initiative to further national development of science and technology, which is the new model for operating scientific institutions in China. In addition, he keeps exploring innovative mechanisms to promote the commercialization of scientific and technological advances, and helps found several companies. Dr. Huang was selected to the “Beijing Overseas Talents Program”, and granted with the senior specialized technique qualification by Beijing Senior Specialized Technique Qualification Evaluation Committee.

Yuanyu Huang

School of Life Science
Beijing Institute of Technology

Dr. Yuanyu Huang, a tenured professor at Beijing Institute of Technology, has been recognized as a national-level young talent and a leading figure in Beijing and Suzhou, and is ranked among the top 2% of scientists worldwide as released by Elsevier. His research focuses on nucleic acid drugs and vaccines, with over 70 papers published as corresponding author in journals such as Nat Rev Bioeng, Sci Adv, Nat Commun, STTT, and Adv Mater. He has authored more than 120 papers in total and filed 60 patents, of which around 20 have been granted. His accolades include being named a Forbes China Industry Leader, RNA Therapy Rising Star, Capital Frontier Academic Achievement awardee, and receiving First-Class Natural Science Awards from Beijing (9/12) and Guangxi (5/6). He serves as associate editor for Exploration and Mol Ther, advisory board member for Trends Mol Med, and editor for Chin Chem Lett and other journals. Dr. Huang leads the development of the siRNA drug RG002C0106, which entered Phase II trials in China in August 2025.

Aimin Hui

Founder, Chairman & CEO，enCureGen Pharma
Professor，State Key Laboratory of Respiratory Diseases

Dr.Hui during the COVID-19 pandemic, in collaboration with Germany's BioNTech, actively participated in the research and development of the first mRNA product (mRNA COVID-19 vaccine Comirnaty/Fubitai) in human history, and led the research and development of the vaccine (Fubitai) in Greater China and its launch in Hong Kong, Macao and Taiwan; prompted the China's mRNA industry. During his career, Dr. Hui has driven the global development and market approval of several anti-tumor blockbusters, including Ixazomib, Isatuximab, et al. In 2013, Dr. Hui pioneered the clinical registration model of ' Chinese extension study of global Phase III clinical trial', substantially shorten the time span for innovative drugs in China. Dr. Hui published 100+ papers in prestigious journals including NEJM, Nature Med, Lancet Onco, Cancer Cell and Blood and authored 8 scientific monographies. Dr. Hui is the recipient of the 2021 International Award of the 4th Translational Medicine Awards among 20+ other prestigious awards. Dr. Hui is the former Executive President, Chair of the Scientific Committee, President of Global R&D and Chief Medical Officer of Fosun Pharma. Former Global Vice President of Sanofi，Director of the Shanghai Key Laboratory for Stem Cell Therapy.

Ka-Kit Hui

Professor and Director
UCLA Center for East-West Medicine

Ka-Kit Hui, MD, FACP, is the Wallis Annenberg Chair in Integrative East-West Medicine, Professor, Founder and Director of the Center for East-West Medicine at the Department of Medicine of the David Geffen School of Medicine at UCLA. Dr. Hui, a Fellow of the American College of Physicians, is an internationally acclaimed educator and researcher and is board-certified in Internal Medicine and Clinical Pharmacology, with an expertise in Geriatrics. He is a recognized authority on Chinese Medicine and integrative medicine, and is bilingual in Chinese and English. Since 1990s, Dr. Hui has served as an advisor to the World Health Organization (WHO) in different areas, including Standard Terminology in Traditional Chinese Medicine, Appropriate Integration of Traditional and Complementary Medicine (T&CM) into Health Systems and Health Care Services, and Quality of Academic Education in Traditional Medicine. He has also provided consultation to the U.S. Food and Drug Administration (FDA), National Institutes of Health (NIH), health insurance companies, drug companies and the media, and has held visiting and honorary professorships in various universities throughout the world.

Darren Ji

Chairman & CEO
Elpiscience Biopharmaceuticals

Darren Ji is the Chairman and CEO of Elpiscience Biopharmaceuticals. He also serves as a board director at Legend Biotech (NASDAQ: LEGN). Previously, Darren was a Venture Partner at Lilly Asia Ventures (LAV), where he co-founded Elpiscience in 2017.

Before that, Darren served as Global Head and Vice President of Roche Business Development for Asia and Emerging Markets. In this role, he led strategy and deal execution across more than 100 countries, championing and closing numerous key transactions. He managed a global team and built a strong business network in major markets, including China, Japan, Korea, Australia/New Zealand, Russia, and Brazil.

A serial entrepreneur, Darren has a distinguished career spanning drug R&D and business development. He held leadership roles at Procter & Gamble and co-founded PharmaLegacy Laboratories, where he served as CEO. A highly respected figure in global life sciences, he is a sought-after speaker at industry forums and an active community builder. He was one of the longest board members of BayHelix Group, a community of life science business leaders of Chinese heritage. He currently serves on the Advisory Committee to BioCEO and Investor Conference.

Darren holds an M.D. from China Medical University, a Ph.D. from the University of Sheffield, and an MBA from the University of Chicago.



Qunsheng Ji

CEO
Sirius Therapeutics

Dr. Qunsheng Ji, the Chief Executive Officer of Sirius Therapeutics, is a seasoned pharmaceutical executive with near 30-year experience in drug discovery, translational medicine, and business leadership. Prior to Sirius Therapeutics, Dr. Ji was Vice President and Head of Oncology and Immunology Unit at WuXi AppTec, where he led team of over 1000 R&D personnel. Prior to WuXi AppTec, Dr. Ji was Head of Bioscience, Asia and Emerging Market iMed of AstraZeneca. He also served as Director of Translational Medicine, overseeing AstraZeneca's global translational medicine portfolio. Dr. Ji started his industry career in the U.S where he worked at ONYX Pharmaceuticals and OSI Pharmaceuticals.
Dr. Ji received his Ph.D. degrees in Cell Biology from Peking Union Medical College and Vanderbilt University in the U.S. He also received his Bachelors degree of Medicine in China, and is the author of more than 50 peer-reviewed research articles and book chapters.



Yonghua Ji

Professor
Hebei University

A former researcher at the Shanghai Institute of Physiology, Chinese Academy of Sciences, Dr Ji Yong Hua is a recipient of the State Council Special Allowance and the National Outstanding Young Scientist Award. He holds a PhD in Pharmacy from Japan. In 1987, he served as a foreign researcher at the School of Medicine of the North Region of Marseille, France, and in 1997, he became a JSPS Special Research Fellow at Shizuoka Prefectural University, Japan. He has served as Secretary-General and Vice President of the Chinese Society of Neuroscience; three terms as Executive Director of the Chinese Biophysical Society; and concurrently served as a member of the National Committee of the Chinese People's Political Consultative Conference (CPPCC) for three terms, an Executive Member of the All-China Federation of Trade Unions for two terms, and Vice Chairman of the Shanghai Citizens' League for two terms. His interests focus on the neuropharmacology and toxicology of natural toxins, and he has published over 200 academic papers. He is currently a Distinguished Research Fellow at Hebei University.

Gina Jiang

Managing Director
Hong Kong Institute of Biotechnology

Dr. Gina Jiang is the Managing Director of the Hong Kong Institute of Biotechnology (HKIB), affiliated with The Chinese University of Hong Kong, where she has led the institute since April 2020. A key architect behind the development of a GMP-certified facility for Advanced Therapy Products, Dr. Jiang is accelerating the growth of cell and gene therapy capabilities in Hong Kong. Her international background spans leadership roles and entrepreneurial ventures in the San Francisco Bay Area and Taipei. She holds degrees from the University of Toronto and Peking University and conducted research at the NIH and Stanford University.



Jewel Fan Jiang

VP, CFO, Executive Director
ecretary of the Board

Ms. Jiang Fan is primarily responsible for the company's investment and financing, overall financial planning and analysis, and strategic planning. Ms. Jiang has over 15 years of experience in strategic consulting, investment, and financing within the pharmaceutical industry, with extensive experience in business strategy planning, transaction structuring, and portfolio development. Ms. Jiang holds a bachelor's degree in biotechnology from Huazhong University of Science and Technology and an MBA from China Europe International Business School.

Crystal Yuanyuan Jin

Co-Founder & CEO
Bound Therapeutics

Dr. Yuanyuan Jin is the Co-Founder and Chief Executive Officer of Bound Therapeutics, a biotechnology company developing AI-driven RNA therapeutics with targeted delivery for treatment-resistant diseases. With over 15 years of expertise in RNA biology, drug delivery, and therapeutic development, she is advancing Bound's mission to establish microRNA-targeted therapy as a new modality in oncology and beyond.

Dr. Jin earned her PhD in Molecular Pharmacology and Structural Biology from Thomas Jefferson University, where she focused on microRNA-based therapeutics for cancer. At Bound, she leads the development of BND6482, a first-in-class miR-21 inhibitor that blocks multiple cancer survival pathways to overcome tumor resistance. Conjugated to a tumor-targeting peptide for selective delivery without lipid nanoparticles, BND6482 has shown superior efficacy and safety in aggressive cancer models.

She also spearheads Bound's proprietary Magic Bullet Designer™ (MBD) platform, which applies AI/ML to discover disease-specific delivery peptides. This innovation enables programmable RNA medicines with applications extending to CNS and fibrotic diseases.

Before founding Bound, Dr. Jin contributed to RNA drug discovery across academia and biotech. At Bio Hong Kong, she will present how rational design and targeted delivery are unlocking the therapeutic potential of microRNAs, shaping the future of precision RNA medicine.

David Kin Jin

Chief medical officer
Deep Harbour Cell Valley Healthcare and Technology Co.Ltd

Dr. David Kin Jin is a Chinese-American scientist holding MD and PhD degrees from the United States, with clinical practice in Internal Medicine, Hematology, and Oncology. As a specially appointed chief medical expert at Shenzhen Cell Valley, he received clinical training and later became a professorship in Internal Medicine, Hematology, and Oncology at New York Presbyterian Hospital (a teaching hospital affiliated with Cornell and Columbia Universities). His career includes residency at Memorial Sloan Kettering Cancer Center (MSKCC), senior research fellowships and clinical directorships at the Ansary Stem Cell Institute of Cornell University School of Medicine and New York Presbyterian Hospital, former FDA Center for Drug Evaluation (CDER) review specialist, and Asia-Pacific special envoy for FACT International Cell Preparation Certification.

Erik Ko

Senior Technical Manager
Nano and Advanced Materials Institute

Dr. Erik Ko holds a BSc degree in Biochemistry and a PhD degree in Chinese Medicine from the Chinese University of Hong Kong. He has over 20 years of experience spanning academic research and commercial R&D, and specializes in advanced materials science and nanotechnology for TCM compound delivery enhancement. Dr. Ko has pioneered breakthrough material innovations including revolutionary water solubility platforms for insoluble natural compounds, rapid-release nanocarrier systems, and smart delivery matrices. Over the past five years, he has provided Hong Kong local industrial clients with R&D expertise, delivering actionable insights and value-added intelligence for different R&D challenges. His interdisciplinary expertise bridges ancient medicinal knowledge with modern materials engineering.

Christopher Koon Chi Lai

President
Hong Kong Society for Microbiology and Infection

He graduated from the Chinese University of Hong Kong in 1998. He started his career as a Physician and obtained his MRCP in 2001 before moving on to Clinical Microbiology in 2003. He is a Fellow of Royal College of Pathologists (UK), Hong Kong College of Pathologists and Hong Kong Academy of Medicine.
He is currently Vice president, and Chairman of Education Committee of the Hong Kong College of Pathologist. His research interests include the application of advanced diagnostic technologies for detection, and control infectious diseases.

Tommy Kam Chun Lam

Senior Electronics Engineer (Medical Device)1
Department of Health

Ir Tommy Lam serves as a Senior Engineer of the Medical Device Division in the Department of Health of the HKSAR Government. He is mainly responsible for the implementation of the Medical Device Administrative Control System and management of relevant IT services, with a view to facilitating the development of a long-term statutory regulatory framework for medical devices in Hong Kong. Drawing on a background in electronics and biomedical engineering, Ir Lam previously worked in various divisions at the Electrical and Mechanical Services Department, including hospital engineering, innovation, and technology and media relations. His work there focused on adopting artificial intelligence and digitalization in engineering services, an area of knowledge he now applies to the medical device regulatory field.



Na Lang

Deputy Director, Disease Prevention Center
Xiyuan Hospital, China Academy of Chinese Medical Sciences

Dr. Lang Na is a Chief Physician and Deputy Director of the Disease Prevention Center at Xiyuan Hospital, China Academy of Chinese Medical Sciences (CACMS). A Ph.D. graduate from CACMS, she is a recognized National Backbone Talent in TCM inheritance. Dr. Lang also serves as a Doctoral Supervisor at CACMS and a Master's Supervisor at Beijing University of Chinese Medicine.
She holds key roles in several prestigious academic committees, including the Dermatology Committee of the Beijing Association of Chinese Medicine. An active researcher, she has led over 10 national and provincial projects and published more than 20 papers as first or corresponding author. Her outstanding research contributions have been honored with the Third Prize of the Chinese Association of Integrative Medicine Science and Technology Award.



Hsiang-Ying Sherry Lee

Associate Professor
Peking University

Hsiang-Ying Lee is a Principal Investigator at the School of Life Sciences, Peking University, and the Peking-Tsinghua Center for Life Sciences. Using red blood cell development as a model, her research integrates multi-omics approaches to elucidate the chromatin regulatory mechanisms underlying hematopoiesis, investigate the pathological processes of hematopoietic development and aplasia, and identify potential diagnostic and therapeutic targets. Her work, as first or corresponding author, has been published in journals including Nature, Cell, Nature Structural & Molecular Biology, and Molecular Cell. She has been awarded the National High-Level Overseas Talent Program and has received the Class A (formerly Distinguished Young Scholar) grant from the National Natural Science Foundation of China.

Shawn Lee

Fouder
Chinese Peptides Company

Dr. Shawn Lee founded Chinese Peptides Company in 2001, leading an international-standard team to achieve significant breakthroughs in peptide R&D and industrialization.
In 1989, Dr. Lee co-founded American Peptide Company in Silicon Valley, where he served as Chief Operating Officer, overseeing all aspects of the company's operations. In 2005, he founded CPC Scientific Inc. in Silicon Valley, and has served as its CEO ever since.
Dr. Lee is an outstanding peptide expert with over 30 years of experience, having propelled the clinical development and industrialization of over a hundred peptide drugs. He possesses extensive experience in complex peptide modification and synthesis, international regulations, peptide drug industrialization, and the creation of novel peptide drugs.
Dr. Lee previously served as Vice Chairman and Director of Xinbang Pharmaceutical. (002390) from 2015 to 2020, and was a co-founder of Lake Ventures from 2017 to 2021. He is also a visiting professor at the University of the Pacific School of Pharmacy in the United States. In 2024, Dr. Li was appointed President of the CPC Innovation Technology Research Institute (CITRI).
Dr. Lee received his Ph.D. in Science from the Chinese Academy of Sciences in 1989, followed by a postdoctoral fellowship at the University of California, Berkeley. He also holds an MBA from IMD business school of Switzerland and an EMBA from Cheung Kong Graduate School of Business, and was recognized as a Centennial PUMC-First Scholar in Medicine and Health Industry.

Simon Ming Yuen Lee

Director
PolyU-BGI Joint Research Centre for Genomics and Synthetic Biology in Global Ocean Resources

Prof Simon Lee's research interests interest lies in the discovery of drug-like agents from natural products including small molecules and biologics for use in various therapeutic areas, including brain disorder and neurodegenerative diseases. His dedication to education and research in the fields of omics, pharmacology and toxicology has led to over 360 scholarly articles, including Nature, Nature Genetics, Nature Communications (4×) and Science Advances, and over 20 granted patents. Simon is in Stanford university's list of top 2% of most-cited scientists in Pharmaceutical Science and Biology (with h-index: 65 from Scopus). His dedication to education and research in the fields of pharmacology and toxicology has led to over 300 scholarly articles, including Nature Communications (4×), and over ten granted patents. He has received over 30 grants (exceeding 80 million Hong Kong dollars),. Prof Simon Lee has extensive collaboration experience with pharmaceutical and biotechnology industries. He has founded AIM Pharmaceutical International Limited (AIM Pharma), specializes in developing innovative nutraceuticals and therapeutic drugs for neurodegenerative diseases, which has been selected for RAISe+ scheme in 2025.

Wayne Lee

Assistant Professor
Department of Orthopaedics and Traumatology, CUHK

Dr. Wayne Lee earned his PhD in Pharmacology from The Chinese University of Hong Kong (CUHK) in 2009, followed by postdoctoral training in Orthopaedics and Traumatology at CUHK, specializing in cell therapy. With over 127 publications in peer-reviewed international journals and a Scopus H-index of 36, his research is supported by prestigious grants, including RGC, HMRF, ITF, InnoHK, and ASBMR. Dr. Lee serves on the Youth Committee of the Journal of Orthopaedic Translation and is Co-Director of the CUHK-Nanjing University Joint Scoliosis Research Society. From 2022 to 2025, he was the Site Authorized Person at the ATP GMP Center, Hong Kong Institute of Biotechnology, securing the first local institution-led ATP manufacturing license and releasing several CAR-T products for clinical trials. His work focuses on GMP-compliant advanced cell therapies and novel drug interventions for musculoskeletal disorders. In 2024, Dr. Lee co-founded Trilateral Biopharmaceutical, a spin-off from the InnoHK Center for Neuromusculoskeletal Restorative Medicine, driving innovation in regenerative medicine to improve patient outcomes.

Chuen Yan Leung

Co-founder
Silver Dart Capital Partner (Healthcare Investments),
Value Partners Group

Dr. Chuen Yan Leung is currently Partner (Healthcare Investments) at Value Partners Group, one of Asia's largest independent asset management firms offering world-class investment services and products for institutional and individual clients globally. He has 14 years of experience in the healthcare ecosystem from R&D, biotechnology start-ups, venture capital, and private equity. Previously Dr. Leung was a co-founder of Silver Dart Capital, a boutique healthcare private equity firm and a private equity vice president at EQT Group, a Swedish global investment organization with EUR 210bn assets under management as of 2023. He has previously held roles such as Vice President at Aeneas Capital and Lead Scientist at Procella Therapeutics. Dr. Leung is currently the Vice President of the Hong Kong Biotechnology Organization, and a member of the Shanghai Pudong Chinese People's Political Consultative Conference. Dr. Leung received his PhD in Stem Cell Biology from the University of Cambridge, and BSc in Biochemistry from Imperial College London.

Bin Li

Associate Director for Research
Shanghai Institute of Immunology

Dr. Li Bin is a renowned immunologist serving as Deputy Director for Research at the Shanghai Institute of Immunology and a Distinguished Professor at Shanghai Jiao Tong University. Recognized as a National Science Fund for Distinguished Young Scholar (2015), Shanghai Leading Talent, and Outstanding Academic Leader, he has held leadership roles including Vice President of the Shanghai Overseas Returned Scholars Association and Chair of its Biopharma Chapter. With over 100 corresponding-author publications in top journals (e.g., Immunity, Nature Immunology) on FOXP3+ Treg research, he has led multiple national/international grants (NSFC Key Projects, Sino-US/Poland collaborations). His industry engagements include Founder/Science Committee Chair of Prometheus Biosciences (2018-2024), Huawei Health Cloud Advisor (2024), and executive roles in academic societies (e.g., Vice President of PENN Medicine China Club, Standing Committee Member of the Chinese Society for Cell Biology).



Chi-kong Li

Research Professor
Department of Paediatrics, The Chinese University of Hong Kong

Prof. Chi-kong LI currently is Research Professor at Department of Paediatrics of The Chinese University of Hong Kong, and honorary consultant at Hong Kong Children's Hospital. Dr. Li is specialized in paediatric haematology, oncology, stem cell transplantation and cellular therapy. He was the past Continental President of Asia of International Society of Pediatric Oncology. His main interest is in childhood leukaemia, palliative care and bioethics. He has published over 400 peer-reviewed papers.

David Li

Vice President
Innovative Institute of Basic Medical Sciences of Zhejiang University

Li Dawei, Ph.D. in Pharmaceutical Sciences, serves as Vice President of the Innovative Institute of Basic Medical Sciences of Zhejiang University. His primary research and translational work focus on the field of synthetic biology. He has led or served as a key contributor in completing eight provincial/ministerial-level research projects and over ten industry-sponsored projects, resulting in more than ten provincially or ministerially recognized scientific achievements. With over 20 published scientific papers and two provincial/ministerial-level science and technology awards, he has extensive practical experience in technology transfer, industrial application of research, industrial strategic planning, and project investment. He has spearheaded multiple projects from inception to commercialization, successfully guiding them through to market launch.

George Li

Managing Partner
Proxima Investment

George Li , Founder and Managing Partner of Proxima Investment, possesses nearly 20 years of experience in management, consulting, entrepreneurship, and investment within the healthcare sector. He serves as a committee member of the Innovation and Entrepreneurship Committee under the Overseas Chinese Affairs Office of the State Council, is recognized as an Innovation and Entrepreneurship Talent by the Ministry of Science and Technology, and acts as a judge for the Chunhui Cup Entrepreneurship Competition under the Ministry of Education.
He holds a Bachelor's degree from Zhejiang University and an MBA from Hult International Business School. Previously, he worked at Huawei Technologies' R&D Testing Department and co-founded BioHermes, a leading company in the diagnostic reagents niche in China. In 2008, he established BioBridge International, providing comprehensive services to healthcare innovation companies—from startup guidance and production system development to regulatory filing support.



Hui Li

CEO & Co-founder
Caike

Dr. Hui Li, CEO and Co-founder of Caike（Suzhou）Biotechnology , holds a Bachelor's degree from the University of Science and Technology of China, Master's degree in Materials Science from Lehigh University, USA, and PhD degree in Materials Science from Shanghai Jiao Tong University. With deep expertise in the high-end scientific instrumentation industry, she previously served as Asia-Pacific Regional Head at both Bruker and Thermo Fisher Scientific. Currently, Dr. Li leads her team in pioneering cutting-edge fields such as opto-electric field cell manipulation and ultra high-sensitivity detection, driving multiple technologies from domestic substitution to surpassing international standards.She is committed to advancing innovation in life science tools and supporting global scientific exploration.

Jinghua Li

Associate Professor
Department of Public Health and Medicinal Administration, Faculty of Health Sciences, University of Macau

Jinghua Li is an Associate Professor at the Faculty of Health Sciences, University of Macau. Her research focus on developing mathematical and statistical models to assess the epidemiological impact and cost-effectiveness of health interventions for infectious diseases. She has received the First Prize in the Educational Achievement Award from Guangdong Province Society for Academic Degrees and Graduate Education (as the first completer) and led a Guangdong Provincial Graduate Demonstration Course. She has served as principal investigator on projects funded by the National Natural Science Foundation of China, the Guangdong Natural Science Foundation, and the China Medical Board. She has published over 100 SCI/SSCI papers in journals such as The Lancet Regional Health–Western Pacific and eClinicalMedicine, with an H-index of 24. The dynamic intervention assessment tools she developed have been widely applied in both domestic and international cities. She has served as a council member of the China Health Policy and Management Society, is an active member of the Public Health and Preventive Medicine Branch of the China International Exchange and Promotive Association for Medical and Health Care, and is a recipient of the Early Career Award from the International Society of Behavioral Medicine.

Michael Li

Head of Quality/BD
3sbio Inc.

Having worked in domestic and international enterprises producing antibiotics, blood products, pharmaceutical excipients, in vitro diagnostic reagents, and monoclonal antibody (mAb) drugs, he possesses over 30 years of experience in drug R&D, registration, production, and quality management. Currently serving as the Quality/Business Head of 3SBio Inc., Vice Chairperson of the Biochemical Drugs Professional Committee of the Shanghai Pharmaceutical Association, and Council Member of the Shanghai Association for Quality.



Xiang Li

SVP
Fosun Pharma

Dr. Xiang Li has nearly 30 years of experience in drug development and management, spanning the development of multiple drug modalities, including small molecules, antibodies, cell therapies, and targeted nuclear medicines. He previously worked at Boehringer Ingelheim's US R&D center for over 21 years, focusing on the discovery of innovative drugs for immune, inflammatory, and metabolic diseases. He also worked at BioDuro-Sundia for six years, where, as President of the Drug Discovery Division, he was responsible for global business across chemistry, biology, pharmacology, oncology, biomacromolecules, and DMPK. He possesses a multifaceted international perspective and extensive experience leading multiple departments and centers. He holds a bachelor's degree from the University of Science and Technology of China, a doctorate from the University of Oxford, and a postdoctoral fellowship at the Scripps Research Institute.

You Li

President
BioInsight LLC

Dr. You Li has more than 15 years of experience in product development and regulatory strategy for pharmaceuticals and medical devices. He currently serves as Founder and President of BioInsight. Dr. Li is also a board member and the past president of the Chinese Biopharmaceutical Association (CBA).
Previously, Dr. Li held various leadership roles in pharmaceutical and medical device companies, as well as a regulatory agency. These positions include:
Vice President, Program Executive and Clinical Strategy at EQRx (acquired by NASDAQ: RVMD in 2023)
Vice President, Head of Regulatory Strategy at Thrive (acquired by NASDAQ: EXAS in 2021)
Senior Lead Reviewer at the US FDA

Dr. Li received his PhD in Human Genetics from the University of Pittsburgh and dual Bachelor's Degrees in Biology and Computer Science from Zhejiang University.

Zengbao Li

CEO
Kangchu Technology (Guangdong) Co. Ltd.

- 1997-2003: Employed at Hong Kong Phoenix TV
- 2004-2009: Served as General Manager of Mainland Affairs at Hong Kong Asia Television
- 2009-2014: Established the Dynamic Ice Storage Project at Guangzhou Institute of Energy Conversion, Chinese Academy of Sciences; awarded as one of the first batch of Guangzhou Leading Talent Enterprises and Huangpu Development Zone Leading Talent Enterprises
- Chairman and CEO, Kangchu Technology (Guangdong) Co., Ltd.

About Kangchu
Kangchu Technology (Guangdong) Co., Ltd. is a cellular biotechnology enterprise based in the Guangdong-Hong Kong-Macau Greater Bay Area, specializing in the research and development of immune cell and stem cell therapeutics. Its business scope encompasses cell storage, cell therapeutic development, production, as well as clinical translation, application and services of cellular technologies. The company operates a nearly 2,000 m² GMP-compliant facility integrating cellular R&D, production, and quality control, alongside a cell storage biobank service center. Its R&D pipeline includes cell therapeutics for oncology, diabetes, and other indications.

Bill Wenqing Liang

CEO
Chairperson of the Board

Dr. LIANG Bill Wenqing is co-founder, the chairperson of the Board, an executive Director and the chief executive officer of CF PharmTech. He had over two decades of experience in the pharmaceutical and related investment industries.
Dr. LIANG obtained a Ph.D. in molecular and cellular biology from the University of Massachusetts in the United States in 1996. After obtaining his doctorate degree, Dr. LIANG pursued his professional career as a post-doctoral fellow at Harvard Medical Schoo. Dr. LIANG also obtained an MBA from University of Southern California in the United States in May 2001.



Xitong Liang

Assistant Professor
School of Life Sciences, Peking University

Dr. Xitong Liang is an Assistant Professor at the School of Life Sciences, Peking University, and an Investigator at the IDG/McGovern Institute for Brain Research, Center for Quantitative Biology, and Peking-Tsinghua Center for Life Sciences. He received B.S. in Biology from Peking University and Ph.D. in Neuroscience from Washington University in St. Louis, USA. Dr. Liang conducted his postdoctoral research with Prof. Gilles Laurent at the Max Planck Institute for Brain Research in Germany. Using cephalopods (e.g., octopus, squid, and cuttlefish) as a novel model system, his research explores the diversity and evolution of animal behavior, AI for neuroscience, and brain-inspired AI.

Jinzhong Lin

Director
Fudan Center for mRNA Translational Research

Dr. Jinzhong Lin is a Professor at Fudan University, where he leads the Fudan Center for mRNA Translational Research and the Shanghai Zhangjiang mRNA Innovation and Translation Center. He received his Ph.D. in Biophysics from the Chinese Academy of Sciences and completed his postdoctoral training at Yale University with Nobel Laureate Thomas Steitz.

Dr. Lin's research focuses on the molecular mechanisms of mRNA translation. His group has established a fully reconstituted human in vitro translation system and combines biochemical, structural, and synthetic biology approaches to dissect how mRNA elements and translation factors regulate protein synthesis. These mechanistic insights form the foundation for rational mRNA design in therapeutics.

Since returning to China in 2017, Dr. Lin has also played a leading role in mRNA drug development. He established the nation's first academic mRNA drug development center and led the development of China's first mRNA COVID-19 vaccine, which completed Phase III clinical trials and received emergency use authorization.

He has authored over 60 peer-reviewed publications, advancing both fundamental RNA biology and its translational applications.

Da Liu

Managing Director
CR CP Life Science Fund

Mr. Liu is now the Managing Director of the CR CP Life Science Fund, whose shareholders, CR Group and CP Group are on the Fortune Global 500 List. Before that, Mr. Liu was the Business Director of the Strategic Management Department at CR Group, responsible for strategic research and project investment in life science and technology; and as Senior Director of China Resources Pharmaceutical Group Co., Ltd. (HK: 03320), responsible for business development and international cooperation. He has also served as the Senior Director of China Resources Pharmaceutical Business Group, the General Manager of China Resources Pharmaceutical Airport (Beijing) International Trading Co., Ltd., the Deputy General Manager of Beijing Pharmaceutical Co., Ltd., and the COO of Zhoulin Bio-spectrum Technology Co., Ltd. Prior to 2004, Mr. Liu was a pharmacy manager at CVS Group in the United States, and worked at the New York Healthcare Group as a clinical pharmacist.

Pengtao Liu

S Y and H Y Cheng Professor in Stem Cell Biology and Regenerative Medicine
The University of Hong Kong

Pentao Liu is a biologist and geneticist. He earned a BS degree from Henan Normal University and an MPhil from the Institute of Genetics, Chinese Academy of Sciences. Pentao pursued his studies in human genetics at Baylor College of Medicine under the guidance of Professor James Lupski, where he obtained his Ph.D. supervised by Professor Allan Bradley. Following a postdoctoral training at the National Cancer Institute in the USA with Professor Neal Copeland and Nancy Jenkins, Pentao joined the faculty of the Wellcome Trust Sanger Institute in Cambridge, U.K. He currently serves as a professor at the University of Hong Kong and leads InnoHK Centre for Translational Stem Cell Biology, focusing on advancing stem cell technologies, producing clinically relevant cell products, and screening drug candidates.

Pentao's group have developed a highly efficient six-factor method for rapidly reprogramming somatic cells into iPSCs, discovered a novel type of cancer cell-killing cell, and successfully derived expanded potential stem cells from preimplantation embryos of various mammalian species. These unique stem cells exhibit broader developmental potential compared to other pluripotent stem cell types, demonstrating genetic and epigenetic stability. They are being investigated for applications in understanding human cell lineage development, drug screening, cell-based therapies, and agriculture.

Shengjiang Liu

CEO & CSO
Avirmax Inc.

Dr. Liu is an experienced biotechnologist, virologist, biochemist, and serial entrepreneur. He leads Avirmax team to innovate, develop and manufacture the next generation of AAV gene therapeutics (NGAGT) for eye diseases. Prior to Avirmax, Dr. Liu was the chief scientist of biological development in Bayer Pharmaceuticals. Dr. Liu was a cofounder and the president of Abmaxis, Inc. which was acquired by Merck in 2006. Dr. Liu was the group leader of Genentech BSL-3 Virology Lab. He developed many bioprocess technologies implemented in biologics manufacturing. In the past 30 years, he played important roles in the innovation, development, manufacturing and regulatory submissions of 35 biologic products including AAV genetic products, out of which 10 are widely used biologics in the market. He co-discovered and characterized a new virus, rabbit hemorrhagic disease virus (RHDV), rabbit calicivirus in 1984.
Dr. Liu received his Ph.D. from Biochemistry from Kansas State University and his post-doctoral training with Dr. Arthur Kornberg (Nobel Laureate), Stanford University. Dr. Liu is a member of ASGCT, AAO, ARVO and an advisor of Bioengineering Department of Santa Clara University.

Shoupeng Liu

Associate Director, Outreach and Strategic Partnerships, Asia，Science/AAAS

Dr. Shoupeng Liu received a B.Sc. Degree in Physics from Beijing Normal University, and a master's degree from the Institute of Physics, Chinese Academy of Sciences (CAS). She then went to the University of Konstanze, Germany, where she earned her Ph.D. in Physics. After her postdoctoral research at the University of Notre Dame, U.S.A., she returned to China to join the Suzhou Institute of Biomedical Engineering and Technology (SIBET), CAS, in 2014. She was a professor in the Medical Electronics Laboratory and one of the founders of the Science partner journal BMEF. She is now working in the Science Beijing office and responsible for outreach and training activities in Asia.

Will Liu

Managing Director, Bioventures
BeOne Medicines

Dr. Will Liu is the Managing Director of Bioventures at BeOne Medicines. He and team create, incubate, and invest in biotech startups at BeOne Venture Labs. Building on 28 years of experience in venture capital, pharmaceutical and biotech industry, Dr. Liu co-conceived the Venture Labs' business model at BeOne. Along with a highly capable scientific team, he has helped scientists and entrepreneurs to turn their original ideas into multiple fledgling biotech startups. Prior to starting the BeiGene Venture Labs, Dr. Liu was a Partner at Eight Roads Ventures focusing on the investment of early-stage biotech companies. In addition to generating high investments returns, he also fostered multiple highly successful biotech companies including Structure Therapeutics and Insilico Medicine. Before becoming a venture capitalist, Dr. Liu spent 20 years in the pharma industry. His industrial experience ranges from R&D to business development, including various important roles at MNC pharmaceutical companies, such as the Head of Worldwide BD for Neuroscience at GSK, and China Head of External Innovation at Merck KGaA. Dr. Liu graduated from Nankai University in China and holds a PhD degree in Chemistry from the University of Michigan.

Xing Liu

General Manager (HK Macau Taiwan)
BGI Group

Dr. LIU Xing obtained his Ph.D. in Biochemistry from The Chinese University of Hong Kong. After that, he engaged in the technology and testing industry. In 2017, he joined BGI Group, a world-leading institution in life science, and is committed to providing affordable precision medicine and public health solutions for local society. In 2022, he was awarded the Chief Executive's Commendation for Community Service of the Hong Kong Special Administrative Region for his contributions during the epidemic. He is a Member of Chongqing Youth Federation. He serves as panelist of Expert Review Panel of Logistics and Supply Chain MultiTech R&D Centre and public adviser of Panel of Film Censorship Advisers.

Yong Liu

Deputy Dean of the School of Artificial Intelligence
Beijing University of Posts and Telecommunications

Dr. Yong Liu is a professor at Beijing University of Posts and Telecommunications. He received his PhD from the Institute of Automation, Chinese Academy of Sciences (CASIA) in 2008 and obtained his MSc from Beijing University of Technology in 2005. From June 2008 to January 2021, he worked at CASIA as an assistant/associate/full professor. He was a visiting scholar from April 2011 to March 2012 in the Brain Mapping Unit at the University of Cambridge.
To date, Dr. Yong Liu has authored more than 100 peer-reviewed journal articles (including Science Advances, eClinicalMedicine, Advanced Science, Brain, Biological Psychiatry, Science Bulletin) and has an h-index of 55. In recent years, Dr. Yong Liu's work has focused on studying generalizable, reproducible, and neuroscientifically interpretable imaging biomarkers for Alzheimer's Disease based on multi-center and multi-modal imaging.



Hau Yi Paulisally Lo

Senior Scientist
ROHTO Pharmaceutical Co., Ltd.

Dr. Lo received her Ph.D. in Clinical Oncology from The University of Hong Kong and pursued postdoctoral training under Professor Yusuke Nakamura at The University of Tokyo. She subsequently joined The Chinese University of Hong Kong, where she introduced the first 3D cell printer to the School of Biomedical Sciences and established the Biofabrication Center to advance research in tissue engineering and regenerative applications. In 2020, Dr. Lo joined Rohto Advanced Research Hong Kong to begin her career in stem cell therapy, contributing to the development of innovative approaches for regenerative medicine. She later relocated to Japan to join Rohto Pharmaceutical's Pharmacological Evaluation Team, where she focuses on translational research, preclinical evaluation, and the development of mesenchymal stem cell–based clinical programs. Her work bridges academia and industry, with a strong emphasis on advancing regenerative medicine through both technological innovation and therapeutic application.



Yuk Lam Lo

President
HK Bio-Med Innotech Association

Professor Lo has extensive experience in biotechnology industry, corporate management, academic research and community service.

Currently Professor Lo is serving as the President of HK Bio-Med Innotech Association, Strategic Advisor to the President and Adjunct Professor to the Division of Life Science of Hong Kong University of Science and Technology.

In the educational area, Professor Lo has been elected an Honorary Fellow of the Hong Kong University of Science and Technology. He is also the Honorary Professor of several universities in China.

Professor Lo was heavily involved in several committees of the HKSAR Government. He was the Chairman of the Advisory Council for Food Safety of the Food and Health Bureau of HKSAR government from April 2015 to March 2021, Director of the Hong Kong Applied R&D Fund Co. Ltd., Chairman of the Biotechnology Committee of the Hong Kong Industry & Technology Development Council, and Chairman of Biotechnology Projects Vetting Committee of the Innovation and Technology Fund of the HKSAR government.

In Mainland China, Professor Lo was a member of Chinese People's Political Consultative Conference in Jilin Province from 2007 to 2022. He was also a consultant of the Centre for Disease Control and Prevention of China. In recognition of his leadership in the community and dedication to his field, Professor Lo has received many awards, such as the "Pericles International Prize" in 2019. He is the second Asian and the first person from Hong Kong to be awarded the Prize since it was founded in 1986. In 2020, Professor Lo was awarded the Bronze Bauhinia Star from the HKSAR government for his outstanding services over the past decades.

In the business sector, Professor Lo had been served as the Chairman of Asia Pacific of PerkinEImer (NYSE: PKI) and the President of Asia Pacific of Bio-Rad Laboratories (NYSE: BIO). Currently he is the Chairman of GT Healthcare Capital Partners, and Partner & Investment Committee Member of Hongsen Investment Management Limited.

Hang Lu

Founder and CEO
NextTranslate Biopharmaceutical Co., Ltd.

Dr. Hang Lu is the founder and CEO of NextTranslate Biopharmaceutical Co.，a clinical stage company focusing on the development and manufacture of mRNA- and advanced technology-based preventive and therapeutics products.
Dr. Lu has over 25 years of experience in biological product development in pharmaceutical and biotechnology industry, including Merck Co. and Emergent BioSolutions (EBSI), a NYSE-listed global life sciences company that seeks to protect and enhance life by providing specialty products including vaccines and therapeutics for civilian and military populations. Dr. Lu held roles of increasing responsibilities at EBSI over the last 20+ years, including director of CDMO Analytical Development or PAD, Principal Scientist of R&D or Nonclinical Development. He was responsible for setting up the Immunotoxicology Lab and GxP Lab and was the core team member of more than ten traditional and new generation vaccines and biologics from the discovery to nonclinical and CMC development over the product life-cycle, from IND to BLA submissions leading to regulatory approvals in USA.
Dr. Lu obtained his medical degree at Zhejiang University and practiced as a pediatric hematologist，and then completed his post-doctoral research training at the University of British Columbia with a sponsorship from the Canadian Institutes of Health Research（CIHR）.
Dr. Lu is an advisory committee member of Vaccine Research Council，China Association for Vaccines and was the Presidents of the Chinese Biopharmaceutical Association (CBA，2021-2022) and CBA-China (2025-2027).

Zhi Lu

Boya Distinguished Professor，Peking University
Founder，Shan Shui Conservation Center

Lu Zhi has a long-term experience in cross-disciplinary researches on nature conservation and human sustainable development. She conducted field researches on the giant pandas and the snow leopard in western China and has expanded her work to promote biodiversity in cities and farmlands in recent years. She also deeply engaged in conservation practices especially community-based initiatives. For years she devoted to build a bridge between research and practice to better understand the interlinks between nature and people, and to provide empirical and practical solutions for their coexistence.

Aiping Lyu

Vice-President (Research and Development) cum Dean of Graduate School
Hong Kong Baptist University

Professor Lyu Aiping is the Vice-President (Research and Development) and Dr. Kennedy Y.H. Wong Endowed Professor in Chinese Medicine at Hong Kong Baptist University. He was elected as a Foreign Member of the Academia Europaea in 2022, recognizing his sustained excellence in systems medicine. Professor Lyu's research bridges Chinese Medicine and Western medicine through the lens of systems medicine, combining advanced techniques in life sciences and data sciences. He is interested in the novel re-classification of rheumatoid arthritis. His research has further delved into the dynamics of network biomarkers for re-classification and the interaction of combined drugs for precise treatment.
Before joining Hong Kong Baptist University, Professor Lyu was the Executive Director (Legal Representative) of the Institute of Basic Research in Clinical Medicine at the China Academy of Chinese Medical Sciences (CACMS). He has since been actively involved in standardization of Chinese Medicine and strategic planning on the Chinese Medicine development in China.
Professor Lyu's contributions to academia are substantial, with 600 academic papers published in leading journals such as Nature Medicine, Nature Communications, and Briefings in Bioinformatics, covering a wide spectrum of integrative medicine. His research innovation has led to the award of more than 60 patents.

C. H. Eddie Ma

Director
Laboratory Animal Research Unit (LARU), City University of Hong Kong

Prof. C.H. Eddie Ma focuses on developing cures for neurological diseases, including glaucoma, nerve injuries, traumatic brain injury, diabetics neuropathy, spinocerebellar ataxia, and Alzheimer's Disease. His team advances neuroscience and regenerative medicine through multidisciplinary approach that combines drug repurposing, deep brain stimulation, cell and molecular biology, animal behavior, and genetics. He has published as corresponding author in top-tier journals such as Neuron, PNAS, Science Advances, Brain, Behavior, and Immunity, Journal of Clinical Investigation, and npj Regenerative Medicine. Over the years, he has delivered keynote speeches in several key international conferences.
Prof. Ma holds nine US/China patents and received Gold (2022) and Silver (2021) awards at the Invention Geneva Evaluation Days. Since joining CityUHK, he has secured HKD 43 million in external research funding such as RIF, GRF, ITF, HMRF, and NSFC. He founded AniTech HK Limited, which recently won both the "Winning Start-up" and "My Favourite Start-up" awards at HKTDC Start-up Express 2025. His company also received funding support from ITC's TSSSU, CityUHK HK Tech 300 and Cyberport. Under his mentorship, many of his PhD students have progressed to faculty and pharmaceutical roles worldwide.
He earned his BSc from HKUST, MPhil from HKU, and DPhil from Oxford. He received postdoctoral training at Harvard Medical School, Massachusetts General Hospital, and Boston Children's Hospital.

Guanghui Ma

Academician, Chinese Academy of Sciences
Professor , Institute of Process Engineering, Chinese Academy of Sciences

Guanghui Ma is a professor of Institute of Process Engineering (IPE), CAS. She received Bachelor degree from Gunma University, Master and PhD degrees from Tokyo Institute of Technology, Japan, respectively. She worked at Tokyo University of Agriculture and Technology (TUAT) as an assistant professor during 1994-2001. She joined IPE as a professor in 2001 and was promoted to the director in 2012. She has published over 500 papers, including Nature, Nat. Mater., Nat Nanotechnol., Nat. Biomed. Eng., Sci Transl Med., Cell Host & Microbe, Sci. Adv., Nat. Commun., JACS, Adv. Mater., edited several books such as “Microspheres and Microcapsules in Biotechnology”. She has more than 90 patents authorized, the technology and products have been commercialized in companies. She has received the State National Invention Award (2nd Class; 2009), the Beijing Science and Technology Award (1st Class; 2005), the Basic Research Achievement Award (1st Class; 2020) of the Chemical Industry and Engineering Society of China.
She was elected as the member of Chinese Academy of Sciences, the Fellow of TWAS, and the Fellow of American Institute of Medical and Biological Engineering (AIBME).

Jie Ma

Head of National Center for Clinical Laboratories and Biotherapy Center at Beijing Hospital

Ma Jie is the head of the National Center for Clinical Laboratories and the Biotherapy Center at Beijing Hospital, and a doctoral supervisor.
Professor Ma is one of the Beijing 100 Leading Talents in Science and Technology, one of the national candidates for the New Century Millions of Talents Project, a State Council Special Allowance expert, the chief expert of a state - key research and development project, the chief expert of a national science and technology major project, and an expert for the "12th Five-Year Major New Drug Creation" and "14th Five-Year Special Guidelines for Stem Cell and Tissue Repair". The tumor cell immunotherapy program developed by Professor Ma received two phase II clinical trial approvals from the State Food and Drug Administration in 2022. Currently, Professor Ma has carried out a number of phase I clinical research projects of tumor immunotherapy, and has won the First Prize of the Beijing Medical Science and Technology Award, the Third Prize of the Beijing Science and Technology Award, and the Second Prize of the China Medical Science and Technology Award, making important contributions to the promotion of tumor immunotherapy in China. Professor Ma's research interests include target screening and new technology development for tumor immunotherapy; Research and development of anti-tumor nanomedicine and new dosage forms modified by nanotechnology; Clinical application of tumor targeting therapy and immunotherapy, etc.

Chuanbin Mao

Professor
The Chinese University of Hong Kong

Professor Chuanbin Mao is a Global STEM Professor at the Chinese University of Hong Kong and Director of Jockey Club STEM Lab for Nature-Inspired Precision Medical Engineering. He has been selected as a Global STEM Scholar through the Hong Kong SAR's competitive Global STEM Professorship Scheme. He is an elected fellow of esteemed professional societies, including American Association for the Advancement of Science (AAAS), American Academy of Microbiology (AAM), American Chemical Society (ACS), American Institute for Medical and Biological Engineering (AIMBE), Biomedical Engineering Society (BMES), Hong Kong Institution of Engineers (HKIE), International Academy of Medical and Biological Engineering (IAMBE), Royal Society of Chemistry (RSC), and ACS Division of Polymeric Materials Science and Engineering (PMSE). He has won multiple awards such as the US National Science Foundation CAREER Award, CAPA Distinguished Junior Faculty award, and All-China Outstanding Doctoral Dissertations prize. He has served as a member/chair of ACS National Award Selection Committee. He has authored over 300 peer-reviewed publications in top-tier journals such as Chemical Reviews, Science, Nature Mater, Nature Nanotechnol, Nature Biomed Eng, Nature Commun, Adv Mater, and Angew Chem Int Ed. His current research focuses on phage-based biomaterials and their applications in biosensing, nanomedicine, regenerative medicine, and antimicrobial therapy.

BLOCKI Anna Maria

Associate Professor, SBS & iTERM
The Chinese University of Hong Kong

Prof. BLOCKI Anna Maria is an Associate Professor at Institute for Tissue Engineering and Regenerative Medicine (iTERM) and School of Biomedical Sciences (SBS), Chinese University of Hong Kong (CUHK). She received her PhD from the National University of Singapore in January 2013. Following that, she joined the Singapore Bioimaging Consortium (SBIC) at the Agency for Science Technology and Research (A*STAR) as a postdoctoral researcher until 2015. In November 2015, Prof. Blocki was able to secure a competitive postdoctoral fellowship from the Charité Universitätsklinikum Berlin, Germany. In February 2018, she joined SBS and iTERM at CUHK as an Assistant Professor and promoted to a tenured Associated Professor position in 2024. Since the beginning of 2022 she is also a Principle Investigator at the Center for Neuromusculoskeletal Restorative Medicine.
Prof. Blocki's research interests lie in the area of tissue engineering and regenerative medicine (TERM) with particular emphasis on biomaterials, cell- and cell-derived product-based therapies for the treatment of noncommunicable diseases, such as ischemic diseases. In particular, she focuses on studying and tailoring cellular microenvironments such as the extracellular matrix (ECM) and develops bioactive therapeutics (e.g. biologics) for clinical application. Moreover, she utilizes her acquired expertise to engineer microphysiological systems, specifically involving microvasculature.

Robert Markelewicz

Chief Medical Officer
Abpro Group

Robert Markelewicz, MD is the Chief Medical Officer of Abpro since 2018. Prior to that, he was Senior Medical Director at Celgene from 2014 to 2018, and Medical Director at Parexel from 2012 to 2014. Dr. Markelewicz received a Bachelors in Biology, a Masters in Medical Science and MD all from Brown University.

Angela Yuxin Men

CMO
Haichang Biotech

Dr. Angela Yuxin Men is the CMO of Haichang Biotech and the CEO The WhiteOak Group. Prior to joining Haichang Biotech, she served as a master reviewer and team leader in the Clinical Pharmacology Office, CDER FDA since 2003 with the responsibility of reviewing IND/NDA/BLA for oncology and neurological new drugs. She has received more than 50 awards from the FDA, including Distinguished Service Award, Outstanding Mentor Award, Outstanding Leadership Award and Outstanding Regulatory Science Award, etc. She has actively organized and presented in various workshops and seminars in the national and international conferences. In May 2022, Dr. Men was selected into the IFPMA ICH E21 expert working group. In addition, Dr. Men acted as a regulatory expert providing reports and presentations to help resolve disputes in ICC arbitrations. She currently serves as President and board member of the Chinese Biopharmaceutical Association (CBA); general secretary, ex-Vice President and board member of FDA Chinese Experts Club; Assistant Chair for the Membership and Community Outreach in Federal Asian Pacific American Council (FAPAC) and a member of China Pharmaceutical Innovation and Research Development Association.
Dr. Men received her PhD in pharmaceutical sciences from Virginia Commonwealth University. Before that, she was a clinical neurologist with a medical degree from Tianjin Medical University.

Holly Meng

CEO, Exin BioPharma Inc.
CEO, Global BioPharma Partnerships LLC

Founder & CEO / Exin BioPharma Inc.
Co-founder & CEO / Global BioPharma Partnerships LLC.
Board of Director & SVP / Chinese Biopharmaceutical Association Greater Philadelphia
Director / Temple University Office of Executive Leadership Education



Laurent Metz

Partner
Robinhood Venture

Dr. Laurent Metz is a global healthcare leader with over 30 years of experience in medical devices, pharmaceuticals, and vaccines, spanning the full product lifecycle from early discovery to post-launch. His expertise includes health economics, market access, medical affairs, commercial strategy, and scaling up organizations to achieve sustainable growth.
He spent 28 years at Johnson & Johnson in senior leadership roles across Europe, the United States, Latin America, Africa, and a decade in Asia-Pacific. In Singapore, he established the Market Access Center of Excellence for Medical Devices, leading regional teams and pioneering value-based healthcare initiatives with policymakers, providers, and academic institutions. Later, as Global Market Access & Policy Head for Johnson & Johnson Global Public Health, he advanced access strategies for breakthrough technologies in underserved markets, including vaccines and treatments for infectious diseases.
Dr. Metz has also served as Chief Medical Officer for Wandercraft, guiding clinical, access, regulatory, and commercial strategies for advanced robotic exoskeletons in the U.S. market. He is a Partner at Robin Hood Ventures, an active early-stage investor group in healthcare, life sciences, and technology, and serves on the Board of StarkAge, a biotech company specializing in oncology and senescence cell-targeted therapies.
His career reflects a commitment to building bridges across markets, fostering innovation, and improving global patient access to transformative healthcare solutions.

Bill Moran

Publisher
Science Family of Journals

Bill Moran is currently the Publisher of the Science Family of Journals. In his role, Bill and the publishing team are responsible for content, rights and permissions, licensing, scientific meetings, publishing collaborations, advertising, outreach, Science Careers and all publishing operations.
During his 20 years with AAAS, Bill has been instrumental in broadening the association's international publishing activities and collaborations. He spearheaded the launch of the Beijing office; in addition, he developed an international collaboration program for Science Publishing that encompasses Science Careers outreach. Bill has also worked with the Science editorial team to raise awareness of Science/AAAS within academic institutions in developed and developing countries.
The first ten years of Bill's career were with the Nature Publishing Group. Bill was a senior VP of Nature America based in New York City. Before moving to Science/AAAS, Bill was recruited by Informa based in the Boston area to help with their launch into the STM market. While at Informa, Bill was responsible for several new product launches and the acquisition of new journals, including the redesign of online products.

Andrew NG

Managing Director and Head of Healthcare, VMS Group
Investment Partner, Panacea Venture

Andrew Ng is a Managing Director and Head of Healthcare of VMS Group and an Investment Partner of Panacea Venture. He has over 13 years of experience in the healthcare industry across Asia and the US. Andrew has established the healthcare practice of VMS Group in 2017 and led multiple growth-stage investments for VMS across the therapeutics, diagnostics, medical device and CRO/CDMO verticals. He has also served as an Investment Partner of Panacea Venture, a global healthcare venture capital firm, since 2021.

Prior to that, Andrew was responsible for the China Healthcare Equity Research at Barclays Capital based in Hong Kong. Before that, he was an investment banker covering healthcare clients across the Asia Pacific region at Barclays Capital with a focus in healthcare cross-border M&A. Andrew started his career as a management consultant at ZS Associate in the United States advising global pharma on sales & marketing strategy and operations.

Andrew has been on the board of multiple companies that carry out product development, manufacturing and sales in the biotechnology, medical equipment and CXO industries. These companies include New Horizon Health, Chime Biologics, Jade Biomedical, SyMap Medical, Yizun Biomedicine and Profusa.

Andrew received an MBA from INSEAD, a M.Eng. degree and a BS degree in Operations Research & Engineering from Cornell University.

Norazli Mohamad Nor

Venture Partner
Xeraya Capital

Norazli Mohamad Nor (“Azli”) is a Venture a Partner and a founding member of Xeraya Capital, having spearheaded its preparatory aspects leading to its establishment while in Khazanah Nasional (“Khazanah”). Within Xeraya, Azli held a dual role in Investments deal-making as well as a corporate function managing a strategic fund, Mudharabah Innovation Fund (“MIF”).

Azli has a background that merges engineering and finance, gaining accreditation as a Professional Engineer with the Board of Engineers Malaysia while holding a Bachelor of Engineering (Electrical and Electronics) from Imperial College, London, United Kingdom, and an MBA with Finance specialisation from International Islamic University Malaysia.

Guangjin Pan

Director
Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences

Dr. Pan's research focuses on understanding the mechanisms underlying fate decision in human pluripotent stem cells (hPSCs); and on generating functional neural stem cells (NSC) or hematopoietic/immune cells from hPSCs for clinical purposes. He has published more than 30 peer-reviewed papers as corresponding author or first author in decent scientific journals, such as Nature Methods, Cell Stem Cell, Nature Communications.

Duanqing Pei

Chair Professor of Regenerative Biology at School of Life Sciences
Westlake University

Dr. Duanqing Pei is Chair Professor of Regenerative Biology at School of Life Sciences, Westlake University. Dr. Pei received his PhD from the University of Pennsylvania in 1991; trained as a postdoctoral fellow at University of Michigan from 1991 to 1996. Dr. Pei's primary interest is to understand cell fate control.
His lab pioneered cellular reprograming and discovered:
1) Vitamin C as an epigenetic regulator that enhances cellular reprograming through histone and DNA demethylations;
2) Epithelial to mesenchymal (EMT) and mesenchymal to epithelial (MET) transitions as drivers for iPSC generation;
3) Urine epithelial cells as a source of stating cells for reprograming.

He has proposed a chromatin open-close binary logic for cell fate control and an conceptual interface between pluripotent and somatic states. These concepts are still driving current works in the lab. Dr. Pei won national natural science award twice and the distinguished achievement medal from Chinese Academy of Sciences. He is EMBO Associate Member and MAE (Member of Academia Europa).

Bo Peng

Distinguished professor
Fudan University

Bo Peng is a professor at Fudan University. He has been honored as a Distinguished Professor under the Chang Jiang Scholars Program by the Ministry of Education, a recipient of the National Science Fund for Excellent Young Scientists, an Elsevier Highly Cited Chinese Researcher. He has received numerous accolades, including the Zhong Nanshan Youth Science and Technology Innovation Award and the Huaxia Medical Science and Technology Youth Award.
Prof. Peng's research is centered on microglia in the central nervous system, with a particular focus on elucidating the mechanisms of their aging, death, and regeneration. Based on these insights, he has pioneered a novel therapeutic strategy involving microglia replacement for the treatment of neurological disorders, and in 2020, his team achieved the world's first efficient microglia replacement. Furthermore, his group conducted the world's first clinical trial of microglia replacement therapy in 2024, demonstrating its effectiveness and paving a new path for treating neurological diseases. His key research findings have been published as last author in high-impact journals including Science (2025), Nature Neuroscience (2018), Nature Aging (2023), Neuron (2021), Cell Reports (2020), Nature Communications (2022), and eLife (2023).

Phoenix Peng

Founder
NeuroXess

Phoenix Peng , Distinguished Researcher at Tianfu Jincheng Laboratory, Founder of NeuroXess, and Vice Chairman of the Brain-Computer Interface and Interaction Branch of the Chinese Neuroscience Society. A well-known serial entrepreneur, he has founded multiple companies across various sectors, including life sciences, SaaS, O2O, database marketing, SNS, and enterprise applications. He previously founded the group-buying platform 24Quan and the SaaS company Keruyun, which was fully acquired by Alibaba for 1 billion RMB in 2019, after which he served as Senior Vice President of Alibaba Local Life Services. In 2021, he founded NeuroXess, an invasive BCI company, which is currently the most clinically advanced, commercially successful, and influential BCI company in China.

Anna Plater-Zyberk

Head of International Affairs
Polish Academy of Sciences

Since February 2017 Anna has been coordinating international relations of the Polish Academy of Sciences. As the head of the unit, she is responsible for recommendations on international policy, coordination of bilateral and multilateral programs, as well as overseeing the activities of the PAS representation centers abroad. Since the outbreak of the war in Ukraine, she coordinated support actions for scholars affected by the war. In 2025, she was appointed by the Polish Minister for Science and Higher Education as an expert responsible for building the strategy of internationalization of science sector in Poland. Prior to joining the Polish Academy of Sciences, Anna had been coordinating international cooperation of the National Science Center, a Polish governmental funding agency set up to fund basic research. In the years 2007-2011, Anna worked in the industry sector. Anna is a recipient of many prestigious fellowships, including the Distinguished H. Humphrey Fellowship at the Harvard Kennedy School of Government. Starting from October 1st, Anna will serve as the Vice President of the Foundation for Polish Science.

Frank Pun

Head
Insilico Hong Kong, Insilico Medicine

Dr. Frank Pun serves as the Head of Insilico Hong Kong at Insilico Medicine, a leading biotechnology company specializing in AI-driven drug discovery. He leads a team of application scientists focusing on AI-powered biological target discovery, indication expansion, and drug repurposing. His team strives to bring cutting-edge AI technology (Pharma.AI) to scientists and medical professionals worldwide, helping them identify promising therapeutic targets and accelerate drug discovery and development.
Frank received his Ph.D. in Biochemistry from the Hong Kong University of Science and Technology in 2010. After graduation, he served as a visiting scholar, leading a team dedicated to studying human CNS diseases and cancer for several years. In 2019, he obtained an MBA from Rutgers Business School in the United States. Throughout his career, Frank has made significant contributions to the fields of target discovery and drug repurposing, with his work appearing in many industry collaborations and peer-reviewed publications.

Kate QI

Chief Executive Officer
SG Diagnostics Pte Ltd

Dr. Kate Qi is the Chief Executive Officer of SG Diagnostics Pte Ltd (Singapore) and SG Diagnostics (HK) Limited, leading efforts in advancing point-of-care diagnostics for chronic and infectious diseases across Asia. A scientist-turned-entrepreneur, she holds a Ph.D. in Materials Science from Nanyang Technological University and has over 10 years of cross-disciplinary experience in nanomaterials, biosensors, and translational diagnostics.
Dr. Qi has successfully led R&D teams, commercialized diagnostic platforms, and driven regulatory and IP strategies. Her work spans multiple research grants and a portfolio of seven patents. She previously held leadership roles at NTU and Nanjing Tembusu Institute. Under her leadership, SG Diagnostics has deployed innovative diagnostic solutions in over 20% of the clinics and expanded operations into Hong Kong and Southeast Asia to tackle major population health challenges.
Her mission is to make healthcare more accessible, decentralized, and data-driven through scalable innovations.

Jian Qu

Department of Pharmacy, the Second Xiangya Hospital, Central South University

Dr. Qu Jian, M.D., Ph.D., is an Associate Professor, Ph.D. Supervisor, and Deputy Chief Pharmacist at the Second Xiangya Hospital of Central South University. A Yale-trained pharmacologist (Ph.D. in Pharmacology, CSU-Yale Joint Program), he serves on key national committees including the Youth Committee of the Chinese Pharmacological Society and the Clinical Pharmacy Branch of the China Association of Gerontology and Geriatrics. His editorial roles include reviewing forCancer LettersandCNS Neuroscience & Therapeuticsand serving on the Editorial Board ofCancer Drug Resistance. Dr. Qu's research focuses onepigenetic pharmacology, pharmacogenomics, and personalized medicine, with 94 SCI publications (62 as first/corresponding author) in elite journals such asMolecular CancerandJournal of Experimental & Clinical Cancer Research, including 6 papers with IF > 10 (peak IF: 33.9). He leads 9 major grants (NSFC, Hunan Provincial Foundation) and contributes to national initiatives like the "863 Program" and "Key New Drug Creation and Manufacturing Program," driving innovations in precision drug therapy.

Feng Ren

Co-CEO and CSO
Insilico Medicine

Dr. Feng Ren is the Co-CEO and CSO of Insilico Medicine, He earned his Ph.D. in Chemistry from Harvard University in 2007 and embarked on a distinguished career in biopharmaceutical innovation.
He began at GlaxoSmithKline (GSK), where he spent a decade advancing drug discovery and development. In 2018, Dr. Ren joined Medicilon, a global contract research organization (CRO), as Senior Vice President and Head of Drug R&D Services, overseeing operations in both the Chemistry and Biology Departments with a team of over 600 chemists and biologists.
Dr. Ren transitioned to Insilico Medicine in 2021 as Chief Scientific Officer (CSO), where he assumed responsibility for advancing internal pipelines and fostering external collaborations in drug discovery and development. His exceptional contributions and leadership were recognized with a promotion to Co-CEO in June 2022. Under his guidance, Insilico R&D team successfully developed 22 pre-clinical candidate compounds, with 10 molecules received IND clearance in therapeutic areas including fibrosis, inflammation, oncology, and anti-viral treatments. Dr. Ren also played a pivotal role in driving four out-licensing agreements for proprietary pipelines as well as forging numerous strategic R&D collaborations, collectively valued at more than $3.5 billion. Dr. Ren publishes over 70 peer-reviewed papers and over 100 patents.

Rose Ritts

Managing Partner
BOSS and BVCC Funds

Rose Ritts, PhD is a Managing Partner of the Black Opus Special Situations Group (BOSS) Fund and the Black Venture Capital Consortium (BVCC) Fund, focused on early-stage investments into Emerging Technology companies. She has 35 years of experience as an investor, founder, and leader and has helped launch dozens of startups across biotech, healthcare and deeptech, with 28 achieving exits over $150mm, including 3 over $1B; and $400mm+ of monetized IP. Prior to joining BOSS and BVCC, Dr. Ritts spent 18 years as a Chief Innovation Officer at US universities and academic health centers, first in North Carolina at Duke University & Duke Health, and then in Philadelphia at Jefferson Health & Thomas Jefferson University. She served in the US Federal Government as a Program Manager at DARPA, in the Department of Defense, where she managed programs in MicroFluidic Systems and Cellular Computing and served as a member of government think tanks and proposal review panels across multiple government agencies. Dr. Ritts received her undergraduate degree from Duke University and earned both her PhD and MS degrees from Stanford University.

Yu Rong

Senior Staff Algorithm Engineer
Alibaba DAMO Academy

Dr. Yu Rong, an IEEE Senior Member and recognized high-level overseas talent by Shenzhen, serves on the AI for Good Technical Advisory Committee of the International Telecommunication Union. He received his Ph.D. from the Chinese University of Hong Kong in 2016. He joined Tencent AI Lab in 2017 as a principal researcher and moved to Alibaba DAMO Academy in 2024 to lead research on scientific multimodal models.

His work centers on graph learning and large language models, focusing on structural data modeling, cross-modal systems, and applications in drug discovery, healthcare, and materials science. He has over 11,000 Google Scholar citations (H-index 42). Two papers were were selected as the most influential papers by PaperDigest. He is listed among Stanford/Elsevier's Top 2% Scientists, ranked second in the mainland China machine learning subfield of the AMiner Rising Star list (2020–2023), and was nominated as a Spotlight Recipient of the 2025 WAIC Yunfan Award.

At Tencent, he built the molecular property prediction module for the iDrug platform and led the championship team in the NeurIPS 2022 Open Catalyst Challenge. At DAMO, he led development of the "Lingchu" medical multimodal large model, surpassing the proprietary models such as GPT-4 in medical multimodal question answering.



Bob Rovinsky

Associate Director of Operations
B+labs(Powered by the Pennsylvania Biotechnology Center)

Bob Rovinsky serves as Associate Director of Operations at B+labs, where he plays a central role in delivering on the organization's mission to accelerate the success of early-stage life science companies. Since joining B+labs in 2021, in addition to being a primary participant of the startup of the life science incubator, Bob has been instrumental in building a safe, efficient, and fully compliant operational environment that enables scientists and entrepreneurs to focus on innovation and successful outcomes.

Drawing on over 36 years of experience in facility design, commissioning, operations, environmental health and safety (EHS), sustainability, and regulatory/quality compliance, Bob develops and oversees operational systems that keep B+labs' shared laboratory and office spaces running seamlessly. His expertise ensures that startups have access to fully functional, BSL-2 compliant laboratories, well-maintained equipment, and robust safety programs—critical foundations for breakthrough research in biotechnology and pharmaceuticals.

Before B+labs, Bob held leadership positions in academia, private industry and public institutions, including Takeda, Sun Pharma, Axalta, Airborne Systems, Frontida BioPharm, URL Pharma, The Wistar Institute and the University of Pennsylvania, as well as service in the U.S. Air Force as a Bioenvironemtal Engineer. Across these roles, he has consistently championed operational excellence, risk management, and sustainability. His work at B+labs reflects his commitment to creating a safe, sustainable, and high-performance environment where life science ventures can thrive and deliver transformative health solutions.

Bob holds a Master of Environmental Studies from the University of Pennsylvania with an emphasis in Policy and Risk Management and a Bachelor of Science in. Environmental Engineering from Temple University, along with specialized training from the U.S. Air Force School of Aerospace Medicine.



Juan Valencia S.

Senior Product Marketing Manager
PharmCube

Juan Valencia S. is Senior Product Marketing Manager at PharmCube, where he tracks and analyses pharmaceutical industry developments, emerging trends and competitive landscapes. With a scientific background in biochemistry, structural biology and physics, he has conducted research at leading institutions across three countries, including the Chinese Academy of Sciences. He carries 7 years of experience in the pharmaceutical consulting sector, delivering strategic insights on market dynamics, R&D pipelines, regulatory shifts and financial trends to diverse industry stakeholders, from emerging biotechs to Big Pharma companies.

Niccolo Santi

CEO – OROJIN
Miskawaan Health Group

Niccolò Santi is the CEO of OROJIN. An Italian, born in Brazil and raised in Hong Kong, Niccolò has a diverse and international background. After completing his university education in the United Kingdom and China, he joined the multi-national conglomerate Swire and John Swire & Sons Management Programme, where he held various roles in Hong Kong, Taiwan, and China. Niccolò later co-founded SV International, which has become an industry leader in luxury hotel supply, completing over 450 projects. He brings to OROJIN a wealth of management experience and entrepreneurial drive.

Hao Shen

President & CEO
BioSyngen Pte. Ltd.

Prof. Hao Shen is the President and CEO of Biosyngen Pte Ltd, a Singapore based biotech focused on developing cutting edge immune cell therapies for cancer patients. Before joining Biosyngen, Professor Shen was the Chief Scientific Officer of FosunKite, the Director of the Shanghai Institute of Immunology, and Professor at University of Pennsylvania Perelman School of Medicine for over 20 yrs. Professor Shen has received numerous awards for his work cross academics and industry. His research focuses on T cell immunology and has contributed significantly to the advancements of immune therapies and vaccines against cancers and infectious diseases.

Xinmei Shen

Reporter
South China Morning Post

Xinmei Shen is a reporter with the South China Morning Post's technology desk covering topics including AI, digital assets and biotech. Previously she produced multimedia stories at the Post's technology news platform Abacus and was a graduate of the University of Hong Kong.

Leo Shi

Managing Director
Warburg Pincus

Leo Shi is based in Shanghai, joined Warburg Pincus in 2019 and focuses on investments in the healthcare sector in Asia. Prior to joining Warburg Pincus, he has been working as Senior Director at Temasek China focusing on healthcare and consumer investing since 2015. Prior to Temasek China, he was a VP at Warburg Pincus for three years and has also worked at investment banking and consulting industry. Mr. Shi currently serves on the boards of HTDK, Insilico Medicine, Haihe Biopharma and Zhenshiming Pharmaceutical.



Yi Shi

Principal Investigator
Guangzhou National Laboratory

Dr. Yi Shi currently works as a principal investigator and full-time professor in the Guangzhou National Laboratory, China. He has graduated from Zhejiang University in 2006, and then moved to the Institute of Microbiology, Chinese Academy of Sciences (CAS) to continue his PhD training under the supervision of Prof. George Fu Gao. He has obtained his PhD degree in 2011, and then he worked as assistant professor and associate professor in different institutions of CAS. Since 2016, he started to work independently as principal investigator and full-time professor in the Institute of Microbiology, CAS, and from March 2025, he moved to the Guangzhou National Laboratory. His expertise mainly focuses on the molecular mechanisms of emerging virus infection and regulation by the host, especially how the virus breakthrough the host barrier to infect humans, and the development of broad-spectrum antivirals and vaccines against different emerging viruses. He has made remarkable progress on a range of important human pathogens including influenza virus, Ebola virus, ZIKV, arenaviruses, coronaviruses and mpox virus. He has published more than 100 refereed papers in the international academic journals including Cell, Nature, and Science.

Yuanyuan Shi

Chairman
Shenzhen Cell Valley Biopharmaceuticals Co., LTD.

Shi Yuanyuan holds dual academic credentials: a Ph.D. in Biochemistry and Molecular Biology from the Chinese Academy of Sciences and postdoctoral research experience at Harvard Medical School's Department of Pathology. As Chairman and General Manager of Shenzhen Cell Valley Biomedicine Co., Ltd., he also serves as Distinguished Professor, doctoral supervisor, and postdoctoral mentor at Beijing University of Chinese Medicine. His professional journey began with mentorship under Academicians Zou Chenglu and Wang Zhizhen of the Chinese Academy of Sciences, and Bert L. Vallee of the U.S. National Academy of Sciences. His research focuses on modifying CAR molecules to enhance antigen recognition specificity, improve cytotoxicity efficiency, and achieve precision in CAR-T therapy. Currently leading the CAR-NK project under Shenzhen's Overseas High-Level Talent Team (Peacock Team), he continues to pioneer innovative approaches in immunotherapy.

Pandy Song

Partner
Northern Light Venture Capital

Pandy Song joined NLVC in 2016 and brought with him a profound understanding of China's pharmaceutical industry. he was extensive experience in corporate strategic planning and implementation, along with a background in clinical trial applications, business development, team building, and marketing management. His primary areas of focus at NLVC are biotech and biopharmaceuticals, with notable investments including SHIP, Zelgene, Belief Biomed, Genfleet, Sanegenebio and NGGT Prior to NLVC, Pandy worked in the Department of Strategic Research at Staidson Biopharmaceutical Co., Ltd., where he handled business development work surrounding global licensing and strategic alliance management, including joint ventures, partnerships, and value-add collaborations, Additionally, he led market marketplace assessments of China's pharmaceutical industry, including policy work and trend identification, before ultimately helping develop the company's long-term strategy and dynamic modeling processes.
Pandy holds a PhD in Biophysics from the Chinese Academy of Medical Sciences, a PhD in Philosophy from Peking Union Medical College, and DBA (doctor business administration) degree from Hong Kong University and Peking University



YunLong Song

CEO
InnovStone Therapeutics, Ltd.

Dr. Song Yunlong is the Chief Executive Officer of InnovStone Therapeutocs Co., Ltd. Expert in small molecule innovative drug design, he has led his team in developing a series of innovative results and accumulated extensive experience in new drug development. He has received four CDE Breakthrough Therapy Designations, three innovative drug projects have entered Phase II clinical trials in China and the United States, and over ten clinical trial approvals have been obtained in both China and the United States. The global rights to the small molecule LPa inhibitor he led in development were transferred to AstraZeneca, with the contract value ranking in the top 10 of the annual global rankings. These R&D achievements have led to a strategic R&D collaboration between CSPC Pharmaceutical Group and AstraZeneca, with a total contract value of US$5.33 billion.

Graeme Spencer

Associate Vice President
Principal Education & Science

Science Principal and a recognised leader in designing future-focused campuses and biomedical precincts across Australia. With over 25 years of cross-disciplinary experience, he brings bold ideas and deep expertise to projects that integrate education, health, science, and data infrastructure. Graeme has led the design of high-impact projects including the Sydney Biomedical Accelerator, Western Sydney University's Bankstown City Campus, and CSIRO's high-containment research facilities. He's a champion of "connectivity by design," creating open, flexible labs and collaborative precincts that accelerate discovery from bench to bedside.
He also spearheads HDR's data-driven design tools, helping institutions visualise and optimise campus assets in real time. Graeme continues to shape the future of education and research through design that is human-centred, rigorous, and strategically impactful.

Richard Stone

Senior International Correspondent
Science Magazine(AAAS)

Richard Stone is the senior international correspondent for the weekly journal Science. He also serves as Special Advisor, Science Diplomacy and Engagement, for the international Human Frontier Science Program organization in Strasbourg, France. His overseas experience includes stints as a Fulbright Scholar at Rostov State University in Rostov-on-Don, Russia in 1995 - 96 and at Kazakh National University in Almaty, Kazakhstan in 2004 - 05. Stone opened the Beijing bureau of Science in 2007, and spent 5 years in China. Among many highlights, he and Bruce Alberts, President Emeritus of the U. S. National Academy of Sciences, interviewed former Premier Wen Jiabao for Science in 2008. He is the author of the nonfiction book Mammoth : The Resurrection of an Ice Age Giant.

Stella Sun

Principal Manager
Life & Health Sciences, Invest Hong Kong

With over 15 years of extensive experience in the Innovation and Technology sector, Dr. Sun has a diverse background spanning academia, pharmaceuticals, and biotechnology companies. Prior to her role at InvestHK, she held a medical affairs position, where she assisted to the launch of blockbuster pipelines at leading pharmaceutical. In the biotech industry, she successfully led the commerisation of the company's leading in vitro diagnostics (IVD) for cancer interception.
Dr. Sun graduated from the University of Manchester in the UK, earning a degree in Clinical Biochemistry and a Master's Degree in Immunology and Immunogenetics from the same institution. She holds a PhD in Cancer Biology from The University of Hong Kong, where she also completed her postdoctoral training.
In addition to her academic qualificiaton, Dr. Sun has obtained several patents and served as an investigator on various research grants. She has also contributed to significant publications throughout her career.

Yuanyuan Sun

Founder&CEO
Zinta Health Biotech

Graduated from Nanjing University with 16 years of experience in omics industry and traditional drug screening platform development, providing genomic/proteomic research products and technical services for domestic universities, government agencies, hospitals, and third-party research institutions. In 2015, assembled a team to pioneer AI applications in novel target discovery and lead compound identification, subsequently developing a proprietary AI drug discovery platform based on logical algorithms. Founded DuoFortuna BioMed (Suzhou) Co., Ltd. in December 2020, currently advancing five drug pipelines targeting disease areas with unmet clinical needs including multiple sclerosis (MS), inflammatory bowel disease (IBD), Parkinson's disease (PD), etc.



Kwong Hang Tam

Vice President& Chair Professor
Macau University of Science and Technology

JP; MBBS(HK); ChM(Liv); FRCS(Eng, Edin, Glas, and Ire); FRCPCH; FHKAM (Surgery);HKAS member

Prof. Paul K.H. Tam is a renowned surgeon, scientist, educator and university leader. He is Chair Professor and Vice-President of the Macau University of Science and Technology, and Emeritus Professor and Honorary Clinical Professor of the University of Hong Kong

Professor Tam has special interests in minimal invasive surgery, genetics and regenerative medicine of birth defects especially Hirschsprung's disease and biliary atresia. He has published 505 articles in internationally refereed journals with 35,314 citations and h-index = 66.

He has received numerous awards including the 2017 Denis Browne Gold Medal- the highest award of the BAPS, the 2020 Rehbein Medal by the European Paediatric Surgeons' Association.

Changyong Tang

Third Affiliated Hospital of Sun Yat-Sen University

Associate Researcher, Dept. of Neurology, The 3rd Affiliated Hospital of Sun Yat-sen University (SYSU); Ph.D. from Univ. of Chinese Academy of Sciences, postdoc at Brown Univ. (USA); SYSU "Hundred Talents Program" recruit, doctoral supervisor.
Main research: Roles of neural stem cells, astrocytes and their microenvironment in neurodegenerative diseases (aging, AD, etc.) and neuroimmunological diseases (NMOSD, MS, etc.).
Academic achievements: Led projects like National Natural Science Foundation programs, "Innovation 2030 Brain Project" youth project; published over 20 papers (first/corresponding author) in Neuron, Science Advances (2), Molecular Psychiatry (2), etc.

Jiawei Tang

COO
Global BioPharma Partnerships LLC.

Jiawei Tang is the Co-founder and COO of Global Biopharma Partnerships. She holds a Master's degree in Digital Transformation in Healthcare Management and brings over 15 years of extensive experience in the healthcare and life sciences industry, with a proven track record in sales, corporate strategy, and marketing.
Her professional background includes 12 years in management roles at Pfizer, a global pharmaceutical leader, and one year as Commercial Strategy Director at Resolian, a renowned contract research organization (CRO). She has successfully led and implemented numerous brand transformation, corporate strategy, integrated marketing communications, and business innovation projects across major markets, including the United States, the United Kingdom, Australia, and China.
In addition to her professional work, Jiawei serves in volunteer leadership roles at several nonprofit healthcare organizations, including as a Geographic Expansion Leadership Member at the Healthcare Business Association,as an Advisory Borad member of One Patient One cure and as Vice President of the Chinese Biopharmaceutical Association Greater Philadelphia.

Mark Tang

Founder, 111 Longevity LLC
Founder, Phagionics Inc.
Founding Partner, Good Health Capital, New York

Mark Tang is the Managing Director of Good Health Capital, a healthcare PEVC firm with offices in New York and Shanghai, and Chairperson of World Biotech Capital LLC, a cross-border venture capital, M&A, licensing, and IPO advisory firm. Mark is also a co-founder of 111 Longevity LLC and Phagionics Inc. Originally from mainland China and educated in the US, Mark is a veteran Chinese biotech investor with over two decades of experience in the field of biotechnology as an entrepreneur, educator, advisor, and investor. He served as the biotech director at Rutgers Business School and as a lecturer at Rockefeller University. Mark has worked at investment banks, including Morgan Stanley Dean Witter and UBS PaineWebber. He is the author of "The Essential Biotech Investment Handbook," which is published in both English and Chinese. Mark has co-founded three tech startups that have achieved successful exits. He holds degrees from NYU Stern School of Business and the Harvard T.H. Chan School of Public Health.

Ming Tang

Chief Executive Officer
YNBY International Limited

Executive Director and Chief Executive Officer of YNBY International Limited. Over 25 years international market development experience. Specialize in building global strategies, setting local teams, and familiar with local regulations and ecosystem to start the new business. Have rich experience across marketing and sales, R&D, supply chain, GTM, etc. Have been worked in Europe, North America and APAC with top tier customers on different verticals.

Naping Tang

DM of Toxicology BU
InnoStar

Dr. Tang Naping is the Director of Toxicology Business Unit at InnoStar, with over 16 years of experience in toxicology research. Dr. Tang serves as a Standing Committee Member of the Safety Pharmacology Society, Chinese Pharmacological Society (CSPS), and a Council Member of the Shanghai Society of Toxicology. He has been awarded the Natural Science Award, Second Class, from the Ministry of Education, and the Shanghai Science and Technology Award, Second Prize. As the first or corresponding author, he has published 18 SCI-indexed papers.

Jie Tao

Director
Nanxiang Branch of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Doctor, Associate Researcher, Supervisor of Master's Degree Students, Future Leader of Key Discipline in Shanghai's Traditional Chinese Medicine, Member of the Sensory and Motor Special Committee of the Chinese Neuroscience Society, and Young Member of the Brain Disease Branch of the Chinese Materia Medica Society. Mainly engaged in the research on the mechanism of refractory epilepsy and individualized treatment. Selected for the Chinese Materia Medica Young Talent Support Program, Shanghai Oriental Talent Young Program, Shanghai Outstanding Young Medical Talent, Shanghai Silver Snake Award Nomination Award and Silver Snake Award – Hengjie Special Support Program. Published 37 SCI papers as the first author, co-first author or corresponding author in academic journals such as J Hepatol, BJP, JMC and Acta Pharmacol Sin. As the first principal investigator, won the second prize of Shanghai Traditional Chinese Medicine Science. Has undertaken 4 National Natural Science Foundation projects and 4 provincial and ministerial projects.

Nicholas Teo

General Manager
GSK Hong Kong & Macau

Nicholas Teo is the General Manager of GSK Hong Kong & Macau. With almost 20 years of pharmaceutical experience and a proven track record in multiple countries, he has been instrumental in driving the company's growth and the access of innovative medicines to patients in various countries.
Nicholas started out as a medical sales representative in Singapore and has progressed to various key leadership positions throughout his career. This includes Business Unit Director roles in Singapore & Taiwan, where he led the local business to growth in Respiratory, Oncology and established portfolios and also above country roles such as Global Marketing Director & Global Market Access Director, based in the London HQ where he was responsible for brand and pricing strategies for various assets.
He is known for his strategic vision, strong leadership skills, and dedication to fostering a collaborative and innovative work environment.

Hui Tian

Founder and CEO
Axbio International Limited ancer Center

Dr. Hui Tian is the founder and CEO of Axbio, a global leader in integrated circuit biotechnology. Axbio is developing a next-generation electrochemical detection platform to transform the life sciences tools and diagnostics industry.
Dr. Tian is a leading scientist who is the inventor of over 100 granted patents globally, with extensive leadership in biotechnology. Before founding Axbio, Dr. Tian was Vice President at a California-based company which develops genetic analysis platform designed for real-time DNA sequencing, and later continued as Vice President at the sequencing division of a global pharmaceutical company until 2016. Dr. Tian also served leadership roles at Silicon Valley technology companies, including vice president at InVisage Technologies Inc., director at Pixim, Inc., and principal sensor scientist of IC Media Corporation.
PhD & MS, Stanford University; MS & BS, Tsinghua University, China.

Wenzhi Tian

Chairman & CEO
ImmuneOnco Biopharma

Dr. Wenzhi Tian, is a renowned expert in cancer immunotherapies with over 30 years of academic and industrial experience in the field of immuno-oncology. Dr. Wenzhi Tian is the Founder, Chairman and Chief Executive Officer of ImmuneOnco Biopharma. Prior to founding our Company in 2015, Dr. Tian co-founded and managed Huabo Biopharm and served as the principal research scientist at ImClone Systems. Before devoting himself to the pharmaceutical industry, Dr. Tian spent close to 15 years conducting academic research specifically on immunology at various research institutes, including Karolinska Institute in
Sweden, Weill Medical College of Cornell University and North Shore University Hospital in the United States. With extensive expertise in cancer immunology, Dr. Tian taught as adjunct professor at Fudan University, Zhengzhou University and Henan University. Based on his in- depth understanding of cancer immunology, Dr. Tian has been at the forefront of scientific research and built a proven track record in target validation, molecule design and drug development for innovative immunotherapies. He identified CD47 as a promising immunotherapeutic target and commenced drug research on CD47 starting from 2010, roughly 10 years earlier than the validation of CD47 by clinical data. His deep expertise and foresight in target selection led to our development of multiple monoclonal antibody and bispecific molecules targeting CD24, another promising checkpoint since 2019, all with global first-in-class potential. A prolific scientist, Dr. Tian invented 28 issued patents and 44 patent applications, and published over 30 scientific papers in the area of immunology and CD47 in internationally-recognized journals.

Cheng Hock Toh

Professor of Haematology
University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, UK

Professor Cheng-Hock Toh is Professor at the University of Liverpool and Consultant Haematologist at the Liverpool University Hospitals NHS Foundation Trust. He is Chair of the National Blood Transfusion Committee in England and distinguished past positions include being the Academic Vice-President of the Royal College of Physicians (London), President of the British Society for Haematology (BSH) and National Haematology Lead of the National Institute of Health Research (NIHR) Clinical Research Network. He has received Achievement awards from the Royal College of Pathologists, European Society of Hematology and the BSH. His translational research programme on understanding blood changes during infection is world leading and he has published in the top journals in medicine, critical care and haematology. He holds several patents related to haemostatic dysfunction in critical illness.
For services to haematology and medicine, he was appointed as Commander of the British Empire (CBE) by the late Queen Elizabeth II in 2022.



Han Chong Toh

Deputy CEO
National Cancer Centre Singapore

Dr Toh Han Chong is Deputy CEO (Strategic Partnerships), National Cancer Centre Singapore and Professor at Duke NUS Medical School. Dr Toh obtained his BSc (Intercalated) from the University of London in 'Infection and Immunity' and his medical degree from the University of Cambridge, UK. His oncology and translational research fellowships were at the Singapore General Hospital, Massachusetts General Hospital, Harvard Medical School and at the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Texas, USA. Dr Toh is alumni of the Harvard Business School General Management Program. He is Principal Lead, Cellular Immunotherapy at the Singhealth Duke NUS Cell Therapy Centre. Dr Toh is recipient of National Senior Clinician Scientist Award in 2017 and National Medical Excellence Award (NMEA) in 2018. He led the NMRC LCG VICTORY (Virus-Induced Cancers Translational Oncology and immunologY) grant and is recipient of the NMRC STaR Award 2022. He is European Society for Medical Oncology (ESMO) Scientific Faculty and on the ESMO Annual Congress 2024 Scientific Committee. He is co-lead of the ESMO Asia 2024 Immunotherapy Educational Session. He is co-founder of the Asia-Pacific Gastrointestinal Cancer Summit. He has published over 155 peer review journal papers.

Gergely Tóth

Chief Executive and Science Officer, and Honorary Associate Professor
Cantabio Pharmaceuticals and University College London

Gergely Tóth, PhD, MBA is the CEO, CSO and founder of Cantabio Pharmaceuticals, a biopharmaceutical company focusing on developing novel disease modifying precision therapeutics and diagnostics for neurodegenerative diseases. Dr. Tóth, is also an Honorary Associate Professor at the School of Pharmacy at University College London, where he lectures about the business of biotech.
Dr. Tóth previously held various research roles in small and global biopharmaceutical companies in the U. S. and later was a Welcome Trust funded research fellow at the University of Cambridge. Dr. Tóth has over 20 years of experience in the research of therapeutics and diagnostics for Alzheimer' s, and Parkinson' s disease His research and publications were highlighted in articles by Biocentury Innovations, Scientific American and the World Economic Forum' s'Top 10 Emerging Technologies 2019.

Amber Tong

Reporter
Bloomberg News

Amber Tong is a reporter at Bloomberg News covering Chinese and Asian biotech and pharma companies – and the growing role they play on the global stage. She has written extensively about the aspirations and challenges of China’s innovative drugmakers, the evolution of the complex Chinese healthcare market and the dynamic relationship between China and multinational pharmaceutical giants. A trusted voice in the sector, her work has been cited by industry insiders and media publications. Previously, Amber was a senior editor at Endpoints News



Zhou Tong

Associate Professor
Institute of Microbiology, Chinese Academy of Sciences (CAS)

Zhou Tong's research focuses on the mechanism of broad-spectrum antibody generation and in vitro antibody engineering. He established a microbial surface antibody display and screening platform based on phages, yeasts, and bacteria, and further integrating microfluidic systems, developed a high-throughput protein genotyping and rapid functional labeling system via microdroplet reactions, enabling high-throughput screening of multi-species antibody libraries and solving the microbial antibody display system's low reproducibility.

He co-founded a rare antibody discovery platform based on the "human distant-source immune animal model" with Ocean University of China, addressing the inability to generate antibodies against low-immunogenicity targets in humans and traditional mammalian models. He also collaborated with the National Microbial Data Center to build an antibody digital database (covering human, cotton rat, shark, etc.) and a modification hotspot prediction algorithm system, and further developed an AI-assisted antibody interpretation and prediction system based on antibody generation rules.

These platforms strongly supported monoclonal identification and reshaping of multiple detection/therapeutic antibodies. He has co-authored 27 SCI papers, with 6 published as first/corresponding author in PNAS, Cell Reports, Nature Communications, and Nucleic Acids Research in recent five years, and holds 18 authorized national invention patents. His "Dia-19 bispecific antibody" for broad-spectrum COVID-19 prevention obtained national clinical trial approval in February 2024 (2024LP00386).

Hung-Fat Tse

Department Chairperson
Department of Medicine, Queen Mary Hospital

Prof. Tse Hung-Fat, MBBS, MD, PhD, FACC, FRCP, FESC
Prof. Hung-Fat Tse is Chair Professor of Cardiovascular Medicine, and William MW Mong Professor in Cardiology; Chairpersons and Chief of Service of the Department of Medicine; Chief in the Cardiology Division, Department of Medicine, Queen Mary Hospital; Co director, Cardiac & Vascular Center, The University of Hong Kong - Shenzhen Hospital. He is also the academic lead, HKUMed Laboratory of Cellular Therapeutics, The University of Hong Kong.

He is a clinician scientist and an international expert in cardiovascular medicine, including cardiac pacing, clinical electrophysiology, and cardiovascular regeneration. Prof. Tse is one of the pioneers for novel therapies, including stem cell and devices for treatment of cardiovascular diseases. He has established the large animal laboratory for cardiovascular research as well the “Good Manufacturing Practice” laboratory for human stem cells and biological therapies in the University of Hong Kong. He has been awarded multiple major local grants (including the Theme Based Research Grant, Research Impact Fund and Innohealth) as well as national research grants (National Natural Science Foundation of China and 973 grants) for his researches. He has been participated into many international and regional clinical trials and studies, and is currently the Associate Editors for several international journals, including Cardiovascular Diabetology, Frontier in Cardiovascular Medicine, Journal of Cardiovascular Electrophysiology, Pacing and Clinical Electrophysiology and Journal of Arrhythmia. He has published over 730 scientific publications in international top-ranking scientific journals, including New England Journal of Medicine, Lancet, Nature Medicine, Nature Cell Biology, Nature Genetic, Nature Protocol, Nature Communication, Nature Biomedical Engineering, Nature Disease Primer, Cell Stem Cell, Circulation, Journal of American College of Cardiology, and European Heart Journal.

Stephen Hsin Tse

Executive director, senior vice president
Sino Biopharmaceutical

Mr. Tse Hsin, aged 55, is an executive director, a member of the executive board committee and a senior vice president of the Company. Mr. Tse Hsin is mainly responsible for mergers and acquisitions and financing activities of the Group. Mr. Tse Hsin graduated from the University of Hong Kong with a Bachelor's Degree (Honors) in Industrial Engineering. He joined the Group in August 1995 as an assistant to the president of the Company and served as the general manager of Xian C.P. Pharmaceutical Co., Ltd. Mr. Tse Hsin was a council member of the first council and an executive council member of the second council of Chaozhou Natives Chamber of Commerce Beijing. He was also an executive member of the Right Protection Association for the Medical Treatment Equipment Enterprises of the Shaanxi Province, a vice chairman of the fourth council of the Foreign Invested Enterprises Association of the Shaanxi Province, an executive member of the third committee of the Shaanxi Cancer Fighting Association and a vice chairman of the World Chinese Medicine and Pharmaceutical Professional Joint Committee. He was awarded the "Outstanding Management Award for Foreign-invested Enterprises of Shaanxi Province" by the Shaanxi Provincial Government and the "Outstanding entrepreneur who cares about his staff" by the Shaanxi Foreign Invested Enterprises Association. Mr. Tse Hsin was a director of CT Tianqing, Beijing Tide, and CP Pharmaceutical (Qingdao) Co., Ltd., and is currently a director of NJCTTQ， HanchorBio Inc. and CP Boai Investment Ltd., the chairman of Chia Tai Shaoyang Orthopedic Hospital, and a supervisor of CT Tianqing.

Rocky S. Tuan

Former Vice-Chancellor and President
The Chinese University of Hong Kong

Professor Tuan (Ph.D., Rockefeller University), the immediate past Vice-Chancellor and President of The Chinese University of Hong Kong (CUHK; 2018 to 2025), is an internationally renowned biomedical scientist who specializes in musculoskeletal biology, tissue regeneration, stem cells, biomaterials, 3D bioprinting, and tissue/organ-on-a-chip technologies. He is currently the Lee Quo Wei Lee Yick Hoi Lun Professor of Tissue Engineering and Regenerative Medicine at CUHK, where he founded the Institute for Tissue Engineering and Regenerative Medicine (iTERM) in 2016. A highly cited author of over 650 publications (h-index, 135), he has received multiple international recognitions, including Fellowship in the National Academy of Inventors (NAI), American Institute for Medical and Biological Engineering (AIMBE), International Combined Orthopaedic Research Societies (ICORS) and Orthopaedic Research Society (ORS), and Tissue Engineering and Regenerative Medicine International Society (TERMIS), the latest being the 2025 Jensen Tissue Engineering Award from TERMIS. He is the founding editor of Birth Defects Research (2003-2017) and Stem Cell Research & Therapy (2009-present), and Associate Editor of Stem Cells Translational Medicine (2011-present).

Gabriel da Luz Wallau

Public Health Researcher
Instituto Aggeu Magalhães (IAM) , Fundação Oswaldo Cruz (Fiocruz) , Brasil

Dr. Gabriel Wallau is a Public Health Researcher at the Oswaldo Cruz Foundation, affiliated with the Department of Entomology and the Bioinformatics Core of the Aggeu Magalhães Institute (IAM) – FIOCRUZ – Pernambuco, as well as the Federal University of Santa Maria (UFSM). He is also a principal investigator at the Bernhard Nocht Institute for Tropical Medicine in Hamburg, Germany, affiliated with the Department of Arbovirology and Entomology. His research group focuses on topics such as viral discovery and evolution, comparative genomics, computational biology, and omics methodologies applied to pathogens and hosts. He leads the Research Group on Pathogen and Host Genomics and is a member of the Fiocruz Genomics Network, a Ministry of Health founded initiative posed to implement pathogen genomic surveillance in Brazil and the region.

Wuzhou Wan

President
Central Research Institute, Yunnan Baiyao Group

President, Central Research Institute, Yunnan Baiyao Group; Ph.D. from Peking University; Post-doc fellowship at the National Institutes of Health (NIH); EMBA from CEIBS.
Possessing a professional background in chemistry, biology, and immunology, with approximately 20 SCI papers published in internationally renowned journals.
From 2014 to 2022, worked in multinational pharmaceutical companies, private enterprises, and innovative pharmaceutical companies such as GlaxoSmithKline (GSK), Shanghai Furen Pharmaceutical, and BoomRay, experience in new drug research and development, investment incubation, business development, and operation management.



Daxi Wang

Head of Infection Omics Research Center
BGI Research

He obtained his PhD from the University of Melbourne, focusing on parasitic genomics. After graduation, he joined BGI Research, where his primary research interests are pathogen mining and molecular evolution. He has published more than 20 papers in high-impact journals, including Science, Nature Ecology & Evolution, and Microbiome. During the early stages of the COVID-19 pandemic, his research group concentrated on investigating the intra-host variation and transmission characteristics of SARS-CoV-2. Currently, leveraging genomic and artificial intelligence technologies, he is dedicated to the global discovery of emerging and re-emerging infectious pathogens, predicting hotspots of pathogen distribution, and providing early warning for potential outbreak events. His research group also undertakes key tasks within the National Key Research and Development Program “Etiology and Epidemic Prevention Technology System Research Special Project.”

Everett X. Wang

Principal Investigator
Beijing Institute of Nanoenergy and Nanosystems,
Chinese Academy of Sciences

PhD in Microelectronics Engineering, University of Texas at Austin; MS from Institute of Theoretical Physics, Chinese Academy of Sciences; BS from Peking University.

With over 30 years of experience in Silicon Valley tech companies (including Intel), he specializes in AI, deep learning, large language models, NLP, and computer vision. He served as Conference Chair for IEEE ICRAE and other international conferences, holds 62 patents (China/US/EU), and has published 75 SCI papers.
Currently, he is a Professor and PhD Advisor at the Beijing Institute of Nanoenergy and Nanosystems, CAS, leading a digital TCM platform initiative. He also holds leadership roles in the World Federation of Chinese Medicine Societies and the Chinese Society of Biomedical Engineering.



Hong-jie Wang

Dean
School of Basic Medical Sciences,Hebei University

Dr. Wang earned her Master's degree in Anesthesiology and PhD in Pharmacology from Hebei Medical University. She has held several key academic and administrative positions, including Deputy Director of the Department of Anesthesiology at Hebei University Affiliated Hospital, Director of the Research Office, and Vice Dean of the School of Medicine at Hebei University. Currently, Dr. Wang serves as a member of the Anesthesiology Teaching Subcommittee under the National Teaching Advisory Board for Higher Education Institutions of the Ministry of Education, China. She is also a committee member of the Anesthesiology Branch of the Hebei Medical Association and a corresponding editorial board member of the Chinese Journal of Anesthesiology.



James Wang

CTO
Juventas

Dr. James Wang currently serves as CTO of Juventas Cell Therapy Ltd, in charge of the strategic planning and development of technology platforms. During the development of China's 1st home-grown CAR-T product: Yuanruida (Ina-Cel) and its marketing, he was fully responsible for pharmaceutical research, clinical production, and consultation with regulatory authorities.
Dr. Wang has long successful career in the field of cell therapy with a broad international perspective, he was trained in Dr. Sadelain's team, where the world's first breakthrough was made proving the clinical feasibility of 2nd generation CD19-CAR-T cell therapy and its safety and efficacy in treating adult Acute Lymphoblastic Leukemia (r/r ALL). He played a pioneering key role in the quality control and management of global commercialization of Novartis KYMRIAH® - the world 1st approved CAR-T cell therapy.
From 2007 to 2020, he served respectively at GenScript USA, MSKCC, and Novartis, he joined Juventas on Jan 1, 2021 as CTO.
Dr. Wang received his PhD from the Hebrew University of Jerusalem in Israel in 2001. From 2002 to 2007, he engaged in postdoctoral research at Iowa State University and Cornell University.

Jianxun Wang

Chief Scientific Officer
Shenzhen Cell Valley Biopharmaceuticals Co., LTD.

Dr. Jianxun Wang is a Ph.D. graduate and postdoctoral researcher from the University of California, San Diego, a Second-Class Professor and doctoral supervisor at Beijing University of Chinese Medicine, and Chief Scientist of Shenzhen Cell Valley Biomedicine Co., Ltd. A former student of U.S. National Academy of Sciences members Michael G. Rosenfeld and Christopher K. Glass, Dr. Wang is an epigenetics expert focused on enhancing T-cell tumor recognition and killing capabilities through epigenetic modifications, achieving breakthroughs in CAR-T therapy for solid tumors. As a senior scientist at Sorrento Therapeutics, he pioneered CAR-T cGMP development from scratch, accumulating extensive experience in industrial-scale production of cell therapies. Recognized as a world-class expert in constructing viral vectors including retroviruses and lentiviruses, Dr. Wang has established cutting-edge standards for cellular therapy production.

Tong Wang

Assistant Professor
School of Life Sciences, Tsinghua University

Dr. Wang Tong is the Principal Investigator (PI) of the School of Life Sciences, Tsinghua University, Tsinghua University-Peking University Joint Center for Life Sciences (CLS) and Beijing Frontier Research Center for Biological Structures. He received Ph.D. degree at Tsinghua University and has research experience as a visiting scholar at Harvard University and work experience at Microsoft Research.

His main research directions include AI-driven biomolecular dynamics simulation, machine learning force fields, molecular structure representation learning, and computer-aided drug discovery. As the primary project leader, he proposed the AI2BMD dynamics simulation program, which has brought protein dynamics to ab initio accuracy, achieving "Top Ten Advances in Chinese Bioinformatics in 2024". He also led his team to win the championship in the first Global AI Drug Discovery Competition.

Over the past five years, he has published more than 30 papers as first author or corresponding author in journals such as Nature, Nature Machine Intelligence, Nature Communications, and Cell Research, and holds more than ten patents in China and the United States.

Yangming Wang

Professor
Peking University

Dr. Yangming Wang is a full Professor and Director of the Institute of Molecular Medicine at the College of Future Technology, Peking University, China. He is also a Principal Investigator at Beijing Advanced Center of RNA Biology (BEACON). His research interest is on RNA biology and stem cell biology. His major contribution to the field includes: systematic dissection of miRNA functions in embryonic stem cells; invention of a miRNA-inducible CRISPR platform (MICR) that can serve as miRNA reporter and cell specific genome editing tools; invention of MAPIT-seq that enables co-profiling in situ RNA binding protein interacting RNAs and transcriptome in single cells and tissues; co-developed a new approach to identify homologs of long noncoding RNAs; developed a highly reproducible and efficient organoid culture system. He currently uses multiple disciplinary engineering approaches to develop novel tools for basic and translational research of RNA and stem cells. He has published over 40 scientific journal papers on peer-reviewed journals including Nature Genetics, Nature Cell Biology, and Nature Methods et al. He is an Advisory Board member for Cell Reports and Cell Proliferation. He is also a co-founder of Xungene Therapeutics.

Yaning Wang

Founder and CEO
Rui Ning Kang Pharma

Dr. Yaning Wang is the Founder and CEO of Rui Ning Kang Pharma, providing consulting service for new drug discovery and development, dose optimization, trial design, biomarker/surrogate/clinical endpoints justification, regulatory interactions, IND/NDA/BLA package preparation, asset and company evaluation, and license in/out negotiation. Between 2021 and 2024, he was the CEO of Createrna, a clinical-stage biopharmaceutical company developing novel therapeutics for multiple diseases. Under his leadership, 500 million RMB was raised during a capital-winter period and multiple billion-dollar license-out deals were achieved. Before 2021, he was the Director of the Division of Pharmacometrics at US FDA and oversaw reviews, research projects, and policy development for all disease areas. Before joining FDA, Dr. Wang received his Ph.D. in Pharmaceutics and master's degree in Statistics from the University of Florida in 2003. He also obtained a master's degree in Biochemistry (1999) from National Doping Control Center and a bachelor's degree in Pharmacy (1996) from Peking University in China. Dr. Wang is an Adjunct Professor in University of Florida, Beijing University, Shanghai University of Traditional Chinese Medicine, and Central South University. Dr. Wang has published over 120 papers and given over 500 presentations at various national and international meetings as an expert in new drug development and regulation. He was selected to be one of the top Healthcare Technology Leaders of Washington, DC for 2023. He is the external advisor for Chinese National Medical Products Administration and the expert reviewer for Chinese Ministry of Science and Technology. He also serves as an expert advisor for Shanghai Free Trade Zone Fund and a senior consultant to multiple American investment companies and banks.

Yi Wang

Partner
Legend Star

Yi Wang is a Partner at Legend Star, where he leverages emerging technologies to address unmet medical needs and unlock health-economic value. Specializing in early-stage venture incubation, he focuses on the intelligent and robotic transformation of medical devices and has played a pivotal role in the growth of innovative companies such as Edge Medical, Longwood Valley MedTech, DeepWise, Union Strong and Healinno Tech. Prior to Legend Star, Yi held business-development and clinical-translation roles at global medicare firms including Johnson & Johnson and 3M.

Ziping Wei

CEO
Bliss Biopharmaceutical Co., Ltd. (BlissBio)

Dr. Ziping Wei is co-founder, Chairman, and Chief Executive Officer of BlissBio, which is a clinical stage company focusing on the development of ADC products. She has had over twenty years of industrial experience in biopharmaceutical development and commercialization in US. She served in CMC development at Novavax, Medimmune-AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson. She contributed to the development of over 40 antibodies and vaccine products, including therapeutic monoclonal antibodies, bispecific antibodies, ADCs, recombinant proteins, and virus vaccine, of which 9 were approved to the market.
Dr. Wei is a former president of Chinese Biopharmaceutical Association-USA. She received her Ph.D. in Chemistry at Rutgers, the State University of New Jersey, and B.S. in Chemistry at the University of Science and Technology of China.

Hoi Leong Xavier Wong

Professor
School of Chinese Medicine, Hong Kong Baptist University

Prof. Wong holds a Bachelor of Science (BSc) and a PhD in Biochemistry from the University of Hong Kong. He is currently a principal investigator at the School of Chinese Medicine, Hong Kong Baptist University, where he leads a multidisciplinary team specializing in biology, neuroscience, and microbiome research.
Collaborating closely with clinicians and bioinformaticians, Prof. Wong's laboratory has achieved multiple groundbreaking discoveries in drug discovery for metabolic disorders, leading to high-impact publications as first or corresponding author in journals such as Nature Communications, Cell Host & Microbe, Nature Metabolism, and Developmental Cell.
In recognition of research excellence, Prof. Wong has received several prestigious awards, including the School Performance Award as Young Researcher (2021), the President's Award for Outstanding Performance as an Early Career Researcher (2022), and the National Natural Science Foundation of China (NSFC) Excellent Young Scientist Fund (Hong Kong and Macau, 2023). As principal investigator, he has secured over HK$20 million in competitive research funding from Hong Kong, Europe, and Mainland China to support his multidisciplinary translational research program.



Jack Wing Tak Wong

Associate Professor
CUHK

Prof. Jack Wing Tak WONG is an Associate Professor at The Chinese University of Hong Kong (CUHK), specializing in vascular and metabolic biology, stem cell research, and cardiovascular regeneration. With over 160 peer-reviewed publications and an h-index >50, his work focuses on novel therapeutic strategies for cardiovascular and metabolic diseases. His research spans bioactive compounds (e.g., asperuloside, isoliquiritigenin), type 2 cytokine-mediated tissue repair, and induced-pluripotent stem cell (iPSC)-derived endothelial cell (EC) therapy in atherosclerosis and diabetes.
As a dedicated innovator, Prof. Wong founded NutrigeneAI Biotech Limited in December 2023, a biotech startup pioneering AI-driven therapies for peripheral arterial disease (PAD). His translational efforts bridge academia and industry, leveraging his expertise in endothelial dysfunction, stem cell biology, and drug discovery. He holds multiple patents, including NRF2 activators for metabolic disorders and cytokine-based PAD therapies.
As Director of CUHK's Biotechnology, Entrepreneurship and Healthcare Management Programme, he fosters interdisciplinary collaboration. His leadership extends as Associate Dean of New Asia College and President of ACRE-Hong Kong. Recognized with awards like the AHA Scientist Development Grant and MoE Outstanding Research Award, Prof. Wong is a key figure in cardiovascular research and innovation. His mission is: transforming scientific insights into clinical solutions for global health challenges.

Wallace Wong

Vice Chairman of Digital Primary Healthcare Sub-committee of Hong Kong Biotechnology Organization

Mr.Wang is currently the Vice Chairman of the Digital Primary Healthcare Sub-committee of Hong Kong Biotechnology Association. Mr.Wang Graduated in 2002 with Master's degree from Communication & Information Systems from Zhejiang University . He previously held engineering roles at Motorola and Freescale and later served as CTO of a digital healthcare company, building the product and R&D system, setting the hardware R&D and manufacturing roadmap, and overseeing schedule, quality, cost, and supply chain. Mr.Wang Led digital primary healthcare products and solution planning, delivering flagship projects in China and overseas, including Hong Kong's primary healthcare digitalization and the integration of medical services with preventive care.

Chengbin Wu

Founder and Chief Executive Officer
EpimAb Biotherapeutics Inc.

Dr. Chengbin Wu is the founder and Chief Executive Officer of EpimAb Biotherapeutics Inc., an innovative, clinical-stage biologics company focusing on developing next generation antibody-based therapies for oncology and other areas of high unmet medical needs. Dr. Wu has over 20 years of experience in discovery, development, and technological innovation in the antibody field, and he is a world renowned expert in bispecific antibody technologies and therapeutic development. Dr. Wu has built a distinguished career in the biopharmaceutical industry, taking on different leadership responsibilities in different parts of the world. Previously he was Chief Scientific Officer and President of R&D at Shanghai CP Guojian Pharmaceutical Co., a leading China-based biopharmaceutical company. Before that he was the Senior Vice President Biologics at Shanghai ChemPartner, where he established a comprehensive antibody R&D platform. Prior to returning to China, Dr. Wu was a Volwiler Associate Fellow at Abbott Laboratories, where he led several novel biologics projects from concept to regulatory filing. Dr. Wu received his Ph.D. degree from the University of Georgia in the US, and postdoctoral fellowship at Harvard Medical School with a grant from the Cancer Research Institute.



Yangyu Wu

Chief Scientist
Shuimu BioSciences

Dr. Yangyu Wu is the Chief Scientist of Shuimu Biosciences, specializing in cryo-electron microscopy (cryo-EM) for membrane protein structure determination and drug discovery. He earned his Ph.D. in Biology from Tsinghua University and completed postdoctoral training at Yale University School of Medicine under Prof. Fred Sigworth, a pioneer in cryo-EM and a member of the U.S. National Academy of Sciences. Dr. Wu has over a decade of experience in membrane protein structural biology, with publications in leading international journals and presentations at major scientific conferences. His work has successfully resolved challenging membrane protein targets, providing critical insights for structure-based drug development.

Since returning to China, Dr. Wu has led the establishment and optimization of Shuimu's cryo-EM platform, with a focus on practical and efficient workflows for sample preparation, data collection, and processing. He has advanced the development of electrospray-based vitrification and its integration with graphene grids, improving data quality and resolution. Currently, he is building scalable cryo-EM solutions to accelerate structural studies of key therapeutic targets, including GPCRs, ion channels, and transporters, driving AI-enabled innovation in life sciences.



Xavier Xie

Chief Innovation and Investment Officer
IASO Bio

Dr. Xie Xuanhui serves as the Chief Innovation and Investment Officer at IASO Bio, where he is responsible for spearheading the incubation and investment of innovative businesses, with a focus on the upstream and downstream incubation of the cell and gene therapy (CGT) industry chain. Prior to joining IASO Bio, Dr. Xie, as a co-founder, successfully incubated and invested in a gene engineering vector vaccine platform. This platform established multiple product lines targeting the markets of economic animals and pets, as well as human vaccines, aiming to meet the demands of import substitution and industrial upgrading. He also co-founded a synthetic biology platform, which set up several product lines in various fields including agriculture, medical aesthetics, and functional foods, exploring the innovative growth potential of biotechnology beyond the pharmaceutical sector. Additionally, Dr. Xie, as a co-founder, incubated several cutting-edge technology platforms including mRNA, siRNA, and phage therapy.
During his tenure as a founding partner at TVM Capital China, Dr. Xie focused on cross-border equity investment and technology transfer in the field of innovative drugs, committed to introducing international advanced pharmaceutical technologies and investment concepts to the Chinese market, and promoting the innovative development of China's pharmaceutical industry.



Ziyao Xu

Head of Strategy
BioMap

Dr. Xu is an industry expert with a unique blend of academic expertise in biocomputing and business acumen. She holds a Bachelor's degree in Pharmacy from Fudan University and a Ph.D. in Computational Chemistry from The University of Hong Kong. As a founding member of BioMap, Dr. Xu has led multiple core initiatives ranging from AI product strategy and innovative R&D to project incubation and strategic investments. She has spearheaded her team in driving deep integration and innovation between biotechnology and computational technologies, resulting in a series of internationally acclaimed foundation model advancements in life sciences.

Kevin Xu

Chairman & CEO
ClinChoice Medical Development Ltd.

Kevin Xu is currently serving as the Chairman & CEO of ClinChoice Medical Development Ltd – a global clinical stage CRO powering biotech innovation across US, China, EU and other APAC markets with end-to-end clinical development solutions.

Previously, Kevin was a Managing Director at Goldman Sachs, where he built and led the firm's Asia-Pacific Healthcare & Life Science Investing business for over 15 years. During his tenure, he directed high-impact investments across biotech, pharma, medtech, CROs/CDMOs, digital health, and AI-driven life science platforms, backing industry-leading innovators.

Kevin holds an MSc in Neuroscience and Clinical Psychology from King's College London's Institute of Psychiatry, Psychology & Neuroscience, a Master of Finance from the University of Cambridge, and a B.S. from the University of Maryland. He also serves as the Queens' Alumni Ambassador for Strategic Partnerships at the University of Cambridge.
and a B.S. from the University of Maryland. He also serves as the Queens' Alumni Ambassador for Strategic Partnerships at the University of Cambridge.



Tony Xue

CEO/Co-Founder
Yilian Biopharmaceuticals

Dr. Xue Tongtong, Founder, Chairman, and CEO of Yilian Biopharmaceuticals, has over 20 years of experience in biopharmaceutical innovation, R&D, and management, encompassing large and small molecule drug design and screening, process development and scale-up, pharmacology and toxicology studies, clinical development, production, and strategic operations. He has led the successful launch of three innovative drug candidates and over 30 projects are currently in clinical and preclinical stages. In the ADC field, he has led the full development of numerous drugs, including B7H3 ADC, HER3 ADC, cMET ADC, and Claudin18.2 ADC, across diverse targets and generations of technology, and has secured numerous licensing agreements. He has published over 10 research papers, including a corresponding author's paper on B7H3 ADC published in Nature Medicine, and holds over 200 invention patents. He has been recognized with numerous honors, including Jiangsu Province's Double Innovation Talent, Jiangsu Province's Industrial Professor, Sichuan Province's "Thousand Talents Plan" Talent, Chengdu City's "Young Talent," Suzhou Major Leading Team Leader, Suzhou Innovation and Entrepreneurship Leading Talent, and Suzhou Industrial Park Innovation and Entrepreneurship Leading Talent.



Cong Yan

director
The Wei Gao Research Institute, Beijing University of Chinese Medicine

Prof. Cong Yan is from School of Life Sciences, Beijing University of Chinese Medicine. He is a member of the Academic Committee and serves as the director of the Wei Gao Research Institute and the Center for Traditional Chinese Medicine Inheritance and Digitalization. He is an editorial board member and reviewer for journals such as TMR Modern Traditional Chinese Medicine Journal and Practical Clinical Medicine Journal, as well as serving as an executive council member of the World Federation of Chinese Medicine Societies' Committee on Evaluation and Promotion of Appropriate Techniques in Traditional Chinese Medicine. Currently, Prof. Yan's group is focusing on the construction of mathematical and physical system of the traditional Chinese medicine, as well as the development of intelligent traditional Chinese medicine diagnosis and treatment technology. At the same time, Prof. Yan undertakes the school-enterprise combination and achievement transformation work in the field of traditional Chinese medicine, focusing on the fields of smart Chinese medicine diagnosis and treatment equipment, traditional Chinese medicine digital therapy, digital Chinese medicine services, etc.. as well as the industrialization of new clinical technologies, new products of traditional Chinese medicine.

Guotao Yang

COO
Quarkmed

Trained as pediatrician, Joined industry in 1998, worked with Asteallas China as head of clinical development for 12 years, worked with Ferring China as head of clinical development for 3.5 years, worked with China Bioteches as head of clinical development and PV for 3 years, joined Quarkmed 1 year ago.



Li Yang

Professor of Graduate School of Chinese Academy of traditional Chinese medicine

Professor of Graduate School of Chinese Academy of traditional Chinese medicine and President of Beijing Zhouyi Research Association Famous Sinology masters, Yi Jing scholars, traditional Chinese medicine scientists, writers, poets, pioneers of elephant number science Professor Yang Li is proficient in literature, history, philosophy and medicine, and has published more than 200 books One million word masterpiece "Zhouyi and traditional Chinese medicine" has been sold in Chinese, English, Japanese, Korean and other versions all over the world It has become a best-selling classic for three decades with "luck of traditional Chinese medicine" and "disease prediction of traditional Chinese medicine", which has a great impact "Elephant number science" will be published in September in Beijing Science and Technology Press.

Ming Yang

Chief Economist
Shanghai Pudong Development (Group) Co., Ltd.

Yang Ming, born in 1968, holds a Bachelor's degree in Economics and a Master's degree in Professional Accounting. He is a certified Accountant and a Senior Economist. His previous roles include Project Manager in the Business Management Department of Guotai Securities Co., Ltd., Deputy Manager of the Brokerage Business Headquarters of Guotai Junan Securities Co., Ltd., Manager of the Investment Banking Department at Shanghai Pudong Development Group Finance Co., Ltd., and later Vice General Manager, Party General Branch Secretary, and General Manager of the same company. He also served as a Partner at New Silk Road Investment Co., Ltd., Deputy General Manager of Shanghai Guozhi Investment Management Co., Ltd., Partner at Shanghai Zhihui Investment Co., Ltd., and General Manager of Shanghai Pudong Road & Bridge Construction Co., Ltd.
Currently, he serves as Chief Economist of Shanghai Pudong Development (Group) Co., Ltd., Chairman of Shanghai Pudong Construction Co., Ltd., and Director of Shanghai Zhangjiang Haoheng Innovation Equity Investment Management Co., Ltd.

Xuerui Yang

Professor/School of Life Sciences
Tsinghua University

Xuerui Yang's research group, established in 2012 at Tsinghua University, uses multi-disciplinary approaches for mining of the multi-omics data and dissection of the multi-level gene regulatory programs. He has been particularly interested in the complex world of RNA, such as the post-transcriptional RNA regulation circuits, the translational regulation, and the non-coding RNA functions, under the contexts of complex diseases such as cancer. Dr. Yang's group has developed a series of bioinformatics algorithms, which in turn provided novel biological insights and led to discoveries of critical translation regulation mechanisms, key regulatory RNAs for normal cell development and tumorigenesis, and noncanonical machineries of post-transcriptional RNA splicing, decay, and modifications.



Jia Yao

Senior Expert
Solid State Research Department, XtalPi Technology

Dr. Jia Yao, a graduate of Sun Yat-sen University, has over ten years of experience in pharmaceutical solid form research and crystallization process development, including a background in R&D at a large pharmaceutical company. Over many years of research and practice, he has led the solid form research and development of hundreds of new and generic drugs, successfully driving the full development process from pilot trials to full-scale production for many of them. He also possesses profound expertise in crystallography, having independently determined over one hundred small molecule crystal structures, demonstrating his solid technical expertise and extensive project experience.



Carl Yeung

CFO
Immvira Group

Mr. Yeung joined Immvira Group in July 2020 and has been serving as the chief financial officer (CFO) of the group since then.
Mr. Yeung has extensive knowledge and more than 20 years' experience in financial industry. Before joining in Immvira, he held senior management positions at multiple listed corporations, playing a key role in leading their listings on the New York Exchange, NASDAQ and Hong Kong Stock Exchange.
Mr. Yeung received his bachelor's degree in economics from the Wharton School, University of Pennsylvania, and his bachelor's degree in applied science from the School of Engineering and Applied Sciences, University of Pennsylvania, in the United States in May 2002.

Peng Yin

Chief Scientific Officer
Phase Sci.

Dr. Peng Yin, currently is the Chief Scientific Officer (CSO) at Phase Sci. Prior to joining PSI, Dr. Yin was the CTO of Sansure Biotech. Dr. Yin worked in Abbott for over 18 years serving various senior roles: Head of Asia R&D; Head of China R&D; Global Scientific and Medical Affairs Director.
Dr. Yin is a Fellow of the AACC Academy (FAACC); previous chair of Industry Division, AACC (ADLM now); Executive Committee Member of the Emerging Technology Division, IFCC; the honorary professor of Tianjin Medical University Cardiovascular Institute and TEDA International Cardiovascular Hospital in China. He is also on the editorial board of both Journal of Human Virology & Retro Virology and Journal of Virology & Current Research. He has published many high-quality scientific research papers in the world's leading science journals such as Cell, Nature, Science and Journal of Virology.
Dr. Peng Yin earned his Medical Doctor Degree (M.D.) from Tianjin Medical School in China and practiced as an abdominal surgeon; earned aa Ph.D. in Molecular Virology from University of Manitoba in Canada. He also completed his postdoctoral training in Virology and oncology at Harvard University Medical School.

Weng Li Yoon

Associate Director
Therapeutics Life and Health Technology

As the Associate Director of Therapeutics at HKSTP, Weng Li leads the account management of Therapeutics companies and Advanced Therapy Products (ATP) initiatives. She is also spearheading the Clinical Translational Catalyst programme which aims to drive the clinical translation of biotech companies through funding support and more effective engagement with comprising to clinicians, CROs etc. through the HKSTP Clinical Professional Network. Weng Li sits on the HKSTP Clinical Research Ethics Committee and Joint Management Committees with HKU and CUHK ATP collaboration to establish PIC/S GMP facilities.
Weng Li obtained her PhD in Pharmaceutical Technology from University College London and MBA from Imperial College London. She then worked at GlaxoSmithKline in the United Kingdom serving as Lead Chemometrician in the New Product Development division. Weng Li was the Senior Research Director at Athenex HK prior to joining HKSTP.

Jingyi Yu

Inaugural Chair Professor, Dean of the School of Information Science and Technology, and Vice Provost
The Shanghai Tech University

Jingyi Yu is an OSA Fellow, IEEE Fellow, and ACM Distinguished Scientist. He directs the MoE Key Lab of Intelligent Perception and Human-Machine Collaboration and is the Inaugural Chair Professor at ShanghaiTech University, where he also serves as Vice Provost and Dean of the School of Information Science and Technology. He received his B.S. with honor in Computer Science and Applied Mathematics from Caltech (2000) and a Ph.D. in EECS from MIT (2005).
Yu's research spans computational imaging, computer vision, computer graphics, and bioinformatics. His honors include the NSF CAREER Award, AFRL Young Investigator Program Award, and the Shanghai Magnolia Memorial Award. He has won multiple top-venue awards, including the 2025 ACM SIGGRAPH Best Paper Award, the 2025 SIGGRAPH Best in Show (Emerging Technology), and a 2024 SIGGRAPH Best Paper nomination. His group earned the 2024 CVPR Best Student Paper Award. He pioneered the use of large visual models in chip design, earning DAC Best Paper Honorable Mentions in 2024 and 2025. He has served on leading journal editorial boards, was Program Chair for CVPR 2021 and ICCV 2027, and General Chair for ICCV 2025.

Max Yu

Former Senior Strategy Expert
China Resources Group

Max Yu is a member of National Association for Hong Kong and Macau Studies and was the former chairman of CRCP Life Science Fund. He was the senior strategy expert and senior deputy general manager at the Strategic Management Department of China Resources Group. He was also a director of China Shanxi Fenjiu liquor (SSE), China Resources Pharmaceuticals (HKSE), and China Resources Building Materials Technology (HKSE). Max has over thirty years of experience in corporate strategy, investment, international trade, and financial management.

Paul Yuan

Assistant Professor
Institute for Translational Brain Research, Fudan University

Dr. Yuan obtained his PhD in neurobiology at Yale University. He then completed his postdoctoral training at Stanford University. Dr. Yuan started his own laboratory at Fudan University on 2021. He is an expert of in vivo optical microscopy and his work primarily focuses on combining high-performance imaging of neuron activities, mathematical modeling, and single-cell manipulation to understand and dissect the principles underlying information representation and neurocomputation. He is also interested in figuring out the information-level abnormality in pathological conditions. Dr. Yuan has published numerous high-profile papers and has been cited for more than 4000 times. His work includes the following: Science 2025; Nature 2022; Nature Methods 2020; Neuron 2016, 2015; Nature Communications 2023, 2015; eLife 2024; Journal of neuroscience 2019, 2016; PNAS 2017; Biological Psychiatry 2018.



Fanyi Zeng

Director
Shanghai Jiao Tong University Institute of Medical Genetics

Professor Zeng received her MD/PhD and postdoctoral training at the University of Pennsylvania, School of Medicine. She is a fellow of the Academic Advisory Committee of the Chinese Academy of Medical Sciences, a Changjiang Scholar, and a chief scientist of the National Basic Research Program of China (973 Program). She is currently Distinguished Professor at Shanghai Jiao Tong University and Director of the Shanghai Institute of Medical Genetics.
Her research focuses on human genetics and developmental biology, particularly the diagnosis and treatment of genetic diseases, stem cell biology, and embryonic development. She has published in leading journals such as Nature and PNAS and has been recognized with awards including second prize of National Prize for Natural Sciences, first prize of Natural Science Award of the Ministry of Education, and inaugural Young Women Scientist Award from TWOWS. She chairs the Human and Medical Genetics Committee of the Genetics Society of China and also serves as Secretary-General of the International Stem Cell Foundation.

Ao Zhang

Dean
College of Pharmaceutical Sciences, Shanghai Jiao Tong University

Ao Zhang is currently a Distinguished Professor and Dean of School of Pharmaceutical Sciences at Shanghai Jiao Tong University, Shanghai, China. His research interests are focused on small molecule drug discovery based on medicinal chemical biology. He has co-authored over 200 publications in prestigious journals and holds over 100 patents. Three candidate drugs developed initially from his group have now been investigated in phase I-III clinical trials.

Daisy Dexing Zhang

School of Nursing
The Hong Kong Polytechnic University

Professor Daisy Dexing Zhang 's research interests are mental health and community primary care, mainly including the evaluation of mental health interventions (such as various mindfulness-based interventions) and comprehensive health interventions, as well as epidemiological studies and systematic reviews of common physical, mental and social health problems. Professor Zhang has received more than 40 grants as PI, Co-I and main project coordinator in the past ten years, including several large-scale charitable community comprehensive service projects. She has published over 100 peer-reviewed research papers (Google Scholar h-index=28, i10-index=63; Scopus h-index=21), a book chapter in the Oxford Textbook of Public Mental Health, and is also an editorial board member of SCI journals such as Nursing Report and BMC Public Health.

Dong Zhang

Professor of Cardiology at Xiyuan Hospital, China Academy of Chinese Medical Sciences

Zhang Dong, Director Physician and Professor of Cardiology at Xiyuan Hospital, China Academy of Chinese Medical Sciences, holds a Doctor of Medicine degree. He is the fourth cohort inheritor of the National Master of Traditional Chinese Medicine Apprenticeship Program and a second cohort Inheritance Postdoctoral Fellow under the National Administration of Traditional Chinese Medicine. Mentored by Professor Weng Weiliang (National Master of Traditional Chinese Medicine) and Academician Wang Yongyan. Graduated from Beijing University of Chinese Medicine. Engaged in clinical practice, scientific research, and teaching for over 30 years at the Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences. Renowned Young and Middle-aged Traditional Chinese Medicine Expert of the China Academy of Chinese Medical Sciences.

Fenping Zhang

CEO
GenOway

Physician at Renji Hospital, Shanghai;
Senior Vice President of Siemens Greater China;
Joined United Imaging Healthcare as a founding executive partner and served as Senior Vice President, responsible for managing the Marketing Department, Sales Department, Customer Service Department, Training Department, and Operations Center. The company went public in August 2022;
In 2023, collaborated with French investment company EXIMIUM to introduce Europe's technology-leading hidden champion enterprises to China. Among these efforts, introduced the French listed biotechnology company genOway in 2023 and established Shanghai GenOway Biotechnology Co., Ltd., serving as Executive Director and General Manager.
China Region Partner at Confluence Global Capital, France.



Genwei Zhang

Senior Director of Peptide R&D Platform
XtalPi

Dr. Genwei Zhang obtained a Ph.D. in biochemistry and a master's degree in computer science in the United States, and he completed postdoctoral research in Prof. Bradley Pentelute's laboratory in the Department of Chemistry at the Massachusetts Institute of Technology (MIT). Prof. Pentelute is a global leader in the field of automated synthesis of peptides and proteins. Dr. Zhang has achieved internationally recognized research results in the fields of automated peptide synthesis, design and screening of peptide-targeted drugs, and the application of artificial intelligence in the research and development (R&D) of biomedicine. He has also accumulated rich industrial experience and has published over 30 SCI scientific papers. With a multidisciplinary background in biochemistry and computer science, he currently serves as the Senior Director of peptide R&D platform at XtalPi Innovation Center.

Haisheng Zhang

Found and CEO
Signet Therapeutics

Dr. Haisheng Zhang is the Founder and CEO of Signet Therapeutics, and currently serves as Director of the Cancer Targeted Therapy Center at Tsinghua Shenzhen Institute and a dual-appointed professor at Nanfang Hospital, Southern Medical University. He completed postdoctoral research at Harvard Medical School's Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard. Dr. Zhang has long focused on targeted therapy and companion diagnostics for gastric cancer, publishing over ten papers in top journals such as Cancer Discovery and Gut, and was the first to identify a key target for diffuse gastric cancer.
In 2020, he founded Signet Therapeutics, the first company to integrate organoids and AI for innovative cancer drug discovery. The company's lead drug, SIGX1094, is the world's first targeted therapy for diffuse gastric cancer and is currently in Phase I trials at Peking University Cancer Hospital. It has received FDA Orphan Drug and Fast Track designations.
Dr. Zhang has been honored as a "Top Emerging Entrepreneur" in Shenzhen's Ten Outstanding Young Entrepreneurs and listed in 36Kr's "36 Under 36 Entrepreneurs."

Hua Zhang

VP and CSO
SPH Biotherapeutics

Dr. Hua Zhang is an experienced immuno-oncologist whose fingerprints are on some of the most exciting advances in cell and gene therapy. He brings over four decades of experience spanning academia, global research, and biopharmaceutical innovation. After serving nearly 20 years as a senior scientist at the National Cancer Institute, where he helped pioneer CAR-T therapies for leukemia and solid tumors, he transitioned to industry leadership. Since 2018, he has served as Vice President and Chief Scientific Officer at SPH Biotherapeutics, spearheading groundbreaking work in oncolytic virus vaccines, logic-gated CAR-T cells, and multi-antibody platforms—garnering over 20 international patents and multi-million dollars in grant funding.

Jiayi Zhang

Principal Investigator and vice dean
Institutes of Brain Science, Fudan University

Dr. Jiayi Zhang received her B. Sc. Degree from Hong Kong Baptist University and Ph.D. degree from Brown University. She was a Brown-Coxe postdoctoral fellow in Yale University and joined Institutes of Brain Science at Fudan University in 2012. Her recent work focused on the decoding and restoration of vision. Her work was published in journals including Science, Nature Biomedical Engineering, Neuron and Nature Communications. She received the Xplorer Prize in 2025, State Science and Technology Advancement Award in 2023 and the Young Innovative Woman Award in Shanghai in 2020. She serves as the Vice chairman of the Neurotechnology Panel, Chinese Neuroscience Society (CNS). She is on the editorial board of Progress in Retina and Eye Research. She is currently the vice director of State Key Laboratory for Brain Function and Diseases. She also serves as the vice dean of Institutes of Brain Science, as well as Institute for Medical and Engineering Innovation at Fudan Affiliated Eye & ENT Hospital.

Jie Zhang

Founder & Chairman
Jiu Zhang Biotech (Chengdu)

Zhang Jie, Founder & Chairman of Jiu Zhang Biotech (Chengdu) and CEO, is the original developer of the globally pioneering new drugs “Chlorogenic Acid Active Pharmaceutical Ingredient (API)” and “Chlorogenic Acid for Injection.” He holds 53 Chinese invention patents and 29 international invention patents related to chlorogenic acid. In 2016, Chairman Zhang Jie was interviewed by Nature magazine, with the feature published in the December 22, 2016, issue. His key research findings have been documented in 5 international SCI-indexed papers.
He led the development of the National Eighth Five-Year Plan Key Scientific and Technological Project “FZ-1 Energy-Saving Friction Reducer and Efficiency Enhancer,” which received the 1992 Second Prize of Sichuan Provincial Science and Technology Progress Award and was included in the National Key New Product Program. He also organized the 2016 National Thirteenth Five-Year Plan Major New Drug Discovery and Development Program for the “Phase I/II Clinical Study of First-in-Class Category 1 New Drug Chlorogenic Acid for Injection,” which passed national review in 2020.

Kun Zhang

Deputy Chief, Department of Traditional Chinese Medicine
Director, Acupuncture Unit
The Third Affiliated Hospital of Sun Yat-sen University

Member, Science and Technology Working Committee, World Federation of Acupuncture-Moxibustion Societies (WFAS)
Member, Constitution Branch, China Association of Chinese Medicine
Standing Committee Member & Deputy Secretary-General, Qihuang Needle Therapy Committee, China Acupuncture-Moxibustion Association
Standing Committee Member, Andrology Branch, Guangdong Association of Chinese Medicine
Vice-Chairman, Allergy Branch, Guangdong Health Science Popularization Promotion Association
Council Member, Guangdong Rehabilitation Medicine Association
Guangzhou Health Science Popularization Expert
Peer Reviewer, Journal of Sun Yat-sen University (Medical Sciences)
Peer Reviewer, The New Medicine
First Deputy Editor-in-Chief, Qihuang Needle Therapy, People's Medical Publishing House
First Deputy Editor-in-Chief, Selected Clinical Case Studies on Qihuang Needle Therapy, China Science & Technology Press
Author of more than ten peer-reviewed publications

Mianzhi Zhang

President
Tianjin Hospital of Integrated Traditional Chinese and Western Medicine (Tianjin Nankai Hospital)

Professor Zhang Mianzhi, Doctor of Nephrology, Postdoctoral Fellow in Traditional Chinese Medicine, Chief Physician, Second-Class Professor, is a doctoral supervisor and postdoctoral co-supervisor at three universities including Beijing University of Chinese Medicine and Tianjin Medical University. He is an expert enjoying special government allowances from the State Council, one of the first "Famous Doctors in Tianjin", a "Famous Traditional Chinese Medicine Doctor in Tianjin", and a leading talent of Beijing's "Yiqilin" program.

He serves as a member of the National Committee of the Chinese People's Political Consultative Conference (CPPCC) and a member of the Education, Science, Health and Sports Committee of the CPPCC National Committee. He is also Vice President of the China Association for the Promotion of Chinese Medicine Research, Director of the Branch of Tonifying Kidney and Activating Blood Circulation of the China Association of Chinese Medicine, and Deputy Director of the Nephrology Branch of the China Association of Chinese Medicine.

Currently, he holds the positions of President of Tianjin Integrated Traditional Chinese and Western Medicine Hospital, Director of the Institute of Traditional Chinese Medicine Nephrology of Tianjin Academy of Traditional Chinese Medicine, Academic Leader of the National Regional TCM (Specialty) Diagnosis and Treatment Center, Academic Leader of Key Specialties of the National Health Commission and the State Administration of Traditional Chinese Medicine, Director of Tianjin Integrated Traditional Chinese and Western Medicine Nephrology Consultation Center, Visiting Professor at the School of Chinese Medicine of The Chinese University of Hong Kong, Distinguished Professor at the First Affiliated Hospital of Zhengzhou University, Leader of the Introduced High-Level TCM Medical Team in Shenzhen, and Leader of Zhang Mianzhi's Beijing Municipal Famous TCM Doctor Team.

Qiangfeng Cliff Zhang

Associate Professor
School of Life Sciences, Tsinghua University

Dr. Qiangfeng Cliff ZHANG is a tenured Associate Professor at the School of Life Sciences, Tsinghua University, and a Principal Investigator at the Tsinghua-Peking University Joint Center for Life Sciences. His research lies at the nexus of structural biology, genomics, and AI-informed big data analysis. His lab has co-invented high-throughput methods for analyzing intracellular RNA structures and designed AI algorithms for single-cell genomics, spatial transcriptomics, and structural biology data analysis. As a corresponding author, he has published in Cell, Nature Genetics, and other leading journals. He leads multiple research projects, including the National Outstanding Young Scientist Fund, the key projects from the National Natural Science Foundation of China, and the National Key R&D Project. Dr. ZHANG's honor include the X-Explorer Award for 2024, the Fifth Promega Biochemistry Award in 2022, and the Sanofi-Cell Research Outstanding Paper Award in 2021. His work was selected as one of the Top Ten Advances in Bioinformatics in China in 2019, 2021 and 2024. He is Director of the Artificial Intelligence and Life Sciences Committee of the China Society of Bioinformatics (under preparation) and serve on the editorial board of Molecular Cell, Cell Systems, and Genomics Proteomics & Bioinformatics

Ralph Zhang

Director and General Manager
Beijing Zhongjian Chanrong Technology Co., Ltd.

2024.12- PresentBeijing Zhongjian Chanrong Technology Co., Ltd. Director and General Manager
2023.04-2024.12 Hainan Guoyao Life Medicine Technology Co., Ltd. General Manager
2022.10-2023.04 Rural Revitalization Work Committee, Ministry of Agriculture and Rural Affairs, Deputy Director
2018.05-2022.10 China Energy Construction Group (Tianjin) Investment Co., Ltd. Executive Deputy General Manager

Xiaobin Zhao

Chairman, CEO
Zhejiang Haichang Biotech Co., Ltd.

Dr. Ben Zhao, with over 20 years of experience at FDA, Abbott, and Shanghai Pharma, specializes in targeted delivery, siRNA, and liposomes. He served as a senior FDA CDER reviewer, focusing on CMC and cGMP, and developed nanomedicine guidelines. Holding FDA Level III certification, he received the FDA Special Achievement Award. In 2014, he founded Haichang Biotech for RNA drugs and 505(b)(2) products. Currently, he is Vice Chairman of PhIRDA and leads the IFPMA ICH Q1 Expert Group, promoting global regulatory harmonization.

Zhi-Jie Zheng

Director
China Office, Gates Foundation

As the Director of the China Country Office (CCO) at the Gates Foundation (BMGF), Dr. Zhi-Jie Zheng leads the CCO team to develop and strengthen partnerships across China's public, private and nonprofit sectors to advance health and development outcomes in China and around the world. Before joining the foundation, he was K.C. Wong Distinguished Professor and Chair of the Department of Global Health, School of Public Health and Senior Vice Dean of the university-wide Institute for Global Health and Development at Peking University. In these roles, he worked with a wide range of partners to launch high-impact programs and initiatives to promote cross-disciplinary global collaborations and cultivate next generation leaders in global health and development. He previously served as Dean of the School of Public Health at Shanghai Jiao Tong University, as Supervisory Medical Officer and Senior Program Director at the National Heart, Lung and Blood Institute, U.S. National Institutes of Health, and as Lead Epidemiologist in the Division for Heart Disease and Stroke Prevention at U.S. Centers for Disease Control and Prevention. He earned his M.D. from Fudan University in Shanghai, China, along with an M.A. in biomedical ethics. He also holds an M.P.H. in health services research and a Ph.D. in epidemiology from the Gillings School of Global Public Health, University of North Carolina at Chapel Hill, United States.

Zongli Zheng

Associate Professor
Department of Biomedical Sciences, City University of Hong Kong

Dr. Zheng focuses on advancing biotechnology to solve clinical problems. Dr. Zheng invented the AMP technology that has been adopted globally for robust molecular diagnosis in both research and clinical settings to guide targeted therapies for cancer patients. Dr. Zheng's pioneering work in precision genome editing includes the CRISPR off-target analysis method GUIDE-seq that is widely used and supported the first FDA-approved therapy utilizing CRISPR Cas9. Dr. Zheng is dedicated to 'liquid biopsy' and 'DNA surgery' research and clinical applications.

Chao Zhou

CEO and Executive Director
Grand Pharma

Mr. Chao Zhou joined the Grand Pharma since June 2019. Since June 2021, he has become the CEO of the Company, being responsible for the general internal management of the Company. He was the legal manager, senior legal manager and business director of Legal Security Management Department of China Grand Enterprises. Now, Mr. Zhou holds directorships in a number of domestic and overseas companies of the Company. Mr. Zhou has headed and participated in several large-scale merger and acquisition projects both locally and overseas, and introduced a variety of products for the Company. In 2011, Mr. Zhou graduated from Ocean University of China with a Bachelor's Degree in Laws and subsequently obtained a Master's Degree in International Economic Law from the University of International Business and Economics.



Grace Zhou

CEO，Chairperson
ImmVira Bioscience Inc.

Dr. Grace Zhou holds a Ph.D. from the Shanghai Institute of Biochemistry, Chinese Academy of Sciences. She is a recipient of China's National Thousand Talents Plan award, was named one of China's Top 10 Outstanding Innovative Women (2024), and is the sole winner of the 2019 International "Antiviral Women Scientist Award". Additionally, she was honored as one of China's Top 10 Outstanding Female Entrepreneurs (2021), "Scientific Chinese of the Year" (2017), and a recipient of the "State Council Special Allowance" (1998). Formerly an Associate Professor in the Department of Microbiology at the University of Chicago (1999–2014), Dr. Zhou dedicated 15 years to herpesvirus research and has nearly 30 years of expertise in antiviral infection and oncolytic herpesvirus-based tumor immunotherapy.

In 2015, Dr. Zhou founded ImmVira Pharma, which has since established the proprietary OVPENS platform—a fully integrated system combining scientific rationale, R&D technology, and manufacturing processes. Building on this foundation, the company has developed two key platforms: Oncolytic Virus Immunotherapy and Engineered Exosome Delivery. Oncolytic Virus Pipelines focus on multiple solid tumors with various routes of administration (intratumoral, intravenous, and intravesical). Exosome Delivery Pipelines targeting applications in large health markets, including complex metabolic, immune, respiratory, ocular, and dermatological diseases.

Houjiang Zhou

Deputy General Manager of the R&D
Zhejiang Hisun Pharmaceutical Co. Ltd

From September 2009 to July 2021, Dr. Houjiang Zhou worked at the University of Ottawa in Canada, the National Center for Proteomics in the Netherlands, University of Cambridge, and the Key Laboratory of Phosphorylation and Ubiquitination in Cellular Signal Transduction under the UK Medical Research Council. During this period, he engaged in research on proteomics, cellular signal transduction, drug target discovery, and drug discovery.
In September 2021, Dr. Houjiang Zhou joined Zhejiang Hisun Pharmaceutical Co., Ltd. as Chief Biological Scientist. Since January 2024, he has served as Deputy General Manager of the R&D Management Center and President of the Innovative Drug Research Institute. After joining Hisun Pharmaceutical, he has led multiple innovative drug R&D projects. Under his leadership, the Innovative Drug Research Institute has overcome numerous technical barriers, with several projects entering the clinical trial. development stage and one project advancing to the IND (Investigational New Drug) development stage. He participated in a collaborative project with Zhejiang University that was selected into Zhejiang Provincial Key Research Program. The innovative drug R&D team he leads has been awarded provincial-level honors.

Jane Jie Zhou

Assistant professor
The University of Hong Kong

Prof ZHOU Jie. Assistant professor. Department of Microbiology, The University of Hong Kong.
Prof Zhou's research interests focus on developing organoid models and organoid-based virus research. She and her team established the first human respiratory organoid culture system and first bat intestinal organoid in the world, which has opened up new avenues for diverse applications in biomedical research and drug development. Her contribution to organoid technology is attributed to her clinical medical training and her experience in clinical pathology and virus research. She obtained her PhD from the University of Hong Kong in 2007 and finished postdoctoral training at UCSF in 2009. She has published over 100 research papers in prestigious journals including Nature Medicine, PNAS and Science Advances, ranked among the top 1% of cited scholars by Clarivate Analytics in 2021, and highly cited scholar since 2022. She and the team founded a startup company BiomOrgan Limited to commercialize the proprietary respiratory organoid technology since 2021.

Liche Zhou

Attending neurologist
Department of Neurology and Institute of Neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Liche Zhou, Attending neurologist in the Department of Neurology at Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine. Dr. Zhou focuses on early diagnosis, intervention, and imaging characteristics of Parkinson's disease and Parkinsonism. Dr. Zhou explores the biomarkers of conversion from Rapid Eye Movement Sleep Behavior Disorder to alpha-synucleinopathies. Dr. Zhou's work has been widely published in peer-reviewed journals such as Brain, Movement Disorders, Neurology, etc.

Lihan Zhou

Cofounder and CEO
MiRXES

Lihan co-founded and serves as CEO of MiRXES, a Singapore headquartered, RNA centric biotechnology company with the mission to improve and save lives through early, actionable, and accessible cancer early detection tests. Lihan oversees MiRXES operations in Singapore, USA, China, and Japan with a team of 300+ staff.

Prior to founding MiRXES in 2014, Lihan was a research scientist at the Bioprocessing Technology Institute, A*STAR where he co-developed a novel microRNA qPCR assay platform for microRNA biomarker and therapeutic target discovery. Lihan obtained his Ph.D. in Biochemistry from Yong Loo Lin School of Medicine, National University of Singapore. Lihan has authored more than 30 peer-reviewed publications and several patent applications.

Lihan was recognized by the MIT Technology Review as a member of the Innovators Under 35 (2015). He was also awarded the A*STAR Scientist-Entrepreneur Award in 2017, the NUS Outstanding Young Alumni Award, the EY Entrepreneur of The Year™ Singapore awards in 2021, and 2023 Singapore Business Award Young Business Leader of the Year. Under his leadership, MIRXES was named Singapore's Most Promising Start-up in 2016 and Singapore's Fastest Growing Companies in 2018, 2019 and 2020. MiRXES has successfully raised USD $180 million venture funding since 2016.

Yonghong Zhu

Chief Medical Officer
EpimAb Biotherapeutics

Dr. Yonghong Zhu is the Chief Medical Officer of EpimAb Biotherapeutics, a bispecific antibody and T cell engager biotech. Dr Zhu's industry career started in the US, with rising roles from discovery scientist to senior medical director at a few biotechs in the San Francisco Bay Area as well as MNCs including Roche, Genentech, and Takeda. In 2017 he returned to China and served as the Head of Clinical Development at Shanghai Henlius. Later, he became global translational program leader at the Roche Shanghai Innovation Center, focusing on early-stage international clinical research. Prior to joining EpimAb, he was the CMO of Maxinovel Pharmaceuticals.
Dr. Zhu completed a 7-year medical program training from Nanjing University Medical School, practiced for a few years, and then received a Ph.D. degree in microbiology & immunology from the University of Rochester School of Medicine & Dentistry. Afterwards he joined an immunology company DNAX (owned by Schering-Plough, later merged into Merck) to complete his industrial postdoctoral training.



Zhengdan Zhu

Co-president of the Drug Discovery Department
DP Technology

Dr. Zhengdan Zhu currently serves as co-president of the drug discovery department at DP Technology, overseeing services and collaborations in early drug discovery and optimization. He earned his Ph.D. from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, followed by joint postdoctoral research at Peking University and the Beijing Institute of Big Data Research. With extensive experience in computer-aided and AI-assisted drug design, Dr. Zhu has published over 30 papers in prestigious international SCI journals, with more than 1,300 citations and an h-index of 19. He also holds several molecular patents as a key contributor. His research interests center on developing innovative strategies to advance drug discovery and molecular optimization from a pragmatic perspective.

Organizers&Sponsors

Organizers

HKBIO Hong Kong Biotechnology Organization 香港生物科技協會

中国生物工程学会 Chinese Society of Biotechnology

AUSVIC Capital

Co-organizers

Beijing Advanced Center of RNA Biology

GB-Partner 美国全球医药共创集团

清華大學 生命科学学院 School of Life Sciences, Tsinghua University

Dimond Sponsors

SHUIMU BIOSCIENCES

云南白药 YUNNAN BAIYAO

雲白國際 YNBY INTERNATIONAL

Platinum Sponsors

DHC

Gold Sponsors

GSK

OROJIN A Daily Act of Self-Respect

Silver Sponsors

5100 TIBET SPRING

ALPHA HYGIENIC

BeOne

mirxes

RoX VENTURES 比邻星创投

HONG KONG-SHENZHEN INNOVATION AND TECHNOLOGY PARK 港深創新及科技園

Funding&Supporting Organizations

Funding Organisation

π 創新科技署
Innovation and Technology Commission

*在本刊物／活动内 (或由项目小组成员) 表达的任何意见、研究成果、结论或建议，并不代表香港特别行政区政府、创新科技署或创新及科技基金一般支援计划评审委员会的观点。
*Any opinions, findings, conclusions or recommendations expressed in this material/event (or by members of the project team) do not reflect the views of the Government of the Hong Kong Special Administrative Region, the Innovation and Technology Commission or the Vetting Committee of the General Support Programme of the Innovation and Technology Fund.

Supporting Organizations

HONG KONG TOURISM BOARD 香港旅遊發展局
龍之家社會服務基金 Dragon Family Society Service Foundation
香港巴林商會 HONG KONG BAHRAIN BUSINESS ASSOCIATION
香港中小型企業聯合會 HONG KONG SMALL AND MEDIUM ENTERPRISES ASSOCIATION
InvestHK 25
上海科创银行 Shanghai Innovation Bank
深圳市生命科学行业协会 Shenzhen Life Science Industry Association
Brillix Intelligence
深洁协 SHENZHEN BIOLOGICAL & INDUSTRIAL CLEANROOM ASSOCIATION
香港中華廠商聯合會 The Chinese Manufacturers' Association of Hong Kong

Media Partner

生物谷 Bioon.com
Bio Partner
eChinaHealth 世界医健
明報
PHARMA BOARDROOM
早筛网 Zao Dx

Acknowledgements

BIOHK extends our deepest gratitude to all the organizations and individuals who contributed to the success of this convention.

We sincerely appreciate all the sponsors and supporting organizations. Your trust and involvement provided a solid foundation for BIOHK2025, bringing vital resources and dynamic momentum to the event.

A special note of thanks goes to the Innovation and Technology Fund (ITF) for their generous financial support. This valuable contribution played a key role in enabling the high-quality content and innovative programmes that defined BIOHK2025.

Special thanks go to all the session chairs, especially those who devoted tremendous effort to planning thematic topics, inviting distinguished speakers, and coordinating their sessions. Your expertise and dedication significantly enhanced the academic quality and participant experience of the convention.

We are also grateful to all the organizing committees, volunteers, and staff members who worked behind the scenes. Your meticulous planning, on-site coordination, and unwavering commitment were essential to the smooth execution of this event.

Last but not least, we warmly thank all the participants from around the world. Your active engagement, insightful exchanges, and shared enthusiasm made BIOHK2025 truly impactful and memorable. We hope this convention has inspired you and look forward to continuing our collaboration in the future journey of scientific exploration.

SPEAKER INDEX

*Surname in Alphabetical Order

SPEAKER INDEX

*Surname in Alphabetical Order

SPEAKER INDEX

*Surname in Alphabetical Order

The Largest Commercial Cryo-EM Platform in the World



8
300kV Cryo-EMs

@ BEIJING / CHINA
Shuimu HQ

@ HANGZHOU / CHINA
Shuimu Global Cryo-EM & AI Drug Innovation Center

SPECS

BioQuantum GIF; K3 camera, Falcon 4 camera direct electron detector; Volta phase plate; C_S corrector; X-FEG electron beam; E-CFEG, the new cold field emission gun; Selectris & Selectris X imaging filters; Cryo-Autoloader

2000+

2.2Å

1.4Å

51kDa

Structure-based drug discovery (SBDD) is an indispensable method for designing and optimizing new therapeutic agents.

Cryo-electron microscopy (cryo-EM) has been rapidly developed and is becoming a critical SBDD tool for providing high-value structural information on pharmacological targets. Our service makes it easier than ever to help you succeed with cryo-EM.

- **Quality Guarantee**
- **Competitive Price**
- **Fast Turnaround**
- **Top Spec TEMs**

Protein Production

Easier access to target proteins

Single Particle Analysis

Cryo-EM

High resolution protein structure determination

MicroED

High resolution protein structure determination

ThermoFisher SCIENTIFIC · sptlabtech · NVIDIA · NIBS · GHDDI · Neurophth · EpimAb · AMGEN · PHOREMOST · HENGRUI · BeiGene · BIOCYTOGEN · Henlius

Contact Us: hi@Shuimubio.com

shuimubio.com

ShuimuBio 水木未来

雲南白藥 YUNNAN BAIYAO | 雲白國際 YNBY INTERNATIONAL

聚焦主業·守正創新·穩健增長

雲南白藥創制於 1902 年，是業內公認的中華老字號中最具創新力的代表。作為擁有 123 年歷史的中華老字號民族品牌，雲南白藥始終致力於推動傳統中醫藥融入現代生活，持續深挖傳統醫學產品的內生潛力，以產品創新回應現代生活需求，不斷為傳統品牌及傳統中醫藥產品注入新的生命力。雲南白藥秉承「守護生命與健康」的使命，圍繞藥品、中藥資源、健康、醫藥新流通四大業務基本盤持續深耕、穩健增長，已建立起包括天然藥物、中藥材飲片、特色藥、醫療器械、健康日化產品、保健食品等多個領域的業務布局。

雲南白藥自上市後，營業收入保持連續增長，從 1993 年的 0.58 億元增長至 2023 年的 391.11 億元，增長 673 倍；歸母淨利潤從 1993 年的 0.13 億元增長至 2023 年的 40.94 億元，增長 314 倍。雲南白藥通過穩健經營和持續分紅，與各利益相關方共享企業發展成果，為長期價值投資者創造優良的價值回報，雲南白藥連續 31 年對股東分紅，截至 2023 年度，累計現金分紅金額已超過 244 億元。

雲南白藥集團產品達 40 個品類 416 個品種，單品銷售上億的產品有 16 個，氣霧劑、創可貼、雲南白藥（散劑+膠囊）、雲南白藥牙膏等 4 個品類在中國細分領域穩居第一，並連續 13 年入榜凱度 Brandz 最具價值中國品牌 100 強榜單，2023 年品牌價值排名醫藥行業第一名。

雲南白藥繼往開來，守正創新，超越自我再出發。堅持「強主業、穩增長、可持續」的原則，做傷科疼痛領域「第一」品牌，雲藥資源高質量發展的「鏈主」企業，高品質健康生活產品的「第一」梯隊，醫藥流通和創新服務的「龍頭」企業，實現規模、質量、結構協同發展，推動百年白藥從「優秀」到「卓越」，力爭成為國內領先、世界一流的千億級現代醫藥產業集團。

發展歷程
DEVELOPMENT HISTORY

弘揚民族醫藥瑰寶
傳承中華文化精粹

持續、穩健、快速增長

40 個品類 | 416 個品種 | 16 個上億單品



企業榮譽
ENTERPRISE HONOR

123年薪火相傳
雲南白藥從雲南走向世界不斷續寫新輝煌。

中國工業大獎					
	一等獎	TOP10	NO.33	NO.25	TOP1


GSK
Ahead Together
We unite science, technology and talent to get ahead of disease together.
gsk.com

Join Us for the Era of Intelligent Prevention™

WE'RE THRILLED TO INVITE YOU TO BIOHK 2025,
ASIA'S PREMIER GATHERING OF HEALTH INNOVATORS,
FOR THE OFFICIAL LAUNCH OF

OROJIN
by Miskawaan

A Daily Act of Self-Respect

Purely 100% Natural

This is more than a product unveiling. It's the culmination of years of scientific research, cultural heritage, and a mission to redefine how we protect our health — not react to illness, but prevent it at its root.

WORLD PREMIERE

Experience the world's most advanced, bioavailable form of Chlorogenic Acid, extracted through a 82-patent-protected process from the rare Eucommia Leaf.

MEET THE OROJIN TEAM

OROJIN was developed through a close collaboration between Jiuzhang Biotech's pioneering technology and Miskawaan Health Group's integrative expertise. Leading our mission, David Boehm, our visionary founder, combines business acumen with a passion for holistic health, whose vision for science-backed longevity inspired OROJIN's creation while Professor Zhang our lead scientist, brings decades of grounding breaking research in botanical biochemistry – together, they're redefining longevity through science and nature

EXPERIENCE THE RITUAL

Discover why OROJIN is A Daily Act of Self-Respect and the defining expression of The Era for Intelligent Prevention™.

11th SEPTEMBER 2025 @ 3-4pm
HONG KONG CONVENTION & EXHIBITION CENTRE
MAIN STAGE

RSVP Now

We can't wait to share this breakthrough with you, and to take the first step together into a future where prevention is the ultimate luxury.

Cat Lam
Director of Sales & Marketing — OROJIN™
cat.lam@miskawaan.com | 5184 9568 | OROJINHEALTH.com

Daily Defense Ancient Wisdom Modern Power

全球首创AI诊疗平台BioRadar®

从“肺炎不再致命”到构建全球疫情防控体系

从“看不见”到“精准治疗”

两小时内全面定量病原体

- 全球唯一床旁超多重定量技术
- 全球最快核酸杂交反应技术
- 全球最准检测结果
- 最有临床价值的检测靶标组合

海康生命科技有限公司

HAI KANG LIFE CORPORATION LTD

China Contact: Ms. Tina Liu (+86 13910338695; tina.liu@haikanglife.com)
International Contact: Dr. Xinzhu Wang (+852 69515619; xinzhu.wang@haikanglife.com)
WWW.HAIKANGLIFE.COM

5100 西藏天然冰川礦泉水

天然低氘水 (DDW)

分子極細，幫助吸收

含豐富人體所需礦物質

健康之選

ALPHA HYGIENIC®

自家品牌系列產品均保證無防腐劑、無添加劑及不含糖，孕婦及糖尿病人士均可安心食用。

時光膠原蛋白飲+

(15000mg德國專利膠原蛋白、不含糖、孕婦及糖尿病人士可服)

倍效益生菌

(250億活性益生菌、不含滑石粉、甘油、蘆薈)

絡樂骨骼飲

(軟骨再生、強健骨骼、強韌筋腱、關節潤滑)

奇清淨血素

(速效溶栓、改善栓塞)

www.alphahygienic.com

alphahygienic　alpha hygienic　+852 6556 6425　Alpha Hygienic

wwww.alphahygienic.com

We are a global oncology company committed to developing innovative medicines and partnering with the global community to serve as many patients as possible.

www.**BeOneMedicines**.com

@BeOneMedicines @BeOneMeds

BeOne

HSITP
港深創科園

Igniting Innovation, Shaping the Future
燃點創新 締造未來

The ecosystem of HSITP serves as a Super Connector of "going global and attracting foreign investment", linking the GBA and international markets in support of local reindustrialization and attracting global leaders to the park.

港深創科園生態圈作為一個超級聯繫平台，實現「引進來、走出去」，
透過融入大灣區以及與國際接軌，支持本地業界再工業化，並引入國際龍頭企業進駐園區。

HKSAR Government Funding of **HK$200 million**
to support HSITP start-ups engaging in the Life and Health Technology Sector

香港特區政府撥款**港幣2億元**
支持入駐港深創科園的生命科技初創企業

BOOTH T12

mirxes

TO KNOW, TO ACT.

Making cancer early detection accessible to all.

Mirxes (Stock Code: 2629.HK), founded in 2014, is a miRNA technology company dedicated to providing blood-based cancer early screening products and services. We have developed and commercialized precise, non-invasive, and affordable blood miRNA detection kits for early cancer and disease screening.

In May 2025, Mirxes successfully listed on the Hong Kong Stock Exchange Main Board. On its debut, the company achieved a market capitalization exceeding USD 1 billion, becoming the first "unicorn" enterprise in Southeast Asia's biotechnology sector.

Commercialization Progress



Product + Service + AI

Commercialization

ProX 比邻星创投
VENTURES

BUILD INVEST GROW

We together create breakthroughs in human health

Investing in Disruptive and Innovative Healthcare Technologies with a Global Vision

全球视野投资颠覆性创新医疗科技

Collaborating to Build a Global Syndicated Healthcare Innovation Ecosystem

携手建立全球共享医疗创业生态

Creating and Accelerating Future-Shaping Healthcare Industry Leaders

培育和加速改变未来的医疗科技龙头企业

Our approaches focus on the following:

INNOVATIONS	**ENGAGEMENT**	**GLOBAL**
TALENTS	**ECOSYSTEM**	**LONG-TERMISM**

我们的理念是：

唯新不破	**比肩前行**	**全球合作**
人才为本	**生态为纲**	**长期主义**

Our official website
https://www.proximavc.com/

Scan QR code to follow us for our latest updates!

THE HONG KONG POLYTECHNIC UNIVERSITY
香港理工大學

CLAIRE Clinical AI Research Limited

CLAIRE Clinical AI Research Limited develops an artificial intelligence-based knee osteoarthritis triage system to facilitate personalised treatment protocolsIt includes a mobile application to provide clinical point-of-care services.

Mr Justin CHAN
Chief Executive Officer, CLAIRE Clinical AI Research Limited
admin@claireai.org

PocNAT Limited

PocNAT is a point-of-care nucleic acid testing technology company. It provides low-cost, rapid, and accurate solutions to solve the current huge demand for decentralized or point-of-care or on-site nucleic acid testing.

Dr Yvette WANG
Chief Scientific Officer, PocNAT Limited
yvette.wang@pocnat.com

Vcare Vision Technology Limited

Vcare prioritizes research to ensure safe and effective solutions. Leveraging expertise in VR technology and eye care, Vcare has developed a VR device with a lens module and a varifocal mechanism and custom software that meets individual visual needs without manual adjustments during the VR experience.

Ms Celia CHAN
Co-founder, Vcare Vision Technology Limited
hs-celia.chan@polyu.edu.hk

PolyVentures

PolyU is committed to fostering innovation and entrepreneurship, cultivating next-generation entrepreneurs that are eager to tackle societal issues with innovative solutions. Via PolyVentures, our signature start-up ecosystem, the University supports PolyU start-ups in every stage of their entrepreneurial journeys – from education and ideation to incubation, acceleration, and fundraising. To equip them with necessary knowledge and skills for sustainable development and accelerated growth, a wide range of support, such as training, mentorship, shared office spaces, funding, and networking opportunities with business partners and investors, are available for our start-ups.

PolyVentures serves as a super network that connects the academia, industry, and the capital market. It offers customised entrepreneurial support, incubates start-up projects, facilitates fundraising, and drives the translation of impactful research outcomes into real-world solutions, thereby bringing tangible benefits to society.

Knowledge Transfer and Entrepreneurship Office

bioBAY
https://www.biobay.com.cn

Introduction of BioBAY

Overview

A life science community of start-ups, scale-ups and MNCs
No.1 Life Science Park in China
No.1 organization awarded as "National Center of Technology Innovation for Biopharmaceuticals" (NCTIB).
650+ biomedical companies (from start-up to MNC)
40,000 talents (70% with bachelor degree and above)
27 Listed enterprises (15 listed in HK or Nasdaq)

Industry Clusters

BioBAY ECO-SYSTEM

Location:

On the east of Dushu Lake
15 min-drive away from CBD in SIP
32 universities and institutes nearby
10 min-walk to a Grade-A tertiary hospital
5 min-ride to talent apartment zone

Layout:

8 campuses
2,000,000 m^2 constructed
2,000,000 m^2 under construction
Designed for pharmaceuticals and MedTech
Support ranging from R&D to industrialization

彩科生物单细胞光导系统

芯片上的全自动细胞实验室
单细胞分选、培养、检测、回收

细胞治疗　抗体发现　疫苗开发　细胞株开发



自主研发半导体生物芯片
光诱导介电泳技术

抗体发现

更快	一天内完成功能抗体筛选，三天内获得抗体序列，加速项目交付
更多	多物种覆盖，小鼠/兔/人/羊驼，浆细胞&记忆B细胞增加抗体多样性
更好	抗原结合、交叉反应、配体阻断、亲和力评分，多轮筛选聚焦功能抗体

疫苗开发

识别中和抗体	仅数天时间内识别出有效、具有保护性的中和抗体
指导疫苗设计	分析出关键抗原表位，为疫苗设计提供重要靶点
评估疫苗效果	提供深度的单细胞蛋白水平的解析，评估疫苗是否能够诱导出与自然感染相似或更优的免疫反应

细胞治疗

发现	基于细胞的功能筛选，从CAR细胞文库或者患者样本中发现反应性CAR/TCR序列
验证	单细胞层面关联分析细胞因子分泌、细胞杀伤、T细胞表型，验证、比较细胞产品功能特征和有效性
转化	寻找差异化功能亚群，发现临床预测性标志物，多组学数据深入探索响应机制

细胞株开发

单克隆	筛选出>99%单克隆保证率的高产细胞株
自动化	一台设备完成从细胞富集、单克隆、培养、计数、检测、分析及克隆回收的全部流程
高通量	支持数千个克隆同时在线培养检测，找到稀有优质克隆

彩科生物 Lychix　400-1186-722

RONGKEMED

荣科(苏州)医疗科技有限公司
RONGKE(SUZHOU)MEDICAL TECHNOLOGY CO.,LTD.

AVID.RK®
全球首款·全自动创面双向压力冲洗疗法

应用于**烧伤、火器伤、海水浸泡伤、术后感染、糖尿病足溃疡、压疮**等各种急慢性伤口治疗
快速将创面坏死组织、细菌、毒素带出体外，有效控制感染，提供良好的生长环境

CASE PRESENTATION
案例展示

SILICONE RUBBER ENCLOSED NEGATIVE PRESSURE DRAINAGE SYSTEM
硅橡胶封闭式负压引流系统

产品介绍 通过独特创伤材料及创新立柱结构，结合防回流、全方位正压单向冲洗技术，将创面坏死组织、细菌、毒素带出体外，克服传统冲洗敷料内附着的坏死组织、细菌、毒素对创面反复污染的问题，有效控制感染，减少抗生素使用。

创新立柱结构　正压单向冲洗　独特创伤表面

有效防堵
支撑柱立体结构
引流通畅
不易堵塞
减少组织清创

有效生长
立体空间间隙，
促进新生肉芽组织，
覆盖外露的骨质
和内固定物。

有效冲洗

超水特性
冲洗液全部
冲洗到创面，
避免材料吸水
导致冲洗效果
衰减。

创面可视化
硅橡胶材质
半透明状，
可随时观察
创面情况。

**生物相容性
优良**
更贴附无粘连，
不损伤肉芽组织，
减少患者
疼痛、出血。

荣科（苏州）医疗科技有限公司
地址：苏州工业园区新庆路1号生物医药产业园三期
电话：0512-67098385　传真：0512-67098100　邮编：215000

药明巨诺
JW Therapeutics

CARTEYVA®

JW Therapeutics (HKEx:2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors, and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China's cell immunotherapy industry.

Starting Today with CARTEYVA®
Reclaim Tomorrow

Relmacabtagene autoleucel injection (trade name:CARTEYVA®, short name:Relma-cel)

Relma-cel independently developed by JW. Based on the platform of juno (Subsidiary of Bristol Myers Squibb)
Relmacel and Liso-cel (Relmacabtagene autoleucel) have higher efficacy and safety compared with other CAR-T products

CARTEYVA® is a targeting CD19 autologous CAR - T product .

CARTEYVA® is the first CAR-T product approved as Category 1 biologics product in China.

CARTEYVA® increased 4 Years OS rate of end-stage large B-cell lymphoma patients from less than 20% to 66.7%, bringing hope to non-Hodgkin lymphoma patients in the RELIANCE[1-4] studies.

CARTEYVA® had been approved by CHINA NMPA for 3 indications:

- Adult patients with r/rlarge B-cell lymphomaafter two or more lines of systemic therapy。
- Adult patients with r/r within 24 months follicular lymphoma after two or more lines of systemic therapy.
- Adult patients r/rmantle cell lymphomaafter second line or above systemic treatment, including treatment with Bruton tyrosine kinase inhibitors.

以创新为先导，成为细胞治疗领域引领者

Become an Innovation Leader in Cell Immunotherapy

1. Jing H, et al. Cancer Med 2021; 10(3):999-1011.
2. Z. Jing et al., Lymphoma 2022; 1-9.
3. Haiyan Wang, et al. J Clin Oncol 42, 2024 (suppl 16; abstr 8001).
4. Ying Z, et al. Lancet Oncol 2022.

PHARMCUBE

Data Intelligence & Consulting

Value

Pharmcube Data Middleware Platform | Achieving Cross-database Insights

Core Base | Drug Big Data | Data Scientist + AI | Pharmaceutical Industry Experts

A RELIABLE DATA PARTNER FOR PHARMACEUTICAL INNOVATION AND INVESTMENT

Follow us on LinkedIn
www.linkedin.com/company/cnpharmcube/

Apply for free trial

Data | Information | Knowledge | Wisdom

www.pharmcube.com/en

TM
HEPO
SHENGWU
合珀生物

上海合珀生物科技有限公司

合珀生物由Karolinska Institute（卡罗琳斯卡医学院）教授创立，主要从事3D微组织模型的开发和应用，主要用于药物临床前安全性、有效性评估及ADME早期探索。目前有肝脏、脂肪、肾脏、肺、肠等微组织模型。我们与国内外的默克，礼来，吉利德，恒瑞，豪森，百济，insilico 等企业正在长期合作。

Founded by a professor at Karolinska Institutet, Hepa Biotechnology focuses on 3D microtissue models development and applications for preclinical safety and efficacy assessment, as well as early-stage ADME studies. At present, we provide microtissue models of liver, adipose, kidney, lung, and intestine. We have established long-term, ongoing collaborations with leading domestic and international companies, including Merck, Eli Lilly, Gilead, Hengrui, Hansoh, BeiGene, and Insilico Medicine.

合作伙伴

GILEAD Creating Possible
MERCK
Lilly
百济神州 BeiGene
恒瑞
CSPC 石药集团
翰森制药
正大天晴
GenSci
华东医药
齐鲁制药
汇伦医药
Insilico Medicine

公众号
合珀生物

如您需要了解，请与我们联系
企业邮箱：hepo@hepabio.cn

和记黄埔医药（上海）有限公司

为全球患者提供自主研发的创新药

和黄医药是一家集研发、生产、商业化于一体的创新型国际生物医药企业，以“为全球患者提供自主研发的创新药”为使命，旨在成为发现、开发及商业化治疗癌症及免疫性疾病靶向治疗及免疫疗法的全球领导者。

历经20余年发展，三款自主研发创新药、一款海外引进创新药已在中国获批。首款创新药呋喹替尼已在中国、美国、欧盟、日本等全球逾30个国家获批，并于2024年在中国香港获批上市，成为首个获纳入香港医管局药物名册的1+机制获批新药。作为上海首个成功出海美、欧、日三大全球标杆市场的中国原创新药，呋喹替尼2024年海外市场销售额逾2.9亿美金，有望成为上海首个全球范围的“小分子、大品种”原创新药。

作为港资企业，和黄医药全面布局全球化网络。在香港设立国际研发中心，在上海设立全球研发中心、跨国公司地区总部，在全球拥有临床开发和监管注册团队。

香港出发、立足上海、走向全球，和黄医药将持续推进管线进展、全力打造创新平台、致力保持全球增长，实现更高质量、更可持续的发展之路。

HUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.



华领医药——核心产品华堂宁®

（多格列艾汀片，Dorzagliatin，HMS5552）

华领医药技术（上海）有限公司是一家中国新药开发生产和销售企业。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医药创新。

华领医药秉持“**患者为先，创新为本，良药为民**”的宗旨，通过“中西合璧、联合创新、共享共赢”的运营模式，实现人类健康发展的远大目标。

- **华堂宁®（多格列艾汀片）**是异位变构葡萄糖激酶（GK）全激活剂，作用于胰岛、肠道内分泌细胞以及肝脏等葡萄糖储存与输出器官中的葡萄糖激酶靶点，改善 2 型糖尿病患者受损的葡萄糖刺激的胰岛素和 GLP-1 分泌，进而改善β细胞功能，减低胰岛素抵抗，从而改善 2 型糖尿病患者血糖稳态失调，具有重塑血糖平衡生理调节的作用机制[1]。

- **华堂宁®（多格列艾汀片）**是国家药监局批准的首个改善 2 型糖尿病患者血糖稳态失调的药物[2]，是全球首创（first-in-class）的葡萄糖激酶激活剂（GKA），也是获得国家十二五、十三五“重大新药创制“科技重大专项支持的 1 类新药。

华领医药发展大事记[3]



瑞宙生物
Reinovax Biologics

Shanghai Reinovax Biologics Co., Ltd.

2017 **2220** m² **24-valent**

Shanghai Reinovax Biologics Co., Ltd. (Reinovax) is a research-oriented clinical stage biotech company focusing on discovery and development of innovative vaccines against bacterial and viral diseases. The company was founded in Shanghai City in 2017 by Dr. Zhu, Xianchao (aka Jeff) who has more than 25 years' extensive experience on R&D of innovative pharmaceuticals and vaccines in the USA and in China, along with a team of more than 150 dedicated scientists well trained in various disciplines.

Reinovax has built an integrated system from early discovery to GMP manufacturing to support polysaccharide or protein-based vaccine programs. The company developed advanced core technology platforms on bacterial polysaccharide (ZIP-PSTM), IP-protected carrier protein (ZIP-CPTM), recombinant protein (ZIP-RPTM), and polysaccharide-protein conjugation (ZIP-PCTM). Reinovax has also established a GMP-like pilot-scale production base for the process development located in Lingang, Shanghai. With a lab space of 8025 m², this plant provides support for upstream process and downstream process as well as the fill-finish production for all active substance, intermediate drug-substance, and drug-product. It has the capacity to produce more than 5 million doses of 24-valent pneumococcal conjugate vaccine, the leading product developed by Reinovax. An EU/WHO compliant manufacturing factory is nearly completed located in Changchun, Jilin province.

Reinovax focuses on discovery and development of novel vaccines against bacterial infection. It has developed a focused project pipeline at different stages against antibiotic resistant bacteria with urgently unmet medical needs and huge market potential. The leading 24-valent pneumococcal conjugate vaccine is the first vaccine product which showed superior safety and immunogenicity profile in the Phase II trial and is progressing into the Phase III trial.

With years of in-depth research and dedication, Reinovax is well positioned for explosive growth. The market authorization of the advanced 24-valent pneumococcal conjugate vaccine is expected in 2028 in China, and the collaboration and development are underway for the global market.

A Novel 24-Valent Pneumococcal Conjugate Vaccine

Streptococcus pneumoniae is the leading cause of morbidity and mortality from low tract respiratory infection and community-acquired pneumonia especially in infants, young children, elderly, and individuals with chronic diseases or immune-compromised. Pneumococcal infection leads to meningitis, bacteremia, pneumonia and otitis media. The World Health Organization (WHO) lists pneumococcal disease as a vaccine preventable disease with highest priority. More than 160 countries include pneumococcal conjugate vaccines (PCV) into their national immunization programs (NIPs).

The licensed pneumococcal conjugate vaccine (PCV10/PCV13) has been a great success in fighting against the infection from the vaccine-type pneumococci. However, the efficacy of the low-valency vaccine decreases rapidly due to the occurrence of serotype replacement and the emerging of the non-vaccine types of pneumococci. Thus, development of high valency pneumococcal conjugate vaccine becomes medically critical for effective prevention of pneumococcal disease.

Reinovax is dedicated to developing the next generation of high-valency pneumococcal conjugate vaccine. The 24-valent pneumococcal conjugate vaccine with dual carrier proteins (PCV24, RC-100) is a novel vaccine developed by Reinovax. With the innovative design and implementation of proprietary technology, this high-valency vaccine can not only increase the protection against 24 prevalent pathogenic pneumococcal strains, but can also elicit sufficiently high antibodies to all twenty-four serotypes, which is superior to the marketed PCVs and those under development.

Reinovax has completed the Phase I and Phase II trials in adults, and Phase I trial in infants and young children for PCV24. The data demonstrated that this novel vaccine has excellent safety and tolerability, and can elicit superior specific antibodies to all 24 serotypes in both adults and infants.

With the establishment of the daunting manufacturing capability and the demonstrated superiority of the PCV24 product from the clinical trials, Reinovax is keen to expand PCV24 along with the pipeline products in the oversea market to benefit more people around the world.

Product Service



电话：021-50999002 邮箱：info@reinovax.com

地址：上海市浦东新区张江科学城盛荣路367号1号楼5楼

三生制药
3SBIO INC

CDMO Business

3SBio is a leading biopharmaceutical enterprise integrating research and development, production, and sales, committed to improving patients' quality of life with high-quality medicines and contributing to human health. Currently, the company holds over 100 authorized national invention patents and has more than 40 marketed products, covering various therapeutic areas such as nephrology, oncology, autoimmune diseases, ophthalmology, and dermatology.

3SBio's Contract Development and Manufacturing Organization (CDMO) business is primarily composed of four CDMO bases, with technical capabilities spanning multiple fields, including biologics, cell and gene therapy, and sterile drug product manufacturing. Leveraging 3SBio's extensive resources and technological advantages, we collaborate with globally renowned pharmaceutical and biotechnology companies, dedicated to providing end-to-end support from drug development to commercial manufacturing for our partners, empowering pharmaceutical innovation and accelerating the delivery of benefits to patients.

Cell and Gene Therapy(CGT)

- Plasmid and mRNA Customization Services
- Autologous Immune Cell and Allogeneic Immune Cell Production Services
- AAV1-13 Serotype Virus Production Services
- Meeting Production Needs in Various Scales(Ranging from 50 ML to 400 L)

Biologics

- Mammalian and Microbial Expression Systems
- Single-Use Systems and Stainless Steel Systems
- Reactors at Scales of 200L/300L/500L /1000L/12000L
- Batch Production and Continuous ProductionModes

Sterile drug product

- Flexible adaptation to multiple dosage forms, including vials (liquid/lyophilized formula -tions), pre-filled syringes, and ampoules.
- cGMP-certified in China, the US, and Europe, ensuring global market access.
- Coordinated operations across global bases to respond promptly to regional client needs.
- Seamless integration with biologics and cell/ gene therapy businesses, enabling end-to-end production from drug substance to drug product.

CDMO Global Layout

上海市浦东新区生物产业行业协会
SHANGHAI PUDONG BIO INDUSTRY ASSOCIATION

Shanghai Pudong Bio Industry Association

上海市浦东新区生物产业行业协会（以下简称“协会”）成立于2002年9月，荣获“5A级社会组织”、“上海市科协星级学会”、“浦东新区科协优秀学协会”、“张江生物医药产业集群促进机构”等多项荣誉。

Shanghai Pudong Bio Industry Association (hereinafter referred to as"SPBIA"), established in September 2002, has been honored with multiple awards including "AAAAA Social Organization", "Star Society of Shanghai Association for Science & Technology", "Outstanding Society / Association of Pudong Association for Science and Technology" and "Zhangjiang Biopharmaceutical Industry Cluster Promotion Organization".

会　长：丁　健　中国工程院院士

President: Jian DING Academician of the Chinese Academy of Engineering

监事长：陈凯先　中国科学院院士

Supervisor: Kaixian CHEN Academician of Chinese Academy of Sciences

协会现有会员单位近300家，理事单位84家。会员单位涵盖浦东新区生物、化学、中药、医疗器械、专业服务等领域的企业以及高等院校、科研院所以及服务平台等生物医药全产业链。协会在政府、科研机构、企业间发挥纽带和桥梁作用，助力打造世界级生物医药产业集群。

SPBIA currently has nearly 300 member organizations, including 84 governing members. Its membership covers a complete biopharmaceutical industry chain including enterprises in fields such as biomedicine, chemistry, traditional Chinese medicine, medical devices and outsourcing services, as well as universities, research institutes, and service platforms. Serving as a bridge between the government, research institutions, and enterprises, SPBIA contributes to building a world-class biopharmaceutical industrial cluster.

上海市浦东新区生物产业行业协会
Shanghai Pudong Bio Industry Association

联系电话（TEL）：86-21-58957033
邮箱（EMAIL）：spbia@spbia.cn

地址：上海市浦东新区峨嵋路812号211室
Add: Room 211, 812 Hefei Road, Pudong New Area, Shanghai

微信公众号：spbia2002
WeChat: spbia2002

About InnoStar

Innostar(Stock Code: 688710) is a contract research organization (CRO) headquartered in China. We hold globally recognized accreditations, providing One-stop Service From Nonclinical to Clinical Translation.

2010
Established in

72,000 m²
Facility Area

1000+
Professionals

920+
Clients

InnoStar Provides One-stop Service From Nonclinical to Clinical Translation

POC → PCC
Screening and discovery

IND
Nonclinical assessment

NDA
Clinical development

- Screening and Discovery Services

- Nonclinical Pharmacodynamics
- Nonclinical Pharmacokinetics
- Nonclinical Safety Evaluation

- Clinical Biological Sample Testing
- Biomarkers and Translational Research

Specialized Platform

- Radioisotope Platform
- Ophthalmology Integrated Evaluation Platform
- Inhalation Drugs Evaluation Platform

Compliance with Global Regulatory Requirements

- NMPA GLP
- OECD GLP
- FDA GLP
- AAALAC
- CAP
- Japan PMDA GLP (Project)
- Korea MFDS GLP (Project)

Shanghai InnoStar

- NMPA GLP 2011/2015/2019/2022/2025
- OECD GLP 2012/2015/2017/2019/2024
- U.S. FDA GLP 2014/2018
- AAALAC 2011/2016/2017/2020/2023
- U.S. CAP 2015/2017/2019/2022/2025

Nantong Innostar

- NMPA GLP 2019/2020/2021/2023/2024
- OECD GLP 2024
- U.S. FDA GLP 2025
- AAALAC 2019/2023



DELONIX BIOWORKS

Delonix Bioworks Introduction

羽冠生物是一家由香港大学团队创立、全球领先的创新细菌疫苗研发企业，致力于通过合成生物学技术推动细菌疫苗研发从经验路径向理性化设计转变。公司总部位于上海张江科学城，拥有一支平均具备15年以上学术及产业经验的资深管理团队。

公司自主研发的PathX病原菌基因组编辑平台在全球处于领先地位，可实现对超过15种病原菌的高效基因组编辑。基于此平台，公司开发了创新的工程化OMV技术平台（OMV Plus™）、工程化组分疫苗平台（BioDVax）等多项核心疫苗技术。目前公司已建立了多个具有重大市场潜力的创新细菌疫苗管线，其中B群脑膜炎球菌OMV疫苗的临床前研究数据显示出全球最优的潜力，预计将于2025年递交临床申报。

凭借突出的创新实力，羽冠生物已获得包括勃林格殷格翰创新大赛冠军、香港大学全国创新创业大赛冠军在内的十余项国内外重要荣誉，并入选上海市"专精特新"中小企业。

欲知更多信息，请访问www.delonixbio.com。

Delonix Bioworks is a globally leading biotech dedicated to developing next generation genetically engineered bacterial vaccines, aiming to transform bacterial vaccine development from empirical approaches to rational design through synthetic biology. Founded by a team from HKU and headquartered in Zhangjiang Science City, Delonix Bioworks is led by a senior management team with an average of over 15 years of academic and industry experience.

The company's proprietary PathX pathogen genome editing platform enables efficient genome editing of more than 15 pathogens. Building on this platform, Delonix has developed several innovative vaccine technology platforms, including the engineered OMV technology platform (OMV Plus™) and the engineered component vaccine platform (BioDVax).

Building on these platforms, Delonix has established multiple bacterial vaccine pipelines with strong market potential. Notably, the preclinical research data for its Meningococcal group B OMV vaccine demonstrates the potential to be world-leading, with clinical trial application expected to be submitted in 2025.

With outstanding innovation capabilities, Delonix Bioworks has received over 10 important domestic and international honors, including the Boehringer Ingelheim Innovation Competition Championship and HKU International Techno-Entrepreneurship Challenge First Prize.

More information: www.delonixbio.com

Meningococcal group B OMV vaccine (DX-104)

流行性脑脊髓膜炎（流脑）是由脑膜炎球菌引起的急性化脓性中枢神经系统感染，致残率高，全球死亡率超10%。B群脑膜炎球菌是当前主要流行的菌株，所引起的感染约占全球流脑病例的48.5%。

目前，全球仅有两款B群脑膜炎疫苗获批上市（GSK的Bexsero和辉瑞的Trumenba），2024年销售额合计超14亿美元。然而，这两款基于西方流行病学设计的产品对中国人群保护率有限，至今未能进入中国市场。中国目前没有获批上市的B群脑膜炎疫苗产品，市场潜力约30亿元人民币。

因为OMV疫苗研发难度高，众多国内企业尝试多年仍未成功。基于羽冠生物全球领先的病原菌编辑能力（PathX）及工程化OMV技术平台（OMV Plus），团队在短短24个月内完成了DX-104从候选疫苗的有效性、安全性验证到生产工艺放大至100升商业化规模的全过程，展示了平台的强大实力和转化效率。DX-104计划于2025年下半年在中国和澳大利亚同步提交临床申请，有望成为中国首个申报临床的工程化OMV疫苗，填补国内市场空白。

Meningococcal meningitis is an acute purulent CNS infection caused by *Neisseria meningitidis*, with a high disability rate and a global mortality exceeding 10%. Serogroup B is currently the predominant strain, responsible for ~48.5% of global cases.

Currently, only two serogroup B vaccines are approved worldwide: Bexsero (GSK) and Trumenba (Pfizer), with combined sales of over US$ 1.4 billion in 2024. However, these vaccines were developed based on Western epidemiology and show limited protection for the Chinese population. No serogroup B vaccine is yet approved in China, despite the potential market is estimated at ~RMB 3 billion.

Leveraging its PathX and OMV Plus platforms, Delonix successfully advanced DX-104 from efficacy and safety validation to 100 L commercial-scale manufacturing within 24 months. This achievement demonstrates world-leading R&D efficiency and robust translational capability. **DX-104 is planned to simultaneously file for clinical trial applications in China and Australia in 2025 H2 and is expected to become the first engineered OMV vaccine to file for clinical trials in China.**



About Zhangjiang Pharma Valley

In advancing the high-quality innovation and development of the biopharmaceutical industry,Pudong New Area continues to strengthen clustering effects,original innovation, forward-looking planning, reform pilots,and efficient services. Focusing on innovation origination and research incubation-transformation,it amplifies both innovation vitality and industrial driving force,striving to build a global hub for the launchpad of new drugs and medical devices,the preferred destination for scientist entrepreneurship,and a pioneering ground for institutional reform.

"3F" innovations -- First-in-Class, First-in-China, and First-in-Human -- continue to emerge. The area has gathered and cultivated over 3,900 innovative entities,established more than 400 technology and service platforms covering the entire R&D chain,and attracted over 140,000 innovation and entrepreneurship talents. There are more than 700 new drug pipelines under research,and the cumulative approvals of Class I new drugs and innovative medical devices account for approximately 1/6 of the national total.

Shanghai Pudong Life Science Industry Development Co., Ltd. was established in May 2024 as a wholly owned subsidiary of Zhangjiang Group. Serving as a professional service platform,the company is dedicated to advancing the life science industry in Pudong New District. It aims to be a key enabler of the innovation and industrial chains within the sector, providing investment promotion,industrial services,and entrepreneurship incubation for the life sciences industry in Pudong New District.

ZHANGJIANG PHARMA VALLEY

HI ZHANGJIANG

中国生物工程学会

www.biotechchina.org.cn

中国生物工程学会（Chinese Society of Biotechnology，CSBT）成立于1993年，是全国性、学术性和非营利性的科技社团组织，是中国科协的组成部分。首任理事长：谈家桢院士，现任理事长：高福院士。

中国生物工程学会团结全国各领域从事生物工程研究开发、生产经营、科研管理、教学普及和情报出版等各方面的科技人员，致力于推动国内外学术交流、科学普及和产业发展，加速研究成果向生产转移，为科技工作者服务、为创新驱动发展服务、为提高全民科学素质服务、为党和政府科学决策服务。

学会分支机构：生物农业分会、生物传感、生物芯片与纳米生物技术分会、合成生物学分会、灵长类生物医学分会、器官芯片与微生理系统分会；医学生物技术专业委员会、工业与环境生物技术专业委员会、海洋生物技术专业委员会、糖生物工程专业委员会、计算生物学与生物信息学专业委员会、转化医学专业委员会、生物资源专业委员会、氨基酸生物技术专业委员会、生命科学仪器专业委员会、林业生物工程专业委员会、精准医学专业委员会、微生物组学与技术专业委员会、动物生物技术专业委员会、细胞分析专业委员会、食品生物技术专业委员会、抗体工程专业委员会、干细胞与组织工程专业委员会、系统生物医学专业委员会、生物基材料专业委员会、一碳生物技术专业委员会、生物医药大数据专业委员会、噬菌体技术专业委员会、疫苗工程专业委员会、生物催化专业委员会、人工智能与生物技术专业委员会、中药生物技术专业委员会、数字化医工技术专业委员会（筹）；国际合作与海外事务工作委员会、科普工作委员会、继续教育工作委员会、生物产业促进工作委员会、生物技术与生物产业信息工作委员会、青年工作委员会、生物安全工作委员会、科创中国工作委员会；全国生物技术职业教育教学指导委员会。

学会拥有一批生物技术研究和生物产业领域的团体会员和个人会员，其专业范围涉及生物技术各领域，研究成果被广泛用于医药、农业、工业、环保、海洋等国计民生的各个方面。

学会出版《中国生物工程杂志》《合成生物学》和《中国生物经济发展报告》，这些出版物已成为我国生物技术科技工作者发表研究成果，沟通学术思想、交流学术经验、促进生物技术产业化的重要园地。

GB-Partner

美国全球生物医药共创集团
Global Biopharma Partnerships

GB-Partner 总部位于美国费城，是一家专注于支持华人生物医药企业拓展北美及全球市场的战略联合团队

三大核心业务板块

出海战略咨询与落地

我们搭建双向桥梁，助力中国生物医药企业制定并实施全球战略，同时引进美国生物技术公司到亚洲市场。

专业项目访问与市场活动策划

打造交流对话平台，促进全球生命科学社区的深度连接与思想引领。

医疗、生物医药初创企业孵化与加速

赋能早期生物医疗公司，提供战略指导和资源支持。

常规服务项目

- 海外战略规划设计
- 投资及融资, Newco设立
- 市场业务拓展（BD）
- 知识产权（IP）申请与管理
- 研发管线市场调研报告及问卷服务
- 财务及税务申报管理
- 法律、政策及合规咨询
- 临床试验设计与管理服务
- 企业及产品在美注册申报
- 市场准入策略计划书
- 全美参展及代展服务
- 海外代理（Agency）服务
- 美国商业营销活动策划与执行（包括企业路演、闭门会、高端沙龙等）
- 人才培训及海外公司人员配置
- 商务考察洽谈定制

China +86 18049920406
微信同号

contact@mygbpartner.com

微信公众号

GynaeSolution

PROEGCG

ENHANCED GREEN TEA ANTIOXIDANT POWER

Visit Booth 3E-S01

- UNIVERSITY LAB PROVEN OF 100X MORE ANTIOXIDANT POWER THAN VITAMIN C
- HELPS REDUCE MENSTRUAL DISCOMFORT
- SUPPORTING WOMEN'S HEALTH
- GMP CERTIFIED MANUFACTURING

TRANSFORMING WOMEN HEALTH THROUGH INNOVATION

TALK TO US

Prof Ronald Wang (Founder) Or Dr Kennes Hung (CEO)
(852) 3505 4267/ (852) 90638698
kenneshung@gynaesolution.biz

Why Biotechs and Emerging Pharma Trust Novotech

- Local relationships, Global execution
- Scientific, regulatory, and medical expertise in advanced and novel therapies
- Development Partner, sophisticated operational infrastructure, and cutting-edge technology
- Accelerate your global clinical development

Biotech's Partner at Every Phase

NOVOTECH-CRO.COM

廣州醫藥集團有限公司
Guangzhou Pharmaceutical Holdings Limited

廣州醫藥集團有限公司（以下簡稱廣藥集團）是廣州市屬國有企業，主要從事藥品（中藥、化學藥、生物製品等）、大健康產品、醫療器械、醫療服務等與醫藥整體相關的產品研製開發、生產銷售以及醫療健康養生服務的提供。目前控股上市公司「廣州白雲山醫藥集團股份有限公司」（香港H股：00874，上海A股：600332）及參股康美藥業（上海A股：600518），旗下共有成員企業30多家，包括「全球歷史最悠久的涼茶品牌」王老吉，已420多年歷史的「世界最長壽製藥廠」陳李濟以及敬修堂、潘高壽、采芝林等13家中華老字號企業。

廣藥集團是世界500強企業，繼2021年成為全球首家以中醫藥為主業進入世界500強的企業後，連續多年上榜《財富》世界500強，2025年名列第459位，是唯一入選製藥分行業榜單的中國企業，位居全球第14位，在國際權威品牌評估機構BF公司發布的2025年全球最具價值醫藥品牌榜單中名列第15位，連續多年榮登中國中藥企業排行榜第一位。

Guangzhou Pharmaceutical Holdings Limited (hereafter referred as GPHL), a state-owned enterprise based in Guangzhou, mainly engages in the R&D, manufacturing and sale of pharmaceuticals (including TCM, chemical drugs and biological products), health products, medical devices and medicine-related products, and provides health and wellness services. GPHL currently holds controlling stakes in the public company of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (00874.HK, 600332.SS, Shanghai A-Share) and has minority investments in Kangmei Pharmaceutical Co., Ltd. (600518.SS). The Company has over 30 subsidiaries, including 13 China's time-honored brands, such as Wong Lo Kat (WALOVI), one of the oldest herbal tea brands in the world, Chenliji, the world's oldest pharmaceutical factory with a history of more than 420 years, Jing Xiu Tang, Pangaoshou and Cai Zhi Lin.

Known as a Fortune 500 company, GPHL first made the list in 2021 as the first company with TCM R&D and production as its main business in the world. After that, the Company has been on the list for several consecutive years. It secured the 459th position on the list in 2025, and it was the sole Chinese company which made the Fortune 500 Pharmaceuticals Industry Ranking and was placed at number 14 in the same year. The Company is the world's 15th strongest pharma brand on the Pharma 25 2025 ranking released by Brand Finance (BF), an internationally authoritative brand valuation agency. GPHL has remained the top brand on the Chinese TCM company ranking for many years.

中华老字号
China Time-honored Brand

陈李济药厂　中一药业　敬修堂　王老吉药业　白云山王老吉

奇星　潘高寿药业　明兴制药　光华制药　何济公制药

PepiX™

Oral macrocyclic peptides design platform

- **15 years** of experience in pharmaceutical chemistry analysis

- Comprehensive biological tests

PepiX.AI

- AI-powerd
- Faster
- **100M** training data
- **2000+NCAAs**

PepiX.LAB

- High-throughput
- **10^{12-14}** in **2 mo.**
- Automatic synthesis
- NCAA

Successful cases

- FIC for an un-druggable target (IDPs) with solid tumor
- RDC/PDC
- Oral weight loss peptide
- Cosmetic peptide
- Cancer vaccine
- Brain/Ocular delivery

Solve challenges in finding high quality peptides

- Low stability
- Low bioavailability
- Poor permeability
- Time consuming
- Low success rate

AI powerd siRNA design

- Better and more novel modification patterns even with the same sequence
- Discovering high-quality sequences that have been overlooked in the traditional siRNA design process
- Combining dry and wet methods, continuously generating data for iterative optimization of the algorithm

康储科技（广东）有限公司

CONSTORAGE TECHNOLOGY (GUANGDONG) CO., LTD.

企业介绍
Enterprise Introduction

康储科技（广东）有限公司，是一家集干细胞、免疫细胞等生物医药产品研发与应用于一体的高新生物科技企业。公司总部位于粤港澳大湾区广州黄埔开发区科学城，已建成近2000㎡符合国家GMP级细胞研发、生产、质检实验室及细胞储存生命银行服务中心。

目前，康储科技技术研发团队正在推进临床转化及应用的产品有：糖尿病细胞药物研发及康复应用、身体健康保养、成人自体免疫细胞储存、肿瘤细胞药物、儿童罕见病细胞药物、细胞外囊泡药物等。

专利 Patent

康储细胞制备储存平台
KangChu Cell Bank System

- 独立自主建立了符合cGMP标准大型细胞生产制备和储存车间，拥有国际领先的细胞检测、优选、冻存和培养等关键设备。
- 免疫细胞与干细胞新技术研发应用转化中心平台，包含康储科技免疫细胞储存中心、康储科技细胞生产制备中心以及康储细胞质控中心。
- 免疫细胞储存基地实现全天候24小时智能信息化监控，目前首期免疫细胞冻存库容量达16万人份。

产学研平台
Industry-Academia-Research

扫一扫
公众号

Contact us!

邮政编码：510700

咨询热线：400-629-6298

地址：广东省广州市黄埔区揽月路80号康储大厦

MILECELL

SEEKING GLOBAL PARTNERS AND DISTRIBUTORS

We are now seeking global partners and distributors who share our passion for scientific advancement and are eager to bring our products to a wider audience. By joining forces with Milecell Bio, you will gain access to a cutting-edge product range, backed by our expertise in cell biology and biotechnology.

Animal Primary Cells

- Hepatocyes
- NPCs, HSCs, Kupffer Cells, LSECs
- PBMCs
- Splenic Lymphocytes



Hepatocytes



Rat Hepatic Stellate Cells

Animal Subcellular Fraction

- Liver Microsomes & S9
- Intestinal Microsomes & S9
- Renal Microsomes & S9
- Induced Liver S9



Cell Freezing Media—CGT

- FDA Master File
- cGMP Manufactured
- Serum-Free
- Aseptic Processing Technique
- Cell-Based Release Testing
- USP Components
- DMSO Pre-Formulated
- Protein-Free
- Ultra Low Endotoxin

DMSO-Free Freezing Media Coming Soon

Milecell Biological Science & Technology Co., Ltd.
APAC & EU:
E-mail: techserv@milecell-bio.com
Phone: +86 21-64169739 ext 803
Add: Lane158, Gu'en Road, Shanghai , China

North America:
E-mail: jakezheng@milecell-bio.com
Add: 10410 Corporate Drive, Sugar Land, TX 77478, US

食德源生物科技
SHIDEYUAN BIOTECHNOLOGY

威海食德源生物科技有限责任公司成立于2022年，公司位于风景秀丽的威海荣成市，是一家专注于以食叶草为主要原料，研究、开发、生产及销售保健食品的创新型科技企业。

公司自成立以来，始终坚持“科技赋创新，健康‘肽’重要”的大健康理念，不断依靠科技力量创新发展，公司以“孝心对长辈、爱心交朋友、匠心做产品、诚心待客户、忠心兴家国”为核心价值观，借最用心的企业，公司希望通过高科技手段和优质的产品，提升人类健康免疫力，增强人类的抗衰老能力，为人类健康事业的发展贡献力量。

公司通过不断的科技创新，打造出食叶草植萃食叶草小分子肽、食叶草口服液、各种口味的固体饮料、压片糖果等系列产品，做健康全产业链，引导健康新风尚。

是否出现过这种状况?

食叶草小分子肽具有以下优势和作用:

1、原料具有新资源食品的优良基础。

2、产品生产工艺先进、纯度高活性强。

3、人体对本产品吸收充分，不增加胃肠功能负担。

4、肽有助于抗衰老、抗疲劳、抗氧化、改善睡眠、提高免疫力。

现代人必须补肽，补肽就是补青春，补活力，补生命。

活性肽

“肽”后基生，人体健康的青春密码

生物活性肽：21世纪营养革命的核心

前沿科技产物　小分子 大能量

全球健康共识

现代人补肽的必要性

对抗生活压力　科学健康补充

对补饮食缺口

产品介绍　食叶草蛋白肽(固体饮料)

食叶草小分子肽也目前国内唯一使用食叶草为原料以高科技手段生产的小分子活性肽，产品中小分子肽占比达80.8%以上，该产品同时富含SOD超氧化物歧化酶及中微量元素(钙、磷、铁、硒、锌、钾、镁等)，经权威机构对该产品营养及生物活性指标表明：食叶草中氨基酸种类齐全高达18种，食叶草小分子肽表现出良好的抗氧化活性，对受损细胞具有再生、更新、清洁、修复、促进新作用。



威海食德源生物科技有限责任公司已获国家发明专利认证(专利号：ZL 2022 1 110039

7.2)该专利围绕一种高SOD含量的食叶草活性肽及其制备方法，突破传统提取工艺瓶颈，通过创新的制备技术，确保食叶草中高SOD含量活性肽的高效提取与稳定存在。其工艺方法经国家知识产权局审查符合专利法规定，为企业在食叶草活性肽开发领域提供了强有力的技术支撑。



产品经CTI华测检测旗下黑龙江省华测检测技术有限公司检测，其超氧化物歧化酶活性达8855U/G，检测方法遵循GB/T 5009.171-2003第一法，结果为宏测值。检测显示，样品状态为固态，各项检测指标合格，且该检测报告可通过扫描二维码或登录官网查询真伪，为产品质量性能及含量提供了科学权威的检测依据。



产品经江南大学分析测试中心监测，其肽分子量分布科学合理，其中<180 DA 的小分子肽占比达55.81%，500~180 DA 区间占比31.09%，10000DA以上大分子占比仅0.05%，检测方法遵循GB/T 22492-2008 标准，结果显示，活性肽分子结构优势显著，各项指标符合国家标准，且通过新食品原料安全性评估，产品无添加防腐剂、色素等化学物质，适合长期服用。

产品介绍　叶草1号食叶草压片糖果

扫描此二维码
访问我们的官方视频号
获取更多信息

联系我们 CONTACT US

联系电话：0631-7680988

联系邮箱：150305735@Q9.COM

联系地址：山东省威海市荣成市崂山街道海湾南路168号

中文网址：WWW.蛋白肽.在线

硕通 JMSOTN

JIANGMEN SHUOTONG MEDICALAPPARATUS and INSTRUMENTS TECHNOLOGIES Co.,Ltd

Serve over 1,000 hospitals. Expand worldwide. Benefit more patients.

Dedicate to innovation. Invest 15% of annual revenue in R&D. Break new ground in technology.

Focus on urinary stone surgery solutions. Set the industry benchmark.
Pioneered integrated stone management via natural orifice. Lead globally.
The only certified modular rigid endoscope.
Drive expert consensus and worldwide recognition.
Achieve simultaneous suction and lithotripsy under negative pressure: minimal invasion, lower cost, fewer complications.
Guide the industry to focus on intrarenal pressure and stone-free rates.
Transform surgical standards.
Dedicate to innovation. Invest 15% of annual revenue in R&D. Break new ground in technology.
Excel in urology. Bring "Innovated in China" to the world.

Innovation

Rigorous

Practical

Develop



Whastapp

Contact Number:(+86)13432238758
Whastapp:(+86)13432238758
Business Email:jmshuotong33@126.com
Address:BUILDING 7, 16 WEST HUANG ZHUANG AVENUE, PENGJIANG DISTRICT JIANGMEN CITY

A WORD FROM YOUR
TRADE COMMISSIONER

Are you looking for a business partner you can trust? Canada is home to a dynamic marketplace supported by an innovative economy and welcoming business community. World-renowned for its capabilities in diverse sectors and has 14 free trade agreements in force with 49 countries, Canada is an ideal environment for partnerships and investment.

The Canadian Trade Commissioner Service (TCS) is a government organization that has facilitated trade with Canada since 1895. With offices in more than 160 cities across Canada and around the world. We are accessible to both Canadian and international companies looking to do business.

With an in-depth knowledge of global markets and insight on Canadian industry sector capabilities, we can connect you with strategic procurement, investment, innovation or education partners in Canada.

Let our team of professionals help you with our free services.

BUY FROM CANADA

We can introduce you to the Canadian organization best suited to meet your needs for high-quality products, services or technologies.

INVEST IN CANADA

Establish or expand your business in Canada to benefit from a stable economy with competitive business costs, a safe and inclusive environment and a highly educated and skilled workforces. Our investment professionals can provide the strategic intelligence you need.

INNOVATE WITH CANADA

Canada is a world leader in science and technology with strong capabilities across a wide range of sectors. We can connect you with the right research and development (R&D) partners in Canada.

STUDY IN CANADA

Canada has some of the world's top research facilities and academic institutions. We can connect you with the right schools, scholarship and potential R&D partners as well as education and training service providers.

CONNECT WITH US

Contact Jaclyn Chan, Trade Commissioner, Email at jaclyn.chan@international.gc.ca to start doing buiness with Canada.

Learn more at **tradecommissioner.gc.ca**

@TCS_SDC **/company/tcssdc** **/TCSSDC**

Centre for Virology, Vaccinology & Therapeutics
病毒與疫苗研究中心

ABOUT US

- Established in 2020
- Affiliated with HKU
- Funded by ITC's InnoHK initiative
- Advance research for infectious disease control and prevention

BIOHK2025 香港國際生物科技論壇展覽

10-13 Sep

Visit us at

HK Exhibition Centre (Hall 3)

Booth : 3E-D09

Vaccine

Cutting-Edge Viral Vector Vaccine Platform

Therapeutics



Δ42PD-1 Antibody for Liver Cancer

Organoid

Pioneering Organoid Technology for Biomedical Innovation

SCAN ME

Email: admin@cvvt.hk
Tel: +852 3910 3688
Address: Unit 208-213, 2/F, Building 15W, Hong Kong Science Park, Pak Shek Kok, N.T.

HK Tech 300
Venture Beyond Boundaries

香港城市大學
City University of Hong Kong

HK TECH 300

Sponsored Training Programme
資助訓練課程

1,900+
Participants
參加者

HK$100,000 Seed Fund
10萬港元種子基金

790+
Start-up Teams
初創團隊

HK$1,000,000 Angel Fund
100萬港元天使基金

200+
Start-up Companies
初創企業

Strategic Partners, Co-investors & Supporting Organisations
策略合作夥伴、共同投資夥伴和支持機構

100+

Mentorships
創導導師

280+

(Data as of Sep 2025)

HK Tech 300 - a large-scale flagship innovation and entrepreneurship programme with an allocation of HK$600 million from CityUHK, aiming to provide development opportunities and entrepreneurial experience for young people. The programme focuses on translating CityUHK's research achievements, intellectual property and technology into practical applications through the establishment of tech start-ups.

HK Tech 300 - 由香港城市大學撥款6億港元進行的大型旗艦創新創業計劃，旨在為年輕人提供發展機會和創業經驗，通過成立科技初創，將城大的研究成果、知識產權及技術轉化為實際應用。

HKTech300
CityU_Innovation
cityu.edu.hk/hktech300

GenEditBio

Affordable Precision DNA Surgery for Genetic Diseases with Unmet Needs

Using next generation precision CRISPR/Cas editing

GenEditBio is a clinical stage gene therapy startup established in 2021 and headquartered in Hong Kong. We're pioneering potentially curative, single-treatment therapies for genetic diseases using highly precise, *in vivo* genome editing. Our innovative approach combines cutting-edge AI-guided Cas nuclease discovery with advanced delivery technologies (LNPs and PDVs) to ensure safety and affordability, offering hope where there was none before. We are also actively seeking partnerships to accelerate our progress toward clinical trials and regulatory approval.

Company Overview

- HQ in **Hong Kong** with operations in **Beijing** & **Boston**
- Team comprised of academic experts and industry veterans
- Raised **$50M USD** to date; **Series A** fundraising this year

Pipeline	Delivery	Discovery	Preclinical	Clinical
GEB-101 Corneal dystrophy	PDV			IIT started
Undisclosed	PDV			
Rare disease	LNP			
Cardiovascular disease	LNP			

Tech platforms of **GenEditBio** comes together to ensure gene editing therapies developed are **fundamentally safe**

- Tissue- / Cell-specific *in vivo* delivery enabled by engineerable **PDVs**
- Site-specific insertion of DNA fragments enabled by proprietary **Lead Editor**
- Sensitive off-target monitoring enabled by **EDITED-Seq**

Highly **precise** genome editing therapies in **target** cells with **minimal off-target** editing

852-21512116 (HK) bd@geneditbio.com www.geneditbio.com

GreenLight Clinical

Specialist CRO,
Built on Partnerships,
Driven by Innovation

ABOUT US

GreenLight Clinical (GLC) is a physician-led, full-service clinical CRO with headquarters in Sydney, Australia. Our dynamic team are located around Australia, the USA and Asia.

At GLC, we specialise in delivering comprehensive early phase clinical trial services in **oncology, ophthalmology, gene & stem cell therapies and medical devices**. With a commitment to speed and precision, we partner with biotech companies to drive innovation and bring life-changing therapies to market faster.

OUR SERVICES

- **Site Start-up, Monitoring & Project Management**
- **Medical Writing**
- **Data Management & Biostatistics**
- **Quality Assurance**
- **Medical Monitoring & Pharmacovigilance**
- **Grant Writing & Applications**
- **Medical Device & TGA Product Registration**

With our medical expertise and deep industry knowledge, we develop bespoke solutions to streamline development of therapies for patients with unmet needs. We conduct our trials according to ICH/GP guidelines and we also have ISO 9001:2015 accreditation.

www.greenlightclinical.com +61 2 9191 0640 info@greenlightclinical.com

Advancing Life and Health Tech: The HKSTP Ecosystem

Hong Kong Science Park is a global hub for innovation in Life and Health Technology, fostering a dynamic ecosystem of Research and Development, Collaboration, Clinical Translation, and Commercialization.

All-Round Support Service to Expedite Your Success

- Funding & Capital
- Office Space & Facilities
- Promotion & Development
- Key Personnel Training
- Technical Support
- Regulatory Support

- State-of-the-art laboratories and PIC/S GMP facilities
- Access to global talent and cutting-edge technology
- Strong partnerships with academia, industry, investors, clinicians, regulatory and government

MORE INFO ON OUR WEBSITE

HKSTP GMP BSC

WWW.HKSTP.ORG



CONNECT WITH AUSTRIAN COMPANIES IN THE MEDICAL TECHNOLOGY SECTOR

COME & MEET US AT THE ADVANTAGE AUSTRIA STAND!

ADVANTAGE AUSTRIA - Austrian Trade Commission
13/F Diamond Exchange Bldg.
8-10 Duddell Street, Central
Hong Kong
Contact Person:
Ms Monica NG & Yvonne CHOI
T +852 2522 2388
E hongkong@advantageaustria.org
W www.advantageaustria.org/cn

ADVANTAGE AUSTRIA WKO

TOWARDS PHARMACEUTICAL SUPER INTELLIGENCE

LEARNING FROM 10+ CLINICAL-STAGE INTERNALLY-DISCOVERED THERAPEUTICS

Biology

PandaOmics
Discover and Prioritize Novel Targets

Generative Biologics
Discover and Optimize Novel Biomolecules

Life Star 2
Automated Lab Operating Environment

Large Language of Life Models (LLLMs)

Precious1GPT
Multiomics Age Prediction & Target ID

Precious2GPT
Multimodal Multiomics Biological Data Synthesis

Precious3GPT
Multi Tissue Multispecies Multiomics Multimodal Life Model

Chemistry

Generative Chemistry
Generate Novel Molecules

Alchemistry
Physics-based Reactive Binding Free Energy Engine

ADMET Profiling
On-the-fly Optimization

Golden Cubes
Kinase Selectivity

Retrosynthesis
Predict Synthetic Routes for Molecular Structures

Model Training
Train a State-of-the-art Model on your data

Nach01
Multimodal Natural & Chemical Languages Foundation Model

Medicine

inClinico
Design and Predict Clinical Trials

Science

DORA
Multi-agent Generative Research Assistant

LLM Assistant

Copilot
Generative Conversational Agent

Environmental Sustainability
Generative AI Technologies for Environmental Sustainability

Data Warehouse
Seamless Cross-application Data Flow via Efficient Integration & Standardization



Insilico Medicine

insilico.com

CONTACT US bd@insilico.com media@insilico.com investors@insilico.com career@insilico.com

JETRO

JETRO and Invest Japan Program

JETRO
Japan External Trade Organization

A Governmental Organization Who Economically Connect Between Japan and World

INVEST JAPAN

Supporting Foreign Entities Throughout The Entire Process of Their Business Expansion Plan into Japan

22K+
Projects Supported (FY 2003-2024)

2.2K+
Establishment Completed (FY2003-2024)

76
Overseas

47+
Domestic

6 JETRO IBSCs (Invest Japan Business Support Centers)
Tokyo, Yokohama, Nagoya
Osaka, Kobe and Fukuoka

Expanding Innovation

Booming up
Open Innovation
From Overseas to All over Japan

Free Consultation

Company Registration
Cost Estimation
Laws & Regulations
Taxes & Accounting

Free Business Support

Market Reports
Customized Research
Introduction to Local Gov.
PR Support

Free Temporary Office

50 business days for free
Meeting Rooms
IBSC Innovation Garden

Free Networking & PR

Japanese Enterprises
Gov./Local Gov./Univ.
Service Providers

INVEST JAPAN

MUNG BLOCKCHAIN LAW FIRM

150.VENTURES

香港首个生命科技 RWA

LIVE BEYOND 150

祝您150生日快乐！

微信：MoninUng
联系电话：+852 9100 7093
https://www.munglegal.com

Quick Gene one Stop Solution for Biologics Quality Control

Dr. Kevin Huang
Founder and CEO,
ex USP experts

Neo Gene Biotech (NGB) is a global Biotech company which is based on HKSTP. Quick Gene (QG) is a subsidiary brand of NGB. Quick Gene dedicates to the quality control of biologic products and offers a comprehensive one-stop solution for impurity testing and related method development. We are providing products, services and total solutions for global biopharma companies.

Services

- Drug developability Evaluation
- Regulation Consultant for Biologic Quality Control
- Residue HCPs study ONE STOP solution
- Residue DNA Testing Kits
- Characterization Reagents and Testing Kit

Products

Residue HCP ELISA Kit

Residue DNA qPCR Kit

Mobile + 852 5518 3950
Email kh@neogbio.com
Website www.neogbio.com

Neo Gene Biotech Co., LIMITED
19/F, Tower 9, Solaria, 9 Core Road
Pak Shek Kok, Tai Po, New Territories, Hong Kong

RAIN BIOTECH
SOLUTIONS

AI-Driven

Cost-Effective

Cell Friendly Handling

Customizable

DYNAMICALLY ENGINEERED

Next-Gen Biotechnology Platform

Microfluidic & AI-Driven Deep Analysis

8+
Products in Pipeline
5 Commercial Ready

2M+ USD
Raised In Private Equity Funding

3
R&D Labs & Production Facilities

4
HK government sponsored Grant Projects

Our Partners & Supporters

DM Healthcare Investment

华源再生医学

康沃生物制造

AKR 华越肾科再生医学 Asia Kidney Rebuilding

rainbiosolutions.com | Rain Biotech Solutions | hkrbs_ | @rainbiosolution

SIIC 上海實業 | SFK 上海医药 | 上药生物治疗

UNLOCKING CELL POTENTIAL

Production Process Technology Platform

✓ We offer the one-stop solution covering CMC of plasmid and virus facility enabling services as well as clinical manufacturing to support early-stage clinical trials

✓ Rapid manufactury platform significantly shorten time, save costs, enhance cell fitness and proliferation capabilities, and achieve better efficacy

✓ CAR-T enhancement technology platform: improve T cell proliferation, persistence, bioactivity, eliminate antigen escape, increase safety and reduce toxicity

✓ Universal cell technology platform: covering iNKTCells, NK cells, explore cooperation with UF, AX-T cells, HSC cells and other types

R&D and Manufacturing Facilities

✓ We have a in-house CAR structure library + various types of cooperative target discovery libraries, and a diversified chassis cell bank. We have collaborated with many well-known hospitals, universities and scientific research institutions to establish a variety of transgenic technology platforms and jointly promote the industrialization of clinical application of cell therapy.

✓ We have a 500m2 early R&D laboratory and connect with several top-tier hospitals in Shanghai by creating a total area of 3600 m2 translational base (including 2 plasmid production lines, 2 virus production lines and 14 cell production lines, and equipped with intelligent production systems)

Rich Industrialization Experience Strong Commercial Support

✓ The team members have rich experience in biopharmaceutical industrialization and have participated in the establishment of multiple drug quality standards and industrial transformation, helping to promote the industrialization process quickly and with high quality

✓ The big pharma Sinopharm company has a strong commercial logistics distribution system and innovative medical and health service platform resources, which can ensure the timeliness of delivery and the accessibility of commercial insurance

About Us

- A clinical-stage biotech company for development of cell therapies including CAR-T and TCR-T, etc. in treatment of tumors and autoimmune diseases.
- Under the leadership of a joint scientist/entrepreneur team, it has built a solid foundation over six-year growth capable to support early-stage clinical trials and produce a number of core pipeline products.
- Well positioned across the border by placing early research and development in Hong Kong and conducting clinical translation/industrialization in Shanghai via a mode of R&D in HK and translation in SH.
- Created a unique model by placing a "factory" in the hospitals and closely connecting the benchtop research to the bedside clinical studies.
- Its best-in-class bicistronic CD19 and CD22 CAR-T currently in Phase 1 trials for treatment of children B-ALL and adult B-NHL. The clinical data were presented in 2024 ASH and attracting international attention.
- Breaking through and advancing on non-gene edited allogeneic platform using iNKT cells.
- Expertise in cell therapy manufacturing with in-house centralized GMP facility and logistical capabilities supporting early-stage CAR-T cell therapy in clinical trials.

Core Pipeline

Project Name	Target	Indications	Cell Type	R&D Progress
B019-101	CD19 & CD22	Childhood B-ALL	Autologous CAR-T	Phase I
B019-102	CD19 & CD22	Adult B-NHL	Autologous CAR-T	Phase I
B019-103	CD19 & CD22	SLE and other autoimmune diseases	Autologous CAR-T	
B023	CD19	SLE and other autoimmune diseases	Universal CAR iNKT	
Logic gating ROR1 CAR-T	ROR1	Solid tumors	Autologous CAR-T	CMC study (IIT validation)
GPC3 CAR-T	GPC3	Solid tumors	Autologous CAR-T	CMC study (IIT validation)
DLL3 CAR-T w/ PD1KO	DLL3	Small cell lung cancer	Autologous CAR-T	CMC study (IIT validation)

Cell Therapy Implants for Liver Disease

Stimuliver

Who We Are

Stimuliver is the spin-out from the University of Edinburgh (UK), currently based at the Bioinnovation Institute in Copenhagen. We're developing ***non-invasive, immunotolerant liver tissue implants*** *to treat different types of liver diseases.*

Problem and Our Vision

Liver disease is a fast-growing global crisis. ***Acute decompensation (AD)*** *alone affects over 600,000 people worldwide. Transplants are the only effective treatment — but they're limited by donor shortages and risks. We've developed a game-changing solution that* ***eliminates the need for donor organs.***

Our Solution – Remote Regeneration

We generate ***3D liver tissue implants*** *capable of secreting a range of enzymes and proteins to support liver detoxification and essential human physiological functions.*



The Potential of Our Technology

Renewable **Scalable** **Implantable** **Non-reactive** **Platform**

Our Partnerships and Collaborations

novo nordisk foundation

novo nordisk

THE UNIVERSITY of EDINBURGH

BI BioInnovation Institute

EIFO

BioLamina

Contact us!

We're are looking for investment and co-development opportunities.

Proactive Partnership. Proven Impact.

At Syneos Health®, our deep experience gives us a clear understanding of the challenges involved in bringing new therapies to market. Our team of experts across clinical development and commercial delivery work together to reduce uncertainty and navigate the complexities of product development. Partnering with us means gaining a forward-thinking ally focused on accelerating progress, reducing risk and delivering therapies to patients faster.

Discover the impact of a proactive partnership—see how we can support you at syneoshealth.com.

Syneos® Health

BIOMICE 百奥动物品牌

百奥赛图公司成立于2009年，立足全球生物医药行业，从技术创新出发，致力成为全球新药发源地。2021年建立“BioMice百奥动物”子品牌，以独立、崭新的形象呈现在广大合作伙伴面前。业务涵盖从创新动物模型的研发制备、生产供应到实验服务等多个方面。

基因编辑	动物模型	药理药效	动物中心相关服务
基因编辑大小鼠定制 基因编辑细胞系定制	重度免疫缺陷小鼠 靶点人源化小鼠及细胞模型 疾病模型鼠 工具鼠 老龄鼠	体内药效学评价 体内药理学研究 药代动力学分析 病理/毒理检测 体外药理药效检测	动物代养 动物保种 动物净化 动物房租赁

免疫缺陷鼠系列

促进PBMC重建，减轻GVHD，延长实验窗口期	促进人髓系细胞分化无需辐照	用于靶点药物药效及毒性验证	用于疫苗的药效及毒性验证	免疫缺陷大鼠
B-NDG B2m KO mice plus B-NDG H2-Ab1 KO mice B-NDG MHC I/II DKO mice plus	B-NDG hTHPO mice B-NDG hCSF1/hTHPO mice B-NDG MOMT3 mice	B-NDG hSIRPA/hCD47 mice B-NDG hSIRPA mice B-hCD39HC/Rag2 KO mice	B-NDG HLA-A2.1 mice	B-Rag2 KO rats B-Rag2/IL2rg KO rats B-IL2rg KO rats

靶点人源化小鼠及细胞模型

Tumor targets	713
Autoimmune targets	489
Metabolic targets	215
Others	60

ADC CD38 TFR1 TROP2 B7-H3	**BsAb** CD3EDG/TROP2 4-1BB/CD40 CTLA4/OX40	**Oncology** PD-1 CCR8 4-1BB CD3E	**Autoimmune** IL6 IL17A TSLP IL4 ....
IC PD-1 4-1BB CD3e CD40	**NK IC** NKp46 NKG2D CD16A NKp30	**McAb** PD-1 4-1BB GITR FcRn	**Cytokine** IL4RA/L4 IL2RA IL36R TSLP ....
GPCR CCR8 GLP1R CB1 GCGR	**TME** CCR8 IL2RA IL1B GARP	**Metabolism** GLP1R GCGR IL11 CTGF	

每2個香港人就有1個用富途!



一站式交易平台 極速捕捉投資機會

騰訊投資
美國上市

港股
一世免佣
0 佣金

美股
5x24小時交易
24 小時

Crypto
持牌安全 靈活充幣
0 佣金

达健生物

广州达健生物科技有限公司

Guangzhou Targene Biotech Co.,Ltd

项目简介

广州达健生物科技有限公司成立于2009年，以“达仁济世，健康中国”为企业使命，致力于癌症早期诊断、辅助诊断、用药指导、复发监测等癌症诊疗全流程应用场景的单癌种、多癌种乃至泛癌种产品的研发。目前公司已发展成中国肿瘤早筛领域头部企业，业务覆盖全国20多个省市超过240家医院。

依托荧光PCR、数字PCR、高通量测试等技术平台，开展基于脱落细胞和外周血游离DNA甲基化、基因突变等早期辅助诊断产品的研发，目前已完成或启动膀胱癌、结直肠癌、宫颈癌、肝癌、食管癌、甲状腺癌、EB病毒、乙型肝炎病毒等产品的注册临床试验工作，其中部分产品已经取得国家药监局NMPA III类体外诊断试剂注册证。

产品癌种图

产品优势

- **精准诊断**
- **早诊**
- **技术领先**
- **快速**
- **非侵入性**
- **易普**
- **注册报证**
- **聚焦**

核心产品

• 国内首证 •

【注册证编号】国械注准20223401301

• 国内首创 四靶标 •

【注册证编号】国械注准20233400970

人Twist1基因甲基化检测试剂盒（甲基化荧光PCR法）

人SDC2、NPY、FGF5、PDX1基因甲基化检测试剂盒（荧光PCR法）

全国首个膀胱癌甲基化检测产品（III类医疗器械）：

人Twist1基因甲基化检测试剂盒（甲基化荧光PCR法）及一次性使用尿液采样器

全国首个四基因结直肠癌甲基化检测产品（III类医疗器械）：

人SDC2、NPY、FGF5、PDX1基因甲基化检测试剂盒（荧光PCR法）及一次性使用粪便采样器

Scan this code to visitour official website formore information!

Contact us!

(86) 020-39341037

ip@targene.cn

www.gztargene.com

生物医药供应链专题展区

BIOPHARMA

11月12-14日 重庆

Nov. 12-14,ChongQing

Scan the QR code to follow us on LinkedIn for more information

第93届中国国际医药原料药/中间体/包装/设备交易会（API China）将于2025年11月12-14日在重庆国际博览中心举办。参展企业聚焦医药工业产业链、供应链，涵盖医药原料药、辅料配料、医药包装、制药设备四大核心领域的1200余家海内外生产及代理经销企业。

本届展会将持续推出“生物医药供应链专题展区”，充分依托西南地区深厚的化学药产业基础、丰富的中药资源及近年来快速崛起的生物药产业，积极发挥重庆作为“一带一路”与长江经济带联结点区位辐射力优势，抢抓中西部地区医药工业需求快速增长的机遇，携手行业同仁，共拓商机，共同擘画医药产业高质量发展新蓝图。

往届参展企业（部分）

联系我们:

Mr. Evan Wang

TEL: +86-10-8455 6523

EMAIL:

ye.wang@reedsinopharm.com

Mrs. Jasmine Wangang

TEL: +86-10-8455 6520

EMAIL:

zheng.wang@reedsinopharm.com

国药励展 Reed Sinopharm Exhibitions

生物医药原材料展区

- 细胞培养基
- 重组蛋白/生长因子（用于细胞培养）
- 定制合成肽与多肽原料（用于API生产、疫苗、诊断、研究等）
- 细胞株及基因工程服务商
- 生物源原料（重组胰岛素、人血清白蛋白替代物等）
- 核酸原料（用于mRNA疫苗/CGT治疗）
- 缓冲盐及基础化学试剂

生物工艺耗材与辅料展区

- 纯化试剂
- 赋形剂
- 稳定剂
- 冻干保护剂
- 增溶剂、
- 表面活性剂
- 糖类/多元醇类冻干保护剂
- 生物工艺填料/层析介质

生物包装材料与给药系统展区

- 一次性使用技术服务企业（如：生物反应器袋、混合袋、储液袋、管组件，连接器，取样器等）
- 玻璃瓶、卡式瓶及瓶盖
- 预灌封注射器（玻璃/PFS，塑料PFS）及组件（推杆，护帽，塞子）
- 弹性体部件（胶塞，注射器柱塞，垫片）
- 铝盖/铝塑组合盖
- 标签与防伪技术
- 冷链包装材料（保温箱，温控容器，干冰）
- 给药装置（注射笔及组件服务商，新型注射器）
- 智能包装（温度指示器，时间温度指示器）

生物设备与系统展区

- 生物反应器
- 过滤系统与膜材服务商
- 切向流过滤系统
- 病毒灭活/除病毒过滤系统
- 制剂灌装设备
- 液体/半固体制剂配制/混合系统
- 冻干机供应商及配套设备
- 灯检设备（自动、半自动）
- 纯化水/注射用水系统
- 自动化过程控制系统
- 细胞与基因治疗（CGT）专用设备
- 检测仪器
- 隔离
- 层析系统
- 发酵罐及培养基
- 超滤/渗滤系统、缓冲液制备系统
- 灌装机
- 环境监测系统
- 清洁蒸汽发生器
- 实验室分析设备

Transfar 传化科技城 | TechCore 钱湾智谷 | Biolinx 钱湾生物港 | Springboard 钱湾加速中心

OVERSEAS RETURNEES TOWN TRANSFAR INNOCITY

海归小镇·传化科技城

海归小镇·传化科技城是欧美同学会总会认定的全国首批三个海归小镇之一，总规划面积3.78平方公里，秉承"政府主导、企业主体"的理念，由传化集团与萧山区共同打造的以生物技术产业为核心的国际创新区。海归小镇·传化科技城围绕**生物技术企业全生命周期发展需求，通过专业平台、精准服务、社群运营，深度陪伴更多科学家及企业成长，提供从孵化、加速到产业化的全过程专业化运营解决方案，以服务科学家创业成功，服务科创企业快速成长为使命**，为顶尖科学家、青年科学家、企业家和创新者们，打造科产城人文深度融合的国际科创社区。

这里吸引了越来越多来自全球的青年科学家，科创人才前来创业发展，超过30000人在这里工作与生活，创新成果不断涌现，国际社区蓬勃繁荣。

Overseas Returnees Town · Transfar Innocity is one of the first three national-level towns recognized by the Western Returned Scholars Association (WRSA), with a total planned area of 3.78 square kilometers. Upholding the principle of "government-led, enterprise-driven," it's an international innovation zone centered around the biotechnology industry, jointly established by Transfar Group and the Xiaoshan District.

Overseas Returnees Town · Transfar Innocity is designed to meet the full lifecycle needs of biotech enterprises through professional platforms, targeted services, and community operations. It provides end-to-end professional operational solutions—from incubation and acceleration to industrialization—deeply supporting the growth of scientists and companies. With a mission to enable scientific entrepreneurship and drive rapid growth of sci-tech enterprises, it aims to build an international innovation community that integrates science, industry, city, and culture, for leading scientists, young researchers, entrepreneurs, and innovators.

This place is drawing an increasing number of young scientists and tech innovators from around the world to start businesses and pursue careers here. With over 30,000 people working and living in the area, innovation continues to thrive, and the international community is vibrant and bustling.

EMPOWER SCIENTISTS ACCELERATE FUTURES

服务科学家创业成功 服务科创企业快速成长

专业平台 | 精准服务 | 深度陪跑 | 社群运营

地　　址：杭州市萧山区传化科技城
联系电话：0571—83781188
Address：Transfar Innocity, Xiaoshan District, Hangzhou, China
Tel：0571-83781188

OranssiBio 华元生物

华元(上海)生物医药有限公司

Your End-to-End CGT Partner – from Lab to Market

Company Overview

OranssiBio, a leading CDMO in Shanghai's Lingang Free Trade Zone, specializes in Cell and Gene Therapy. We partner with global biopharma companies and research institutions to provide end-to-end solutions, from early-stage development to commercial manufacturing. Committed to quality, agility, and global compliance, OranssiBio delivers GMP-compliant services to accelerate innovation and bring transformative therapies to market.

Our Core CGT Platform

- **Plasmid**
  packaging plasmids, GOI plasmids
- **mRNA-LNP**
  IVT, encapsulation
- **LVV**
  VSVG, BaEV, RD114A
- **AAV**
  2/5/6/8/9/Anc80
- **Exosome**
  Ex-IPSC, Ex-MSC, Ex-AAV
- **Cell**
  CAR-T, CAR-NK, HSC, iPSC

GMP Manufacturing
Global Compliance
Trusted Delivery

- 27,000 sq.ftR&D laboratory and 65,000 sq.ft GMP manufacturing facility
- GMP-compliant manufacturing aligned with FDA, EMA, and NMPA standards
- Multiple GMP production lines with scalable capacity ranging from 0.1L to 400L
- Experienced CMC team supporting global regulatory submissions

Earn Partner Love
– Quality, Speed, IP Protection

Contact

(021) 5753 5558

bd@oranssibio.com

www.oranssibio.com

labcorp

Your trusted global science and laboratory partner for any stage of development.

2,000+

Biopharmaceutical companies choose to develop their novel drug with Labcorp every year.

SPONSOR'S NOVEL THERAPEUTIC CANDIDATE

NONCLINICAL	CLINICAL TRIAL SUPPORT	COMMERCIALIZATION
CONSULTING & REGULATORY	DATA INSIGHT	DATA ANALYTICS
DISCOVERY	TRIAL TESTING & PLANNING	RECALL & SAFETY ALERT SUPPORT
SAFETY ASSESSMENT	TRIAL DELIVERY SUPPORT	LABCORP TV
DMPK	BIOMARKER & CDx DEVELOPMENT	SPONSORED TESTING & CDx
BIOANALYTICAL (NONCLINICAL)	BIOANALYTICAL (CLINICAL)	LONG-TERM FOLLOW-UP
LATE-STAGE NONCLINICAL STUDIES	CHEMISTRY MANUFACTURING & CONTROLS	CHEMISTRY MANUFACTURING & CONTROLS
11k+ nonclinical studies **160+** IND/CTA programs annually	**1.6M** patient results* **5,000+** protocols* **100+** countries*	Supported **76%** of all drugs and therapeutic products approved by the FDA in 2024

SPONSOR'S NEW THERAPEUTIC REACHES RIGHT PATIENTS

Together, let's break through.

Meet us at booth **3E-E08**

Visit ***www.labcorp.com/biopharma***

for more information and follow "**Labcorp**" on Linkedin

美迪科技（香港）有限公司

MEDDY

Meddy Technology (Hong Kong) Limited

美迪科技作为包装行业先进的机械研发设计、制造、销售、和技术服务商，为用户打造使用方便、品质优越的智能自动化设备为宗旨。

我们为全球客户提供广泛的初级和二级包装解决方案，以满足各种类型的生产及预算需求。无论是传统机械结构还是便捷的机器人应用我们的技术都能胜任。

在过去的运作中，我们在全球范围内，为不同行业各式各样的应用交付了多套包装解决方案。并且通过不懈的努力，坚持诚信的原则，生产品质卓越的产品，赢得德与客户建立了持久的合作关系。

从包装解决方案的现场演示，生产线的布局设计，设备的生产及测试，到工厂的验收，安装和售后技术支持，我们的服务全程体现着专业和责任，为您的投资保驾护航——这就是我们独一无二的"美迪服务"。

As an advanced mechanical R&D, design, manufacturing, sales, and technical service provider in the packaging industry, Meidi Technology aims to create intelligent automation equipment that is easy to use and of superior quality for users.

We provide a wide range of primary and secondary packaging solutions to meet various types of production and budget needs for our global customers. Our technology is capable of handling both traditional mechanical structures and convenient robot applications.

In our past operations, we have delivered multiple packaging solutions for various industries and applications worldwide. And through unremitting efforts, adhering to the principle of integrity, producing high-quality products, Jiameide has established a lasting cooperative relationship with customers.

From on-site demonstrations of packaging solutions, layout design of production lines, production and testing of equipment, to factory acceptance, installation, and after-sales technical support, our services embody professionalism and responsibility throughout the entire process, safeguarding your investment - this is our unique "Medi Service".

液体灌装

粉末填充

纸盒包装

装箱码垛

对于不同形状、不同尺寸的包装，我们有都着不同的解决方案。您只需要提出需求，我们专业的设计针对每一个生产工艺都采用最合适的方式去实现，无论是一次包装的包膜装载入盒还是纸盒装箱及搬运工艺，专业为您的产品包装定制解决方案。

We have different solutions for packaging of different shapes and sizes. You only need to put forward your requirements, and our professional design adopts the most suitable way to implement each production process, whether it is the loading of the packaging film into the box or the packaging and handling process of the paper box. We specialize in customizing solutions for your product packaging.

美迪科技（香港）有限公司

Meddy Technology (Hong Kong) Limited

默赛尔 BIOMEDICAL

Morecell Biomedical Technology Development co.,Ltd. Shenzhen

Overall solution provider in cell therapy industry, UC-MSCs, NK cells, DCs, TILs, γδT cells, iPscs, Exosome purification system and more!

Natural Killer Cell Culture Kit

- GMP-grade humanized cytokines
- Animal serum-free formulation
- High-purity, high-activity NK cells
- Suitable for peripheral or cord blood mononuclear cells
- 1000-fold expansion in 17 days
- 8–10 billion cells per process
- >95% $CD3^-CD56^+$ NK cells
- >60% $CD3^-CD56^{dim}$ subset
- >95% cell viability
- >80% tumor cell killing at 10:1 ratio

Exosome Purification System

- Biosafety cabinet compatible
- Wide volume range: 50–15,000 ml
- Easy operation
- Unattended preparation
- Low-cost consumables
- Regenerable core filter

Single-Use Cell Culture Bag

- PE material
- High strength and flexibility
- Fully sealed, contamination-proof

hiPSCs/hESCs Culture Kit

- Animal Component-Free
- Ethical & Infection Risk-Free
- Flexible Feeding Schedule
- Cost-Effective with Stable Supply
- Enzyme-Free Digestion
- Rapid Dissociation
- High Cell Viability

Contact us!

Website : qiray.com.hk

Scan this code to visit our Hong Kong Distributor Website for more information!

GenScript Reagents & Services

Scripting Possibilities with 20+ Years of Experience

Molecular Biology
- FLASH Gene
- Plasmid DNA Preparation
- Antibody Gene to Plasmid Package
- Gene Fragments
- DNA Mutant Libraries & Oligo Pools
- mRNA & AAV Plasmids
- GenSmart Online Tools

CRISPR Gene Editing
- Synthetic OmniGuide RNA
- ssDNA/dsDNA HDR Templates
- Cas Proteins & mRNA

Oligo Services
- DNA & RNA Oligos
- siRNA/ASO Drug Discovery

Cell Engineering
- Lentivirus Packaging
- AAV Packaging
- CRISPR Cell Line Development
- Assay Cell Line Development

cGMP Services
- CRISPR Cas9 Guide RNAs
- ssDNA/dsDNA HDR Templates
- Peptide Synthesis

Protein Expression
- TurboCHO™ Antibody Expression
- *E. coli* Expression
- Insect Expression
- Cell Free Expression
- Enzyme Expression
- Protein Analysis Platform

Antibody Services
- Anti-ID Antibody Development
- Monoclonal Antibody Development
- Polyclonal Antibody Development
- Antibody Sequencing

Peptide Services
- TurboTide Guaranteed Synthesis
- Peptide Libraries
- Neoantigen Peptides

IVT RNA Services
- Linear mRNA
- Circular RNA
- Self-amplifying mRNA
- LNP Formulation
- Rush mRNA Synthesis
- GMP-like mRNA

Learn More About GenScript

732-885-9188

860 Centennial Ave.,
Piscataway,
NJ 08854, USA

www.genscript.com

ProBio

Vision:

To be a leading global CDMO, renowned for cutting-edge technology to enable our customers to deliver life-changing therapies worldwide.

Mission:

Through our commitment to quality, collaboration, and innovation, ProBio delivers customized solutions to transform scientific discoveries into market-ready therapies, to make a lasting impact on patients health and well-being.

Values:

Customer Centric · Innovation · Integrity

Contact us

www.probiocdmo.com/

+1-732-885-9188 (US)

ProBio Inc. Building 9, 311 Pennington Rocky Hill Rd, Pennington, NJ

USA: cdmo.us@probiocdmo.com

China: cdmo.cn@probiocdmo.com

APAC: cdmo.apac@probiocdmo.com

Europe: cdmo.eu@probiocdmo.com

Japan: cdmo.jp@probiocdmo.com

South Korea: cdmo.kr@probiocdmo.com

Unlimitics — AI-powered Intervention Optimising Executive Functioning for Neurodivergent Individuals

Founder Profile

Caley Y. T. Lin is a Harvard graduate & Board Certified Behaviour Analyst (BCBA) who brings 8+ years of solid clinical experience, supporting over 3,000 neurodivergent students. Her work stands at the intersection of behavioural science, Gen-AI, & global inclusion.

How We Measure Progress

1. Pre-Post EF Skill Assessment
- **Behavior Rating Inventory of Executive Function (*BRIEF-2*)**
- **Delis-Kaplan Executive Function System (*D-KEFS*)**

2. Scenario-Based Performance Tracking (In-Game)
- Emotion Regulation: How quickly & appropriately they identifies & tags emotions during scenarios (*linked to Gross's Emotion Regulation framework*).
- Perspective-Taking: Ability to switch viewpoints within the simulation, building on **Theory of Mind** research.
- Response Inhibition & Flexibility: Whether students can pause, choose a non-impulsive response, or adapt strategies when the same scenario changes.

3. Behavioural Generalisation (Outside the Game)
- ABC Data Logs by Adults:
  - Frequency and intensity of behavioural outbursts
  - Speed of recovery after dysregulation
  - Initiation of self-regulation strategies

4. Parent & Teacher Feedback
- **Goal Attainment Scaling (*GAS*)**: Parents, educators, and therapists co-define personalised EF goals (e.g. "initiate homework with one prompt" or "use words instead of hitting when frustrated").

Unlimitics

@unlimitics

www.unlimitics.com

Boston · Hong Kong

SOLUTION

Unlimitics is a AI-powered simulation platform designed for school-aged children with self-regulatory, social-emotional, and behavioural challenges. Students revisit specific real-life moments and explore different choices through personalised, interactive scenarios that enhance decision-making, emotional insight, and real-world readiness.

MILESTONES & RECOGNITION

- Harvard Innovation Labs Accelerator (i-Lab)
- HKSTP Ideation Programme
- HK Tech 300 Seed Fund Recipient

- HKB Technology Excellence Award 2024
- HKCT Business Awards 2025 Winner
- Top 100 Finalist - Alibaba Jumpstarter 2025
- Asia Smart Innovation Awards 2025
- ICANX Startup Awards 2025

KEY DIFFERENTIATORS

AI-Generated Replay of Real Moments

Unlimitics lets students revisit the **exact moments** where they lost control or struggled — not through pre-set storylines, simulations rooted in their own experience.

From Reaction to Realisation

Our system helps students detect **what sets them off** and **when it tends to happen**, unveiling emotional triggers & behavioural patterns.

Power of Manifestation

Our **Future Self Preview** lets students visualise & rehearse a version of themselves making better choices, experiencing it as if it already happened.

上海外高桥生物医药产业发展有限公司

Shanghai Waigaoqiao Biomedical Industry Development Co.,Ltd.

外高桥作为产业链条最完整、生态最优良、人才最集聚、创新最活跃的区域之一，已集聚800余家国内外医疗器械和生物医药企业，其中全球收入排名前十大医疗器械公司悉数落户。为更好地服务国际及本土创新药械企业，上海外高桥生物医药产业发展有限公司整合现有资源，提供贯通行业研究、产业招商、项目孵化、创新投资、空间匹配的全流程全生命周期服务。主要经营职能包括：发挥自贸区保税区域功能政策优势推动生物医药产业在保税区域的发展，为生物医药产业提供专业化的产业配套服务，对接金融机构开展投资融合促进投招联动，统筹空间载体匹配加速重点项目在保税区域的健康发展等。

Waigaoqiao is one of the areas in China with the most complete industrial chains, the best business environment, the most aspiring talents, and the most vibrant innovation. Over 800 domestic and international pharmaceutical and medical device enterprises are registered in the area, including all the world's top 10 medtech companies. Shanghai Waigaoqiao Biomedical Industry Development Co., Ltd. is a professional service provider of the entire industrial chain, providing services such as policy research, company registration, startup incubation, venture capital investment, and property lease. The company focuses on the systematic innovation of industrial policies, links the international and domestic markets, and promotes the integrated development of the biomedical industry in the Shanghai Free Trade Zone.

项目发展的伴跑者　功能创新的培育者
生态环境的营造者　变革发展的领指者

全产业链生命周期服务

FULL LIFE-CYCLE SOLUTIONS

STARTUP 初创 — GROWTH 成长 — DEVELOPMENT 发展 — EXPANSION 扩张 — MATURITY 成熟

LEASING 载体/工程服务

Leasing

Engineering Management Consultancy

GSP Warehouse | GMP Lab | Clean Room | EIA Consultancy

OPERATION 企业综合服务

Enterprise Registration

Establishment, change, cancellation, etc. | Various licence applications

Talent Service

Settlement | Subsidy | Labour dispatch, etc.

Fiscal and Policy

Bookkeeping | Fiscal Subsidy | TAX | Intelligent Tax System

Financial Service

Financial Advisor | PE/VC | Debt

CONSULTING 企业专业咨询

Supply Chain

Endangered species and related products | Bonded maintenance etc.

Clinical CRO Services

MRCT | Clinical Data Applications

Biological Product Registration

Drug&Medical device Innovative Catalogue | Localization | MAH

Inspection Service

Drug | Medical Device

Access Service

Products into hospitals | Procurement Consultancy

CDMO Service

Commercialization of Scientific and technological achievements

Data Productisation Services

COLLABORATION 企业出海服务

Offshore investment

Structure and Establishment QFLP | QDI | QDLP

Registration Service

FDA | CE | PMDA | AMDD

Bio+ Trading Center

Supply and demand matching

Global Landing Services

Law&Policy | Talent Service

INNOVATION 政策与产业研究

Think-tank platform

Specialists | Full-range Element Platform

Functional Breakthrough Research

Innovation Pilot | Industry Research

Policy Research

【Scan for Details】

Please contact via email: info@bioftz.com

通瑞生物
C-RAY

C-Ray Therapeutics

Transformative One-stop CRDMO Services for Next Generation Radiotherapy

C-Ray Therapeutics is dedicated to delivering end-to-end solutions for innovative radiopharmaceuticals to clients around the world. Our services span process development, quality research, preclinical evaluation, IND Enabling, clinical supply, and commercial scale cGMP production, all backed by a reliable, robust logistics network. As of 2024, we have raised over USD 187 million in total funding.
C-Ray Therapeutics has successfully delivered and continues to operate 50 CRDMO projects: 35 preclinical and molecular-imaging CRO programs and 15 CDMO programs. Of these, 6 are in the IND and IND-enabling stages, 7 have progressed to investigator-initiated trials (IIT), and 2 are in the clinical supply phase—fully covering every critical link in the radiopharmaceutical R&D and manufacturing chain.

Class A
Production Facilities

Global cGMP
Compliance with global standards

CRDMO
Full-Service Platform

Production Facilities in Chengdu

World-class R&D and production facilities with Class A premises and global cGMP compliance

28,000+M²
Phase I R&D and production base

GLP-Like
Well established facilities/qualifications for non-clinical evaluation of radiotheranostics

35+CRO projects
Completed and ongoing CRO projects for Radiotheranostics and Molecular Imaging

IND
6 projects entering the IND enabling and IND stages

WeChat
Channels
linkedin

C-Ray Therapeutics
Web: www.c-raytherapeutics.com
Email: BD@c-raytherapeutics.com

CHINESE PEPTIDE
A MEDTIDE COMPANY

CHINESE PEPTIDE

Tides Partner,Concept to Commercial.

Company Overview

Chinese Peptide Company is a peptide and oligonucleotide-focused Contract Research, Development, and Manufacturing Organization (CRDMO), offering full-cycle services ranging from early-stage discovery, pre-clinical research and clinical development to commercial-stage production. The company was founded in 2001 and is headquartered in Hangzhou, China, with its international headquarters located in California, USA. It has commercial production sites and offices in both China and the United States.

Hangzhou, China

Headquarter & Manufacturing Site

No.69, 12 Street, Qiantang District

Rocklin, CA, US

International Headquarter
US-based Manufacturing Site

3880 Atherton Rd, Rocklin, CA 95765

Hangzhou, China

DP Research and Pilot Center

Hangzhou Biopharma Town

Milpitas, CA, US

Business Office

1900 McCarthy Blvd. STE 204, Milpitas, CA 95035

Commercial Manufacture

● Current ● Up-coming in 2025

Qiantang Site, Hangzhou

~20,000 sqm

Biopharma Town Site, Hangzhou

~26,700 sqm

Rocklin Site, California

~4,000 sqm

Global New Production Facility Plan

Targeting Tons-scale Annual Capacity

No.69, 12 Street, Qiantang District, 31600
sales@chinesepeptide.com
+86-57186737011
www.chinesepeptide.com

i-ImmunDx®

Tear Biomarker Point Of Care Tests for Diagnosis of Ocular Conditions

—— A Potential Unicorn in Changing Eye Care
Seinda Biomedical Corp.

泪液免疫快速检测

—— 改变眼健康诊断方式
盛泽康华公司

www.Seindabio.com
+86 (20) 89629373
info@Seindabio.com
Guangzhou International Bio-Island, Guangzhou, China

EtownBio
亦庄生物医药

链接全球医药创新合作伙伴
Connecting Global Pharmaceutical Innovation Partners

北京亦庄国际生物医药投资管理有限公司成立于2010年，系北京市属国企亦庄控股旗下专业平台，同时也是北京经开区"管委会+平台公司"模式下的生物医药平台公司。公司定位为经开区生物医药产业生态的核心运营商，通过整合空间、资本、政策、技术等资源要素，为产业发展提供全链条支撑。公司以服务生物技术和大健康产业战略为导向，打造"具有全国引领作用的生物技术和大健康产业平台"，助力北京经开区建设全球"新药智造"产业高地。

Etown Bio was established in 2010 as a specialised platform under Yizhuang Holdings, a state-owned enterprise of Beijing Municipality. It also serves as the biomedical platform company within the Beijing Economic-Technological Development Area's 'Administrative Committee + Platform Company' model. Positioned as the core operator of the development area's biomedical industry ecosystem, the company provides comprehensive support across the entire industrial chain by integrating spatial, capital, policy, technological and other resource elements. Guided by a strategy to serve the biotechnology and broader health industries, the company aims to establish 'a nationally leading platform for biotechnology and health industries,' thereby supporting Beijing Economic-Technological Development Area's ambition to become a global hub for 'intelligent new drug manufacturing.'

打造具有全国引领作用的
生物技术和大健康产业平台
ESTABLISH A NATIONALLY LEADING PLATFORM
FOR THE BIOTECHNOLOGY AND HEALTH INDUSTRY

芬蘭國家館

展位 3D-A11,A12

---

73 HEALTH

遠程醫療診斷SaaS平台

AQSENS

無創疾病檢測

PULSE ON

心律不正監測可穿戴設備

PROBIONT

ICI抗癌藥物個性化療效測試

醫療激光器及光學產品

modulight

FOLLOW BIOHK ON SOCIAL MEDIA

Facebook

Linkedin

WeChat:
BIOHK2025

WeChat:
HKBIO

SEE YOU AT BIOHK2026

09 - 12
SEPTEMBER 2026